FINAL PROGRAMME

FINAL 

PROGRAMME 

Congress Organizers 

The 81st EAS Congress 

1-3, rue du Chantepoulet; P.O. Box 1726 

CH-1211 Geneva 1, Switzerland 

Tel: +41 22 908 0488; Fax: +41 22 906 9140 

E-Mail: eas@kenes.com 

Website: www.kenes.com/eas

II 

CONTENTS 

Welcoming Words III 

Committees IV 

Faculty List V 

EAS Society VI 

Acknowledgements VII 

About Lyon X 

Anitschkow Prize in Atherosclerosis Research XI 

Young Investigator Awards XII 

General Information XIII 

Mandatory Conflict of Interest Disclosure XV 

Instructions for Presenters XVI 

Overview of Moderated Poster Sessions XVII 

Poster Overview XVIII 

Company Sponsored Educational Symposia XX 

Opening Ceremony XXIII 

Social Events XXIV 

Hall Name Eulogy of Distinguished Scientists XXV 

Venue Floor Plans XXIX 

Exhibition Floor Plan and Exhibitors List XXX 

Sponsor and Exhibitor Profiles 

Scientific Programme 

XXXI 

Sunday, June 2, 2013 1 

Monday, June 3, 2013 5 

Tuesday, June 4, 2013 15 

Wednesday, June 5, 2013 25 

Poster Presentations 29 

Index 129

WELCOMING WORDS 

Dear Colleagues, 

It is our pleasure to welcome you to the 81st EAS Congress in Lyon, France, from 2 to 5 June 2013. The 

Congress is hosted by the New French Society for Atherosclerosis. The local Organizing Committee and the 

EAS Scientific Programme Committee have worked together to prepare a programme that will include the 

latest developments in the field of atherosclerosis, together with timely reviews presented by outstanding 

plenary speakers. 

The EAS meeting remains a unique opportunity to bring together the various actors in the field of 

atherosclerosis. The EAS 2013 programme is of interest to both junior and established basic scientists, as well 

as clinical researchers and practitioners. 

The meeting promotes interactions between these different groups, and provides cutting-edge basic research 

translatable into disease prevention and treatment. More than 800 posters are on display and organized into 

interesting and interactive poster sessions. 

The Congress takes place in the Lyon Convention Center, designed by Renzo Piano, and located downtown on 

the banks of the Rhone River. 

Lyon, named a UNESCO Humanities World Heritage Site, is famous not only for world-class landmarks and 

thousands of years of history but also for its gorgeous food. Ranked among the top European cities for quality 

of life, Lyon in June provides an excellent opportunity to discover the charm of this unique location. 

On behalf of the Organizing Committee, we welcome you to Lyon. We are delighted that you joined us for the 

81st EAS Congress in 2013 - a stimulating meeting offering enjoyable and rewarding interactions between 

basic and clinical researchers in the field of atherosclerosis. 

Philippe Moulin 

Congress Chair EAS 2013 

Petri Kovanen 

Chairman of the Scientific 

Programme Committee 

Alberico L. Catapano 

EAS President 

III

IV 

COMMITTEES 

CONGRESS CHAIRPERSON 

Philippe Moulin, France 

EAS EXECUTIVE COMMITTEE 

Alberico L. Catapano, President 

Olov Wiklund, Vice President 

M. John Chapman, Past President 

Petri Kovanen, Secretary & Award Committee Chair 

Jan Borén, Treasurer 

Geesje Dallinga-Thie 

Børge Nordestgaard 

Arnold von Eckardstein 

Michal Vrablík 

SCIENTIFIC PROGRAMME COMMITTEE 

Petri Kovanen, Finland, Chair 

Alberico Catapano, Italy 

Matti Jauhiainen, Finland 

Jan Kuivenhoven, Holland 

Jesús Millán Núñez-Cortés, Spain 


Børge Nordestgaard, Denmark 

Marju Orho-Melander, Sweden 

Gabriele Riccardi, Italy 

Wolfgang Schneider, Austria 

Bart Staels, France 

Lale Tokgozoglu, Turkey 

LOCAL ORGANIZING COMMITTEE 

Jacques Bonnet, Bordeaux 

Eric Bruckert, Paris 

M. John Chapman, Paris 

Geneviève Derumeaux, Lyon 

Alain Gadeaux, Bordeaux 

Michel Krempf, Nantes 

Michel Lagarde, Lyon 

Pierre Morange, Marseille 

Agnes Sassolas, Lyon 

Bart Staels, Lille 

CONGRESS COMMITTEE 

Marja-Riitta Taskinen, Finland, Chair 

Jan Borén, Sweden 

Alberico L. Catapano, Italy 



Olov Wiklund, Sweden

FACULTY LIST 

Marcello Arca, Italy 

Jean-Francois Arnal, France 

Maurizio Averna, Italy 

Christie Ballantyne, USA 

Philip Barter, Australia 

Christoph Binder, Austria 

Dirk Blom, South Africa 

Jacques Bonnet, France 

Jan Borén, Sweden 

Adrian J.B. Brady, UK 

Eric Bruckert, France 

Sebastiano Calandra, Italy 

Giuseppina Caligiuri, France 

François Cambien, France 


M. John Chapman, France 

Yiannis Chatzizisis, Greece 

Xavier Collet, France 

Claudio Cortese, France 

Jean-Claude Coubard, Canada 

Filippo Crea, Italy 

Marina Cuchel, USA 

Geesje Dallinga-Thie, The Netherlands 

George Davey-Smith, UK 

Menno De Winther, The Netherlands 

John Deanfield, UK 

Vincent Durlach, France 

Michel Farnier, France 

Steven Feinstein, USA 

Edward Fisher, USA 

Robert Gerszten, USA 

François N. Gilly, France 

Henry Ginsberg, USA 

Andreas Habenicht, Germany 

Marten Hofker, The Netherlands 

G. Kees Hovingh, The Netherlands 

Frank Hu, USA 

Patricia Iozzo, Italy 

Matti Jauhiainen, Finland 

Dimitris Kardassis, Greece 

Sander Kersten, The Netherlands 

George D. Kitas, UK 

Wolfgang Koenig, Germany 

Petri Kovanen, Finland 

Michel Krempf, France 

Jan Kuivenhoven, The Netherlands 

Muriel Laffargue, France 

Laurent Lagrost, France 

Gilles Lambert, France 

Eicke Latz, Germany 

Gary Lewis, Canada 

Peter Libby, USA 

Jean-Baptiste Michel, France 


John Millar, USA 

Gilles Montalescot, France 

Kathryn Moore, USA 

Pierre Morange, France 


Jan Nilsson, Sweden 

Steven Nissen, USA 

Danilo Norata, Italy 


Vesa M. Olkkonen, Finland 

Anders G. Olsson, Sweden 

Marju Orho-Melander, Sweden 

Chris Packard, UK 

Klaus Parhofer, Germany 

Terje Pedersen, Norway 

Jogchum Plat, The Netherlands 

Frederick Raal, South Africa 

Željko Reiner, Croatia 

Gabriele Riccardi, Italy 

Angela Rivellese, Italy 

Robert Ross, Canada 

Yasushi Saito, Japan 

Raul D. Santos, Brazil 

Agnes Sassolas, France 

Naveed Sattar, UK 

Wolfgang Schneider, Austria 

Catherine Shanahan, UK 

Henrik Sillesen, USA 


Anton Stalenhoef, The Netherlands 

Evan Stein, USA 

Erik Stroes, The Netherlands 

Marja-Riitta Taskinen, Finland 


Maciej Tomaszewski, UK 

Anne Tybjaerg-Hansen, Denmark 

Luc Van Gaal, Belgium 

Arie van Tol, The Netherlands 

Arnold von Eckardstein, Switzerland 

Michal Vrablík, Czech Republic 

Olov Wiklund, Sweden 

Qingbo Xu, UK 

Laurent Yvan-Charvet, France 

Rudolf Zechner, Austria 

Andreas M. Zeiher, Germany 

APPRECIATION AND THANKS 

We would like to thank the reviewers of the submitted abstracts and the Young Investigator Award Jury for their valuable help and 

assistance. 

V

VI 

THE 

EUROPEAN 

ATHEROSCLEROSIS 

SOCIETY 

Advancing and exchanging knowledge of the causes, natural history, treatments and prevenon 

of atheroscleroc disease. 

EAS Acvies 

EAS organizes educaonal acvies, including Advanced Courses and an annual Congress. Online educaonal 

content will be available from the Society's E-learning resource, EAS Academy, starng summer 2013. 

The Society is also acve in the development and publicaon of Guidelines and Consensus Posion Papers on 

atherosclerosis-related topics. 

The Society’s journal, Atherosclerosis, brings together from diverse sources papers concerned with research 

and invesgaon on atherosclerosis. 

EAS also supports researchers and clinicians in the eld of atherosclerosis with various grants and awards. 

EAS Members 

• have access to online educaonal material via the Society's E-learning plaorm, EAS Academy 

• receive complimentary online access to the EAS Journal Atherosclerosis 

• benet from reduced registraon fee at EAS Congress*, Workshops and Symposia 

• are eligible to apply for EAS Grants and Awards 

• are eligible to apply to aend EAS educaonal acvies, including Advanced Courses 

• receive 15% reducon on Elsevier books purchased via the EAS Website 

• receive regular scienc commentaries and newsleers with informaon on the Society’s acvies 

* Payment of EAS annual membership subscripon means you are eligible for member-rate congress registraon fee for the 

following year (i.e. members who have paid membership subscripon during 2013 are eligible for member-rate registraon 

fee at EAS 2014 Madrid) 

For futher details about the acvies of the Society, or to become a member, visit the EAS 

website www.eas-society.org or contact us using email address office@eas-society.org

ACKNOWLEDGEMENTS 

CORPORATE PARTNERS 

The EAS Executive Committee would like to express its sincere appreciation to the following Corporate Partners for their continued 

support of the goals and activities of the European Atherosclerosis Society 

VII

VIII 

ACKNOWLEDGEMENTS 

The Organising Committee and the EAS Executive Committee would like to express their sincere appreciation to the following 

organisations for their support in the 81st EAS Annual Congress. 

PLATINUM SPONSORS 

GOLD SPONSOR 

SILVER SPONSOR

SPONSORS 

EXHIBITORS 

INSTITUTIONAL SUPPORT 

IX

X 

AbOUT LYON 

Lyon is France’s second-largest city and capital of the Rhône-Alpes region. Combining an exceptional historical heritage with a natural 

liking for good food, Lyon is an ideal city for discovering all the charm of the French way of life. 

A stage for more than 2000 years of history, the city has a remarkable architectural heritage. Expanding towards the east throughout 

the centuries, while preserving the existing areas, 500 hectares of its city centre became a UNESCO World Heritage Site in 1998. 

Wandering around Lyon is like embarking on a fascinating journey through time. In each district Lyon displays an astonishing variety 

of architecture, from the roman theatres and the medieval district, via the elegant peninsula situated between the Rhône and the 

Saône, to the contemporary and original creations by Renzo Piano, Jean Nouvel and Santiago Calatrava. 

The city also has a strong academic profile with 120 000 students (12 500 from outside France) in 3 universities, and - with a rich 

medical history from Rabelais, to Claude Bernard, Alexis Carrel, Marcel and Charles Merieux - was a cradle of pharmaceutical industry. 

All year round at nightfall the city is lit up thanks to its “Lighting Plan” that shows off some 325 monuments. For night owls, the city 

is teeming with festive, friendly places, with trendy bars from the Old Lyon to barge-restaurants moored on the banks of the Rhône, 

not forgetting the wine bars on the peninsula. 

Lyon has several famous museums, such as the Lumière Institute, on the invention of cinematography, and the Fabric Museum, 

which traces two thousand years of the history of textile and silk weaving. Located in a wonderful Renaissance building, the Lyon 

History Museum and the Puppets of the World Museum have formed the Gadagne Museums in Old Lyon since 2009. The Fine Arts 

Museum is one of the largest museums in France - its collections, spread out over 70 rooms, giving visitors an exceptional journey 

from Antiquity to Modern Art. 

Lyon has been the ultimate gastronomic city for centuries, reputed around the world thanks to Chef Paul Bocuse. It now boasts more 

than 2 000 restaurants, including the famous bouchons (typical local eateries) as well as Michelin star-awarded establishments. From 

traditional Mères Lyonnaises (19th century cooks for the bourgeoisie) to inspired and innovative young chefs, Lyon is a place for 

culinary experimentation with new tastes and concepts to be savoured. 

The city was the first to establish a public bicycle-rental system, and has more than 350 stations with 2500 bicycles available, offering 

visitors the opportunity to explore by bike the parks beside the river banks and to visit new districts such as the confluences. 

The EAS Congress venue is situated downtown, within walking distance from several congress hotels and 10-20 minutes from others by 

public transportation system. Easy to get to, and easy to get about, its various resources and charms at the cross-road of influences from 

south and north of Europe makes Lyon an ideal venue for the EAS. Your visit to EAS2013 will be both an exciting scientific experience 

and a memorable taste of French culture.

THE ANITSCHKOW PRIZE 

THE ANITSCHKOW PRIZE IN ATHEROSCLEROSIS RESEARCH, 2013 

PROFESSOR PETER LIbbY 

MALLINCKRODT PROFESSOR OF MEDICINE AT HARVARD MEDICAL 

SCHOOL AND CHIEF OF THE CARDIOVASCULAR DIVISION AT BRIGHAM 

AND WOMEN’S HOSPITAL, BOSTON, MASSACHUSETTS, USA 

The EAS is delighted to announce that the recipient of the Society’s prestigious Anitschkow Prize 

2013 is Professor Peter Libby, Mallinckrodt Professor of Medicine at Harvard Medical School and 

Chief of the Cardiovascular Division at Brigham and Women’s Hospital, Boston, Massachusetts. 

Professor Libby will give the Anitschkow Lecture as part of the Congress Opening Ceremony 

Sunday June 02, 2013, 18:00. 

Over the past three decades Prof. Libby has made numerous major discoveries that have changed 

the way we think about the etiology and potential management of atherosclerotic cardiovascular 

disease. Prof. Libby’s seminal experimental and translational observations on the pathophysiological 

pathways leading to plaque formation and destabilization have affected our current knowledge 

of atherosclerosis with far reaching clinical implications. His work will pave the way for new 

strategies designed to prevent the onset and progression of atherosclerosis in those who do not 

yet have manifest cardiovascular disease. 

Prof. Libby has been a role model, gifted teacher and mentor for a generation of emerging 

clinical and basic cardiovascular researchers who have been inspired by his ability to translate 

basic research into clinical setting. This attribute has greatly magnified his contribution to the 

understanding of atherosclerosis. 

XI

XII 

YOUNG INVESTIGATOR AWARDS 

THESE ANNUAL AWARDS ARE PRESENTED BY THE EAS FOR OUTSTANDING PUBLICATIONS BY YOUNG SCIENTISTS 

IN THE FIELD OF ATHEROSCLEROSIS. 

MACIEj TOMASZEWSKI, UK 

DEPARTMENT OF CARDIOVASCULAR SCIENCES, UNIVERSITY OF LEICESTER, 

CLINICAL SCIENCES WING, GLENFIELD GENERAL HOSPITAL, LEICESTER, UK. 

For his publication Inheritance of coronary artery disease in men: an analysis of the role of the 

Y chromosome, the LANCET, 2012; 379: 915–22. Fadi J Charchar, Lisa D S Bloomer, Timothy 

A Barnes, Mark J Cowley, Christopher P Nelson, Yanzhong Wang, Matthew Denniff, Radoslaw 

Debiec, Paraskevi Christofi dou, Scott Nankervis, Anna F Dominiczak, Ahmed Bani-Mustafa, 

Anthony J Balmforth, Alistair S Hall, Jeanette Erdmann, Francois Cambien, Panos Deloukas, 

Christian Hengstenberg, Chris Packard, Heribert Schunkert, Willem H Ouwehand, Ian Ford, Alison 

H Goodall, Mark A Jobling, Nilesh J Samani, Maciej Tomaszewski. 

Dr Tomaszewski is a specialist in internal medicine. He holds a senior clinical lectureship in cardiovascular medicine in the Department 

of Clinical Sciences, University of Leicester. He is also a consultant physician in University Hospitals of Leicester NHS Trust. He chairs 

New Investigators Committee of the International Society of Hypertension. His main research interests focus on genomics and 

genetics of cardiovascular disease with a particular emphasis on the role of sex chromosomes. 

LAURENT YVAN-CHARVET, FRANCE 

DEPARTMENT OF MOLECULAR MEDICINE, RESEARCH CENTER C3M, UMR 

INSERM U1065/UNS, NICE, FRANCE. 

For his publication Cholesterol efflux and atheroprotection: advancing the concept of reverse 

cholesterol transport, Cell Stem Cell 2012; Vol 11, Nr.2, p. 195-206. Marit Westerterp, Samuel 

Gourion-Arsiquaud, Andrew J Murphy, Alan Shih, Serge Cremers, Ross L Levine, Alan R Tall and 

Laurent Yvan-Charvet. 

Dr. Laurent Yvan-Charvet obtained his Ph.D. in Endocrinology in 2005 from the University of 

Paris XI, France. His research work at Columbia University has been mainly focused on how regulation of inflammation and stem 

cell biology by cholesterol efflux pathways affect cardiovascular diseases. He was the recipient of the Roger Davis Award in 2010 

and finalist of the I.H. Page Young Investigator Award in 2011. After a contribution to the development of new therapeutics for 

cardiovascular diseases at Pfizer, his current research interest as a group leader lies in hematopoietic cell metabolism – a new area of 

research for cardiovascular diseases.

GENERAL INFORMATION 

VENUE 

LYON Congress centre 

50 Quai Charles de Gaulle 69463 Lyon cedex 06 

Tel. no. 33(0) 4 72 82 26 26 

Website: www.ccc-lyon.com 

DIALING CODES & IMPORTANT TELEPHONE 

NUMBERS 

The International dialing code for France is +33 

The Lyon area code is +04 

Emergency numbers are as follows: 

Police - 17; Fire brigade - 18; Medical emergency – 15 or CCC 

security 04 72 82 27 67 (direct access for medical assistance) 

REGISTRATION / INFORMATION / 

SECRETARIAT DESK 

The Registration Desk will be situated at the Congress Centre 

for the duration of the congress and will be open as follows: 

OPENING HOURS 

Sunday, June 2, 11:00 – 20:30 

Monday, June 3, 7:30 – 18:30 

Tuesday, June 4, 7:30 – 19:00 

Wednesday, June 5, 7:30 – 13:00 

BADGES 

On registering you will receive your name badge. You are kindly 

requested to wear your badge during all congress sessions and 

events. 

EXHIBITION HOURS 

Sunday, June 2, 17:30 – End of Welcome Reception 

Monday, June 3, 10:00 – 17:00 

Tuesday, June 4, 10:00 – 17:00 


FOOD & BEVERAGE 

We wish to thank for providing their products during 

the Tuesday, June 4 morning coffee break. 

CYBER CENTER 

A Cyber Centre will be available for participants’ use in the 

exhibition area during exhibition hours. 

ABSTRACT BOOK 

The congress abstracts will be published in an online Abstract 

Book available on the website. If you would like to print any of 

the abstracts while at the congress, please look for the printing 

stations in the exhibition area. 

CERTIFICATE OF ATTENDANCE 

The Certificate of Attendance may be printed from one of the 

automatic registration areas from Tuesday, June 4, 2013. 

EBAC CME ACCREDITATION 

The 81st EAS Congress is accredited by the European Board 

for Accreditation in Cardiology (EBAC) for18 hours of External 

CME credits - Up to 3 hours per half-day and up to 6 hours per 

full day. 

Each participant should claim only those hours of 

credit that have actually been spent in the educational 

activity. EBAC works according to the quality standards of the 

European Accreditation Council for Continuing Medical Education 

(EACCME), which is an institution of the European Union of 

Medical Specialists (UEMS). 

Participants are kindly requested to scan their badges when they 

enter and leave the congress area. 

BANKING & EXCHANGE 

The official currency is the Euro. Foreign currency may be 

changed at banks during normal banking hours, at hotels, at 

airports and in exchange offices. All major credit cards are 

acceptable in most hotels, restaurants and shops. 

MAIL, MESSAGES, MEDICAL ASSISTANCE, 

LOST & FOUND 

Please approach the Registration Desk. 

XIII

XIV 

LANGUAGE 

English is the official language of the Congress. All presentations 

will be made in English. 

CLOTHING 

Clothing is informal for all occasions. 

MOBILE PHONES 

Please note that mobile phones must be switched off during all 

sessions. 

SESSIONS 

Please make sure to be in session halls on time as all sessions 

will begin as per schedule. 

SMOKING POLICY 

Smoking is prohibited at all times in the meeting halls, exhibit 

halls and restrooms. 

Your compliance is appreciated. 

LIABILITY AND INSURANCE 

The Congress Secretariat and Organisers cannot accept liability 

for personal accidents or loss of or damage to private property 

of participants and accompanying persons. Participants are 

advised to take out their own personal travel and health 

insurance for their trip. 

SAFETY AND SECURITY 

Please do not leave bags or suitcases unattended at any time, 

whether inside or outside session halls. 

Hotels strongly recommend that you use their safety deposit 

boxes for your valuables. 

PRESS ROOM 

A press lounge with internet access including Wi-Fi is freely 

available to registered journalists. Journalists must register at 

the Registration Desk. Upon registration the journalists will 

receive a press kit including the detailed press briefing schedule. 

Press releases will be available to the journalists in association 

to the press briefings in the Press Briefing Room. 

PRESS ROOM HOURS 

Sunday, June 2, 11:00 – 20:30 

Monday, June 3, 7:30 – 18:30 

Tuesday, June 4, 7:30 – 19:00 


WEBCAST 

A selection of sessions will be webcast and will be available on 

the Society website after the congress. 

PAPERLESS SCIENTIFIC PROGRAMME ON 

SMARTPHONES AND TABLETS 

The paperless application is designed for cross platform 

access via laptop and mobile devices such as Smartphone, 

iPad, Android etc. This innovative and intuitive app gives the 

participant the power to choose and plan and, therefore, 

maximize his or her time at the congress. Access to the 

application is via http://eas.ekonnect.co 

Participants will have full access to the scientific programme 

and the abstracts. The application has smart search possibilities 

within the scientific programme by session type and faculty. 

TRANSPORTATION 

The public transportation pass, available at the congress center, 

gives access to any subway, tram, cable car and bus line for the 

4 Congress days, Sunday to Wednesday. 

CONGRESS ORGANISERS 

The 81st EAS Congress 

1-3, rue du Chantepoulet; P.O. Box 1726 

CH-1211 Geneva 1, Switzerland 

Tel: +41 22 908 0488 

Fax: +41 22 906 9140 

E-Mail: eas@kenes.com

MANDATORY CONFLICT OF INTEREST DISCLOSURE 

EAS wishes to promote independence, objectivity, scientific rigor and a fair balance of representation, and has adopted a Conflict of 

Interest (COI) Disclosure Policy for this purpose. 

Persons taking part in the Society’s Congress are therefore expected to disclose their financial or in-kind relationships both with 

health industry that develop, manufacture, distribute or sell health care materials or services, or other organizations that could 

represent a potential COI. Such relationships exclude personal or family medical care. Full disclosure is expected even when it is not 

clear whether a relationship or affiliation constitutes a conflicting interest. 

EAS recognizes that these relationships do not necessarily imply bias or decrease the value of participation. 

Please note that it is mandatory for all Congress participants to include in their presentation a statement either to disclose any 

potential or direct conflict of interest, or, alternatively, to state that they have no conflict of interest. 

» For oral presentations: your conflict of interest disclosure statement should be at the beginning of your presentation (i.e., first 

or second slide to be the disclosure statement slide) 

» For poster presentations: your conflict of interest disclosure statement should be included at the bottom of your poster 

Even if you have no conflict of interest to declare, your presentation must include the statement 

“I have no potential conflicts of interest to report” 

Please note that this policy will be strictly enforced – presentation at EAS 2013 Lyon will only be permitted if 

your slides or poster contain a Conflict of Interest disclosure statement. 

XV

XVI 

INSTRUCTIONS FOR PRESENTERS 

SPEAKERS’ READY ROOM 

A Speakers’ Ready Room will be available every day throughout the Congress for speakers. 

If using a PowerPoint (or any other computer) presentation, please note you need to bring it on a CD, a DVD or on a “disk on key” 

memory stick (using the USB port in the computer) and load it on one of the congress’ computers in the Speakers’ Ready Room, at 

least 1 hour before the start of the session. You may supply your own laptop computer as a back-up. 

If combining video films with PowerPoint, please make sure to check it in the session hall where your lecture is taking place during a 

coffee or lunch break prior to your session, at least 30 minutes before the start of the session - even after checking it in the Speakers’ 

Ready Room. 

Please note that the Congress’ computers in the session halls are being supplied with Windows and Office 2007. 

IMPORTANT NOTE FOR MACINTOSH USERS 

In order to use MAC presentations on a PC compatible computer please note that you need to prepare it according to the instructions 

below, before bringing it to the Speakers’ Ready Room. 

» Use a common font, such as Arial, Times New Roman, Verdana, etc. (special fonts might be changed to a default font on a 

PowerPoint based PC). 

» Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be visible on a PowerPoint based PC). 

» Use a common movie format, such as AVI, MPG and WMV (MOV files from QuickTime will not be visible on a PowerPoint based PC). 

You may use your own Macintosh laptop computer as a back-up. In such a case, please confirm that it has a VGA socket for external 

signal and come to check it first in the Speakers’ Ready Room as soon as you arrive and later on in the session hall where your lecture is 

taking place during the coffee or lunch break prior to your session, at least 30 minutes before the start of the session. Please note that 

VHS Video projection, 35 mm’ slide projection and Overhead projection (projection of transparencies) will not be available. 

INSTRUCTIONS FOR POSTER PRESENTERS 

Posters will be on display for the entire congress. Please check the Scientific Programme to see the exact poster board number, date, 

and time of the poster discussion groups. Posters may be mounted from Sunday, June 2 from 15:30. 

Presenters are requested to stand next to their posters during the lunchtimes on 

» Monday June 3 from 12:40 - 14:45 and 

» Tuesday, June 4 from 12:40 - 14:45. 

The organisers are not responsible for any posters that have not been removed by the end of sessions on Wednesday, June 5. 

MODERATED POSTER PRESENTATIONS 

EAS is proud to have moderated poster sessions that will be located in the Exhibition area, providing the unique opportunity for 

convivial scientific discussions and exchange. For further details please refer to the Overview of Moderated Poster Sessions on the 

following page.

OVERVIEW OF MODERATED POSTER SESSIONS 

Session Topic Moderator Poster Number 

Moderated Session A: Monday, june 3, 13:40 – 14:40 

1 Endothelium and atherothrombosis Yiannis Chatzizisis, Greece T1: M1-M8 

2 Regulation of cellular lipid metabolism in atherogenesis Bart Staels, France T2: M59-M66 

3 Role of lipases in lipid and lipoprotein metabolism 

Geesje Dallinga-Thie, 

Netherlands 

T2: M67-M74 

4 

Evaluation and treatment of cardiovascular risk factors in the young and the 

elderly 

George Davey-Smith, UK T3: M117-M125 

5 Inflammation and HDL Dimitris Kardassis, Greece T2: M75-M81 

6 Thrombosis and hemostasis: relation to atherothrombosis and lipoproteins Pierre Morange, France T1: M9-M14 

7 Fatty acids influence atherosclerosis and its risk factors: the double bonds decide Michel Lagarde, France T3: M126-M130 

8 Insulin-resistant states: modulators of lipid metabolism and cardiovascular disease Klaus Parhofer, Germany T3: M131-M139 

Moderated Session b: Tuesday, june 4, 12:40 – 13:40 

9 Cell dysfunctions in atherogenesis Catherine Shanahan, UK T1: M15-M22 

10 Angiogenesis Jan Nilsson, Sweden T1: M23-M30 

11 Lifestyle Angela Rivellese, Italy T3: M140-M148 

12 CV risk factors 1 Jacques Bonnet, France T3: M149-M157 

13 Atherosclerosis-regulating factors in mouse and man 2 Christoph Binder, Austria T1: M31-M38 

14 Multiple roles of HDL and its transporters in atherosclerosis and related diseases Arie van Tol, Netherlands T2: M82-M89 

15 Novel insights into the role of micronutrients in cardiovascular risk and disease Eric Bruckert, France T3: M158-M164 

16 Treatment of dyslipidemia: from guidelines to goals and mechanisms Anders G. Olsson, Sweden T2: M90-M99 

17 

Imaging of the arterial wall as a diagnostic and prognostic indicator of 

atherosclerotic disease 

Lale Tokgozoglu, Turkey T3: M165-M171 

Moderated Session C: Tuesday, june 4, 13:40 – 14:40 

18 Immunity and atherosclerosis 

Menno De Winther, 

Netherlands 

T1: M39-M44 

19 Metabolic regulation of apoliprotein A-I-containing lipoproteins Laurent Lagrost, France T2: M100-M106 

20 

Cardiovascular disease and its prevention in patients with chronic inflammatory 

and chronic renal disease 

Naveed Sattar, UK T3: M172-M181 

21 Primary dyslipidemia Sebastiano Calandra, Italy T2: M107-M116 

22 Inflammation and infection in experimental and clinical atherosclerosis Giuseppina Caligiuri, Italy T1: M45-M53 

23 Regulation of ischemia reperfusion injury Jean-Francois Arnal, France T1: M54-M58 

24 Exercise and cardiovascular health: both quantity and quality count Matti Jauhiainen, Finland T3: M182-M187 

25 CV risk fators 2 

Anne Tybjaerg-Hansen, 

Denmark 

T3: M188-M195 

ACKNOWLEDGEMENT OF POSTER MODERATORS 

EAS is indebted to the distinguished scientists and clinicians who have kindly accepted the role of moderator during the Moderated 

Poster Sessions at the Congress. 

XVII

XVIII 

POSTER OVERVIEW 

Posters will be on display from Monday June 3 – Wednesday June 5. 

Poster presenters are requested to stand by their posters during lunch breaks 

Track 1: 

VASCULAR BIOLOGY OF THE 

ARTERIAL WALL 

Topic Poster Board 

Numbers 

1-134 

Endothelial cells and function 1-20 

Endothelial dysfunction clinical assessment 21-29 

Smooth muscle cells 30-44 

Extracellular matrix and calcification 45-67 

Gene expression 68-74 

Infection and atherosclerosis 75-82 

Inflammation 83-103 

Innate immunity 104-120 

Adaptive immunity 121-128 

Hormones and atherosclerosis 129-134 

Track 2: 

LIPID AND LIPOPROTEIN METABOLISM: 

FROM ALTERATIONS TO TREATMENTS 

Topic Sub-topic Poster Board 

Numbers 

135-330 

apoB-Containing 

lipoproteins 

Modified lipoproteins 135-137 

apoB-Containing 

lipoproteins 

Lp(a) 138-140 

HDL CETP 141-145 

HDL Cholesterol efflux 146-152 

HDL Function and metabolism 153-164 

HDL apoA1 functions 165-168 

Intracellular metabolism 169-177 

Lipases and lipoprotein 

metabolism 

178-183 

Lp-PLA2 184-195 

Biomarkers 

Dyslipidaemia: 

Lipid metabolism 196-199 

epidemiology, 

biomarkers 

Dyslipidaemia: 

HDL 200-205 

epidemiology, 

biomarkers 

206-227 

Familial 

hypercholesterolaemia 

229-246 

Primary dyslipidaemia 247-255 

Secondary dyslipidaemia 256-262 

Genetics HDL metabolism 263-266 

Genetics Lipid metabolism 267-282 

Lipid-lowering therapy Ezetimibe 283-290 

Lipid-lowering therapy Miscellaneous 291-296 

Lipid-lowering therapy Nicotinic acid 297-299 

Lipid-lowering therapy PCSK9 300-304 

Lipid-lowering therapy Statins 305-330

Track 3: 

RISK FACTORS, EPIDEMIOLOGY, PREVENTION, AND TREATMENT OF 

CARDIOVASCULAR DISEASES 


Numbers 

331-684 

Cardiovascular epidemiology 331-351 

Woman and cardiovascular 

risk 

352-356 

Biomarkers 357-370 

Functional assessment of 

arterial wall 

371-383 

Imaging IMTc 384-387 

Imaging 

Calcifications 

assessment 

388-396 

Imaging Miscellaneous 397-402 

Imaging Vulnerability 403-408 

Genetics 409-426 

Obesity and fat distribution 427-445 

Metabolic syndrome 446-467 

NASH and related disorders 468-480 

Sub inflammatory states 481-494 

Diabetes macroangiopathy Dyslipidaemia 495-499 

Diabetes macroangiopathy Treatment 500-507 

Diabetes macroangiopathy Miscellaneous 508-523 

Nephropathy 524-536 

Thrombosis 537-551 

Aneurysms 552-554 

Arteriopathy 555-561 

Lifestyle and CV risk Exercise 562-577 


Numbers 

331-684 

Lifestyle and CV risk Miscellaneous 578-580 

Lifestyle and CV risk Tobacco 581-584 

Lifestyle and CV risk 

Therapeutic 

education 

585-588 

Lifestyle and CV risk 

Psychosocial 

factors 

589-591 

Nutrition and CV risk Alcohol 592-593 

Nutrition and CV risk Antioxidants 594-597 

Nutrition and CV risk 

Carbohydrates/ 

fibres 

598-600 

Nutrition and CV risk Fatty acids 601-605 

Nutrition and CV risk Miscellaneous 606-619 

Omega-3 fatty acids 620-631 

Phytosterols 632-634 

Treatment Miscellaneous 635-647 

Treatment 

Blood pressure 

treatment 

648-653 

Intravascular procedures 654-660 

Miscellaneous 665-700 

Phytosterols 634-636 

Treatment Miscellaneous 637-649 

Treatment 

Blood pressure 

treatment 

650-655 

Intravascular procedures 656-622 

Miscellaneous 633-684 

Please note that posters of Abstract Presenters that were not registered to the Congress by the deadline, were not allocated poster 

boards. Such Abstract Presenters are requested to approach the Poster Helpdesk to receive an available poster board onsite. 

XIX

XX 

EDUCATIONAL SYMPOSIA AND SPECIAL SESSIONS 

SUNDAY, JUNE 2, 2013 

13:30-15:00 - EbAC ACCREDITED EDUCATIONAL PROGRAMME - Claude bernard Hall 

Supported by an unrestricted educational grant from AstraZeneca 

ADVANCES IN THE UNDERSTANDING OF CARDIOVASCULAR DISEASE AND DYSLIPIDAEMIA IN DIABETES 

Programme created in collaboration with Sahlgrenska Academy, University of Gothenburg 

See page 1 of the Scientific Programme 

14:15-15:00 - Special Lecture - Marcel Mérieux Hall 

HYPERCHOLESTEROLEMIA – WHAT CAN WE DO FOR HIGH-RISK PATIENTS? 

Sponsored by Amgen 


15:15-16:00 - Special Lecture - Michel Macheboeuf Hall 

CETP INHIBITION: WHAT’S NEW? 

Sponsored by Merck 


16:20-17:50 - Educational Symposium - Michel Macheboeuf Hall 

NEW STRATEGIES FOR THE MANAGEMENT OF PATIENTS WITH HoFH 

Sponsored by Aegerion 

See page 3 of the Scientific Programme

MONDAY, JUNE 3, 2013 

13.00–14.30 - Educational Programme - Claude bernard Hall 

CLINICAL ADVANCES IN DIFFICULT-TO-TREAT PATIENTS WITH HYPERCHOLESTEROLEMIA 

Sponsored by Sanofi/Regeneron & Genzyme 


17.00–18.30 - Educational Symposium – Anitschkow Hall 

ON THE FOREFRONT OF CHOLESTEROL MANAGEMENT: CLINICAL CONSIDERATIONS AND PRACTICAL 

APPROACHES BEYOND STATINS 

Sponsored by MSD 


17.00–17.45 - KOWA Special Lecture - Claude bernard Hall 

NORMALISING DYSLIPIDEMIA AND REVERSING ATHEROSCLEROSIS IN CARDIO-METABOLIC DISEASE 

Sponsored by KOWA 


17.00–17.45 - Special Lecture - Michel Macheboeuf Hall 

THE ROLE OF PLANT STANOLS/STEROLS IN THE MANAGEMENT OF DYSLIPIDAEMIAS 

Sponsored by BASF, Danone, Raisio, Unilever 


XXI

XXII 

TUESDAY, JUNE 4, 2013 

13:00–14:30 - Educational Symposium – Anitschkow Hall 

CONTEXT AND FUTURE CHALLENGES IN THE EFFECTIVE MANAGEMENT OF DYSLIPIDAEMIA 

Sponsored by Roche 


15:40–16:40 - Meet the Expert - Michel Macheboeuf Hall 

CLINICAL EXPERIENCE OF LOMITAPIDE THERAPY IN PATIENTS WITH HoFH DURING CLINICAL TRIALS 

Sponsored by Aegerion 


17:00–19:00 - Reviewer & Author Workshop - Meeting room “Rene Leriche” 

Sponsored by Elsevier 

See page 23 of the Scientific Programme

Opening Ceremony 

SUNDAY 

JUNE 2, 2013, 18:00 

N.N. Anitschkow Hall 

WELCOME FROM THE EAS PRESIDENT 


WELCOME FROM THE PRESIDENT OF THE CLAUDE BERNARD LYON UNIVERSITY 

François Noel Gilly, France 

WELCOME FROM THE NFSA PRESIDENT 


IAS AND EAS WORKING TOGETHER 

Philip Barter, IAS President, Australia 

WELCOME FROM THE CONGRESS CHAIRPERSON 


Choir Resonance IUFM de Lyon, Conductor: Jean Duvillard 

Magnificat (John Rutter) 

INTRODUCTION OF THE ANITSCHKOW PRIZE WINNER 


THE ANITSCHKOW LECTURE 


Choir Resonance IUFM de Lyon, Conductor: Jean Duvillard 

Les Djinns (Victor Hugo – Gabriel Fauré) 

Followed by a Wine and Cheese Welcome Reception 

Choir Resonance IUFM de Lyon, Conductor: Dany Landry 

Carmina Burana (Carl Orff) 

XXIII

XXIV 

SOCIAL EVENTS PROGRAMME 

SUNDAY, JUNE 2 2013 

OPENING CEREMONY FOLLOWED BY A WINE AND CHEESE WELCOME RECEPTION 

Guests will enjoy glorious choir music in the opening ceremony followed by a Wine and Cheese Welcome Reception in the exhibition 

area at the congress centre. 

For non-registered participants €15 

MONDAY, JUNE 3 2013 

FACULTY DINNER (FOR INVITEES ONLY) 

This event is exclusive to Invited Speakers 

Time: 20:00 

Pick-up from Hilton Hotel: 19:30 

TUESDAY, JUNE 4 2013 

EAS INTERNATIONAL EVENING (TICKET REQUIRED) 

A ‘not to be missed’ networking evening will be held in at Lyon’s imposing City Hall. 

This magnificent building, with its tall clock tower and blue-domed pavilions, is an excellent example of the French tradition of 

dignified government buildings. 

The event is catered by JP Pignol who was named “meilleur ouvrier de France” (MOF Best Chef of France in 1979) 

Tickets can be purchased at the Registration Desk (Limited Availability) 

Time: 20:00 

Ticket Price: €35 and €25 for students.

HALL NAME EULOGY OF DISTINGUISHED SCIENTISTS 

NIKOLAI N. ANITSCHKOW (1885-1964) 

PROFESSOR OF THE DEPARTMENT OF PATHOLOGICAL PHYSIOLOGY OF THE MILITARY MEDICAL ACADEMY 

ST. PETERSBURG, RUSSIA 

In 1913, experimental pathologist Dr. Nikolai N. Anitschkow showed that simply feeding to rabbits purified cholesterol dissolved in 

sunflower oil induced vascular lesions closely resembling those of human atherosclerosis, both grossly and microscopically. Controls 

fed with only the sunflower oil showed no lesions. It is fair to say that this paper marked the beginning of the modern era of atherosclerosis 

research. Dr. Anitschkow was not only a keen-eyed structural pathologist and a careful experimentalist; he thought in terms 

of function and time-related pathogenesis. 

However, the landmark studies by Dr. Anitschkow were largely rejected at the time. An important reason for this was that the 

findings were inconsistent with the prevailing view of atherosclerosis. It was generally accepted to be an inevitable accompaniment 

of aging (the “senescence hypothesis”). If the full significance of his findings had been appreciated at the time, we might have saved 

more than 30 years in the long struggle to settle the cholesterol controversy. 

In honor of Dr. Nikolai N. Anitschkow, the “Anitschkow Prize in Atherosclerosis Research” awarded annually by the EAS recognizes 

outstanding research in the field of atherosclerosis and linked metabolic disturbances. 

XXV

XXVI 

CLAUDE bERNARD (1813-1878) 

PHYSIOLOGIST. BORN: 1813, SAINT-JULIEN NEAR LYON. DIED: 1878, PARIS 

By the age of 21, Bernard had already written several plays and set off to Paris, France, to show them around. He entered the 

Faculty of Medicine, obtaining a medical degree in 1843. He became an assistant to François Magendie, one of France’s most 

prominent--and controversial--physiologists. 

In 1855, when Magendie died, Bernard took his place as Professor of Experimental Medicine at the College de France. Bernard, who 

tended to be more disciplined and organized than Magendie had been, began attracting more and more scientific attention to the 

comparatively new discipline. 

Bernard found that the stomach was not the sole digestive organ: while the stomach began the digestive process, much more digestion 

took place throughout the small intestine. He also demonstrated the importance of the pancreas, whose secretions were clearly 

necessary to break down fat molecules, and later went on to identify the various nerves that control gastric secretion. In 1857, 

Bernard isolated glycogen in the liver of animals and evidenced that it served as the body’s reserve supply of carbohydrates. 

In 1851, he discovered that certain specific nerves governed the dilation and constriction of blood vessels. He theorized that, by doing 

so, the body was better able to control its distribution of heat. While studying the vasomotor system, Bernard also discovered that 

the blood’s red corpuscles carry oxygen from the lungs to body tissues. He therefore concluded that the body must be under the 

control of one strong and central regulating force. Bernard’s theory, although widely accepted today, appeared quite radical in his 

own time, when most scientists believed that the body’s various organs acted quite independently of each other. 

In 1865, Bernard published the highly influential textbook, An Introduction to the Study of Experimental Medicine, which won him 

election to the prestigious French Academy in 1869. He even served in the French senate under Napoleon III (1808-1873) and, when 

he died in 1878, Bernard became the first scientist to be given a national funeral.

MARCEL MéRIEUx (1870-1937) 

BIOCHEMIST. BORN: 1870 TERRENOIRE NEAR LYON. DIED: 1937. 

In 1894 Marcel Mérieux became the personal assistant of Émile Roux at the Pasteur Institute of Paris. As a student of Louis Pasteur 

he worked on the bacillus Yersinia pestis and on asepsis. He founded a private laboratory in order to produce an anti-streptococcic 

serum used against puerperal fever in Lyon. This laboratory would become Institut Mérieux, today part of Sanofi Pasteur. He set up a 

private research lab. 

In 1937, his son, Dr. Charles Mérieux, took up the reins of his father’s laboratory. In the 1940’s, Charles Mérieux introduced a 

technique developed by the Dutch Professor Frenkel - in vitro culture – which revolutionized the manufacture of vaccines and led to 

the production of reagents for in vitro diagnostic testing. In 1963, his grandson Alain Mérieux, established the diagnostics company, 

bioMérieux. Today it is part of the Institut Mérieux, whose companies work in the area of diagnostics, immunotherapy, food safety 

and nutrition. 

MICHEL MACHEbOEUF (1900-1953) 

HEAD OF LABORATORY AT PASTEUR INSTITUTE, PARIS (1929). PROFESSOR OF BIOCHEMISTRY AT LILLE 

UNIVERSITY, THEN BORDEAUX UNIVERSITY (1936-1942). HEAD OF DEPARTMENT OF BIOCHEMISTRY AT 

PASTEUR INSTITUTE, PARIS (1942-1954). 

BORN: 1900, CHâTEL-GUYON (PUY-DE-DOME). DIED: 1953, PARIS. 

In 1929, Michel Macheboeuf, working at the Pasteur Institute in Paris, reported the isolation from horse serum of a stable, watersoluble 

lipoprotein that could be precipitated from a neutral 50% saturated ammonium sulfate extract of serum by lowering the pH 

to 3.8. This lipoprotein contained 59% protein and 41% lipid, which consisted of 18% cholesterol and 23% phospholipid and could 

be redissolved in water to form a clear solution. Later on it was shown that this lipoprotein was an α-globulin and had the same 

composition as the α-lipoprotein that we now recognize as HDL. 

Adapted from: Olsson R, J. Nutr. February 1, 1998 vol. 128 no. 2 439S-443S 

Macheboeuf M., Recherches sur les phosphoaminolipides et les steroids du serum et du plasma sanguins. II Etude physiochimique de 

la fraction proteidique la plus riche en phospholipids et in sterides. Bull. Soc. Chim. Biol.,1929; 11:485–503 

XXVII

XXVIII 

RENé LERICHE (1879-1955) 

SURGEON. BORN: 1879, ROANNE, LOIRE. DIED: 1955, CASSIS, NEAR MARSEILLE. 

Leriche began his career in Lyon. In 1924 he was appointed Professor of Surgery at the University of Strasbourg. In 1927 he was 

made an honorary Fellow of the Royal College of Surgeons of England. He was the first surgeon to be made Professeur au Collège de 

France. 

Leriche was a technically gifted surgeon and had flair for teaching. He emphasized the importance of regarding the patient as a whole 

- the holistic approach. He was a flamboyant character who enjoyed French cuisine and fine wine. He had a fine collection of art - one 

of his patients was Matisse. He was also an excellent public speaker who never needed notes. 

Leriche gave his name to two syndromes: 

Leriche’s syndrome - Impotence and buttock claudication and absent pulses in the groin and legs due to saddle embolus or 

atherosclerosis at the aortic bifurcation. 

Sudek-Leriche syndrome - Aseptic necrosis of bone following injury (also known as Sudek atrophy) 

He devised a surgical procedure, the sympathectomy, to increase blood flow within arteries. 

Leriche was awarded the Lister Medal in 1939 for his contributions to surgical science. 

Adapted from: Wikipedia

VENUE FLOOR PLANS 

XXIX

XXX 

ExHIbITION FLOOR PLAN 

01 

@ 

17 

11 

10 

12 

09 

13 

08 07 

02A 

16 

03 

ENTRANCE 

06 

14 05 

04 

ENTRANCE 

TO POSTER 

AREA 

ExHIbITION LIST 

Company booth # 

Aegerion 5 

Amgen 14 

B. Braun Avitum AG 2A 

Denka Seiken 8 

DIADEXUS Inc 12 

European Atherosclerosis Society 7 

Fresenius Medical Care 9 

Itamar Medical Ltd 17 

Merck 3 

Mercodia 16 

NSFA 11 

Randox Cardiology 1 

Sanofi/Regeneron/Genzyme 4 

Synageva Biopharma 10 

Wisepress Medical Bookshop 6

SPONSOR AND ExHIbITOR PROFILES 

Aegerion Pharmaceuticals, Inc. 

101 Main Street - Suite 1850 

Cambridge, MA 02142 

USA 

www.aegerion.com 

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of novel life-altering 

therapies for patients with debilitating, often fatal, rare diseases. Founded in 2005, our emerging global organization is based in 

Cambridge, Massachusetts with an established presence in Europe, and is growing internationally. In 2013, we successfully launched 

in the US our first product, Juxtapid (lomitapide) as an adjunct to a low fat diet and other lipid lowering treatments, including 

apheresis, for patients with homozygous familial hypercholesterolemia (HoFH). Lomitapide is currently in review by the European 

Medicines Agency (EMA). 

The company’s mission statement is: 

To develop therapeutic compounds on behalf of people with serious diseases using the highest ethical standards with demonstrated 

patient benefits. 

Aegerion is motivated by its commitment to patients first. We are also attentive to our core values of integrity, innovation, responsibility 

to healthcare providers, development of employees and always – scientific excellence. 

Amgen (Europe) GmbH 

Dammstrasse 23 

6301 Zug 

Switzerland 

www.amgen.com 

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen 

was one of the first companies to realise the new science’s promise by bringing safe, effective medicines from lab to manufacturing 

plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight 

against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of 

potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about 

our pioneering science and vital medicines, visit www.amgen.com. Follow us on twitter at www.twitter.com/amgen. 

AstraZeneca 

SE-431 83 Mölndal 

Sweden 

www.astrazeneca.com 

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation 

of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, 

oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by 

millions of patients worldwide. 

XXXI

XXXII 

BASF 

BASF’s Nutrition & Health division develops, produces and markets a comprehensive range of products and services for the human 

and animal nutrition, pharmaceutical as well as flavor and fragrance industries. The division strives to contribute to a better life 

through improving the nutrition, health and wellbeing of people across the world. Important human nutrition products are vitamins 

and carotenoids, plant sterols, emulsifiers and omega-3 fatty acids. Its feed additives such as vitamins, carotenoids, enzymes and 

organic acids make Nutrition & Health a worldwide leader for the animal nutrition market. The division provides the pharmaceutical 

industry with active ingredients such as caffeine and ibuprofen, as well as excipients and custom synthesis services. Furthermore, it 

produces aroma ingredients such as citral, geraniol and L-menthol for the flavor and fragrance industry. 

B. Braun Avitum AG 

Schwarzenberger Weg 73-79 

34212 Melsungen 

Germany 

www.bbraun.com 

B. Braun is one of the world´s leading healthcare suppliers. Our four divisions orient their products and services toward different 

medical fields: hospital, surgery, private practice (medical care and doctors´ offices) and extracorporeal blood treatment. The B. 

Braun Avitum Division concentrates on therapy systems for hemodialysis, acute dialysis and apheresis and is one of the largest 

systems providers in the field of extracorporeal blood treatment worldwide. The competency held herein extends from high-grade 

equipment and disposables to an international network of dialysis centers. As a full-range systems provider B. Braun Avitum works as 

an interface, linking theory to practice. 

DANONE 

17 Boulevard Haussmann 

75009 Paris cedex 

France 

www.danone.com 

DANONE is one of the largest healthy food companies worldwide with 4 expertise areas in dairy products, bottled waters, baby and 

medical nutrition. Its mission is to bring health through food to as many people as possible at all the ages of the life, in more than 

120 countries. 

DANONE and its 100,000 employees are entirely focused on this mission and R&D budget is dedicated to projects associated with 

nutrition and health. 

Its major research centres, Palaiseau (France) and Wageningen (Netherlands) have established more than 200 external scientific 

partnerships, to develop products with relevant, scientifically proven health benefits.

DENKA SEIKEN CO.,LTD. 

Nihonbashi Mitsui Tower 

2-1-1, Nihonbashi-Muromachi 

Chuo-ku, Tokyo 103-8338 

Japan 

www.denka-seiken.co.jp 

Denka Seiken manufactures clinical chemistry and latex-enhanced serum protein reagents for automated chemistry analyzers such as 

CRP, Lp(a), Myoglobin, HDL-C, LDL-C, etc. Denka Seiken currently features a reagent that can quantitatively determines small, dense 

low-density lipoproteins (small, dense LDL). The s LDL-EX “SEIKEN” is a homogeneous assay consisting of two ready-to-use liquid 

reagents to be used on automated chemistry analyzers. The test is fully automated and has within-run precisions of 1 – 2 %. Test 

result is available in 10 minutes. The assay methodology correlates well with the traditional ultracentrifugation method. 

diaDexus, Inc. 

349 Oyster Point Blvd 

South San Francisco, CA 94080 

USA 

www.diadexus.com 

diaDexus, Inc., is a biotechnology company focused on the development and commercialization of novel in vitro diagnostic tests 

for cardiovascular disease. The PLAC Test for Lp-PLA2 (lipoprotein-associated phospholipase A2) is a blood test that measures the 

enzyme activity of Lp-PLA2. Lp-PLA2 is a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. 

Plaque rupture and thrombosis cause the majority of cardiac events. The PLAC Test helps to identify the patients with hidden CVD 

risk independent from traditional risk factors. Visit www.plactest.com for more information. 

European Atherosclerosis Society 

Kronhusgatan 11 

Gothenburg 411 05 

Sweden 

www.eas-society.org 

The Society’s goal is to provide a framework for concerted scientific and clinical discussion of new developments in basic research, 

diagnosis and therapy of atherosclerosis. 

EAS is active in the publication of Guidelines and Consensus Position Papers, and its official Journal is Atherosclerosis. The Society 

organizes an annual Congress for approximately 2000 delegates, and runs a programme of Advanced Courses for both basic scientists 

and clinicians. 

Our website, www.eas-society.org, contains information on activities involving the Society and its members, and online educational 

material, including webcasts recorded both at Congress and Advanced Courses, Featured Commentaries, and a newsfeed direct from 

theheart.org. 

XXXIII

XXXIV 

Fresenius Medical Care Deutschland GmbH 

Else-Kröner-Str. 1 

Bad Homburg v.d.H., 61352 

Germany 

www.fmc-ag.com 

Fresenius Medical Care is the world’s largest integrated provider of products and services for individuals undergoing dialysis because 

of chronic kidney failure, a condition that affects more than 2 million individuals worldwide. 

In patients suffering from severe liver failure (like acute or “acute-on-chronic”), elimination of toxins by dialysis is not enough 

because here albumin-bound toxins have to be removed too. With Prometheus®, Fresenius Medical Care offers a therapy system 

that combines a procedure where a fraction of plasma is separated from blood to remove albumin bound toxins by adsorption with 

hemodialysis to clear the blood from water soluble substances. 

Itamar Medical Ltd 

9 Halamish St. 

PO Box 3579 

Caesarea 38900 

Israel 

www.itamar-medical.com 

Itamar Medical a publicly-traded medical technology company developing state-of-the-art biomedical products based on a proprietary 

signal for noninvasive, early detection of heart disease & obstructive sleep apnea. 

Technology & Product: 

The patented Peripheral Arterial Tone (PAT®) signal -- the noninvasive “window” to both the cardiovascular and autonomic nervous 

systems. 

EndoPAT: The only noninvasive, FDA-cleared device diagnosing endothelial dysfunction – the early indicator of arterial health. This 

15-minute, office-based diagnostic is used by Mayo Clinic, Framingham Heart Study & others. 

WatchPAT: Convenient, portable sleep apnea testing device installed by the patient in their own home. 

Genzyme, a Sanofi Company 

Genzyme Corporate Offices 

500 Kendall Street 

Cambridge, MA 02142 

USA 

www.genzyme.com 

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating 

diseases for over 30 years. 

With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and 

families we serve. 

Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represent groundbreaking and 

life-saving advances in medicine. 

In partnership with Isis Pharmaceuticals, we are committed to the development of potential innovative treatments for severe Familial 

Hypercholesterolemia (severe FH).

Kowa 

105 Wharfedale Road 

Winnersh Triangle 

Wokingham, RG41 5RB 

UK 

www.kowa.co.jp/eng 

Kowa Company, Ltd. (KCL) is a privately held multinational company headquartered in Nagoya, Japan. Established in 1894, KCL is 

actively engaged in manufacturing activities in the fields of pharmaceutical, life science, information technology, textiles, machinery 

and various consumer products. KCL’s pharmaceutical division is focused on cardiovascular therapeutics, with sales of the company’s 

flagship product, LIVALO (pitavastatin) making sales of 51 billion JPY during 2012 in Japan. 

KCL has research and commercial affiliates in the US (Kowa Research Institute and Kowa Pharmaceuticals America) and Europe 

(Kowa Research Europe and Kowa Pharmaceutical Europe). 

Mercodia AB 

Street: Sylveniusgatan 8A 

Uppsala 754 50 

Sweden 

www.mercodia.com 

Mercodia AB is a Swedish biotech company focusing on the development of immunoassays for research within the field of metabolic 

disorders. Our assays are applicable to both animal and human models and are used for research ranging from basic scientific studies 

to large pre-clinical and clinical phase trials. 

The company was founded in 1991 and is today a world-leading supplier of products to all major international markets. More than 

ninety percent of our production is exported from our facilities in Uppsala to approximately 100 different countries around the world. 

MSD 

One Merck Drive 

Whitehouse Station, NJ 08889 

USA 

www.merck.com 

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States 

and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we 

work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our 

commitment to increasing access to healthcare through far-reaching policies, programs and partnerships that donate and deliver our 

products to the people who need them. For more information, visit www.merck.com 

Raisio Group 

Raisio Group is an international expert in plant-based nutrition with strong international and local food brands. Benecol® is the expert 

brand in cholesterol reduction and a pioneer in the cholesterol lowering functional food category. 

Raisio Group produces the unique cholesterol-lowering ingredient, Plant stanol ester, and licenses the Benecol brand worldwide. 

Benecol products are manufactured and sold by local food companies in 30 countries on five continents. 

Over 70 clinical studies support the use of Benecol as an effective, easy and safe dietary tool to lower LDL-cholesterol. The 

cholesterol-lowering effect of Benecol is additive to those of a healthy diet and statin medication. 

XXXV

XXXVI 

NSFA 

13 Avenue des Arts 

94100 Saint maur 

France 

http://www.nsfa.asso.fr 

French Atherosclerosis Society (NSFA) is composed of more than 200 members and is involved in the promotion of fundamental 

and clinical researches in the domain of atherosclerosis and thromboembolic complications. NSFA supports institutional research 

laboratories by allocating PHD grants. 

NSFA supports different national and international actions or educational programs for prevention of atherosclerosis. The society 

is also involved in the diffusion of information, research programs and clinician education by organizing seminars, conferences and 

workshops. The next annual meeting of the society will be held in Biarritz, June 19-21, 2014 

Randox Cardiology 

55 Diamond Road, Crumlin, Co. Antrim 

BT29 4QY 

Northern Ireland, UK 

www.randox.com 

Randox are an international clinical diagnostics company based in Northern Ireland, with a presence in over 150 countries worldwide. 

Cardiovascular disease is a key area of focus for Randox and we offer a huge range of relevant products, both for clinical research 

and clinical practice. Such products include automated clinical chemistry assays for Lp(a), sdLDL, Heart-type Fatty Acid Binding 

Protein (H-FABP), aspirin resistance, lipids and anti-oxidants. In addition to these is Randox’s pioneering multiplexing platforms, utilising 

the revolutionary Biochip Array Technology. Arrays available include cytokines, adhesion molecules, cardiac, cerebral & metabolic 

biomarkers. 

Regeneron 

777 Old Saw Mill River Road Tarrytown 

NY 10591 

USA 

www.regeneron.com 

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes 

medicines for the treatment of serious medical conditions. Regeneron markets two products, ARCALYST® (rilonacept) Injection For 

Subcutaneous Use and EYLEA (aflibercept) Injection. Regeneron also has completed several Phase 3 studies and is conducting an 

additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion. Additional 

therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in 

development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune 

conditions, and cancer

Roche 

Grenzacherstrasse 124 

4070 

Switzerland 

www.roche.com 

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals 

and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, 

metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in 

diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible 

improvements in the health, quality of life and survival of patients. For more information: www.roche.com 

Sanofi 

174 avenue de France 75635 

Paris Cedex 13 

France 

www.sanofi.com 

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. 

Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative 

drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in 

New York (NYSE: SNY). 

Unilever 

www.unilever.com 

Make sustainable living commonplace 

Unilever’s purpose is to make sustainable living commonplace. We help people feel good, look good 

and get more out of life with brands and services that are good for them and good for others. 160 

million times a day, in 190 countries, people use our home, personal care and foods products at key 

moments of their day. We produce world-leading brands including Lipton, Knorr, Hellmann’s, 

Becel/Flora, Ben & Jerry’s, Dove, Axe, and Omo. 

Wisepress Medical Bookshop 

25 High Path, Merton Abbey 

London, SW19 2JL 

UK 

www.wisepress.com 

Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of 

the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver 

worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online 

with great offers. 

XXXVII

81 st Congress of the European Atherosclerosis Society • 2 – 5 June 2013 • Lyon, France 

Satellite Symposium Sponsored by MSD 

CETP Inhibition: What’s New? 

MODERATOR: 

M. John Chapman 

Director Emeritus , INSERM 

Past- President, EAS 

Research Professor 

Pitie-Salpetriere University Hospital 

Paris, France 

FACULTY: 

Henry Ginsberg 

Irving Professor of Medicine 

Columbia University College of 

Physicians and Surgeons 

Director, Irving Institute for Clinical 

and Translational Research 

Columbia University Medical Center 

New York, New York, USA 

John Millar 

Director 

Metabolic Tracer Resource 

Institute for Diabetes, 

Obesity and Metabolism 

University of Pennsylvania 

Philadelphia, Pennsylvania, USA 

Sunday, 2 June 2013 

15:15 – 16:00 

Lyon Convention Center 

Hall D 

Lyon, France 

Moderator: John Chapman (France) 

AGENDA Sunday, 2 June 2013 

15:15 – 15:20 Introduction John Chapman 

15:20 – 15:35 HDL and CETP Metabolism Henry Ginsberg 

15:35 – 15:50 Apo B and PCSK9 Kinetics John Millar 

15:50 – 16:00 Q&A/Conclusion John Chapman 

Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. All rights reserved. 

CVT-177134-AB

SCIENTIFIC PROGRAMME 

SUNDAY, JUNE 2, 2013

Clinical advances 

in difficult-to-treat patients 

with hypercholesterolemia 

© 2013, Sanofi and Regeneron Pharmaceuticals, Inc. 

5/2013 PCS-0184 

GLB.ALI.13.05.01 

Agenda 

13:00 

13:05 

13:30 

13:55 

14:20 

14:30 

13:00–14:30, Monday, 3 June 2013 

81st European Atherosclerosis Society Congress 

Claude Bernard Hall 

Lyon Congress Centre, Lyon, France 

Introduction and welcome 

Michel Farnier and Christie M. Ballantyne (Co-Chairs) 

The spectrum of difficult-to-treat 

hypercholesterolemic patients 

Christie M. Ballantyne 

New and emerging LDL-C lowering therapies – 

Targeting production 

Erik S. G. Stroes 

Emerging LDL-C lowering therapies – 

Targeting clearance 

Michel Farnier 

Panel discussion 

M. John Chapman (Moderator) and all faculty 

Close of symposium

Sunday, June 2, 2013 

11:00-20:30 Registration Area 

REGISTRATION DESK OPEN 

13:30-15:00 Forum 1: Claude Bernard 

EBAC ACCREDITED EDUCATIONAL PROGRAMME 

ADVANCES IN THE UNDERSTANDING OF CARDIOVASCULAR DISEASE AND 

DYSLIPIDAEMIA IN DIABETES 

Supported by an Unrestricted Educational Grant from AstraZeneca 

Programme created in collaboration with Sahlgrenska Academy, University of Gothenburg 

Chairperson: Olov Wiklund 

Time 

13:30 INTRODUCTION 


13:35 CHARACTERISTICS OF THE VASCULAR LESION IN DIABETES 


14:00 LIPID METABOLISM AND CARDIOVASCULAR DISEASE IN DIABETES 


14:20 RISK OF DIABETES DEVELOPMENT DURING STATIN TREATMENT 


14:40 CURRENT TREATMENT OF DYSLIPIDAEMIA IN PATIENTS WITH THE 

METABOLIC SYNDROME AND DIABETES 


14:55 DISCUSSION 


1


14:15-15:00 Forum 2: Marcel Mérieux 

HYPERCHOLESTEROLEMIA – WHAT CAN WE DO FOR HIGH-RISK PATIENTS? 

SPONSORED BY AMGEN 

Chairperson: Alberico L. Catapano 

Time 



14:20 HYPERCHOLESTEROLEMIA - WHAT CAN WE DO FOR HIGH-RISK 

PATIENTS? 

G. Kees Hovingh, The Netherlands 

14:50 Q&A AND CLOSE 


15:15-16:00 Forum 3: Michel Macheboeuf 

CETP INHIBITION: WHAT'S NEW? 

SPONSORED BY MSD 

Chairperson: M. John Chapman 

Time 



15:20 HDL AND CETP METABOLISM 


15:35 APO B AND PCSK9 KINETICS 

John Millar, USA 

15:50 Q&A/CONCLUSION 


2



NEW STRATEGIES FOR THE MANAGEMENT OF PATIENTS WITH HoFH 

SPONSORED BY AEGERION 

Chairpersons: Alberico L. Catapano 


Time 

16:20 WELCOME 

Børge Nordestgaard; A.L. Catapano, Denmark, Italy 

16:25 WHAT ARE WE ABLE TO ACHIEVE FOR OUR PATIENTS TODAY? 

Raul D. Santos, Brazil 

16:50 EAS/ESC RECOMMENDATIONS FOR THE MANAGEMENT OF 

PATIENTS WITH HoFH 


17:15 LOMITAPIDE IN THE MANAGEMENT OF HoFH - CLINICAL EXPERIENCE 

Marina Cuchel, USA 

3


18:00-19:30 Auditorium Anitschkow 

OPENING CEREMONY, INCLUDING THE ANITSCHKOW LECTURE 


Philippe Moulin 

Time 

18:00 WELCOME FROM THE EAS PRESIDENT 


18:10 WELCOME FROM THE PRESIDENT OF THE CLAUDE BERNARD 

LYON1 UNIVERSITY 

François N. Gilly, France 

18:13 WELCOME FROM THE NFSA PRESIDENT 


18:16 IAS AND EAS WORKING TOGETHER 


18:19 WELCOME FROM THE CONGRESS CHAIRPERSON 


18:22 Choir 

18:30 INTRODUCTION OF THE ANITSCHKOW PRIZE WINNER 


18:35 THE ANITSCHKOW LECTURE 


19:25 Choir 

19:30-20:30 Exhibition Area 

WINE AND CHEESE WELCOME RECEPTION 

4


MONDAY, JUNE 3, 2013

81 st Congress of the European Atherosclerosis Society 

2 – 5 June 2013 • Lyon, France 

Satellite Symposium Sponsored by MSD 

On The Forefront of CHOLESTEROL MANAGEMENT: 

Clinical Considerations and Practical Approaches Beyond Statins 

CHAIRMAN: 


President EAS 

Professor of Pharmacology 

Director, SISA Center for the Study 

of Atherosclerosis 

Director, Center of Epidemiology and 

Preventive Pharmacology 

Director, Laboratory of Lipoproteins 

and Atherosclerosis 

Department of Pharmacological and 

Biomolecular Sciences 

University of Milan 

Milan, Italy 

FACULTY: 

Philip Barter 

President, International 

Atherosclerosis Society 

Conjoint Professor 

The University of New South Wales 

Sydney, Australia 

John E. Deanfield 

BHF Vandervell Chair of Congenital 

Heart Disease 

Director, Centre for Cardiovascular 

Prevention & Outcomes 

Deputy Cardiovascular Program 

Director, UCL Partners 

London, United Kingdom 


Department of Endocrinology and 

Lipidology 

Point Medical Clinic 

Dijon, France 

17:00 – 18:30 

Lyon Convention Center 

Hall A 

Lyon, France 

Chairman: Alberico Catapano (Italy) 

AGENDA Monday, 3 June 2013 

Monday, 3 June 2013 

17:00 – 17:05 Chair Welcome and Opening Remarks Alberico Catapano 

17:05 – 17:25 Unmet Medical Needs in Dyslipidemia Philip Barter 

17:25 – 17:45 Achieving Superior Efficacy by intensive LDL-C lowering; Michel Farnier 

Arguments for the use of a cholesterol absorption inhibitor 

17:45 – 18:05 Improving Clinical Outcomes in Statin Treated Patients John Deanfield 

18:05 – 18:25 Panel Discussion Alberico Catapano 

Philip Barter 


18:25 – 18:30 Closing Remarks Alberico Catapano 

Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., 

Whitehouse Station, NJ, USA. All rights reserved. 

CVT-176000-AB

Monday, June 3, 2013 


PLENARY SESSION: PLAQUE INSTABILITY AND ATHEROTHROMBOSIS 


Lale Tokgozoglu 

Time 

08:30 BIOMARKERS OF PLAQUE OF INSTABILITY 

Jean-Baptiste Michel, France 

09:00 NEW INSIGHTS INTO THE ROLE OF HEMODYNAMICS IN PLAQUE 

INSTABILITY 

Yiannis Chatzizisis, Greece 

09:30 ADVANCES IN VISUALIZING THE UNSTABLE PLAQUE 

Filippo Crea, Italy 

10:00 PREVENTION AND TREATMENT OF PLAQUE THROMBOGENICITY 

Gilles Montalescot, France 


COFFEE BREAK, POSTER VIEWING AND EXHIBITION 


ADVANCED CLINICAL SEMINAR EVALUATION AND MANAGEMENT OF LOW HDL: WHY 

AND HOW? 

Chairpersons: Anne Tybjaerg-Hansen 

Sebastiano Calandra 

Time 

10:50 GENETIC AND NON-GENETIC FACTORS AFFECTING HDL LEVELS 

AND FUNCTIONS 

Dimitris Kardassis, Greece 

11:20 WHAT IS THE MESSAGE FROM INTERVENTION STUDIES? 

Klaus Parhofer, Germany 

11:50 HDL AND REVERSE CHOLESTEROL TRANSPORT: HOW TO 

PROCEED? 


5



REGULATION OF CELLULAR LIPID METABOLISM IN ATHEROGENESIS 

Chairpersons: Vesa M Olkkonen 

Marcello Arca 

Time 

10:50 OXYSTEROL-BINDING PROTEINS: EMERGING FUNCTIONS IN CELL 

REGULATION AND ATHEROGENESIS 

Vesa M. Olkkonen, Finland 

11:15 PPARS, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND 



Abstract No 

11:40 TRANS INTESTINAL CHOLESTEROL EXCRETION IS AN ACTIVE 

METABOLIC PROCESS MODULATED BY PCSK9 AND STATIN, 

INVOLVING ABCB1 

Jean Mathieu Berger, C. Le May, B. Pillot, J. Magré, X. Prieur, E. 

Letessier, B. Cariou 1,2 , P. Costet 1,2 , France 1037 

11:55 IDENTIFICATION OF AN ENDOGENOUS PROTEIN WHICH BLOCKS 

THE INTERACTION BETWEEN OXLDL AND ITS RECEPTORS 

Akemi Kakino, Y. Fujita, T. Sawamura, Japan 1471 

12:10 MYELOID CELL-SPECIFIC SERINE PALMITOYLTRANSFERASE 

SUBUNIT 2 HAPLOINSUFFICIENCY REDUCES ATHEROSCLEROSIS IN 

MICE 

M. Chakraborty, C. Lou, M.-S. Kuo, G. Cao, Xian-Cheng Jiang, USA 185 

12:25 AGGREGATED LDL INDUCES LRP1 PROTEIN STABILIZATION 

THROUGH E3 UBIQUITIN-LIGASE CHFR DOWNREGULATION IN 

HUMAN VSMC 

R. Cal, M. Garcia-Arguinzonis, E. Revuelta-Lopez, J. Castellano, T. 

Padro, L. Badimon, Vicenta Llorente-Cortes, Spain 473 

6



EVALUATION AND TREATMENT OF CARDIOVASCULAR RISK FACTORS IN THE YOUNG 

AND THE ELDERLY 

Chairpersons: George Davey-Smith 

Michel Krempf 

Time 

10:50 IS THERE AN UPPER AGE LIMIT FOR LIPID LOWERING IN 

CARDIOVASCULAR PREVENTION? 


11:15 EPIDEMIOLOGICAL METHODS TO IDENTIFY STRENGTH OF CAUSAL 

ASSOCIATIONS BETWEEN RISK FACTORS AND CARDIOVASCULAR 

OUTCOMES 

George Davey-Smith, UK Abstract No. 

11:40 ELEVATED REMNANT CHOLESTEROL CAUSES LOW-GRADE 

INFLAMMATION AND ISCHEMIC HEART DISEASE 

Anette Varbo, M. Benn, A. Tybjærg-Hansen, B.G. Nordestgaard, Denmark 985 

11:55 COMBINED EFFECTS OF CHILD AND ADULT ELEVATED BLOOD 

PRESSURE ON SUBCLINICAL ATHEROSCLEROSIS. THE 

INTERNATIONAL CHILDHOOD CARDIOVASCULAR COHORT 

CONSORTIUM 

Markus Juonala, J. Juhola, C.G. Magnussen, M.A. Sabin, T. Dwyer, A. 

Venn, T.L. Burns, G.S. Berenson, M. Kähönen, J.S. Viikari, S.R. Daniels, 

O.T. Raitakari, Finland, Australia, USA 336 

12:10 SOCIOECONOMIC POSITION AND TRUNCAL FAT INFLUENCE 

CAROTID INTIMA-MEDIA THICKNESS IN ADOLESCENTS: THE 

HELENA STUDY 

Christophe Lamotte, C. Iliescu, L. Beghin, J. Salleron, S. De Henauw, 

L.A. Moreno, C. Libersa, F. Gottrand, France, Belgium, Spain 1480 

12:25 SERUM LEVELS OF DEHYDROEPIANDROSTERONE (DHEA) AND ITS 

SULFATE (DHEA-S) PREDICT THE FIVE YEAR RISK OF 

CARDIOVASCULAR EVENTS IN ELDERLY MEN 

Åsa Tivesten, M. Nilsson, D. Carlzon, L. Vandenput, M.K. Karlsson, Ö. 

Ljunggren, E. Barrett-Connor, D. Mellström, C. Ohlsson, Sweden, USA 875 

7



ENDOTHELIAL DYSFUNCTION IN ATHEROTHROMBOSIS 

Chairpersons: Qingbo Xu 

Erik Stroes 

Time 

10:50 ENDOTHELIAL REPAIR BY STEM CELLS 

Qingbo Xu, UK 

11:15 ROLE OF ENDOTHELIAL MICRORNAS IN VASCULAR DISEASE 

Andreas M. Zeiher, Germany 

Abstract No. 

11:40 ADRENOMEDULLIN IS ASSOCIATED TO ARTERIAL STIFFNESS: AN 

INTEGRATIVE APPROACH COMBINING MONOCYTE ADM 

EXPRESSION, PLASMA MR-PROADM AND GENOME-WIDE 

ASSOCIATION STUDY 

Farzin Beygui 1,2 , P.S. Wild, T. Zeller, M. Germain, R. Castagné, T. Münzel, 

G. Montalescot 2,5 , D.-A. Trégouët, F. Cambien, S. Blankenberg, L. Tiret, 

France, Germany 553 

11:55 HEDGEHOG PATHWAY AGONISM AMELIORATES DYSFUNCTION OF 

VASCULAR ENDOTHELIUM IN OBESITY: ROLE OF 

PHOSPHATIDYLINOSITOL-3-KINASE AND ENDOTHELIUM NITRIC 

OXIDE SYNTHATASE 

Saurabh Sharma, P.L. Sharma, India 365 

12:10 THE RNA-BINDING PROTEIN QUAKING MAINTAINS ENDOTHELIAL 

BARRIER FUNCTION THROUGH TARGETING VE-CADHERIN MRNA 

Janine M. van Gils, R.G. de Bruin, I. Schmidt, E.P. van der Veer, M.K. 

Roeten, T.J. Rabelink, A.J. van Zonneveld, The Netherlands 1035 

12:25 PLASMA ASYMMETRIC DIMETHYLARGININE, ENDOTHELIUM- 

DEPENDENT NITRIC OXIDE-MEDIATED RELAXATION AND VASCULAR 

REMODELING OF UTERINE SMALL ARTERIES IN PREGNANT WOMEN 

Malene Rohr Andersen, U. Simonsen, S. Stender, M. Hedegaard, C. 

Aalkjær, Denmark 1518 


LUNCH BREAK, EXHIBITION AND POSTER PRESENTATIONS 

13:40 – 14:40 MODERATED POSTER SESSION A (See page 29) 

8



EAS GENERAL ASSEMBLY 


CLINICAL ADVANCES IN DIFFICULT-TO-TREAT PATIENTS WITH 

HYPERCHOLESTEROLEMIA 

SPONSORED BY SANOFI / REGENERON / GENZYME 

Chairpersons: Michel Farnier 

Christie Ballantyne 

Time 

13:00 INTRODUCTION AND WELCOME 

C. Ballantyne; M. Farnier, USA, France 

13:05 THE SPECTRUM OF DIFFICULT-TO-TREAT HYPERCHOLESTEROLEMIC 

PATIENTS 

C. Ballantyne, USA 

13:30 NEW AND EMERGING LDL-C-LOWERING THERAPIES - TARGETING 

PRODUCTION 


13:55 EMERGING LDL-C-LOWERING THERAPIES - TARGETING CLEARANCE 



JOINT ICCR/EAS SYMPOSIUM: LIFESTYLE FACTORS AND CARDIOVASCULAR 

DISEASES 

Chairpersons: Marja-Riitta Taskinen 

Frank Hu 

Time 

14:50 OPENING REMARKS 

15:00 TARGETING HEALTHY DRINKING FOR CVD RISK REDUCTION 

Frank Hu, USA 

15:25 PHYSICAL ACTIVITY AND CVD RISK MANAGEMENT 

Robert Ross, Canada 

15:50 ECTOPIC FAT AS A NEW TARGET FOR CVD RISK MANAGEMENT 


16:15 EVOLVING MOSAIC OF MODIFIABLE CVD RISK FACTORS 

Luc Van Gaal, Belgium 

9



ROLE OF LIPASES IN LIPID AND LIPOPROTEIN METABOLISM 

Chairpersons: Sander Kersten 

Matti Jauhiainen 

Time 

14:50 REGULATION OF PLASMA TRIGLYCERIDE CLEARANCE BY 

ANGIOPOIETIN-LIKE PROTEINS 

Sander Kersten, The Netherlands 

15:15 THE COMPLEXITY OF LPL ACTION IN TG METABOLISM 

Geesje Dallinga-Thie, The Netherlands 

Abstract No 

15:40 LOSS-OF-FUNCTION MUTATION IN THE ANGPTL3 GENE IS 

ASSOCIATED WITH INCREASED LPL ACTIVITY AND DECREASED 

SERUM FREE FATTY ACIDS 

Matti Jauhiainen, M. Robciuc, A. Lahikainen, A. Bensadoun, D. Rader, M. 

Maranghi, K. Öörni, I. Minicocci, M. Arca, C. Ehnholm, Finland, USA, Italy 56 

15:55 NOVEL SMALL MOLECULE LIPOPROTEIN LIPASE ACTIVATOR LP071 

IMPROVES PLASMA LIPID PARAMETERS IN VIVO 

M. Eriksson, M. Larsson, R. Caraballo, P.-A. Enquist, M. Elofsson, G. 

Olivecrona, Stefan K Nilsson, Sweden 304 

16:10 EXPRESSION OF GROUP IIA SECRETORY PHOSPHOLIPASE A2 

(SPLA2) INHIBITS CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) 

ACTIVITY IN TRANSGENIC MICE 

E. Hurt-Camejo, T. Gautier, B. Rosengren, M. Behrendt, D.S. Grass, D.J. 

Rader, Uwe J.F. Tietge, Sweden, France, USA, The Netherlands 235 

16:25 MULTIPLE MOLECULAR DEFECTS ASSOCIATED TO NOVEL APOA5 

MUTATIONS FOUND IN PATIENTS WITH SEVERE 

HYPERCHYLOMICRONEMIA 

Josep Julve 1,2 , E. Mendoza-Barberà, S.K. Nilsson, A. Lookene, J.M. Martín- 

Campos, R. Roig 2,5 , A.M. Lechuga-Sancho, J.J. Sloan, P. Fuentes-Prior, F. 

Blanco-Vaca 2,5,8 , Spain, Sweden, Estonia, USA 594 

10



CELLULAR GROWTH, DEATH, TRAFFICKING, AND MICROVESICULATION IN 

ATHEROGENESIS 

Chairperson: Wolfgang Schneider 

Edward Fisher 

Time 

14:50 MACROPHAGE PHENOTYPIC DIVERSITY DURING ATHEROSCLEROSIS 

REGRESSION 

Edward Fisher, USA 

15:15 MATRIX VESICLES RELEASED BY SMOOTH MUSCLE CELLS: KEY 

INITIATORS OF VASCULAR CALCIFICATION 

Catherine. M. Shanahan, UK 

Abstract No 

15:40 CARTILAGENOUS METAPLASIA IN ATHEROSCLEROSIS IS 

ASSOCIATED WITH TRAIL-DEFICIENCY AND ALTERED EXPRESSION 

OF GENES INVOLVED IN CALCIFICATION 

B. Di Bartolo, S. Cartland, H. Harith 1,2 , M. Schoppet, Mary Kavurma 1,2 , 

Australia, Germany 938 

15:55 TARGETING CHONDROITIN SULFATE N- 

ACETYLGALACTOSAMINYLTRANSFERASE 2 IN THE 

MODIFICATION OF SUBENDOTHELIAL LIPOPROTEIN RETENTION 

AND FOAM CELL FORMATION 

Dyah Samti Mayasari, N. Emoto 1,2 , K. Yagi, K. Nakayama, N. Arfian, H. 

Ali, K.-I. Hirata, Japan 904 

16:10 NOTCH PATHWAY POLARIZES MONOCYTES INTO M2 

MACROPHAGES AND INHIBITS ATHEROSCLEROSIS IN APOE 

KNOCKOUT MICE 

Dinender Singla, B. Yan, L. Abdeli, S. Parthasarathy, USA 1091 

16:25 CD4 + CD28 NULL T CELLS FROM PATIENTS WITH MYOCARDIAL 

INFARCTION HAVE DEREGULATED APOPTOSIS PATHWAYS AND 

ARE RESISTANT TO APOPTOTIC CELL DEATH 

Ingrid Elena Dumitriu, E. Kovalcsik, R. Antunes, J.C. Kaski, UK 1464 

11



EAS INITIATIVES UPDATE 

OVERVIEW OF CURRENT STATUS AND FORTHCOMING DEVELOPMENTS IN THE 

SOCIETY’S KEY INITIATIVES 


Lale Tokgozoglu 

Time 

15.45 

INTRODUCTION BY SESSION CHAIRS 

Alberico L. Catapano, Lale Tokgozoglu 

15.50 EAS GUIDELINES AND CONSENSUS PAPERS INITIATIVE 


15.55 EAS CONSENSUS POSITION PAPER INITIATIVE – FOCUS ON FH 


16.15 GLOBAL GUIDELINES 

Olov Wiklund 

12



ON THE FOREFRONT OF CHOLESTEROL MANAGEMENT: CLINICAL CONSIDERATIONS 

AND PRACTICAL APPROACHES BEYOND STATINS 

SPONSORED BY MSD 

Chairperson: Alberico L. Catapano 

Time 

17:00 WELCOME AND OPENING REMARKS 


17:05 UNMET MEDICAL NEEDS IN DYSLIPIDEMIA 


17:25 ACHIEVING SUPERIOR EFFICACY BY INTENSIVE LDL-C LOWERING; 

ARGUMENTS FOR THE USE OF A CHOLESTEROL ABSORPTION 

INHIBITOR 


17:45 IMPROVING CLINICAL OUTCOMES IN STATIN TREATED PATIENTS 

John E. Deanfield, UK 

18:05 PANEL DISCUSSION 

A.L. Catapano; P. Barter; M. Farnier; J.E. Deanfield, Italy, Australia, 

France, UK 

18:25 CLOSING REMARKS 



SPECIAL LECTURE SPONSORED BY KOWA 

Chairperson: Yasushi Saito 

Time 

17:00 INTRODUCTION TO KOWA SPECIAL LECTURE 

Yasushi Saito, Japan 

17:05 NORMALISING DYSLIPIDEMIA AND REVERSING ATHEROSCLEROSIS 

IN CARDIO-METABOLIC DISEASE: INSIGHTS FROM STATIN 

PHARMACOTHERAPY 


13



THE ROLE OF PLANT STANOLS/STEROLS IN THE MANAGEMENT OF DYSLIPIDAEMIAS 

JOINTLY SPONSORED BY BASF, DANONE, RAISIO, UNILEVER 

Chairpersons: Henry Ginsberg 

Petri Kovanen 

Time 

17:00 INTRODUCTION AND OPENING REMARKS 


17:05 BASIC SCIENCE OF PLANT STEROLS/STANOLS 

Jogchum Plat, The Netherlands 

17:25 CLINICAL APPLICATION & SAFETY OF PLANT STEROLS/STANOLS 


17:45 SUMMARY AND CLOSING REMARKS 

Petri Kovanen, Finland 

14


TUESDAY, JUNE 4, 2013

Tuesday, June 4, 2013 


PUSHING THE FRONTIERS IN CARDIOVASCULAR BIOLOGY 

Chairpersons: Philippe Moulin 

Olov Wiklund 

Time 

08:30 GUT-LIVER INTERACTION IN TRIGLYCERIDE RICH LIPOPROTEIN 

METABOLISM 

Gary Lewis, Canada 

09:00 MICRO-RNA AND EPIGENETIC CONTROL OF ATHEROGENESIS 

Kathryn Moore, USA 

09:30 THERAPEUTIC OPTIONS TO INDUCE REGRESSION OF CORONARY 


Steven Nissen, USA 

10:00 PHARMACOLOGICAL TARGETS IDENTIFIED BY GENETIC 

APPROACHES 

François Cambien, France 




ADVANCED CLINICAL SEMINAR: WHEN STATINS ARE NOT TOLERATED OR ARE NOT 

SUFFICIENT ALONE: HOW TO HANDLE THE PROBLEM? 

Time 

10:50 PATIENTS NOT AT GOAL: WHAT ARE THE CAUSES? 


11:15 WHAT IS THE ROOM FOR THE ASSOCIATION THERAPY 

Marcello Arca, Italy 

11:40 LOWERING LDL-CHOLESTEROL -BEYOND STATIN THERAPY 

Frederick Raal, South Africa 

15



HEPATIC REGULATION OF LIPID AND LIPOPROTEIN METABOLISM IN 

CARDIOMETABOLIC DISORDERS 

Chairpersons: Marten Hofker 

Maurizio Averna 

Time 

10:50 DERANGEMENT OF HEPATIC LIPID METABOLISM 

Jan Boren, Sweden 

11:15 MACROPHAGES LINK FATTY LIVER DISEASE AND 


Marten Hofker, The Netherlands 

Abstract No 

11:40 P2Y13 RECEPTOR DEFICIENCY DECREASES HEPATOBILIARY AND 

FAECAL LIPID EXCRETIONS AND PROMOTES ATHEROSCLEROSIS IN 

APOE KNOCKOUT MICE 

Laeticia Lichtenstein, N. Serhan, B. Perret, M. Laffargue, L.O. Martinez, 

France 1486 

11:55 NAFLD AND CARDIOVASCULAR DISEASE: MAY A SUFFERING LIVER 

BE A PREDICTOR MARKER OF CARDIOVASCULAR RISK? 

Carmela Viscomi 1,2 , A. Minutolo, M. Arciello, B. Conti, R. Maggio, A. Longo, 

E. Scarpellini, C. Balsano 2,4 , Italy 609 

12:10 EXENDIN-4 REDUCES THE DEVELOPMENT OF NON-ALCOHOLIC 

STEATOHEPATITIS IN ADDITION TO ATHEROSCLEROSIS IN APOE*3- 

LEIDEN.CETP MICE 

Yanan Wang, E.T. Parlevliet 1,2 , J.J. Geerling, S.J.L. van der Tuin, V. Bieghs, 

A.H.M. Jawad, H. Zhang, R. Shiri-Sverdlov, L.M. Havekes 1,4,5 , J.A. Romijn 1,2 , 

K. Willems van Dijk 1,6 , P.C.N. Rensen, The Netherlands 524 

16



LIFESTYLE FACTORS AND CARDIOVASCULAR DISEASES 

Chairpersons: Adrian JB Brady 

Zeljko Reiner 

Time 

10:50 DIET AND CARDIOVASCULAR RISK: EVIDENCE AND POSSIBLE 

MECHANISMS 

Angela Rivellese, Italy 

11:15 DIET AND EXERCISE - JUST A BIG WASTE OF TIME? 

Adrian J. Brady, UK 

Abstract No. 

11:40 CHROMOSOME 9P21 VARIANT INTERACTS WITH DIETARY 

VEGETABLE AND WINE INTAKE ON THE RISK OF CARDIOVASCULAR 

DISEASE 

George Hindy, V. Hamrefors, U. Ericson, I. Drake, E. Wirfält, O. Melander, 

M. Orho-Melander, Sweden 1361 

11:55 EFFECT OF DIFFERENT EXERCISE MODALITIES IN EXPERIMENTAL 

PERIPHERAL ARTERY DISEASE AND ASSESSMENT OF POTENTIAL 

UNDERLYING MECHANISMS 

Maxime Pellegrin, K. Bouzourene, C. Poitry-Yamate, V. Mlynarik, J.-F. 

Aubert, C. Amstutz, R. Gruetter, L. Mazzolai, Switzerland 617 

12:10 INCREASING LONG-CHAIN N-3PUFA CONSUMPTION IMPROVES 

SMALL PERIPHERAL ARTERY FUNCTION IN PATIENTS AT 

INTERMEDIATE-HIGH CARDIOVASCULAR RISK 

Jordi Merino, A. Sala-Vila, R. Kones, R. Ferré, N. Plana, J. Girona, D. 

Ibarretxe, M. Heras, E. Ros, L. Masana, Spain, USA 1318 

17



INFECTION, INFLAMMATION AND IMMUNITY IN ATHEROGENESIS 

Chairpersons: Eicke Latz 

Michal Vrablík 

Time 

10:50 MOLECULAR REGULATION OF MACROPHAGES: IMPLICATIONS FOR 


Menno P.J. De Winther, The Netherlands 

11:15 CHOLESTEROL CRYSTALS AS A DANGER SIGNAL IN 


Eicke Latz, Germany 

Abstract No. 

11:40 CYTOTOXIC CD8 + T CELLS PROMOTE VULNERABLE 

ATHEROSCLEROTIC PLAQUE DEVELOPMENT IN APOE -/- MICE 

T. Kyaw, C. Tay, A. Winslop, P. Kanellakis, H. Hosseini, A. Cao, A. Bobik, P. 

Tipping, Ban-Hock Toh, Australia 175 

11:55 METAGENOMICS REVEALS GUT SIGNATURES IN ATHEROSCLEROSIS 

MICROBIOME 

Emi Kozarov 1,2 , S. Kalachikov, A. Morozov, N. Chalmers 4,5 , M. Chien, Spain, 

USA 758 

12:10 THE NEUTROPHIL ACTIVATION MARKER MRP8/14 CORRELATES 

WITH CAROTID PLAQUE AREA AND PREDICTS CARDIOVASCULAR 

EVENTS IN HEALTHY INDIVIDUALS 

O. Cotoi, N. Ko, P. Dunér, H. Björkbacka, J. Nilsson, Alexandru Schiopu 2,3 , 

Romania, Sweden 1068 

12:25 OPTIMIZING NATURAL OCCURRING IGM ANTIBODIES FOR 

THERAPEUTIC USE: INFLAMMATORY VASCULAR DISEASE 

TREATMENT WITH ANTI-PHOSPHORYLCHOLINE IGG 

M.M. Ewing, J.C. Karper, M.R. De Vries, R.C.M. de Jong, I. Dahlbom, J. 

Kuiper, S. Karabina, E. Ninio, J.W. Jukema, K. Pettersson, Paul Quax, The 

Netherlands, Sweden, France 1023 


LUNCH BREAK, EXHIBITION AND POSTER PRESENTATIONS 

12:40 – 13:40 MODERATED POSTER SESSION B (See page 37) 

13:40 – 14:40 MODERATED POSTER SESSION C (See page 47) 

18



CONTEXT AND FUTURE CHALLENGES IN THE EFFECTIVE MANAGEMENT OF 

DYSLIPIDAEMIA 

SPONSORED BY ROCHE 

Chairpersons: Chris Packard 

Terje Pedersen 


Time 


Terje Pedersen, Norway 

13:05 LDL CHOLESTEROL AND CARDIOVASCULAR RISK REDUCTION - 

SUCCESSES AND CHALLENGES 


13:30 PCSK9 INHIBITION, A SAFE AND EFFICIENT STRATEGY TO LOWER 

LDL CHOLESTEROL? 

Gilles Lambert, France 

13:55 TRANSLATING NEW APPROACHES TO REDUCE LDL CHOLESTEROL 

INTO FUTURE THERAPIES 

Evan Stein, USA 

14:20 SUMMARY AND CLOSE 


19



CARDIOVASCULAR DISEASE AND ITS PREVENTION IN PATIENTS WITH CHRONIC 

INFLAMMATORY OR CHRONIC KIDNEY DISEASE 

Chairpersons: Eric Bruckert 

Naveed Sattar 

Time 

14:45 CARDIOVASCULAR DISEASE AND IT'S PREVENTION IN PATIENTS 

WITH CHRONIC INFLAMMATORY MUSCULOSKELETAL DISEASES 

George D. Kitas, UK 

15:10 CARDIOVASCULAR DISEASE AND IT'S PREVENTION IN PATIENTS 

WITH CHRONIC INFLAMMATORY MUSCULOSKELETAL DISEASES 


Abstract No. 

15:35 IMPACT OF MILD CHRONIC KIDNEY DISEASE ON CORONARY 

ATHEROSCLEROSIS, CARDIAC SYSTOLIC FUNCTION AND 

MORTALITY 

Andrea Natali, B. Boldrini, S. Baldi, M. Rossi, A. L'Abbate, E. Ferrannini, 

Italy 561 

15:50 INHIBITION OF MATRIX METALLOPROTEINASE-9 ATTENUATES 

DIABETIC NEPHROPATHY BY MODULATING PODOCYTE FUNCTIONS 

AND DOWNREGULATION EPITHELIAL-MESENCHYMAL TRANSITION 

Po-Hsun Huang, S.-Y. Li, S.-J. Lin, Taiwan R.O.C. 352 

16:05 ATHEROPROTECTIVE CHANGES IN HDL COMPOSITION IN 

RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TNF-INHIBITORS 

Johannes Levels, A. Jamnitski, I. van den Oever, M.T. Nurmohamed, The 

Netherlands 1404 

16:20 LIPOPROTEIN(a) IS CAUSALLY ASSOCIATED WITH TYPE 2 DIABETES 

Pia R. Kamstrup 1,2 , B.G. Nordestgaard 1,2 , Denmark 1177 

20



JOINT ESC/EAS SYMPOSIUM: BEHIND ENEMY LINES: IMMUNOMODULATION IN 


Chairpersons: Christoph Binder 

Jan Nilsson 

Time 

14:50 ANTIBODIES TO OXIDIZED LIPIDS 

Christoph Binder, Austria 

15:15 CD31 PEPTIDES 

Giuseppina Caligiuri, France 

15:40 ARTERY TERTIARY LYMPHOID ORGANS (ATLOS) CONTROL KEY 

STEPS OF ATHEROSCLEROSIS T CELL RESPONSES IN APOE-/- MICE 

DURING AGING 

Andreas Habenicht, Germany 

16:05 VACCINES 

Jan Nilsson, Sweden 

21



LATE BREAKING SESSION 

Chairpersons: Geesje Dallinga-Thie 

Arnold von Eckardstein 

Time Abstract No. 

14:50 THE SUSCEPTIBILITY OF LDL TO AGGREGATION DEPENDS ON LDL 

COMPOSITION 

Katariina Öörni, H. Lähteenmäki, T. Aittokallio, M. Jauhiainen, L. Rudel, 

P.T. Kovanen, Finland, USA 1650 

15:05 VALIDATION OF A NEAR-INFRARED SPECTROSCOPIC SIGNATURE OF 

LIPID LOCATED AT CULPRIT LESIONS IN ST-SEGMENT ELEVATION 

MYOCARDIAL INFARCTION 

David Erlinge, J.E. Muller, R. Puri, J. Harnek, M. Götberg, R. McNamara, D. 

Wohns, S. Vanoosterhout, K. Wolski, S. Madden, S. Nicholls, R.D. Madder, 

Sweden, USA, Australia 1637 

15:20 PROTECTIVE EFFECTS OF PLANT STEROL AND STANOL ESTERS IN 

DIET-INDUCED NONALCOHOLIC STEATOHEPATITIS IN 

HYPERLIPIDEMIC MICE 

Jogchum Plat, V. Bieghs, T. Hendrikx, M. Jeurissen, S. Walenbergh, P.J. 

van Gorp, E.D. de Smet, M. Konings, A.C.E. Vreugdenhil, Y.D. Guichot, D. 

Lutjohann, R.P. Mensink, R. Shiri-Sverdlov, The Netherlands, Germany 1628 

15:35 EFFECT OF Ω-3 FATTY ACID ETHYL ESTERS ON POSTPRANDIAL 

APOLIPOPROTEIN B-48 KINETICS IN OBESE SUBJECTS ON A WEIGHT 

LOSS DIET 

Dick C. Chan, A.T.Y. Wong, P.H.R. Barrett, G.F. Watts, Australia 1634 

15:50 FIRST REPORT OF ENZYME REPLACEMENT THERAPY IN A PATIENT 

WITH FAMILIAL LCAT DEFICIENCY: RAPID IMPROVEMENT OF LIPID 

AND CLINICAL MANIFESTATIONS 

Robert Shamburek, R. Bakker-Arkema, B. Krause, B. Auerbach, L. 

Freeman, R. Homan, B. Asztalos, E. Schaefer, C. Schwartz, M. Amar, A. 

Remaley, USA 1635 

16:05 NEW INSIGHTS INTO STATIN ACTION ON THE DYSLIPIDEMIA OF 

METABOLIC SYNDROME: NORMALISATION OF BIOACTIVE 

PLASMALOGENS AND SPHINGOLIPIDS IN HDL 

Peter J. Meikle, G. Wong, A.R. Tan, B.A. Kingwell, A.K. Orsoni, N. 

Hounslow, P. Giral, M.J. Chapman, Australia, France, UK 1643 

16:20 TRIAL EVALUATING AMG 145, A PCSK9 ANTIBODY, IN PATIENTS 

WITH HOMOZYGOUS FH: RESULTS OF AN INITIAL DOSE- 

SCHEDULING STUDY 

Evan A. Stein, N. Honarpour, S.M. Wasserman, F. Xu, R. Scott, F. Raal, 

USA, South Africa 1625 

22



YOUNG INVESTIGATOR AWARD SESSION 

Chairpersons: Petri Kovanen 

Danilo Norata 

Time 

14:50 WINNER IN BASIC RESEARCH 

STEM CELL MOBILIZATION AND CHOLESTEROL EFFLUX 

Laurent Yvan-Charvet, France 

, 

15:10 WINNER IN CLINICAL RESEARCH 

Y-CHROMOSOME AND CARDIOVASCULAR DISEASE 

Maciej Tomaszewski, UK 


CLINICAL EXPERIENCE OF LOMITAPIDE THERAPY IN PATIENTS WITH HoFH DURING 

CLINICAL TRIALS 

SPONSORED BY AEGERION 

Chairperson: Raul D. Santos 

Time 

15:40 SELECTING THE RIGHT PATIENTS WHO MAY BE SUITABLE FOR 

LOMITAPIDE THERAPY 

M. Averna; D. Blom, Italy, South Africa 

16:00 PRACTICALITIES OF DRUG ADMINISTRATION INCLUDING DOSE 

TITRATION AND DRUG INTERACTIONS 


16:20 MANAGEMENT AND MONITORRING OF ADVERSE EFFECTS 



REVIEWER, AUTHOR WORKSHOP 

SPONSORED BY ELSEVIER 

23


WEDNESDAY, JUNE 5, 2013

Wednesday, June 5, 2013 


LIPIDS AND LIPOPROTEINS: EMERGING RISK FACTORS AND THERAPIES 

Chairpersons: Marja-Riitta Taskinen 

M John Chapman 

Time 

08:30 TAILORING TREATMENT ACCORDING TO LIPID PHENOTYPE 

Anton Stalenhoef,, The Netherlands 

09:00 NEW INSIGHTS OBTAINED FROM LIPIDOMICS AS RISK MARKERS 

Robert Gerszten, USA 

09:30 LIPID SIGNALING AND LIPOTOXICITY 

Rudolf Zechner, Austria 

10:00 EMERGING THERAPEUTIC APPROACHES TO TREAT DYSLIPIDEMIAS 





ADVANCED CLINICAL SEMINAR: CLINICAL UTILITY OF NON-INVASIVE IMAGING IN CVD 

RISK ASSESSMENT 

Chairperson: Jacques Bonnet 

Time 

10:50 ASSESSMENT OF CORONARY ARTERY DISEASE BY COMPUTED 

TOMOGRAPHY IS BETTER 


11:10 ASSESSMENT OF CAROTID ARTERY DISEASE BY ULTRASOUND AND 

MAGNETIC RESONANCE IMAGING IS BETTER 

Henrik Sillesen, USA 

25



PRIMARY AND FAMILIAL DYSLIPIDEMIAS 

Chairpersons: Vincent Durlach 

Jan A. Kuivenhoven 

Time 

10:50 DYSLIPIDEMIA IN CHOLESTERYL ESTER STORAGE DISEASE 

Sebastiano Calandra, Italy 

11:15 MOLECULAR GENETIC STUDIES IN PATIENTS WITH FAMILIAL 

HYPERCHOLESTREOLEMIA 

Jan A. Kuivenhoven, The Netherlands 

Abstract No. 

11:40 A FOURTH TYPE OF AUTOSOMAL DOMINANT 

HYPERCHOLESTEROLEMIA CHARACTERIZED BY AN ALTERATION 

OF THE LDL ENDOSOMAL TRANSPORT 

Mathilde Varret, E. Girard, B. Védie, K. Ouguerram, A. Marques-Pinheiro, 

S. Lestavel, M. Guerin, Y. Zair, M. Devillers, M. Krempf, M. Abifadel, J.-P. 

Rabès, C. Lamaze, C. Boileau, France, Lebanon 1101 

11:55 FAMILIAL HYPERCHOLESTEROLEMIA IS NOT RELATED TO BRAIN 

WHITE MATTER DAMAGE BUT ACCENTUATES CORTICAL ATROPHY 

IN AGE-RELATED REGIONS 

C. Valls-Pedret, D. Vidal-Piñeiro, N. Bargalló, D. Bartrés-Faz, Emilio Ros, 

Spain 1503 

12:10 GENETICS IN FAMILIAL HYPERCHOLESTEROLEMIA AND THE RISK 

OF CARDIOVASCULAR EVENTS 

Joost Besseling, B. Sjouke, B. Hutten, J. Kastelein, K. Hovingh, The 


12:25 NATURAL HISTORY OF AUTOSOMAL DOMINANT 

HYPERCHOLESTEROLEMIA CAUSED BY GAIN-OF-FUNCTION 

MUTATIONS IN PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 

9 (PCSK9) (FUNDED BY REGENERON/SANOFI) 

Joep C. Defesche, S.W. Fouchier, B. Sjouke, J. Mendoza, S. Mellis, K. 

Miller, G.D. Swergold, on behalf of the PCSK9 Natural History Study (NHS) 

Group, The Netherlands, USA 147 

26


10:50-12:40 Room René Leriche A 

METABOLIC REGULATION OF APOLIPROTEIN A-I-CONTAINING LIPOPROTEINS 

Chairpersons: Arnold von Eckardstein 

Xavier Collet 

Time 

10:50 CONSTITUTIVE INHIBITION OF PLASMA CHOLESTERYL ESTER 

TRANSFER PROTEIN (CETP): FUNCTIONALITY AND 

DYSFUNCTIONALITY IN ANIMAL MODELS AND HUMAN POPULATIONS 

Laurent Lagrost, France 

11:15 ROLE OF THE ENDOTHELIUM IN HDL METABOLISM 

Arnold von Eckardstein, Switzerland 

Abstract No 

11:40 APOA-I INCREASES INSULIN SECRETION FROM PANCREATIC BETA 

CELLS VIA A CAMP-PKA-FOXO1 DEPENDANT MECHANISM 

Blake J. Cochran, R.J. Bisoendial, K.-A. Rye, Australia 1312 

11:55 THE ROLE OF HIGH DENSITY LIPOPROTEINS IN HUMAN 

MACROPHAGE POLARIZATION 

X.L. Moore, M.K. Lee, Y. Fu, J.Y. Wong, L. Fang, A.M. Dart, D. Sviridov, 

Jaye Chin-Dusting, Australia, China 403 

12:10 HIGH-DENSITY LIPOPROTEINS ASSOCIATED MICRORNAS: ORIGINS 

AND FUNCTION 

Fatiha Tabet, K.C. Vickers, L.F. Cuesta Torres, P.J. Barter, A.T. Remaley, 

K.-A. Rye, Australia, USA 946 

12:25 GLYCATION OF APOLIPOPROTEIN C1 LEADS TO A LOSS OF ITS 

ABILITY TO INHIBIT CHOLESTERYL ESTER TRANSFER PROTEIN 

ACTIVITY DURING DIABETES 

Benjamin Bouillet 1,2 , T. Gautier, D. Blache, J.-P. Pais de Barros, L. 

Duvillard, J.-M. Petit 1,2 , L. Lagrost, B. Verges 1,2 , France 435 

27


10:50-12:40 Room René Leriche B 

ADVENTITIA AND PERIVASCULAR FAT 

Chairpersons: Patricia Iozzo 

Steven B. Feinstein 

Time 

10:50 UPDATE ON ARTERIAL VASA VASORUM: DIAGNOSIS MONITORING 

AND POTENTIAL THERAPIES 

Steven.B. Feinstein, USA 

11:15 PERIVASCULAR AND EPICARDIAL FAT 

Patricia Iozzo, Italy Abstract No 

11:40 AUTOCRINE PRODUCTION OF SONIC HEDGEHOG ENHANCES PDGF 

BB-MEDIATED MIGRATION AND PERICYTE RECRUITMENT TO 

NEOVESSELS 

Q. Yao 1,2 , M.-A. Renault, C. Chapouly, S. Vanderdionck, I. Belloc, B. 

Jaspard-Vinassa, C. Desgranges, Alain-Pierre Gadeau, France 1330 

11:55 ROLE OF THE TUMOR SUPPRESSOR CDKN2A/P16 INK4A IN THE 

DEVELOPMENT OF PERIVASCULAR ADIPOSE TISSUE 

K. Wouters, S.A. Hannou, C. Cudejko, J. Vanhoutte, A. Lucas, K. 

Bantubungi, E. Vallez, E. Bouchaert, A. Tailleux, B. Staels, Réjane 

Paumelle, France 1015 

12:10 PERIVASCULAR ADIPOSE TISSUE AND CORONARY 


Rudolf Poledne, Z. Tonar, D. Kautznerova, I. Malek, J. Pirk, V. Lanska, J. 

Pitha, Czech Republic 284 

12:25 MACROPHAGES BULLYING T CELLS IN TYPE-A STANFORD ACUTE 

AORTIC DISSECTION 

Livia Ferri, M. Proietta, C. di Gioia, L. Tritapepe, M. Leopizzi, C. Fantozzi, C. 

Chiappetta, I. Nofroni, C. Della Rocca, E. Marinari, A.P. Mitterhofer, A. 

Negro, A. Koverech, M. Taurino, F. Del Porto, Italy 699 


ADVANCED CLINICAL SEMINAR: DO NEW BIOMARKERS HAVE ANY ADDED VALUE IN 

CLINICAL DECISION MAKING? 

Chairperson: Jan Boren 

Time 

11:40 LIPIDS AND LIPOPROTEINS 

Borge Nordestgaard, Denmark 

12:05 INFLAMMATION AND IMAGING 

Wolfgang Koenig, Germany 

28

POSTER 

PRESENTATIONS

Written by top experts in the field 

Advances in Cardiology 

Editor: J.S. Borer 

Vol. 47 

Antiplatelet Therapy in 

ACS and A-Fib 

Editors 

V.L. Serebruany 

D. Atar 

Ticlopidine 

Clopidogrel 

Prasugrel 

Ticagrelor 

TXA 2 

TXAS 

PGH2 COX 

Aspirin 

AA 

PLA2 TP 

ADP 

Platelet 

acvaon 

TRAP 

IIb3 

Thrombin 

Fibrinogen 

GP IIb/IIIa 

inhibitors 

Antiplatelet Therapy 

in ACS and A-Fib 

(Advances in Cardiology, Vol. 47) 

Editors: 

Serebruany, V.L. (Towson, Md.); 

Atar, D. (Oslo) 

Over the last several decades, a better understanding of the pathogenesis of coronary heart 

disease and atrial fibrillation has led to refinements in anti thrombotic strategies and clinical 

outcomes. With this in mind, some of the issues outlined in this book are: 

• New insights in genetic testing 

• Modifi cation of individualized antiplatelet therapy based on rapid bedside platelet analyzers 

• Current update of pros and cons of novel antiplatelet agents (such as prasugrel and ticagrelor) 

• Conventional antiplatelet strategies with aspirin and clopidogrel 

• Experimental antiplatelet agents like PAR-1 thrombin receptor antagonists or aptamers 

Please visit www.karger.com/adcar and read 

free chapter excerpts, more details and full table of contents. 

Get your copy at the Wisepress booth! 

ki13248


13:40-14:40 Moderated Poster Area 

MODERATED POSTER SESSION A 

Session 1: ENDOTHELIUM AND ATHEROTHROMBOSIS 

Moderator: Yiannis Chatzizisis, Greece 

Poster Board No. Abstract No 

M1 HOMOCYSTEINE REDUCES PROTEIN S-NITROSYLATION IN 

ENDOTHELIAL CELLS 

Y. Chen, Enqi Liu, J. Fan, China, Japan 170 

M2 CILOSTAZOL ENHANCES CIRCULATING ENDOTHELIAL PROGENITOR 

CELLS AND COLLATERAL FORMATION MEDIATED BY MODIFYING 

VASCULO-ANGIOGENIC BIOMARKERS IN PATIENTS WITH 

PERIPHERAL ARTERIAL DISEASE 

I-Chih Chen, T.-H. Chao , S.-Y. Tseng, Y.-S. Tsai, Y.-Y. Huang, P.-Y. Liu, 

H.-Y. Ou, Y.-H. Li, G.-Y. Shi, H.-L. Wu, J.-H. Chen, Taiwan R.O.C. 214 

M3 TAMOXIFEN ELICITS ATHEROPROTECTION THROUGH ESTROGEN 

RECEPTOR ALPHA AF-1 BUT DOES NOT ACCELERATE 

REENDOTHELIALIZATION 

Coralie Fontaine, A. Abot, A. Billon-Gales, G. Flouriot, E. Grunenwald, A. 

Vinel, M.-C. Valéra, P. Gourdy, J.-F. Arnal, France 356 

M4 DELETION OF FHL2 GENE IMPAIRED ISCHEMIA-INDUCED BLOOD 

FLOW RECOVERY 

Pao-Hsien Chu, P.-H. Huang, S.-J. Lin, Taiwan R.O.C. 459 

M5 OXIDIZED-HDL3 MODULATES THE EXPRESSION OF T-PA IN HUMAN 


Feng Tao Liu, Z.Y. Yu, Z. Ren, Z.H. Tang, R. Wang, L.S. Liu, Z. Wang, Z.S. 

Jiang, China 725 

M6 ENDOTHELIAL CELL-SPECIFIC ROLE OF THE CHEMOKINE RECEPTOR 

CXCR4 IN WIRE INJURY-INDUCED ATHEROSCLEROSIS 

Baixue Zhou, Germany 1155 

M7 RED BLOOD CELL INFILTRATION OF ATHEROMATOUS LESIONS 

INDUCE A VICIOUS CYCLE LEADING TO ENDOTHELIAL ACTIVATION 

AND CYTOTOXICITY 

Viktória Jeney 1,2 , L. Potor, M. Soares, G. Balla 1,2 , J. Balla, Hungary, 

Portugal 1323 

M8 REMODELING AND ENDOTHELIAL SHEAR STRESS EXHIBIT 

SIGNIFICANT LONGITUDINAL VARIATION IN HUMAN CORONARY 

ARTERIES: IMPACT ON PLAQUE PROGRESSION 

Antonios P. Antoniadis, M.I. Papafaklis, S. Takahashi, M. Tsuda, S. 

Mizuno, Y. Makita, T. Domei, T. Ikemoto, A.U. Coskun, J. Honye, S. 

Nakamura, S. Saito, C.L. Feldman, P.H. Stone, USA, Japan 1526 

29



MODERATED POSTER SESSION A (contd.) 

Session 2: REGULATION OF CELLULAR LIPID METABOLISM IN ATHEROGENESIS 

Moderator: Bart Staels, France 


M59 ADIPOCYTE ENHANCER-BINDING PROTEIN 1 OVER-EXPRESSION 

PROMOTES AND ABLATION ATTENUATES ATHEROSCLEROSIS IN 

APOE -/- AND LDLR -/- MICE 

Amin Majdalawieh, O. Bogachev, X. Pan, L. Zhang, H.-S. Ro, United Arab 

Emirates, Canada 315 

M60 AUTOPHAGY IS NOT INVOLVED TO PROVIDE FREE CHOLESTEROL 

FOR ABCA1-MEDIATED EFFLUX IN CHOLESTEROL-LOADED HUMAN 

MONOCYTE-DERIVED MACROPHAGES 

Natalie Fournier 1,2 , M. Passet, E. Girard, B. Vedie, J.-L. Paul 1,2 , France 512 

M61 CHOLESTEROL EFFLUX IS ASSOCIATED WITH PLASMA 

TRIACYLGLYCEROL SPECIES CONTAINING SATURATED FATTY 

ACIDS 

Peter J. Meikle, T.W. Ng, R. Tan, K. Huynh, G. Wong, C.K. Barlow, J.M. 

Weir, A.J. White, B.A. Kingwell, Australia 640 

M62 ACUTE EFFECT OF PLANT STANOL ESTERS ON HEPATIC STEROL 

METABOLISM IN MICE 

Els De Smet, R. Mensink, M. Konings, G. Brufau, B. Groen, R. Havinga, M. 

Schonewille, A. Kerksiek, D. Lütjohann, J. Plat, The Netherlands, Germany 801 

M63 GENETIC DETERMINATION OF PLASMA CHOLESTEROL EFFLUX 

CAPACITY IS GENDER-SPECIFIC AND INDEPENDENT OF HDL- 

CHOLESTEROL LEVELS 

Elise Florence Villard, P. El Khoury, E. Frisdal, E. Bruckert, K. Clement, D. 

Bonnefont-Rousselot, R. Bittar, W. Le Goff, M. Guerin, France 973 

M64 GLOBAL NRF2 DEFICIENCY ALLEVIATES DIET-INDUCED 

ATHEROSCLEROSIS IN LDL RECEPTOR DEFICIENT MICE 

Anna-Kaisa Ruotsalainen, E. Tapper, J. Lappalainen, S. Ylä-Herttuala, A.- 

L. Levonen, Finland 984 

M65 PHYTOSTEROL FEEDING DOWNREGULATES MOUSE PERITONEAL 

MACROPHAGE ABCG1 MRNA AND PREVENTS ATHEROSCLEROSIS IN 

LDL-RKO MICE 

Renata Bombo, R. Machado, M. Afonso, M.S. Lavrador, E. Nakandakare, V. 

Nunes, C. Lin, M. Koike, E. Quintao, A.M. Lottenberg, Brazil 1053 

M66 CHOLESTEROL CRYSTALS IN EARLY HUMAN ATHEROMA 

B. Ho-Tin-Noé, V. Ollivier, J.-B. Michel, Sophie Vo, France 1461 

30




Session 3: ROLE OF LIPASES IN LIPID AND LIPOPROTEIN METABOLISM 

Moderator: Geesje Dallinga-Thie, Netherlands 


M67 THE EFFECTS OF VEGF-A ON ATHEROSCLEROSIS, LIPOPROTEIN 

PROFILE AND LIPOPROTEIN LIPASE IN HYPERLIPIDEMIC MOUSE 

MODELS 

Annukka Kivelä, S. Heinonen, M. Dijkstra, E. Gurzeler, J. Huusko, P. 

Mäkinen, P. Leppänen, V. Olkkonen, U. Eriksson, M. Jauhiainen, S. Ylä- 

Herttuala, Finland, Sweden 229 

M68 AAV-DRIVEN OVEREXPRESSION OF HANGPTL4 IN APOE-/- MICE 

AGGRAVATES PLASMA TG LEVELS BUT DOES NOT AFFECT POST- 

HEPARIN PLASMA LIPOPROTEIN LIPASE ACTIVITY 

Madelene Eriksson, S.K. Nilsson, C. Schlein, J. Heeren, Sweden, Germany517 

M69 RELATIONSHIP OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 

MASS AND ACTIVITY WITH TRADITIONAL LIPOPROTEIN 

BIOMARKERS IN A TUNISIAN STUDY 

Mazen Belhabib, M. Caslake, A. Bekir, H. Chahed, J. Cooney, A. Lewis, D. 

Bedford, T. Trimech, F. Maatouk, S. Ferchichi, A. Miled, Tunisia, UK 518 

M70 LIPOPROTEIN LIPASE MASS IS A PREDICTIVE MARKER OF 

CARDIOVASCULAR AND CEREBROVASCULAR EVENT IN FUTURE 

Haruki Imamura, K. Endo, A. Saiki, T. Murano, Y. Sato, T. Yamaguchi, N. 

Ban, H. Kawana, D. Nagayama, A. Nagumo, M. Ohira, S. Yamamura, K. 

Shirai, I. Tatsuno, Japan 652 

M71 A NEW POSSIBLE ROLE FOR ANGIOPOIETIN LIKE 3, A REGULATOR 

OF TRIGLYCERIDE METABOLISM, IN MODULATING INSULIN 

RESISTANCE 

Marianna Maranghi, I. Minicocci, G. Tiseo, A. Montali, P. Coletta, D. 

Pergolini, G. Pigna, E. Ciociola, C. Durante, G. Labbadia, M. Arca, Italy 1017 

M72 APOA5 DOWN-REGULATION THROUGH MIRNA INTERACTION WITH 

POLYMORPHIC 3'UTR 

Cyrielle Caussy 1,2 , S. Charrière 1,2 , C. Marçais 2,3 , M. Di Filippo 2,4 , A. 

Sassolas 2,4 , E. Lefai, S. Rome, P. Moulin 1,2 , France 1090 

M73 HUMAN POLYMORPHISMS OF ENDOTHELIAL LIPASE DISPLAY 

IMPAIRED HYDROLYSIS OF HIGH-DENSITY LIPOPROTEINS 

Kate Shearston, D. Marais, K.-A. Rye, G. Lambert, Australia, South Africa, 

France 1316 

M74 ANGPTL4 MEDIATES THE SHORT-POSTER BOARD NO. EFFECTS OF 

TNF-ALPHA ON THE LPL SYSTEM IN 3T3-L1 ADIPOCYTES 

Evelina Vorrsjö, E. Makoveichuk, T. Olivecrona, G. Olivecrona, Sweden 1378 

31




Session 4: EVALUATION AND TREATMENT OF CARDIOVASCULAR RISK FACTORS IN 

THE YOUNG AND THE ELDERLY 

Moderator: George D. Davey-Smith, UK 


M117 ENDOGENOUS SEX HORMONES, ISCHEMIC HEART DISEASE AND 

EARLY DEATH IN WOMEN FROM THE GENERAL POPULATION 

Marianne Benn, S.S. Voss, G.B. Jensen, B.G. Nordestgaard, Denmark 977 

M118 HIGH PREVALENCE OF ATHEROSCLEROSIS IN ARTERIES OF 

ANCIENT MUMMIES DETERMINED BY NEAR INFRARED 

SPECTROSCOPY 

Mohammad Madjid, N. Fuenffinger, K. Stutler, R. Lodder, USA 328 

M119 LIPOPROTEIN(A): FASTING AND NONFASTING LEVELS, 

INFLAMMATION, AND CARDIOVASCULAR RISK PREDICTION 

Anne Langsted, P.R. Kamstrup, B.G. Nordestgaard, Denmark 1175 

M120 INCREASE IN THE INCIDENCE OF ACUTE CORONARY SYNDROME 

AFTER THE 2011 EAST JAPAN NATURAL DISASTER: CONCORDANCE 

WITH SEQUENTIAL QUAKE SHOCKS 

Masanobu Niiyama, F. Tanaka, K. Sato, T. Takahashi, T. Onoda, T. 

Segawa, M. Onodera, M. Kawakami, M. Ogawa, H. Endoh, T. Matsumoto, K. 

Sakata, M. Nakamura, Japan 1413 

M121 FIBROBLAST GROWTH FACTOR 23, PARATHYROID HORMONE AND 

RISK OF HEART FAILURE IN A MIDDLE-AGED GERMAN POPULATION 

Romina di Giuseppe, B. Buijsse, F. Hirche, J. Wirth, M. Arregui, H.W. 

Hense, J. Dierke, H. Boeing, G.I. Stangl, C. Weikert, Germany, Norway 1475 

M122 LABORATORY VS. NON-LABORATORY YOUTH RISK MEASURES FOR 

PREDICTING CAROTID INTIMA-MEDIA THICKNESS IN ADULTHOOD: 

THE INTERNATIONAL CHILDHOOD CARDIOVASCULAR COHORT 

CONSORTIUM 

Costan G. Magnussen 1,2 , M. Juonala, J.S.A. Viikari, G.S. Berenson, T. 

Dwyer, A. Venn, O.T. Raitakari, Finland, Australia, USA 1477 

M123 USE OF FIBRATES IN PRIMARY PREVENTION IN TYPE 2 DIABETIC 

PATIENTS AT HIGH CARDIOVASCULAR RISK 

Ronan Roussel 1,2 , C. Chaignot, A. Weill, B. Hansel, F. Travert, P. 

Ricordeau, F. Alla, H. Allemand, France 1514 

M124 NAFLD IS INCREASED IN PATIENTS WITH CV RISK FACTORS AND IS 

CORRELATED WITH ATHEROSCLEROSIS AND THE FRAMINGHAM 

SCORE 

R. Pais, D. Rosenbaum, P. Lebray, D. Thabut, M. Rudler, V. Ratziu, Philippe 

Giral, France 1242 

M125 EFFECT OF SHIFTWORK ON BODY MASS INDEX AMONG FEMALE 

NURSES IN KOREA: NURSES' HEALTH STUDY 

Min-Ju Kim, H.-Y. Park, K.-H. Son, M.-C. Cho, D.-J. Choi, the Nurses Health 

Study(NHS) Group, Republic of Korea 1435 

32




Session5: INFLAMMATION AND HDL 

Moderator: Dimitris Kardassis, Greece 


M75 EVIDENCE FROM AN INTEGRATED ANALYSIS COMBINING 

GENOMICS, TRANSCRIPTOMICS, AND LIPIDOMICS HIGHLIGHTS THE 

ROLE OF INFLAMMATION IN LOW HDL-C STATE 

Pirkka-Pekka Laurila, I. Surakka, A.-P. Sarin, J. Tang, T. Hyötyläinen, S. 

Söderlund, J. Naukkarinen, J. Kettunen, D. Mirel, J. Soronen, T. Lehtimäki, 

A. Ruokonen, C. Ehnholm, J. Eriksson, V. Salomaa, A. Jula, O. Raitakari, M.- 

R. Järvelin, A. Palotie, M. Oresic, S. Ripatti, M. Jauhiainen, M.-R. Taskinen, 

Finland, USA 429 

M76 HUMAN APOA-I AFFECTS THE INFLAMMATORY RESPONSE 

MEDIATED BY CD4+ T-LYMPHOCYTES DURING ATHEROSCLEROSIS 

PROGRESSION 

Marco Busnelli, F. Sala, L. Arnaboldi, C. Parolini, S. Manzini, D. Norata, G. 

Chiesa, Italy 1497 

M77 GENETIC ABLATON OF THE P2Y2 NUCLEOTIDE RECEPTOR REDUCES 

VASCULAR INFLAMMATION AND ATHEROSCLEROSIS IN MICE 

Cheikh Seye, S. Qian, USA 1360 

M78 PREVALENCE OF CLASSICAL CD14++/CD16- BUT NOT OF 

INTERMEDIATE CD14++/CD16+ MONOCYTES IN HYPO- 

ALPHALIPOPROTEINEMIA 

Fabrizia Bonacina, L. Cutuli, F. Sala, L. Grigore, S. Fiorelli, K. Garlaschelli, 

G. Chiesa, A.L. Catapano 1,3 , G.D. Norata 1,2 , Italy 1533 

M79 RESVERATROL ADMINISTRATION OR SIRT1 OVEREXPRESSION DOES 

NOT INCREASE LXR SIGNALING AND MACROPHAGE-TO-FECES 

REVERSE CHOLESTEROL TRANSPORT IN VIVO 

J.C. Escolà-Gil, J. Julve, G. Llaverias, M. Urpi-Sarda, R. Silvennoinen, M. 

Lee-Rueckert, C. Andres-Lacueva, Francisco Blanco-Vaca, Spain, Finland1288 

M80 OXLIG-1, A NOVEL PPAR GAMMA AGONIST, INCREASE ABCA1 

EXPRESSION AND PROMOTE CHOLESTEROL EFFLUX FROM THP-1 

MACROPHAGES 

Yan Chi, R. Wang, F. Zhang, X. Han, Z. Liu, Q. Liu, China 1379 

M81 ASSOCIATION BETWEEN REVERSE CHOLESTEROL TRANSPORT 

RATE AND LIPOPROTEIN BIOMARKERS USING A NOVEL IN SILICO 

MODEL OF LIPOPROTEIN METABOLISM AND KINETICS 

James Lu, K. Hϋbner, E.A. Brinton, M.N. Nanjee, N.A. Mazer, Switzerland, 

Germany, USA 1108 

33




Session 6: THROMBOSIS AND HEMOSTASIS: RELATION TO ATHEROTHROMBOSIS AND 

LIPOPROTEINS 

Moderator: Pierre Morange, France 


M9 HIGH CONCENTRATIONS OF LOW DENSITY LIPOPROTEINS (LDL) 

INCREASE TISSUE FACTOR-DEPENDENT PROCOAGULANT ACTIVITY 

IN PLATELETS 

Susana Contreras-Duarte, C. González, P. Hidalgo, A. Rigotti, D. Mezzano, 

O. Panes, Chile 227 

M10 ANTAGONIZING THE EP3 RECEPTOR FOR PGE2 WITH DG-041 

PREVENTED THROMBOSIS WITH NO IMPACT ON HEMOSTASIS 

P. Tilly, A.-L. Charles, S. Ludwig, J.-B. Michel, B. Geny, Jean-Etienne 

Fabre, France 682 

M11 IS PLATELET MEDIATED LEUKOCYTE RECRUITMENT A DRUGABLE 

TARGET IN ATHEROSCLEROSIS? 

Matthew James Harrison, G. Nash, S. Watson, E. Rainger, UK 988 

M12 OXIDIZED HDL INHIBIT HUMAN PLATELET AGGREGATION 

Catherine Calzada, E. Véricel, Q.-H. Le, M. Lagarde, P. Moulin, France 1041 

M13 HDL-BASED THERAPY REDUCES THE HEMORRHAGIC 

COMPLICATIONS ASSOCIATED WITH TISSUE PLASMINOGEN 

ACTIVATOR TREATMENT IN EXPERIMENTAL STROKE 

Bertrand Lapergue, B.Q. Dang, J.P. Desilles, G. Ortiz, S. Delbosc, S. 

Loyau, L. Louedec, P.O. Couraud, M. Mazighi, J.B. Michel, O. Meilhac, P. 

Amarenco, France 301 

M14 PENTRAXIN 3 DEFICIENCY IS ASSOCIATED WITH INCREASED 

ARTERIAL THROMBOSIS IN ANIMAL MODELS 

Fabrizia Bonacina, S.S. Barbieri, L. Cutuli, P. Amadio, M. Sironi, B. 

Bottazzi, C. Garlanda, E. Tremoli 1,2 , A. Mantovani, G.D. Norata 1,4 , A.L. 

Catapano 1,5 , Italy 1553 

34




Session 7: FATTY ACIDS INFLUENCE ATHEROSCLEROSIS AND ITS RISK FACTORS: 

THE DOUBLE BONDS DECIDE 

Moderator: Michel Lagarde, France 


M126 IMPACT OF N-3 TO N-6 POLYUNSATURATED FATTYACID RATIO ON 

VASCULAR FUNCTION IN ISCHEMIC HEART DISEASE PATIENTS WITH 

IDEAL LDL LEVEL 

Hitoshi Adachi, H. Takamatsu, J. Tomono, S. Oshima, Japan 241 

M127 MEDITERRANEAN DIET AND 2.4-YEAR CHANGES IN ULTRASOUND- 

ASSESSED CAROTID INTIMA-MEDIA THICKNESS AND PLAQUE: A 

SUB-STUDY OF THE PREDIMED TRIAL 

Aleix Sala-Vila, E.S. Romero-Mamani, R. Gilabert, I. Núñez, E. Toledo, V. 

Ruiz-Gutiérrez, R.M. Lamuela-Raventós, X. Pintó, F. Arós, M. Fiol, M.I. 

Covas, M.Á. Martínez-González, R. Estruch, E. Ros, Spain 981 

M128 OMEGA 3 FATTY ACIDS PROMOTE MACROPHAGE REVERSE 

CHOLESTEROL TRANSPORT IN HAMSTER FED HIGH FAT DIET 

Fatima Kasbi Chadli 1,2 , E.-H. Nazih, M. Krempf, P. Nguyen, K. Ouguerram, 

France 421 

M129 VASCULAR FUNCTION AFTER N-3 POLYUNSATURATED FATTY ACIDS 

SUPPLEMENTATION IN AN ANIMAL MODEL OF EXPERIMENTAL 

MENOPAUSE 

Andrea Grillo, P. Losurdo, E. Panizon, M. Jevnikar, L. Macaluso, M. Zanetti, 

B. Fabris, R. Carretta, Italy 450 

M130 IMPACT OF DIFFERENT DIETARY TREATMENTS ON THE MOLECULAR 

LIPID PROFILE OF AORTIC PLAQUES DEVELOPED IN APOE-/- MICE 

C. Parolini, M. Busnelli, Stefano Manzini, G. Ganzetti, M. Jänis, K. Tarasov, 

R. Hurme, K. Ekroos, R. Laaksonen, G. Chiesa, Italy, Finland 1509 

Session 8: INSULIN-RESISTANT STATES: MODULATORS OF LIPID METABOLISM 

AND CARDIOVASCULAR DISEASE 

Moderator: Klaus Parhofer, Germany 

M131 INFLUENCE OF LIPIDS AND APOLIPOPROTEINS ON INSULIN 

SENSITIVITY: A CROSS-SECTIONAL ANALYSIS OF THE RISC STUDY 

Simona Baldi, F. Bonnet, M. Laville, C. Morgantini, E. Ferrannini, A. Natali, 

on behalf of the RISC Investigators, Italy, France 419 

M132 HETEROZYGOUS GLUCOKINASE KNOCKOUT MICE IN APOE 

DEFICIENT BACKGROUND REPRESENT A NOVEL DISEASE MODEL 

FOR TYPE 2 DIABETES AND ATHEROSCLEROSIS 

Suvi E. Heinonen, A.-C. Andréasson, M. Brusberg, L. Hägerstrand, K. 

Jennbacken, A. Ahnmark, B. Leighton, A.-C. Jönsson-Rylander, Sweden, UK632 

35




Session 8: INSULIN-RESISTANT STATES: MODULATORS OF LIPID METABOLISM 

AND CARDIOVASCULAR DISEASE (contd.) 


M133 ASSOCIATION OF FASTING GLUCOSE LEVEL 6 MONTHS AFTER PCI 

WITH THE DEVELOPMENT OF MACE IN DES-IMPLANTED PATIENTS 

ON STATIN THERAPY 

Dong Oh Kang, H.S. Seo, B. Choi, C. Choi, E.M. Lee, S.I. Lim, S.W. Kim, 

J.O. Na, C.U. Choi, H.E. Lim, J.W. Kim, E.J. Kim, S.-W. Rha, C.G. Park, D.J. 

Oh, Republic of Korea 661 

M134 PCSK9 CIRCULATING LEVELS ARE INCREASED IN TYPE 2 DIABETIC 

PATIENTS REGARDLESS OF METABOLOMIC DIFFERENCES IN LIPID 

PROFILE 

Anna Cabré, N. Plana, D. Ibarretxe, M. Heras, S. Guaita, J. Merino, J. 

Ribalta, L. Masana, Spain 979 

M135 LIPID PROFILES IN DIABETIC SUBJECTS - ASSOCIATIONS WITH 

CARDIOVASCULAR DISEASE 

O. Piksasova, V. Schnecke, F. Agakov, P. McKeigue, K. Leander, U. 

deFaire, I. Brady, H. Looker, H. Colhoun, A. Hamsten, John Öhrvik, 

SUMMIT Consortium, Sweden, UK 1057 

M136 CHARACTERIZATION OF ATHEROGENIC DYSLIPIDEMIA USING A 

NOVEL NMR-BASED ADVANCED LIPOPROTEIN TEST IN TYPE 2 

DIABETIC SUBJECTS 

Roger Mallol 1,2,3 , A. Cabré 1,2,3 , M.A. Rodríguez 1,2,3 , N. Amigó 1,2,3 , M. 

Vinaixa 1,2,3 , N. Plana, M. Heras 1,2,3 , L. Masana 1,2,3 , X. Correig 1,2,3 , Spain 1502 

M137 PREVALENCE AND DETERMINANTS OF FATTY LIVER IN NORMAL 

WEIGHT AND OVERWEIGHT YOUNG ADULTS. THE CARDIOVASCULAR 

RISK IN YOUNG FINNS STUDY 

Mervi Oikonen, M. Kähönen, J. Viikari, M. Juonala, O.T. Raitakari 1,4 , The 

Young Finns Study Group, Finland 1537 

M138 VANCOMYCIN DECREASES INSULIN SENSITIVITY AND IS 

ASSOCIATED WITH ALTERATIONS IN INTESTINAL MICROBIOTA 

AND BILE ACID COMPOSITION IN METABOLIC SYNDROME 

SUBJECTS 

Ruud Kootte, C. Out, S. Fuentes, L. Jonker, A. Vrieze, E. Van Nood, F. 

Holleman, G. Dallinga-Thie, H. Romijn, M. Soeters, E. Blaak, D. 

Reijnders, M. Ackermans, M. Serlie, F. Knop 8,9 , J. Holst, E. Stroes, E. 

Zoetendal, W. De Vos 3,10 , J. Hoekstra, B. Groen, M. Nieuwdorp 1,4 , The 

Netherlands, Denmark 1546 

M139 ISCHEMIC HEART DISEASE IN OVERWEIGHT AND OBESITY WITH AND 

WITHOUT THE METABOLIC SYNDROME 

M. Thomsen, Børge Nordestgaard, Denmark 1472 

36



MODERATED POSTER SESSION B 

Session 9: CELL DYSFUNCTIONS IN ATHEROGENESIS 

Moderator: Catherine Shanahan, UK 


M15 AUTOPHAGY AND ER STRESS ARE INDUCED BY OXIDIZED LDL: 

ROLE IN VASCULAR ENDOTHELIAL CELLS APOPTOSIS AND 

ATHEROGENESIS 

C. Muller, M. Bisserier, A. Swiader, A. Nègre-Salvayre, F. Lezoualc'h, R. 

Salvayre, Cécile Vindis, France 478 

M16 SPHINGOSINE-1-PHOSPHATE (S1P) INHIBITS TNFA-STIMULATED 

MMP-9 EXPRESSION IN MACROPHAGES AND SMOOTH MUSCLE 

CELLS VIA DIFFERENT S1P RECEPTORS 

Petra Keul, G. Heusch, B. Levkau, Germany 619 

M17 IN VIVO IMAGING OF APOPTOSIS AT ATHEROSCLEROTIC PLAQUE 

USING APOPTOSIS-TARGETED PEPTIDE PROBE 

Byung-Heon Lee, Republic of Korea 731 

M18 SP1, ACETYLATED HISTONE-3 AND P300 REGULATE TRAIL TO 

PROMOTE PDGF-BB-MEDIATED VASCULAR SMOOTH MUSCLE CELL 

PROLIFERATION AND MIGRATION 

N.S. Azahri, B. Di Bartolo, L. Khachigian, Mary Kavurma 1,2 , Australia 936 

M19 DISSECTION OF ACTIVATION FUNCTIONS (AF-1 AND AF-2) OF 

ESTROGEN RECEPTOR ALPHA IN VIVO: UNCOUPLING VASCULAR 

AND SEXUAL EFFECTS 

Anne Abot, C. Fontaine, I. Raymond-Letron, G. Flouriot, M. Adlanmerini, 

M. Buscato, P. Gourdy, F. Lenfant, J.-F. Arnal, France 1021 

M20 EFFECT OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 

(PCSK9) ON SMOOTH MUSCLE CELL PROLIFERATION AND 

MIGRATION 

Nicola Ferri, G. Tibolla, F. Maglione, P. Costet, A. Corsini, A.L. Catapano 1,3 , 

Italy, France 1209 

M21 MACROPHAGE PHENOTYPIC DIVERSITY DURING 

ATHEROSCLEROSIS REGRESSION 

J.E. Feig, Y. Vengrenyuk, B. Hewing 1,2 , K.J. Moore, Edward A. 

Fisher, USA, Germany 1424 

M22 MICRORNAS 143/145 DEFICIENCY LIMITS ATHEROSCLEROSIS IN 

ANIMAL MODELS 

Federica Sala, L. Elia, G. Condorelli 1,2 , A.L. Catapano 1,3 , G.D. Norata 1,4 , 

Italy 1468 

37



MODERATED POSTER SESSION B (contd.) 

Session 10: ANGIOGENESIS 

Moderator: Jan Nilsson, Sweden 


M23 NOGO B EXPRESSION AND THE ADVENTITIAL LYMPHANGIOGENESIS 

IN HUMAN DONOR'S ARTERIES 

Katarzyna Magdalena Drożdż, I. Grzegorek, M. Chmielewska, A. 

Gomułkiewicz, K. Jabłońska, A. Piotrowska, D. Janczak, M. Podhorska- 

Okołów, P. Dzięgiel, A. Szuba, Poland 152 

M24 ANTI-ATHEROSCLEROTIC EFFECT OF AN ANTIBODY THAT BINDS TO 

EXTRACELLULAR MATRIX GLYCOSAMINOGLYCANS 

Ana María Vázquez, Y. Soto, E. Acosta, L. Delgado, A. Pérez, V. Falcón, 

M.A. Becquer, A. Fraga, V. Brito, I. Alvarez, T. Griñán, Y. Fernández- 

Marrero, A. López-Requena, M. Noa, E. Fernández, Cuba 238 

M25 QA-1-RESTRICTED CD8 + T REGULATORY CELLS CONTROL THE 

DEVELOPMENT OF PRO-ATHEROGENIC ADVENTITIAL TERTIARY 

LYMPHOID ORGANS IN APOLIPOPROTEIN E KO MICE 

Marc Clement 1,2 , K. Guedj 1,2 , M. Morvan, J. Khallou-Laschet 1,2 , A.-T. Gaston, 

H.-J. Kim 3,4 , H. Cantor 3,4 , G. Caligiuri, A. Nicoletti 1,2 , France, USA 386 

M26 ELASTASE INHIBITOR TREATMENT PREVENTS ABDOMINAL AORTIC 

ANEURYSM GROWTH 

Sandrine Delbosc 1,2 , J.-M. Alsac 1,3 , M. Rouer, L. Louedec 1,2 , M. Philippe 1,2 , 

O. Meilhac 1,2 , C. Whatling, J.B. Michel 1,2 , France, Sweden 610 

M27 NON-INVASIVE ASSESSMENT OF NEOANGIOGENESIS AND 

INFLAMMATION IN INTERMEDIATE LESIONS OF HUMAN CAROTID 

ARTERIES 

Maria Drakopoulou, K. Toutouzas, G. Benetos, C. Aggeli, C. Nikolaou, I. 

Felekos, H. Grassos, A. Synetos, K. Stathogiannis, A. Karanasos, E. 

Tsiamis, E. Siores, C. Stefanadis, Greece, UK 837 

M28 TRAIL -/- MICE DISPLAY REDUCED NEOVASCULARISATION AFTER 

HIND-LIMB ISCHEMIA: IMPLICATIONS FOR TRAIL IN REGULATING 

PROANGIOGENIC GENES 

Belinda Ann Di Bartolo, L.P. Lourenco, N.S. Azahri 1,2 , L.M. Khachigian, 

M.M. Kavurma 2,3 , Australia 924 

M29 SIRT1 SUPPRESSES HYPOXIA-INDUCED HIF-1Α EXPRESSION AND 

ATTENUATES NEOINTIMA FORMATION VIA INHIBITION OF 

NEOVASCULARIZATION AFTER ARTERIAL INJURY IN MICE 

Jinung Bae, S.J. Lee, K.W. Hong, S.Y. Park, C.D. Kim, Republic of Korea 933 

M30 ESSENTIAL ROLE FOR SPHINGOSINE-1-PHOSPHATE IN OXIDIZED 

LOW DENSITY LIPOPROTEIN-INDUCED ANGIOGENESIS. PREVENTION 

BY ANTI-S1P ANTIBODY 

Caroline Camaré, M. Trayssac, B. Garmy-Susini, R. Sabbadini, R. Salvayre, 

A. Nègre-Salvayre, France, USA 1257 

38




Session 11: LIFESTYLE 

Moderator: Angela Rivellese, Italy 


M140 GENETIC VARIATION IN FADS MODIFIES THE ASSOCIATION 

BETWEEN ALA/LA AND INCIDENCE OF CARDIOVASCULAR DISEASE 

Sophie Hellstrand, E. Sonestedt, U. Ericson, B. Gullberg, E. Wirfält, M. 

Orho-Melander, Sweden 411 

M141 TRANS-FATTY ACID ACCELERATES THROMBUS FORMATION IN VIVO 

THROUGH INHIBITING ENDOTHELIAL ANTI-THROMBOGENIC ACTIONS 

Kensuke Kondo, T. Yasuda, J. Yamamoto, T. Monguchi, K. Mori, M. 

Hasokawa, H. Haraguchi, H. Nakajima, M. Shinohara, R. Toh, T. Ishida, K. 

Hirata, Japan 414 

M142 CARBOHYDRATE-RICH FOODS AND RISK OF CARDIOVASCULAR 

DISEASE IN THE MALMÖ DIET AND CANCER COHORT 

Emily Sonestedt, S. Hellstrand, M. Orho-Melander, Sweden 597 

M143 THE EFFECTS OF DARK CHOCOLATE ON ENDOTHELIAL FUNCTION 

AND PULSE-WAVE SHAPE IN HEALTHY PERSONS 

Oxana Dikur, A. Parfenov, Y. Ashikhmin, Russia 810 

M144 THE DECREASE IN CARDIORESPIRATORY FITNESS IS RELATED TO 

THE RISK OF ACUTE MYOCARDIAL INFARCTION AND ALL-CAUSE 

MORTALITY IN MEN 

Jari Laukkanen, S. Kurl, R. Rauramaa, KIHD, Finland 853 

M145 REPLACING A SFA DIET WITH DIETARY PUFA REDUCES HEPATIC 

PCSK9 MRNA AND PLASMA LIPIDS IN RATS 

Sara Straniero, L. Persson, B. Angelin, M. Rudling, Sweden 1225 

M146 EFFECTS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS ON 

ADIPOKINE LEVELS IN PATIENTS UNDERGOING PERCUTANEOUS 

CORONARY INTERVENTION 

Grzegorz Gajos, M. Mostowik, J. Zalewski, J. Nessler, A. Undas, Poland 1235 

M147 EFFECTS OF LIFESTYLE MODIFICATION PROGRAM IN REDUCTION OF 

RISK FACTORS IN PATIENTS WITH CORONARY HEART DISEASE 

Solmaz Aminpour, M. Shahamfar, J. Shahamfar, Iran 704 

M148 THE FREQUENCY OF ALCOHOL CONSUMPTION IS ASSOCIATED WITH 

THE INCREASED RISK OF STROKE MORTALITY 

Sanna Helena Rantakömi, S. Kurl, J. Sivenius, J. Kauhanen, J.A. 

Laukkanen, Finland 1345 

39




Session 12: CV RISK FACTORS 1 

Moderator: Jacques Bonnet, France 


M149 ASSOCIATIONS BETWEEN SERUM URIC ACID AND MARKERS OF 

SUBCLINICAL ATHEROSCLEROSIS. THE CARDIOVASCULAR RISK IN 

YOUNG FINNS STUDY 

Mervi Oikonen, M. Wendelin-Saarenhovi, L.-P. Lyytikäinen 3,4 , O.T. 

Raitakari, Cardiovascular Risk in Young Finns Study, Finland 444 

M150 OUTCOMES FOLLOWING CORONARY REVASCULARIZATION IN 

CHINESE, SOUTH ASIAN AND WHITE PATIENTS WITH ACUTE 

MYOCARDIAL INFARCTION 

D. Gasevic 1,2 , N. Khan, H. Qian, S. Karim, G. Simkus, H. Quan, M. Mackay, 

Amir Ayyobi, Canada 514 

M151 SKIN CANCER AS A MARKER OF SUN EXPOSURE AND RISK OF 

MYOCARDIAL INFARCTION, HIP FRACTURE, AND EARLY DEATH 

Peter Brøndum-Jacobsen, B.G. Nordestgaard, S.F. Nielsen, M. Benn, 

Denmark 573 

M152 MAXIMAL BLOOD PRESSURE RESPONSE TO EXERCISE IS 

ASSOCIATED WITH SUBCLINICAL ATHEROSCLEROSIS IN 

NORMOTENSIVE ADOLESCENTS 

Egle Silva, J.J. Villasmil, L. Chacin, G. Bermudez, M. Bracho, A. Gonzalez, 

Venezuela 638 

M153 HIGH LEVEL OF TRIGLYCERIDES IN CHILDREN OF PATIENTS WITH 

EARLY CORONARY ARTERY DISEASE: RELATION TO OWN AND 

PARENTAL RISK FACTORS 

Mikhail Konnov, L. Dobordzhginidze, N. Gratsiansky, Russia 919 

M154 PROGNOSTIC ROLE OF EOSINOPHILIC CATIONIC PROTEIN IN 

PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION TREATED 

BY PRIMARY PERCUTANEOUS CORONARY INTERVENTION 

A. Imaeva, F. Fracassi, N. Cosentino, L. Cataneo, M. Roberto, D. Schiavino, 

G. Niccoli, F. Crea, Giorgia Copponi, Russia, Italy 1183 

M155 FACTOR V LEIDEN AND PROTHROMBIN G20210A MUTATION IN 

ISCHEMIC STROKE PATHOGENESIS: ESH STROKE SURVEY 

Alena Krajcoviechova, P. Wohlfahrt, O. Mayer, J. Vanek, J. Kvasnicka, T. 

Kvasnicka, J. Filipovsky, R. Cifkova, Czech Republic 1473 

M156 METABOLOMIC PROFILES IN LEAN AND OBESE ADOLESCENTS 

Yun Chen, M. Peitzsch, G. Eisenhofer, P. Friberg, Sweden, Germany 1483 

M157 THE RELATION OF ALCOHOL CONSUMPTION LEVELS WITH THE 

CARDIO-ANKLE VASCULAR INDEX (CAVI) IS J-SHAPED IN HEALTHY 

MIDDLE-AGED JAPANESE MEN 

Masatsune Ogura, T. Kobayashi, K. Ikewaki, Japan 494 

40





Session 13: ATHEROSCLEROSIS-REGULATING FACTORS IN MOUSE AND MAN 2 

Moderator: Christoph Binder, Austria 

M31 LACK OF NICOTINE ALPHA 7 RECEPTOR ACCELERATES 

ATHEROSCLEROSIS IN LDLR-/- MICE 

Maria E. Johansson 1,2 , M.A. Ulleryd, A.M. Lundberg, L. Fogelstrand, Z.-Q. 

Yan, G.K. Hansson, Sweden 591 

M32 LOW DOSE ASPIRIN REDUCES PLASMA CHEMERIN LEVELS IN 

CORONARY ARTERY DISEASE PATIENTS THROUGH REDUCTION OF 

ADIPOSE TISSUE INFLAMMATION 

Magdalena Herová 1,2 , C. Loretz, M. Schmid, M. Hersberger 1,2 , Switzerland 1027 

M33 CROSS-TALK BETWEEN ACTIVATED MONOCYTES AND SMOOTH 

MUSCLE CELLS UP-REGULATES RESISTIN EXPRESSION BY 

ACTIVATION OF STAT3 TRANSCRIPTION FACTOR 

A.M. Gan, M. Pirvulescu, D. Stan, V. Simion, M. Calin, I. Manduteanu, Elena 

Butoi, Romania 1326 

M34 THE EXTRACELLULAR TOLL LIKE RECEPTOR 4 REGULATOR RP105 

(CD180) AMELIORATES ATHEROSCLEROSIS VIA ITS ROLE ON B- 

CELLS 

J.C. Karper, S.C.A. de Jager, M.M. Ewing, M.R. De Vries, I. Bot, R. Arens, 

J.W. Jukema, Z. Mallat, C.J. Binder 6,7 , J. Kuiper, Paul H.A. Quax, The 

Netherlands, France, Austria 987 

M35 THERAPEUTIC TARGETING OF JAK/STAT/SOCS PATHWAY REDUCES 

ATHEROSCLEROSIS IN DIABETIC MICE 

Carlota Recio, A. Oguiza, I. Lazaro, B. Mallavia, J. Egido, C. Gomez- 

Guerrero, Spain 509 

M36 TWEAK/FN14 INTERACTION PROMOTES OXIDATIVE STRESS 

THROUGH NADPH OXIDASE ACTIVITY IN MACROPHAGES 

J. Madrigal-Matute 1,2 , Valvanera Fernández-Laso, C. Sastre, J. Egido, J.L. 

Martín-Ventura, G. Zalba, L.M. Blanco-Colio, Spain, USA 268 

M37 MOLECULAR MECHANISMS INVOLVED IN RESISTIN DEPENDENT 

ENHANCED MONOCYTES INFILTRATION IN THE VESSEL WALL 

Monica Madalina Pirvulescu, A.M. Gan, E. Butoi, D. Stan, V. Simion, M. 

Calin, I. Manduteanu, Romania 1400 

M38 CANNABINOIDS INCREASE ENDOGENOUS HYDROGEN SULFIDE (H2S) 

SIGNALING IN PERIVASCULAR ADIPOSE TISSUE BY IMPAIRING 

MITOCHONDRIAL BIOGENESIS 

Jerzy Bełtowski, A. Jamroz-Wiśniewska, Poland 1511 

41




Session 14: MULTIPLE ROLES OF HDL AND ITS TRANSPORTERS IN 

ATHEROSCLEROSIS AND RELATED DISEASES 

Moderator: Arie van Tol, Netherlands 


M82 HDL IMPROVES GLUCOSE HOMEOSTASIS AND REDUCES 

ATHEROSCLEROSIS IN TRAIL -/- APOE -/- MICE 

Belinda Di Bartolo, S.P. Cartland, K.-A. Rye, M.M. Kavurma 1,3 , Australia 941 

M83 LOWER ADRENAL STEROID PRODUCTION IN MICE AND HUMANS 

WITH LOW HDL-CHOLESTEROL DUE TO MUTATIONS IN LCAT 

Andrea Bochem, A. Holleboom, J.A. Kuivenhoven, M. van Eck, G.K. 

Hovingh, E. Stroes, M. Hoekstra, The Netherlands 1305 

M84 HIGH-DENSITY LIPOPROTEINS INHIBIT CHEMOKINE EXPRESSION 

AND PROLIFERATION OF VASCULAR SMOOTH MUSCLE CELLS 

Christina Bursill, E. van der Vorst, L. Vanags, L. Dunn, H. Prosser, K.-A. 

Rye, Australia, The Netherlands 1315 

M85 APOLIPOPROTEIN A- I INHIBITS LPS-INDUCED ATHEROSCLEROSIS IN 

APOE-/- MICE 

K. Yin, Chao-Ke Tang, China 1329 

M86 WHAT HAPPENS TO HDL PARTICLE FUNCTIONALITY FOLLOWING 

ACUTE MYOCARDIAL INFARCTION? 

Fabiana Hanna Rached 1,2 , L. Camont, M. Lhomme, M. Miname, R.D. 

Santos, C.V. Serrano Jr, M.J. Chapman, A. Kontush, Brazil, France 1415 

M87 EFFECTS OF THE CETP INHIBITOR DS-1442 ON REVERSE 

CHOLESTEROL TRANSPORT AND ATHEROSCLEROSIS 

Naoki Terasaka, Japan 1277 

M88 PARAOXONASE 1 (PON1) REGULATES THE CHOLESTEROL EFFLUX 

VIA THE PPARΓ-LXRΑ-ABCA1 PATHWAY 

Souade Ikhlef, H. Berrougui, P. Camponova, S. Loued, A. Khalil, Canada 1250 

M89 THE CELL SURFACE-RESIDENT ATP-BINDING CASSETTE 

TRANSPORTER A1 (ABCA1) IS UBIQUITINATED AND SORTED TO 

LYSOSOME FOR DEGRADATION 

Tadahaya Mizuno, H. Hayashi, S. Naoi, Y. Sugiyama, H. Kusuhara, Japan 1399 

42



M ODERATED POSTER SESSION B (contd.) 

Session 15: NOVEL INSIGHTS INTO THE ROLE OF MICRONUTRIENTS IN 

CARDIOVASCULAR RISK AND DISEASE 

Moderator: Eric Bruckert, France 


M158 VITAMIN D SUPPLEMENTATION REDUCES RESTENOSIS FOLLOWING 

CORONARY INTERVENTION IN HYPERCHOLESTEROLEMIC SWINE 

Devendra K. Agrawal, G.K. Gupta, M.G. Delcore, W.J. Hunter, USA 843 

M159 CONSUMPTION OF PLANT STEROL-ENRICHED FOODS MODESTLY 

INCREASES PLASMA/SERUM PLANT STEROL CONCENTRATIONS - A 

META-ANALYSIS 

Rouyanne T. Ras, H. Hiemstra, Y. Lin, M. Vermeer, G.S.M.J.E. Duchateau, 

E.A. Trautwein, The Netherlands 1022 

M160 EFFECTS OF DIETARY POLYPHENOLS AND/OR N-3 FATTY ACIDS ON 

OXIDATIVE STRESS IN PEOPLE AT HIGH CARDIOVASCULAR RISK: 

THE ETHERPATHS PROJECT 

Giuseppina Costabile, G. Annuzzi, L. Bozzetto, G. Della Corte, A. Giacco, 

M. Vitale, E. Griffo, S. Cocozza, G. Della Pepa, L. Di Marino, F. Pasanisi, G. 

Riccardi, A.A. Rivellese, Italy 1495 

M161 IS TAKING HEALTH FUNCTIONAL FOOD BENEFICIAL FOR 

CARDIOVASCULAR SYMPTOMS? 

Mi-Seung Shin, B.R. Kim, I.-M. Chung, D.-J. Choi, Republic of Korea 1559 

M162 PHYTOSTEROL SUPPLEMENTATION AFFECTS STEROL PLASMA 

LEVELS IN PATIENTS UNDER LIPID-LOWERING THERAPIES 

Livia Nascimento Matos, D.M. Tegani, F.A. Fonseca, S.A. Barbosa, S.H. 

Kasmas, R.M. Povoa, M.C. Izar, Brazil 145 

M163 FLAVANOL METABOLITES REDUCE MONOCYTE ADHESION AND 

MODULATE GENE EXPRESSION INVOLVED IN ATHEROSCLEROSIS 

DEVELOPMENT THROUGH MAPK-P38 OR NFKB-P65 SIGNALING 

PATHWAYS 

S. Claude, Dragan Milenkovic, C. Boby, C. Morand, France 438 

M164 DIETS RICH IN POLYPHENOLS AND/OR N-3 FATTY ACIDS REDUCE 

FASTING AND POSTPRANDIAL TRIGLYCERIDE- RICH LIPOPROTEINS: 

THE ETHERPATHS PROJECT 

Lutgarda Bozzetto, G. Annuzzi, R. Giacco, P. Cipriano, A. Mangione, G. 

Costabile, G. Anniballi, C. Vetrani, F. Conte, A. Rivieccio, L. Patti, G. 

Riccardi, A.A. Rivellese, Italy 1576 

43




Session 16: TREATMENT OF DYSLIPIDEMIA: FROM GUIDELINES TO GOALS AND 

MECHANISMS 

Moderator: Anders G. Olsson, Sweden 


M90 BRIDGED NUCLEIC ACID (BNA)-BASED ANTISENSE THERAPEUTICS 

TARGETING PCSK9 

Mariko Harada-Shiba, T. Yamamoto 1,2 , H. Yasuhara 1,2 , S. Wada 1,2 , F. 

Wada 1,2 , M.-A. Shibata, S. Obika, Japan 331 

M91 CHANGES IN BIOMARKER LEVELS WITH ROSUVASTATIN OR 

SIMVASTATIN IN COMBINATION WITH EZETIMIBE: RESULTS FROM 

GRAVITY 

Christie M. Ballantyne 1,2 , R. Hoogeveen 1,2 , V.A. Cain, M.K. Palmer, B.W. 

Karlson 5,6 , on behalf of the GRAVITY Study Investigators, USA, UK, Sweden1054 

M92 EFFECTS OF 12 WEEKS OF TREATMENT WITH RN316 (PF-04950615), A 

HUMANIZED MONOCLONAL ANTIBODY BINDING PCSK9, IN 

HYPERCHOLESTEROLEMIC SUBJECTS ON STATINS 

B. Gumbiner, T. Joh, C. Udata, P. Forgues, C. Baum, Pamela D Garzone, 

USA 1271 

M93 MIPOMERSEN, AN APOLIPOPROTEIN B SYNTHESIS INHIBITOR, 

REDUCES LDL-C IN HoFH PEDIATRIC PATIENTS 

Frederick J. Raal, S. Selvey, South Africa, USA 1368 

M94 INHIBITION OF PCSK9 WITH AMG 145, A MONOCLONAL ANTIBODY, 

REDUCES LP(A): INSIGHTS FROM THE POOLED PROFICIO STUDY 

Evan A. Stein, R.P. Giugliano, M.S. Sabatine, M.J. Koren, G. Langslet, H. 

Bays, D. Blom, M. Eriksson, R. Dent, S.M. Wasserman, F. Huang, T. Liu, M. 

Albizem, R. Scott, F. Raal, USA, Norway, South Africa, Sweden 1621 

M95 RAMIPRIL INCREASES WALKING ABILITY IN PERIPHERAL ARTERY 

DISEASE PATIENTS WITH CLAUDICATION; POTENTIAL ROLE OF 

INFLAMMATION, ADHESION, COAGULATION AND ANGIOGENESIS 

A.A. Ahimastos, A.K. Natoli, C. Latouche, M. Reddy-Luthmoodoo, J. 

Golledge, Bronwyn A. Kingwell, Australia 719 

M96 THE IMPACT OF LOW DENSITY LIPOPROTEIN RECEPTOR (LDLR) 

GENE MUTATION ON THE RESPONSE TO THERAPY IN PATIENTS 

WITH FAMILIAL HYPERCHOLESTEROLEMIA 

Vasiliki Metaxa, C. Pitsavos, I. Skoumas, E. Oikonomou, A. Miliou, C. 

Masoura, L. Papadimitriou, C. Stefanadis, Greece 1135 

M97 GUIDELINES EAS/ESC AND VERY HIGH RISK TYPE 2 DIABETIC 

PATIENTS IN A FRENCH REGISTRY: HOW FARE TO LDL-C GOAL? 

Michel Krempf, B. Cariou, M. Le Bras, N. Fuertes, E. Nobecourt, France 1608 

44




Session 16: TREATMENT OF DYSLIPIDEMIA: FROM GUIDELINES TO GOALS AND 

MECHANISMS (contd.) 

Moderator: Anders G. Olsson, Sweden 


M98 EFFECTS OF STATINS ON LIPID PROFILE IN CHRONIC KIDNEY 

DISEASE PATIENTS: A META-ANALYSIS OF RANDOMIZED 

CONTROLLED TRIALS 

D. Nikolic, S. Nikfar, P. Salari, M. Rizzo, K.K. Ray, M.J. Pencina, D.P. 

Mikhailidis, P.P. Toth, S.J. Nicholls, J. Rysz, M. Abdollahi, Maciej Banach, 

Lipid and Blood Pressure Meta-Analysis Collaboration Group, Italy, Iran, 

USA, UK 1414 

M99 EFFECTS OF HIGH-DOSE ATORVASTATIN MONOTHERAPY ON 

CIRCULATING PCSK9 LEVELS IN HETEROZYGOUS FAMILIAL 

HYPERCHOLESEROLEMIA 

Kouji Kajinami, E. Ueno, K. Tanabe, N. Fujioka, H. Akao, T. Tsuchiya, Y. 

Kawai, M. Kitayama, Japan 247 

Session 17: IMAGING OF THE ARTERIAL WALL AS A DIAGNOSTIC AND 

PROGNOSTIC INDICATOR OF ATHEROSCLEROTIC DISEASE 

Moderator: Lale Tokgozoglu, Turkey 

M165 DIFFERENCES IN CULPRIT RUPTURED PLAQUE MORPHOLOGY IN 

STEMI AND NSTEMI BY OPTICAL COHERENCE TOMOGRAPHY 

Konstantinos Toutouzas, A. Karanasos, E. Tsiamis, M. Riga, M. 

Drakopoulou, A. Synetos, A. Papanikolaou, K. Stathogiannis, D. Tousoulis, 

C. Stefanadis, Greece 557 

M166 THE EFFECT OF AGING ON ATHEROSCLEROTIC PLAQUE 

INFLAMMATION AND MOLECULAR CALCIFICATION: A PET CT 

IMAGING STUDY 

Björn Alexander Blomberg, A. Thomassen, J.A. Simonsen, M. Hildebrandt, 

A.C.P. Diederichsen, H. Mickley, A. Alavi, P.F. Høilund-Carlsen, Denmark, 

USA 1107 

M167 CONTRAST-ENHANCED ULTRASOUND: EARLY DIAGNOSIS METHOD 

FOR CAROTID ATHEROSCLEROSIS 

Adelina Baleanu-Curaj 1,2 , Germany 1131 

45




Session 17: IMAGING OF THE ARTERIAL WALL AS A DIAGNOSTIC AND 

PROGNOSTIC INDICATOR OF ATHEROSCLEROTIC DISEASE (contd.) 

Moderator: Lale Tokgozoglu, Turkey 


M168 CLINICAL AND ECHOCARDIOGRAPHIC FACTORS RELATED TO FALSE 

RESULTS OF EXERCISE TOLERANCE TEST 

Hakimeh Sadeghian, E. Hakki Kazazi, A. Zoroufian, M. Sahebjam, A. Jalali, 

M. Pashang, Iran 116 

18 

M169 F-FLUOROMETHYLCHOLINE PET IMAGING OF INFLAMED 

ATHEROSCLEROTIC PLAQUES IN MICE 

Sanna Hellberg, A. Roivainen 1,2 , J. Silvola, H. Liljenbäck 1,2 , P. Saukko, J. 

Knuuti, A. Saraste 1,4 , Finland 993 

M170 PROGNOSTIC VALUE OF CORONARY CALCIFICATION USING 64- 

SLICE CORONARY CT ANGIOGRAPHY FOR PREDICTING CORONARY 

DISEASE EXTENT AND CARDIAC EVENTS 

Y.-C. Liu, Zhonghua Sun, T. Chan, P.-K. Tsay, I.-C. Hsieh, C.-C. Chen, M.- 

S. Wen, Y.-L. Wan, Taiwan R.O.C., Australia, Canada 310 

M171 MULTILEVEL ASSESSMENT OF ATHEROSCLEROTIC BURDEN USING 

64-SLICE MULTI-DETECTOR CT IN ACUTE STROKE PATIENTS: 

COCASE STUDY, PART TWO 

Laura Mechtouff, L. Boussel, S. Cakmak, J.-L. Lamboley, A.-M. Schott, T.- 

H. Cho, L. Derex, N. Nighoghossian, P.-C. Douek, France 422 

46



MODERATED POSTER SESSION C 

Session 18: IMMUNITY AND ATHEROSCLEROSIS 

Moderator: Menno De Winther, Netherlands 


M39 THE BALANCE OF T-REGULATORY AND T-HELPER 1 AND 17 

LYMPHOCYTE SUBSETS IN BLOOD OF PATIENTS WITH CORONARY 


Alexandra Potekhina, E. Pylaeva, K. Raskina, A. Kuranova, S. Provatorov, 

E. Noeva, T. Arefieva, Russia 958 

M40 ROLE OF HIF1Α IN IMMUNE REGULATION OF ATHEROSCLEROSIS 

Sweena M. Chaudhari, J.C. Sluimer, M. Koch, H.D. Manthey, M. Busch, 

H.M. Hermanns, A. Zernecke 1,3 , Germany, The Netherlands 1454 

M41 ROLE OF PSGL-1 EXPRESSING CD4 T CELLS IN ACUTE CORONARY 

SYNDROME 

Kayoko Sato, K. Kitamura, K. Gomita, N. Hagiwara, Japan 1310 

M42 INDUCTION OF DENDRITIC-CELL MEDIATED T-CELL ACTIVATION BY 

MODIFIED BUT NOT NATIVE LDL: HEAT SHOCK PROTEINS AS 

POSSIBLE T-CELL ANTIGENS 

A. Liu, J. Ming, Y. He, R. Fiskesund, A. Frostegård, E. Ninio, S.-A. Karabina, 

Johan Frostegård, Sweden, France 1505 

M43 IMMUNOSENESCENCE CHARACTERIZED BY A RESTRICTED T CELL 

RECEPTOR REPERTOIRE IN ACUTE CORONARY SYNDROMES 

Roland Klingenberg, C. Brokopp, A. Grives, A. Courtier, N. Pasqual, E. 

Vlaskou, L.A. Altwegg, O. Gämperli, C.A. Wyss, S. Hoerstrup, W. Maier, R. 

Corti, U. Landmesser, T.F. Lüscher, C.M. Matter, Switzerland, France 961 

M44 T-CELL CO-STIMULATION BY CD28-CD80/86 AND ITS NEGATIVE 

REGULATOR CTLA-4 STRONGLY INFLUENCE ACCELERATED 

ATHEROSCLEROSIS DEVELOPMENT 

M.M. Ewing, R.C.M. de Jong, J.C. Karper, M.R. De Vries, R. Arens, J.W. 

Jukema, J. Kuiper, Paul H.A. Quax, The Netherlands 1020 

Session 19: METABOLIC REGULATION OF APOLIPROTEIN A-I-CONTAINING LIPOPROTEINS 

Moderator: Laurent Lagrost, France 

M100 AUTOANTIBODIES TO APOLIPOPROTEIN A-1 AND 

MYLEOPEROXIDASE AS PREDICTORS OF MAJOR ADVERSE 

CARDIOVASCULAR EVENTS AFTER CAROTID ENDARTERECTOMY 

Nicolas Vuilleumier, F. Montecucco, G. Spinella, S. Pagano, M. Bertolotto, 

B. Pane, A. Pende, P. Roux-Lombard, C. Combescure, F. Dallegri, F. Mach, 

D. Palombo, Switzerland, Italy 55 

47



MODERATED POSTER SESSION C (contd.) 

Session 19: METABOLIC REGULATION OF APOLIPROTEIN A-I-CONTAINING LIPOPROTEINS 

Moderator: Laurent Lagrost, France 


M101 HDLS PREVENT HEMORRHAGE INDUCED BY NEUTROPHIL 

ELASTASE 

Lourdes Maria Varela Perez, C. Hoteit, J.-B. Michel 1,2,3 , B. Ho-Tin-Noé 1,2 , O. 

Meilhac 1,2,4 , France 589 

M102 ADDITION OF S1P TO RECONSTITUTED HDL ENHANCE POST- 

ISCHEMIC PROTECTION IN VIVO 

M. Frias, V. Braunersreuther, F. Montecucco, S. Lecour, F. Mach, Richard 

William James, Switzerland, South Africa 475 

M103 INTRAPERITONEAL ADMINISTRATION OF 2S, APOA-I MIMETIC 

PEPTIDE, INHIBITS THE ATHEROSCLEROTIC LESION DEVELOPMENT 

IN HIGH FAT HIGH CHOLESTEROL-FED APOE -/- MICE 

B.-S. Lee, S.H. Han, Y. Kim, J. Yu, Jeong Euy Park, Republic of Korea 960 

M104 ARE EXTREMELY AND MODERATELY INCREASED LEVELS OF HDL 

CHOLESTEROL PROTECTIVE AGAINST ALL-CAUSE MORTALITY IN 

THE JAPANESE GENERAL POPULATION? 

Tomonori Okamura, Y. Murakami, H. Iso, A. Tamakoshi, M. Yamada, K. 

Miura, H. Ueshima, for the EPOCH-JAPAN Research Group, Japan 213 

M105 OXIDATIVE STRESS AND IMPAIRED HIGH-DENSITY LIPOPROTEIN 

ANTI-OXIDANT CAPACITY IN HUMAN ABDOMINAL AORTIC 

ANEURYSM 

Sandrine Delbosc 1,2 , T. Dejouvencel 1,2 , D. Diallo 1,2 , L. Louedec 1,2 , P. 

Rossignol 3,4 , G. Leseche 1,5 , J.B. Michel 1,2 , O. Meilhac 1,2 , France 673 

M106 THE ROLE OF APOA-I VS HDL-C AS A DETERMINANT OF CAROTID 

INTIMA-MEDIA-THICKNESS 

Sanni Söderlund, M. Jauhiainen, C. Ehnholm, M.-R. Taskinen, Finland 1258 

Session 20: CARDIOVASCULAR DISEASE AND ITS PREVENTION IN PATIENTS WITH 

CHRONIC INFLAMMATORY AND CHRONIC RENAL DISEASE 

Moderator: Naveed Sattar, UK 

M172 USEFULNESS OF NEW STAGING SYSTEM FOR PREDICTING 

CARDIOVASCULAR RISK AND ALL-CAUSE DEATH IN CHRONIC 

KIDNEY DISEASE: A VALIDATION STUDY 

Yorihiko Koeda, T. Segawa, F. Tanaka, M. Ohsawa, K. Tanno, K. Sakata, 

M. Nakamura, Iwate KENCO, Japan 28 

M173 ACCELERATED ADIPOSE TISSUE DYSFUNCTION AND 

CARDIOVASCULAR RISK IN INDIVIDUALS OF SOUTH ASIAN 

ETHNICITY 

Shirya Rashid, P. Power, M. Melone, Canada 198 

48





CHRONIC INFLAMMATORY AND CHRONIC RENAL DISEASE (contd.) 



M174 ANACETRAPIB DOSE-DEPENDENTLY DECREASES 

ATHEROSCLEROSIS DEVELOPMENT AND ADDS TO THE BENEFICIAL 

EFFECTS OF ATORVASTATIN IN APOE*3LEIDEN.CETP MICE 

S. Kühnast 1,2 , Sam J.L. van der Tuin 3,4 , L.M. Havekes 1,2,3 , P.C.N. Rensen, 

K. Willems van Dijk 3,4 , J.W.A. Van der Hoorn 1,2 , J.W. Jukema, H.M.G. 

Princen, The Netherlands 382 

M175 HIGH-DENSITY LIPOPROTEIN CHOLESTEROL EFFLUX CAPACITY 

PREDICTS GRAFT FAILURE BUT NOT CARDIOVASCULAR AND ALL- 

CAUSE MORTALITY IN RENAL TRANSPLANT RECIPIENTS 

Wijtske Annema, A. Dikkers, J.F. de Boer, R.P.F. Dullaart, J.-S.F. Sanders, 

S.J.L. Bakker, U.J.F. Tietge, The Netherlands 484 

M176 DIFFERENT ASSOCIATIONS BETWEEN VISCERAL AND 

SUBCUTANEOUS ADIPOSITY AND CORONARY ARTERY 

CALCIFICATION 

Sophie Eastwood, T. Tillin, J. Heasman, A. Wright, P. McKeigue, A. 

Hughes, N. Chaturvedi, UK 1099 

M177 THE EFFECT OF MAXIMUM BODY WEIGHT IN LIFEPOSTER BOARD 

NO. ON THE DEVELOPMENT OF CORONARY ARTERY DISEASE IN 

TYPE 2 DIABETES: MAXWEL-CAD STUDY 

Soo Lim, J.-W. Suh, S.M. Kang, M.K. Moon, H.C. Jang, S.H. Choi, Republic 

of Korea 1171 

M178 ESTROGENS CONTROL THE STROMA-VASCULAR FRACTION OF 

ADIPOSE TISSUE AND PREVENT HIGH-FAT DIET-INDUCED 

INFLAMMATION 

Elodie Riant, S. Handgraaf, A. Fabre, M. Guillaume, A. Zakaroff, D. Teixeira, 

A. Bouloumié, R. Burcelin, J.-F. Arnal, P. Gourdy 1,3 , France, Portugal 1373 

M179 DYSFUNCTIONAL HIGH-DENSITY LIPOPROTEIN AS A NOVEL 

CARDIOVASCULAR RISK FACTOR AFTER KIDNEY 

TRANSPLANTATION 

Chantal Kopecky, M. Haidinger, C. Kaltenecker, M. Antlanger, G. Marsche, 

M. Holzer, J. Kovarik, J. Werzowa, M. Hecking, M.D. Säemann, Austria 1383 

M180 EFFECTS OF STATINS ON CARDIOVASCULAR ENDPOINTS IN 

CHRONIC KIDNEY DISEASE PATIENTS: A META-ANALYSIS OF 

RANDOMIZED CONTROLLED TRIALS 

D. Nikolic, S. Nikfar 2,3 , P. Salari, D.P. Mikhailidis, M. Rizzo 1,6 , P.P. Toth, J. 

Rysz, M. Abdollahi, Maciej Banach, Italy, Iran, UK, USA, Poland 1409 

49





CHRONIC INFLAMMATORY AND CHRONIC RENAL DISEASE (contd.) 



M181 RENAL OUTCOMES OF USE OF STATINS IN CHRONIC KIDNEY 

DISEASE PATIENTS: A META-ANALYSIS OF RANDOMIZED 

CONTROLLED TRIALS 

Maciej Banach, D. Nikolic, S. Nikfar, P. Salari, D.P. Mikhailidis, M. Rizzo, 

P.P. Toth, M. Abdollahi, J. Rysz, Poland, Italy, Iran, UK, USA 1410 

Session 21: PRIMARY DYSLIPIDEMIA 

Moderator: Sebastiano Calandra, Italy 

M107 HIGH FREQUENCY AND MILD PHENOTYPE IN TRUE HOMOZYGOUS 

OR DOUBLE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 

CAUSED BY PCSK9 MUTATION (E32K) IN JAPAN 

Hiroshi Mabuchi, A. Nohara, T. Noguchi, J. Kobayashi, M.-A. Kawashiri, H. 

Tada, M. Mori, T. Inoue, C. Nakanishi, M. Yamagishi, A. Inazu, Hokuriku FH 

Research Group, Japan 307 

M108 ELEVATED MONOCYTE-DERIVED MICROPARTICLES IN PATIENTS 

WITH FAMILIAL HYPERCHOLESTEROLEMIA: A POTENTIAL 

ATHEROSCLEROSIS RISK MARKER 

Morten Hjuler Nielsen, H. Irvine, S. Vedel, B. Raungaard, H. Beck-Nielsen, 

A. Handberg, Denmark 457 

M109 AFTER LDLR, APOB AND PCSK9, APOE IS ANOTHER MAJOR GENE 

OF AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA 

Mathilde Varret 1,2 , M. Marduel, K. Ouguerram, V. Serre 2,4 , D. Bonnefont- 

Rousselot, K.E. Berge, M. Devillers, G. Luc, J.-M. Lecerf, L. Tosolini, M. 

Abifadel 1,9 , T.P. Leren, J.-P. Rabès 1,10,11 , C. Boileau 1,10,11 , The French 

Research Network on ADH, France, Norway, Lebanon 562 

M110 FAMILIAL HYPERCHOLESTEROLEMIA AND EXOME SEQUENCING: 

IDENTIFICATION OF THE FIRST COMPOUND HETEROZYGOTE FOR 

APOB AND PCSK9 MUTATIONS 

Marianne Abifadel 1,2 , G. Peloso 3,4 , J.-P. Rabès 1,5,6 , J.P. Pirruccello 3,4,7 , M. 

Varret, V. Carreau, N. Stitziel 3,4 , L. Tosolini, Y. Ghaleb, N. Gupta, S. Gabriel, 

A. Carrié, E. Bruckert 8,9 , S. Kathiresan 3,4 , C. Boileau 1,5,6 , France, Lebanon, 

USA 636 

M111 CIRCULATING PCSK9 IS A STRONG DETERMINANT OF PLASMA 

TRIGLYCERIDES, BUT NOT OF LDL CHOLESTEROL IN FAMILIAL 

DYSBETALIPOPROTEINEMIA 

Martijn Brouwers, M. van Greevenbroek, R. Konrad, J. Troutt, N. Schaper, 

C. Stehouwer, The Netherlands, USA 845 

50




Session 21: PRIMARY DYSLIPIDEMIA (contd.) 

Moderator: Sebastiano Calandra, Italy 


M112 PREVALENCE AND CLINICAL CHARACTERISTICT OF PATIENTS WITH 

HOMOZYGOUS AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA 

IN THE NETHERLANDS 

Barbara Sjouke, D.M. Kusters, I. Kindt, J. Besseling, J. Defesche, E.J. 

Sijbrands, J.E. Roeters van Lennep, A. Stalenhoef, S.W. Fouchier, J.J.P. 

Kastelein, G.K. Hovingh, The Netherlands 865 

M113 PCSK9 IN HETEROZYGOUS FH (HEFH) PATIENTS 

Mathias Chatelais, F. Petrides, D. Marais, G. Lambert 2,4 , France, Australia, 

South Africa 903 

M114 FAMILIAL COMBINED HYPERLIPIDEMIA: IDENTIFICATION OF LDLR 

MUTATIONS IN A POPULATION FROM SOUTHERN ITALY 

Maria Nicoletta D'Agostino 1,2 , M.D. Di Taranto, A. D'Angelo, A. Ruotolo, C. 

Giacobbe, G. Marotta, M. Gentile, P. Rubba, G. Fortunato 1,2 , Italy 1093 

M115 IDENTIFICATION OF NOVEL ANGPTL3 MUTATIONS ASSOCIATED 

WITH SEVERE HYPOBETALIPOPROTEINEMIA 

Patrizia Tarugi, R. Spina, E. Pinotti, A.B. Cefalù, D. Noto, E. Di Leo, I. 

Crisci, R. Miccoli, M. Averna, Italy 1263 

M116 LDL-CHOLESTEROL ASSOCIATED GWAS SNPS INTERFERE WITH THE 

CLINICAL PHENOTYPE OF FAMILIAL HYPERCHOLESTEROLEMIA 

Sigrid W. Fouchier, G.M. Dallinga-Thie, J.C. Defesche, J.J.P. Kastelein, S. 

Kathiresan, G.K. Hovingh, The Netherlands, USA 1493 

Session 22: INFLAMMATION AND INFECTION IN EXPERIMENTAL AND CLINICAL 


Moderator: Giuseppina Caligiuri, Italy 

M45 NLRP3 INFLAMMASOME ACTIVATION IN MONOCYTES OF PATIENTS 

WITH ACUTE CORONARY SYNDROME 

Kai Yin 1,2 , J.-F. Li, D. Xie, J.-Y. Peng, J.-J. Zhang, G. Wang, Q.-J. Gui 2,3 , Y.- 

L. Tu, Z.-S. Jiang, C.-K. Tang, China 97 

M46 MICRORNA-1264 UPREGULATES SUPPRESSOR OF CYTOKINE 

SIGNALING 3 EXPRESSION UNDER INFLAMMATORY CONDITIONS IN 

HUMAN CORONARY ARTERY SMOOTH MUSCLE CELLS 

Devendra K. Agrawal, K. Dhar, D. Pankajakshan, USA 836 

M47 CORRELATION BETWEEN ACTIVATION OF T LYMPHOCYTES AND 

HERPES VIRUSES IN ATHEROSCLEROTIC PLAQUES 

Jean-Charles Grivel, O. Ivanova, N. Pinegina, A. Lebedeva, E. Nikitskaya, 

A. Shpektor, L. Margolis, E. Vasilieva, USA, Russia 974 

51




Session 22: INFLAMMATION AND INFECTION IN EXPERIMENTAL AND CLINICAL 

ATHEROSCLEROSIS (contd.) 

Moderator: Giuseppina Caligiuri, Italy 


M48 HIV INFECTION AND LONG TERM PROGNOSIS OF ACUTE CORONARY 

SYNDROME. FINAL RESULTS FROM THE PACS-HIV STUDY 

Franck Boccara 1,2,3 , M. Mary-Krause, E. Teiger, S. Lang, P. Lim, K. Wahbi, 

P.G. Steg, C. Funck-Brentano, M. Slama, D. Costagliola, A. Cohen, France 1239 

M49 MYXOMAVIRUS-DERIVED SERPIN REDUCES VASCULAR 

INFLAMMATION AND PROLONGS SURVIVAL IN UNRELATED LETHAL 

HEMORRHAGIC MOUSE VIRAL SEPSIS 

H. Chen, D. Zheng, J. Davids, Alexandra Lucas, USA 1423 

M50 ELASTIN-DERIVED PEPTIDES POTENTIATE ATHEROSCLEROSIS 

THROUGH IMMUNE PI3KΓ 

Stephanie Gayral, R. Garnotel, A. Castaing-Berthou, S. Blaise, E. Berge, N. 

Malet, P. Maurice, L. Martiny, L. Martinez, L. Duca, M. Laffargue, France 1241 

M51 THE PRESENCE OF EXTRA DOMAIN A IN FIBRONECTIN INFLUENCES 

THE ACUTE INFLAMMATORY RESPONSE 

Vivek Krishna Pulakazhi Venu, P. Uboldi, A. Muro, A.L. Catapano 1,3 , G.D. 

Norata 1,4 , Italy 1299 

M52 CROSSROAD BETWEEN INFLAMMATION, IRON AND LIPIDS IN 

ATHEROGENESIS 

Liliana Marques 1,2,3 , L. Robert, A. Auriac, F. Canonne-Hergaux, L. Costa 1,2 , 

Portugal, France 1333 

M53 PHOSPHOINOSITIDE 3-KINASE GAMMA DRIVES CD4+ T CELLS 

INDUCED INTIMAL HYPERPLASIA 

N. Smirnova, S. Gayral, C. Pedros, N. Malet, A.P. Gadeau, M. Wymann, E. 

Hirsch, A. Sahoudi, L. Martinez, Muriel Laffargue, France, Switzerland, Italy1567 

Session 23: REGULATION OF ISCHEMIA REPERFUSION INJURY 

Moderator: Jean-Francois Arnal, France 

M54 THIOREDOXIN AND THIOREDOXIN REDUCTASE CONTROL TISSUE 

FACTOR ACTIVITY BY THIOL-REDOX-DEPENDENT MECHANISM 

P. Wang, Y. Wu, X. Li, X. Ma, Liangwei Zhong, China 1419 

M55 DAILY ISCHEMIC PRECONDITIONING PROVIDES SUSTAINED 

PROTECTION FROM ISCHEMIA AND REPERFUSION: A HUMAN STUDY 

Mary Clare Luca, K. McLaughlin, A. Liuni, J.D. Parker, Canada 778 

52




Session 23: REGULATION OF ISCHEMIA REPERFUSION INJURY (contd.) 

Moderator: Jean-Francois Arnal, France 


M56 HIGH ESTROGEN LEVELS DURING THE LATE FOLLICULAR PHASE OF 

THE MENSTRUAL CYCLE PROVIDE PROTECTION FROM ISCHEMIA 

AND REPERFUSION INJURY 

Mary Clare Luca, A. Liuni, S. Mak, T. Gori, H. Paula, J. Parker, Canada, 

Germany 914 

M57 RELATION BETWEEN LOCAL AND SYSTEMIC LEVELS OF OXIDATIVE 

STRESS AND NO-REFLOW IN MYOCARDIAL INFARCTION 

Karim Stamboul, J. Lorin, A. Kahli, M. Zeller, L. Rochette, Y. Cottin 1,2 , L. 

Lorgis 1,2 , C. Vergely, France 1375 

M58 INCREASED OEDEMA AND DECREASED CARDIAC FUNCTION IN RIP2- 

DEFICIENT MICE AFTER MYOCARDIAL ISCHEMIA 

Annika Lundqvist, M. Scharin Täng, M. Lindbom, B. Redfors, K. Skålén, M. 

Heyden, J. Borén, M. Levin, Sweden 1442 

Session 24: EXERCISE AND CARDIOVASCULAR HEALTH: BOTH QUANTITY AND 

QUALITY COUNT 

Moderator: Matti Jauhiainen, Finland 

M182 ASSESSMENT OF PHYSICAL SELF-EFFICACY IS PREDICTIVE FOR 

CARDIOVASCULAR EVENTS DURING 13-YEARS OF FOLLOW-UP IN 

INITIALLY HEALTHY 58-YEAR-OLD MEN 

Caroline Schmidt, G. Bergström, Sweden 202 

M183 EXERCISE TRAINING REDUCES VISCERAL FAT INFLAMMATION IN 

OBESE WOMAN: F-18 FDG TOF (POSTER BOARD NO. OF FLIGHT) 

PET/CT STUDY 

Sungeun Kim, H.S. Seo, E.J. Kim, J.H. Na, J.H. Park;, C.U. Choi, H.E. Lim, 

J.W. Kim, S.-W. Rha, C.-G. Park, D.J. Oh, Republic of Korea 413 

M184 ENDURANCE EXERCISE LOWERS AORTAL PLAQUE FORMATION IN 

YOUNG APOE -/- MICE AND LEADS TO AN INCREASE IN TREGS 

Bojana Jakic, M. Carlsson, C. Grundtman, G. Wick, Austria 888 

M185 MODULATING EFFECT OF CARDIAC REHABILITATION ON 

AUTONOMIC NERVOUS SYSTEM FUNCTION IN CORONARY ARTERY 

DISEASE PATIENTS 

T. Pereira-da-Silva, Marta Nogueira, A. Abreu, P. Rio, N. Santos, T. Alves, 

S. Silva, R. Cruz Ferreira, Portugal 895 

53




Session 24: EXERCISE AND CARDIOVASCULAR HEALTH: BOTH QUANTITY AND 

QUALITY COUNT (contd.) 

Moderator: Matti Jauhiainen, Finland 


M186 AEROBIC EXERCISE TRAINING IS THE BEST TREATMENT TO 

INCREASE THE HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN 

PATIENTS WITH DYSLIPIDEMIA 

Hiroaki Tanaka, R. Michishita, H. Kumahara, M. Ayabe, T. Tobina, E. 

Yoshimura, T. Matsuda, Y. Higaki, A. Kiyonaga, Fukuoka University 

Randomized Control Trial (FURCT), Japan 918 

M187 THE ROLE OF PHYSICAL ACTIVITY AND BROWN ADIPOSE TISSUE IN 

THE AMELIORATION OF METABOLIC SYNDROME DISORDERS IN 

HEREDITARY HYPERTRIGLYCERIDEMIC RATS 

Vojtech Skop, H. Malinska, J. Trnovska, M. Huttl, L. Kazdova, Czech 

Republic 1025 

Session 25: CV RISK FACTORS 2 

Moderator: Anne Tybjaerg-Hansen, Denmark 

M188 ANALYSIS OF THE BASAL DATA ON INTIMA-MEDIA THICKNESS OF 

THE SPANISH MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY 

OF ATHEROMATOSIS IN CKD (NEFRONA) 

Àngels Betriu, M. Borràs, M. Martinez, J.M. Valdivielso, E. Fernández, and 

the Investigators of the Nefrona Study, Spain 498 

M189 ARTERIAL STIFFNESS AND LP(A) LEVELS AS PROGNOSTIC FACTORS 

FOR FIRST-EVER ISCHEMIC STROKE IN A GREEK POPULATION 

SAMPLE 

Christina Voulgari, S. Tesfaye, C. Karagiannis, S. Paximadas, S. Pagoni, 

Greece, UK 312 

M190 REDUCED 25-HYDROXYVITAMIN D CONCENTRATIONS AND 

INCREASED RISK OF VENOUS THROMBOEMBOLISM, MYOCARDIAL 

INFARCTION, AND ISCHEMIC STROKE 

Peter Brøndum-Jacobsen, M. Benn, A. Tybjærg-Hansen, B.G. 

Nordestgaard, Denmark 571 

M191 MULTIMARKER APPROACH COMBINING BIOMARKERS OF 

HAEMOSTASIS, INFLAMMATION AND ENDOTHELIAL ACTIVATION, 

CHEMOKINES AND ADIPOCYTOKINES TO PREDICT ISCHAEMIC 

STROKE 

Christof Prugger, G. Luc, B. Haas, P.-E. Morange, J. Ferrieres, P. Amouyel, 

F. Kee, P. Ducimetiere, J.-P. Empana, France, UK 1261 

54




Session 25: CV RISK FACTORS 2 (contd.) 

Moderator: Anne Tybjaerg-Hansen, Denmark 


M192 GENETICALLY REDUCED NONFASTING TRIGLYCERIDES AND 

REDUCED ALL-CAUSE MORTALITY 

M. Thomsen, A. Varbo, A. Tybjærg-Hansen, Børge Nordestgaard, Denmark1501 

M193 IL-18 +183 A/G POLYMORPHISM, SINGLE AND IN COEXISTENCE WITH 

THE MMP-9 -1562 C/T POLYMORPHISM, ASSOCIATES WITH CLINICAL 

EVENTS IN CAD 

Trine Baur Opstad 1,2 , A.Å. Pettersen 1,2 , H. Arnesen 2,3,4 , I. Seljeflot 1,2,4 , 

Norway 555 

M194 GENETIC DEFECTS IN PROTEIN GLYCOSYLATION AS CAUSE OF 

DYSLIPIDEMIA 

Adriaan G. Holleboom, G.K. Hovingh, M.M. Motazacker, G.M. Dallinga- 

Thie, J.A. Kuivenhoven, H. Aerts, R. Wevers, E.S.G. Stroes, D.J. Lefeber, 

The Netherlands 896 

M195 THE NATURAL HISTORY OF CORONARY OBSTRUCTIONS IS 

INFLUENCED BY THE PRESENCE OF ADJACENT PROXIMAL 

OBSTRUCTIONS 

Masaya Tsuda, S. Takahashi, M.I. Papafaklis, A.P. Antoniadis, S. Mizuno, 

Y. Makita, S. Nakamura, S. Gohara, M. Shibata, A. Namiki, T. Matsumura, S. 

Tanaka, A.U. Coskun, S. Saito, C.L. Feldman, P.H. Stone, PREDICTION 

Study Investigators, USA, Japan 1521 

55

Monday, June 3 – Wednesday, June 5, 2013 

10:00-17:00 Poster Area Track 1 

POSTERS TRACK 1: VASCULAR BIOLOGY OF THE ARTERIAL WALL 


Endothelial cells and function 

1 BLOOD FLOW INVESTIGATION AT THE BOUNDARY LAYER IN 


Merab Beraia, E. Beraia, Georgia 156 

2 ASSOCIATION BETWEEN CIRCULATING ENDOTHELIAL PROGENITOR 

CELLS AND TRADITIONAL CARDIOVASCULAR RISK FAKTORS IN 

PATIENTS WITH CORONARY ARTERY DISEASE 

Alexander E. Berezin, A.A. Kremzer, Ukraine 267 

3 RAPAMYCIN ATTENUATES ENDOTHELIAL CELL OXIDATIVE 

APOPTOSIS INDUCED BY LOW SHEAR STRESS THROUGH 

PROMOTION OF SESTRIN1 EXPRESSION VIA MTORC2 INHIBITION 

Junxia Zhang, Z. Wang, S. Chen, China 277 

4 CLINICAL FEATURES OF PATIENTS WITH CRITICAL LIMB ISCHEMIA 

WHO RESPONDED TO AUTOLOGOUS MONONUCLEAR CELL 

TRANSPLANTATION FOR THERAPEUTIC ANGIOGENESIS 

Naoyoshi Aoyama, M. Nishinari, O. Shinichi, A. Kanai, N. Chiharu, M. 

Hirata, T. Izumi, Japan 318 

5 HIGH DENSITY LIPOPROTEINS LIMIT NEUTROPHIL-INDUCED DAMAGE 

TO THE BLOOD BRAIN BARRIER IN VITRO 

Bao Quoc Dang, B. Lapergue 1,2,3 , A. Tran-Dinh 1,2,3 , D. Diallo, J.-A. 

Moreno 1,4 , M. Mazighi 1,2,3 , J.-B. Michel 1,5 , P. Amarenco 1,2,3 , O. Meilhac 1,2,3 , 

France, Spain 508 

6 THE ROLE OF THE GLYCOCALYX IN ENDOTHELIAL CELL RESPONSE 

TO WALL SHEAR STRESS 

Karli McDonald, S. Cooper, P. Jonak, R.L. Leask, Canada 618 

7 SEX DIFFERENCES IN MESENTERIC NITRIC OXIDE PRODUCTION AND 

NADPH OXIDASE MRNA EXPRESSION OF STREPTOZOTOCIN- 

INDUCED DIABETIC RATS 

R. Zhang, X. Han, L. Anderson, Roshanak Rahimian, USA 639 

8 RESEARCHING OF THE ENDOTHELIAL DYSFUNCTION MARKERS AND 

THE APOPTOSIS OF ENDOTHELIOCYTES DURING EXPERIMENTAL 

ATHEROSCLEROSIS IN A RAT MODEL 

Svetlana Kryvorot, T. Vladimirskaya, I. Sved, N. Moskaleva, Belarus 754 

9 L-ARGININE INHIBITS ENDOTHELIAL CELL APOPTOSIS IN RABBIT 

MODEL OF HYPERCHOLESTEROLEMIA 

Shaghayegh Haghjooy Javanmard, M. Nematbakhsh, Iran 1032 

56

POSTERS TRACK 1 VASCULAR BIOLOGY OF THE ARTERIAL WALL (contd.) 


10 SYNDECAN-4 INTRACELLULAR DOMAIN ORCHESTRATES 

RANTES/CCL5-INDUCED ENDOTHELIAL CELL MIGRATION BY 

MODULATION OF PKC ACTIVATION 

Loic Maillard, V. Friand, N. Suffee, H. Hlawaty, O. Haddad, F. Chmilewsky, 

O. Oudar, N. Saito, L. Martin, D. Letourneur, N. Charnaux 1,5 , A. Sutton 1,5 , 

France, Japan 1052 

11 MNA-INDUCED PGI2 RELEASE IN THE ISOLATED, PRESSURIZED AND 

PERFUSED CAROTID ARTERY 

Magdalena Sternak, B. Sitek, T. Wójcik, A. Broniec, B. Proniewski, A. 

Fedorowicz, S. Chłopicki 1,2 , Poland 1072 

12 ENDOTHELIAL SR-B1 LIMITS CEREBRAL INFARCTION IN A STROKE 

MODEL 

Alexy Tran-Dinh 1,2,3 , L. Varela-Perez, S. Gilibert 4,5,6 , B. Lapergue 1,3 , D. 

Diallo, L. Louedec, S. Delbosc, J.-B. Michel 1,2,7 , P. Amarenco 1,2,3 , T. Huby 4,5,6 , 

O. Meilhac 1,2,3 , France 1078 

13 UNCOUPLING OF ENOS IS RELATED TO ADMA ACCUMULATION IN 

THE ENDOTHELIUM ADJACENT TO ATHEROSCLEROTIC LESIONS 

Leszek Kalinowski, M. Stepnowska, A. Siekierzycka, M. Wozniak, A. 

Szeffler, L.W. Dobrcucki, J. Wojciechowski, J. Rogowski, I.T. Dobrucki, 

Poland, USA 1127 

14 ENDOTHELIAL EXPRESSIONS OF ENDOGLIN AND ENOS DIFFER 

BETWEEN C57BL/6J AND C3H/HEJ MICE AFTER CHOLESTEROL DIET - 

IMPLICATIONS IN ENDOTHELIAL DYSFUNCTION? 

Jana Pfeiferova, Z. Strasky, K. Jezkova, P. Nachtigal, Czech Republic 1213 

15 ENDOTHELIAL RESPONSE TO SUNITINIB TREATMENT IN 

NORMOTENSIVE AND HYPERTENSIVE RATS - PILOT STUDY 

Ivana Nemeckova, O. Lencova, M. Sterba, P. Nachtigal, Czech Republic 1289 

16 CHANGE OF CONCEPT ABOUT THE REGULATION OF MONOCYTE 

CHEMOATTRACTANT PROTEIN-1 PRODUCTION IN HUMAN 

ENDOTHELIAL CELLS STIMULATED WITH ANGIOTENSIN II 

María Isabel Castiñeiras-Landeira, B.K. Rodiño-Janeiro, B. Paradela- 

Dobarro, S. Raposeiras-Roubín, M. González-Peteiro, R. Ucieda-Somoza, 

J.R. González-Juanatey, E. Alvarez, Spain 1372 

17 DIFFERENTIAL EFFECTS OF EARLY GLYCATED PROTEINS AND 

ADVANCED GLYCATION END-PRODUCTS ON ENDOTHELIAL 

RESPONSES INVOLVED IN DIABETIC VASCULAR COMPLICATIONS 

Beatriz Paradela-Dobarro, B.K. Rodiño-Janeiro, J. Alonso, M.I. Castiñeiras- 

Landeira, S. Raposeiras-Roubín, M. González-Peteiro, R. Ucieda-Somoza, 

J.R. González-Juanatey, E. Alvarez, Spain 1388 

18 EFFECT OF ENDOTHELIAL PROGENITOR CELLS ON PLATELET 

ACTIVATION IN VITRO 

Vasilios Chantzichristos, F. Gkrozou, M. Paschopoulos, A. Tselepis, 

Greece 1460 

57



19 EFFECTS OF PURE TOCOTRIENOLS ON ENDOTHELIAL ACTIVATION 

IN PREVENTING EXPERIMENTALLY INDUCED SEVERE 


Nurmazni Zulkafli, T.H. Abdul Rahman, N.K. Mohd Kornain, N.F. Hassim, 

A. Mohd Ismail, H. Mohd Nawawi, Malaysia 1491 

20 LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY IN MICE 

ALTERS ENDOTHELIAL FUNCTION 

Stefano Manzini, P. Cinquanta, C. Pinna, C. Parolini, M. Busnelli, L. 

Calabresi, G. Chiesa, G. Franceschini, Italy 1504 

Endothelial dysfunction clinical assessment 

21 INCREASED ASYMMETRIC DIMETHYLARGININE LEVEL IS THE MOST 

POWERFUL FACTOR ASSOCIATED WITH LOW HDL LEVELS IN 

PATIENTS WITH ACUTE MYOCARDIAL INFARCTION 

Julie Lorin, J.-C. Guilland, C. Korandji, Y. Cottin 1,2 , L. Rochette, C. Vergely, 

M. Zeller, France 17 

22 SYMMETRIC DIMETHYLARGININE SERUM LEVEL AS A NEW MARKER 

OF LEFT VENTRICULAR EJECTION FRACTION IN PATIENTS WITH 

ACUTE MYOCARDIAL INFARCTION 

Julie Lorin, J.-C. Guilland, C. Korandji, P. Gambert, Y. Cottin 1,3 , L. Rochette, 

C. Vergely, M. Zeller, France 24 

23 DYSLIPIDEMIA, ARTERIAL STIFFNESS AND ENDOTHELIAL 

DYSFUNCTION; UTILITY OF THE RADIAL ARTERY PULSE WAVE 

ANALYSIS 

Pablo Corral, F. Clara, G. Blanco, Argentina 41 

24 ANALYSIS OF ARTERIAL FUNCTION IN ADULTS WITH A HISTORY OF 

KAWASAKI DISEASE 

Hisako Tobayama, H. Fukunaga, K. Takahashi, T. Furukawa, H. Oda, K. 

Akimoto, M. Kishiro, T. Shimizu, Japan 786 

25 ENDOTHELIAL DYSFUNCTION AND AUTONOMIC NERVOUS SYSTEM 

ACTIVITY IN THE DEVELOPMENT OF CORONARY ARTERY DISEASE 

Tonka Kurteva, D. Somleva, N. Spasova, E. Kinova, A. Goudev, Bulgaria 959 

26 FMD TEST RESULTS CAN PREDICT SPONTANEOUS AND EFFECTIVE 

PHARMACOLOGICAL REPERFUSION IN STEMI PATIENTS 

Anna Kalinskaya, I. Urazovskaya, E. Vasilieva, A. Shpektor, Russia 975 

27 NON-INVASIVE DETECTION OF ENDOTHELIAL PERMEABILITY AND 

FUNCTION BY MRI 

Alkystis Phinikaridou, M.E. Andia, A. Protti, R.M. Botnar, UK 1014 

28 SMALL LDL CHOLESTEROL CONCENTRATION IS A DETERMINANT OF 

ENDOTHELIAL DYSFUNCTION BY PERIPHERAL ARTERY TONOMETRY 

IN JAPANESE MEN 

Ryotaro Takahashi, K. Okumura, N. Taguchi, M. Suzuki, N. Ikeda, T. 

Murohara, Japan 1607 

58



29 THE EFFECT OF ENDOTHELIAL DYSFUNCTION BIOCHEMICAL 

MARKERS AND FLOW-MEDIATED DILATION ON THE PREDICTIVITY OF 

EXERCISE ECG 

Muhammed Sait Toprak, H. Sonmez, Z. Ozturk, H. Ekmekci, O.B. Ekmekci, 

H.A. Cakmak, B. Ikitimur, B. Karadag, B. Ilerigelen, Turkey 1610 

Smooth muscle cells 

30 NEUROPILIN ROLE IN THE DEVELOPMENT OF NEOINTIMAL 

HYPERPLASIA 

Caroline Pellet-Many, V. Mehta, I. Evans, J. Ruivo, I. Zachary, UK 446 

31 EFFECTS OF A NOVEL BIOISOSTER OF FLAVONOIDS ON AORTIC 

SMOOTH MUSCLE CELL PROLIFERATION AND INFLAMMATION 

Cassandra Sentieri, C. Saponaro, S. Del Turco, S. Sartini, C. La Motta, G. 

Basta, Italy 482 

32 S100A12 PROTEIN INDUCES THE PROLIFERATION AND 

CALCIFICATION OF VASCULAR SMOOTH MUSCLE CELLS 

Eiko Matsuoka, Y. Mori, A. Kosaki, Japan 542 

33 TRANSCRIPTOME ANALYSIS IDENTIFIES NOVEL MECHANISMS OF 

CAMP-MEDIATED GROWTH ARREST IN VSMC: PKA AND EPAC 

SYNERGISE TO SUPPRESS EGR-1 EXPRESSION 

Tomomi Kimura-Wozniak, C. Hindmarch, M. Bond, UK 807 

34 MECHANICAL STRETCH-INDUCED MMP-2 PRODUCTION REQUIRES 

ACTIVATION OF PDGFR-Β AND AKT IN VASCULAR SMOOTH MUSCLE 

Kyo Won Seo, J.U. Bae, Y.H. Kim, S.Y. Park, S.J. Lee, C.D. Kim, Republic 

of Korea 929 

35 PLATELET ACTIVATING FACTOR ENHANCES MMP-2 PRODUCTION IN 

RAT AORTIC VASCULAR SMOOTH MUSCLE CELLS VIA Β-ARRESTIN2- 

DEPENDENT ERK SIGNALING PATHWAY 

Yun Hak Kim, J. Bae, K.W. Seo, S.J. Lee, S.Y. Park, C.D. Kim, Republic of 

Korea 930 

36 EXTRACELLULAR S100A4 PROMOTES ARTERIAL SMOOTH MUSCLE 

CELL PHENOTYPIC TRANSITION: IMPLICATION IN 

ATHEROSCLEROSIS AND RESTENOSIS 

Chiraz Chaabane, C.W. Heizmann, M.-L. Bochaton-Piallat, Switzerland 1013 

37 NUCLEAR TARGETING OF APELIN IN VASCULAR SMOOTH MUSCLE 

CELLS: IMPLICATIONS IN CELL PROLIFERATION AND 

ATHEROSCLEROTIC PLAQUE FORMATION? 

Chiraz Chaabane, C. Brun, A. Roatti, Y. Audigier, A.J. Baertschi, M.-L. 

Bochaton-Piallat, Switzerland, France 1043 

38 PARADOXICAL STIMULATION OF MATRIX METALLOPROTEINASE 

EXPRESSION BY BISPHOSPHONATES IN RAT VASCULAR SMOOTH 

MUSCLE CELL CULTURE 

Mehmet Zuhuri Arun, B. Reel, G.B. Sala-Newby, M. Bond, A.C. Newby, 

Turkey, UK 1048 

59



39 CALMODULIN EXPRESSION DISTINGUISHES THE SMOOTH MUSCLE 

CELL POPULATION OF THE HUMAN CAROTID PLAQUE 

Matteo Coen, G. Marchetti, P.M. Palagi, C. Zerbinati, G. Guastella, T. 

Gagliano, F. Bernardi, F. Mascoli, M.-L. Bochaton-Piallat, Switzerland, Italy 1082 

40 INFLUENCE OF THE PHENOTYPE OF VASCULAR SMOOTH MUSCLE 

CELLS ON THE RENIN-ANGIOTENSIN SYSTEM IN RAT 

Sabrina Bennia, O. Lohez, G. Bricca, France 1528 

41 EPAC 2 IS INVOLVED IN THE INFLAMMATORY RESPONSE OF TRANS- 

DIFFERENTIATED AC8-EXPRESSING VASCULAR SMOOTH MUSCLE 

CELLS 

Amélie Vromman, N. Clément, K. Blirando, I. Limon, France 1570 

42 HEAT SHOCK PROTEIN-60 MEDIATED INDUCTION OF VASCULAR 

SMOOTH CELL PROLIFERATION THROUGH NUCLEOCYTOPLASMIC 

TRAFFICKING 

Justin F. Deniset 1,2 , M. Hlaváčková, T.E. Hedley, M.N. Chahine, E. Dibrov, 

G.N. Pierce 1,2 , Canada 1627 

43 INTRINSIC SEROTONERGIC SYSTEM IN HUMAN CORONARY ARTERY 

SMOOTH MUSCLE CELLS: POTENTIAL IMPLICATION IN CORONARY 

ARTERY DISEASE 

Vithya Selvaraj, K. Baskar, S. Sur, D.K. Agrawal, USA 1642 

44 THE EFFECTS OF ALENDRONATE ON CONTRACTILE RESPONSES IN 

HUMAN LEFT INTERNAL MAMMARY ARTERY 

Buket Reel, M. Arun, M. Guzeloglu, G. Albayrak, E. Hazan, Turkey 1220 

Extracellular matrix and calcification 

45 WALL PROPERTIES OF THE APOLIPOPROTEIN E-DEFICIENT MOUSE 

AORTA 

Aristotelis Agianniotis, N. Stergiopulos, Switzerland 182 

46 PREVENTION OF CARDIAC EVENTS IN PATIENTS WITH 

ATHEROSCLEROSIS UNDERGOING VASCULAR OPERATIONS 

Elena Medvedeva, Y. Shchukin, E. Seleznev, Russia 272 

47 EFFECT OF DIFFERENT TYPES OF PLAQUE ON HEMODYNAMIC 

CHANGES TO THE LEFT CORONARY ARTERY 

T. Chaichana, Zhonghua Sun, Australia 313 

48 CHRONIC ANGIOTENSIN II INFUSION CHANGES MICRORNA PROFILE 

IN MURINE AORTAS 

Maria Gabriela Dulak, M. Siedlinski, T. Mikolajczyk, R. Nosalski, R. Korbut, 

A. Jozkowicz, T.J. Guzik, Poland 399 

49 VITRONECTIN EXPRESSION IN AORTIC VALVES FROM SUBJECTS 

WITH SEVERE AORTIC STENOSIS 

M. Ledesma, L.M. Salazar-Pelaez, M. Correa, J.S. Jaramillo, S. Franco, Lina 

Maria Yassin-Norena, A.M. Herrera, Colombia 627 

60



50 DIFFERENTIAL GENE EXPRESSION IN CAROTID PLAQUES WITH 

CALCIFICATION 

Hiroyuki Katano 1,2 , K. Yamada, Japan 687 

51 INTERPLAY OF INFLAMMATION AND OXIDATIVE STRESS IN HUMAN 

ABDOMINAL AORTIC ANEURYSMS 

Agnieszka Sagan, W. Mrowiecki, T. Mikolajczyk, K. Urbanski, G. Filip, B. 

Kapelak, T. Mrowiecki, R. Korbut, T. Guzik, Poland 868 

52 ATHEROSCLEROSIS AND FIBRO-DYSPLASIA: TWO 

PATHOPHYSIOLOGICAL STREAMS INTO THE CALCIFIC AORTIC 

VALVE DISEASE. HOW COULD WE STEM THE DISEASE 

PROGRESSION? 

A. Vianello, S. Perlini, S. Cappelli, G. Palladini, A. Cerillo, D. della Latta, D. 

Chiappino, P. Tanganelli, M. Glauber, S. Berti, Annamaria Mazzone, Italy 884 

53 ELASTIN PEPTIDES, NEW REGULATORS OF INSULIN RECEPTOR 

B. Romier-Crouzet, C. Kawecki, S. Baud, P. Maurice, L. Duca, L. Debelle, V. 

Durlach, Sebastien Blaise, France 948 

54 CORONARY CALCIFICATION CORRELATES WITH VALVE AND ROOT 

CALCIFICATION IN ISOLATED AORTIC STENOSIS: AN EVIDENCE FOR 

CARDIAC-BASE CALCIFICATION DISEASE 

P. Hällgren, A. Holmgren, K. Sörensen, U. Näslund, K. Riklund, Michael 

Henein, Sweden 967 

55 DEREGULATION OF SMOOTH MUSCLE CELL CYTOSKELETON WITHIN 

THE HUMAN ATHEROSCLEROTIC CORONARY MEDIA LAYER 

Fernando Vivanco, Spain 976 

56 TLR ACCESSORY MOLECULE RP105 (CD180) IS INVOLVED IN POST- 

INTERVENTIONAL VASCULAR REMODELING AND SOLUBLE RP105 

MODULATES NEOINTIMA FORMATION 

J.C. Karper, M.M. Ewing, M.R. De Vries, S.C.A. de Jager, E.G. Huizinga, J. 

Kuiper, J.W. Jukema, Paul Quax, The Netherlands 997 

57 THE EFFECT OF PROLONGED SYSTEMIC DOXYCYCLINE THERAPY 

ON SERUM TISSUE DEGRADING PROTEINASES IN CORONARY 

BYPASS PATIENTS 

Hatem Alfakry, I. Kormi, P. Pussinen, J. Sinisalo, T. Sorsa, Finland 1036 

58 ROLE OF S100A4 IN EARLY STAGE OF ATHEROSCLEROSIS AND 

ANEURYSM OF THE AORTA 

Ziad Touat, V. Ollivier, L. Louedec, K. Guedj, J.-B. Michel, G. Jondeau 1,2 , 

France 1096 

59 ATHEROSCLEROTIC PLAQUES IN EX VIVO SYSTEM 

Anna Lebedeva, J.-C. Grivel, O. Ivanova, A. Shpektor, E. Vasilieva, L. 

Margolis, O. Ivanova, Russia, USA 1125 

60 ZOLEDRONATE ATTENUATES ANGIOTENSIN II-INDUCED ABDOMINAL 

AORTIC ANEURYSM THROUGH INACTIVATION OF RHO/ROCK 

DEPENDENT JNK AND NF-KB PATHWAY 

Po-Hsun Huang, S.-H. Tsai, S.-J. Lin, Taiwan R.O.C. 1227 

61



61 FGF-23 AND CAROTID ATHEROSCLEROSIS: A DANGEROUS AFFAIR 

Angela Koverech, F. Del Porto, L. Ferri, C. Fantozzi, L. Rizzo, M. Taurino, 

M. Proietta, Italy 1259 

62 PROTEOMIC ANALYSIS OF THE ELASTIC ARTERIAL MEDIA IN AGING 

Motoji Sawabe, S. Yoshida, A. Hamamatsu, T. Toda, T. Arai, M. Iwamoto, T. 

Endo, Y. Miura, Japan 1207 

63 ROLE OF FIBRONECTIN EXTRA DOMAIN A IN CARDIOVASCULAR 

DISEASE: EVIDENCES FROM ANIMAL MODELS OF 


V.K. Pulakazhi Venu, Giuseppe Danilo Norata 1,2 , P. Uboldi, A. Muro, L. 

Arnaboldi, A. Corsini, A.L. Catapano 1,4 , Italy 1300 

64 WHOLE TRANSCRIPTOME SEQUENCING OF APOE-KO MOUSE AORTA 

REVEALS DIFFERENTIALLY EXPRESSED GENES IN ADVANCED 


Stefano Manzini, M. Chiara, M. Busnelli, C. Parolini, G. Ganzetti, C.R. 

Sirtori, D.S. Horner, G. Chiesa, Italy 1522 

65 EXTRACELLULAR MATRIX PROTEINS FROM PIG ARTERIES: FROM 

TISSUE TO BLOOD MARKERS OF ATHEROGENESIS 

Silvia Rocchiccioli, G. Pelosi, A. Cecchettini 1,2 , F. Viglione, M. Puntoni, L. 

Citti, O. Parodi, M.G. Trivella, Italy 1540 

66 REGULATION OF ELASTIN SYNTHESIS IN AORTA THROUGH A CA 2+ - 

ERK-DEPENDANT PATHWAY 

M. Lannoy, C. Choqueux, L. Louedec, Marie-Paule Jacob, France 1571 

67 MMP-13 PREDOMINATES OVER MMP-8 AS THE FUNCTIONAL 

INTERSTITIAL COLLAGENASE IN MOUSE ATHEROMATA 

Thibaut Quillard, H.A. Araújo, Y. Tesmenitsky, P. Libby, USA 1647 

Gene expression 

68 MIR-21, -133B, -146A, -150, -155, -181B AND LET-7A ARE UP- 

REGULATED IN ATHEROSCLEROTIC CORONARY VALVES FROM 

PATIENTS WITH AORTAL STENOSIS 

Jana Borucka 1,2 , J. Petrkova 2,3 , V. Lonsky, T. Tomankova, M. Petrek, Czech 

Republic 344 

69 GENE EXPRESSION RESPONSES TO AORTAL ATHEROGENESIS 

T.A. Shchelkunova, I.A. Morozov, P.M. Rubtsov, L.M. Samokhodskaya, Igor 

A. Sobenin 4,5 , A.N. Orekhov 5,6 , A.N. Smirnov, Russia 322 

70 COORDINATION BETWEEN GENES EXPRESSION DURING 

ATHEROGENESIS 

T.A. Shchelkunova, I.A. Morozov, P.M. Rubtsov, L.A. Samokhodskaya, I.A. 

Sobenin 4,5,6 , Alrexander N. Orekhov 5,6 , A.N. Smirnov, Russia 323 

62



71 GENOME-WIDE EXPRESSION PROFILING HIGHLIGHTS THE ROLE 

PLAYED BY COMPLEMENT SYSTEM AND WNT PATHWAY DURING 

EARLY-STAGE ATHEROSCLEROSIS IN APOEKO MICE 

Marco Busnelli, S. Manzini, M. Chiara, C. Parolini, G. Ganzetti, C.R. Sirtori, 

D.S. Horner, G. Chiesa, Italy 1513 

72 TRANSFORMING GROWTH FACTOR-BETA (TGF-ß) 

TRANSCRIPTIONAL REGULATION IN HUMAN CAROTID ATHEROMA: 

IN SILICO STUDY 

Nedra Dhaouadi, C. Paultre, P. Feugier, M.-P. Gustin, K. Kacem, J.-Y. Li, G. 

Bricca, C. Cerutti, France, Tunisia 1516 

73 TRANSCRIPTIONAL ORGANIZATION AND FUNCTIONAL 

INTERACTIONS BETWEEN CORTICOIDS AND ANGIOTENSIN II 

SYSTEMS IN HUMAN ATHEROMA AND VASCULAR SMOOTH MUSCLE 

CELLS 

Hanene Ayari, L. Legedz, S. Barrot, P. Lantelme, P. Feugier, G. Bricca, O. 

Lohez, J.Y. Li, C. Cerutti, M.-P. Gustin, France 1519 

74 ANNEXIN A5 INHIBITS ATHEROGENIC AND PRO-INFLAMMATORY 

EFFECTS OF LYSOPHOSPHATIDYLCHOLINE 

H. Domeij, X. Hua, J. Su, A. Bäcklund, Z. Yan, A. Frostegård, J. Haeggström, 

T. Modéer, Johan Frostegård, Sweden 1520 

Infection and atherosclerosis 

75 ASSOCIATION OF CHLAMYDIA PNEUMONIAE INFECTION WITH 

ATHEROGENIC LIPID PROFILE 

Hosseinali Habibinejad, A. Riahin, Iran 664 

76 PERIODONTITIS IS CLOSELY ASSOCIATED WITH CAROTID ARTERIAL 

INFLAMMATION 

Sungeun Kim, H.-S. Seo, E.J. Kim, J.H. Na, J.H. Park, C.U. Choi, H.E. Lim, 

J.W. Kim, S.-W. Rha, C.-G. Park, D.J. Oh, Republic of Korea 689 

77 MONO- AND POLYMICROBIAL PERIODONTAL PATHOGEN-INDUCED 

INFLAMMATORY CYTOKINE PROFILES IN HYPERLIPIDEMIC APOE NULL 

MICE 

I. Velsko, S. Chukkapalli, M. Rivera, A. Lucas, Lakshmyya Kesavalu, USA1092 

78 HIV INFECTION REDUCES THE CAPACITY OF HDL PARTICLES TO 

MEDIATE CHOLESTEROL EFFLUX FROM HUMAN MACROPHAGES 

Petra El Khoury, E.F. Villard, C. Legeai, G. Catalano, P. Yeni, C. Goujard, 

M. Guerin, France 1104 

79 INDUCTION OF TOLL-LIKE RECEPTOR-2 MEDIATED INFLAMMATION 

IN HUMAN ATHEROMA DERIVED SMOOTH MUSCLE CELLS BY ORAL 

BACTERIA AND CHLAMYDIA PNEUMONIAE 

Tanja Pessi, L. Viiri, N. Astola, M. Pyysalo, K. Lounatmaa, A.H. Davies, T. 

Lehtimäki, P.J. Karhunen, C. Monaco, Finland, UK 1282 

63



80 MOLECULAR DETECTION OF BACTERIAL RNA IN ATHEROMATOUS 

PLAQUES OF PATIENTS WITH STROKE 

Macarena Gomez Lira, S. Ferronato, S. Olivato, A. Bertoncelli, S. 

Mazzucco, C. Signoretto, Italy 1353 

81 DETECTION OF PERIODONTAL BACTERIA DNA IN CAROTID 

ATHEROSCLEROTIC PLAQUES. ASSOCIATION WITH THE 

HAPTOGLOBIN GENOTYPE 

Hélène Rangé 1,2,3 , M. Varret 1,4 , S. Delbosc, J.-B. Michel 1,2,5 , P. Bouchard 2,3,6 , 

O. Meilhac 1,2,7 , France 1455 

82 DETECTION OF HUMAN HERPES VIRUSES IN ATHEROSCLEROTIC 

LESION IN PATIENTS WITH CORONARY ARTERY DISEASE 

J.-C. Grivel, Elizaveta Nikitskaya, O. Ivanova, N. Ryazankina, N. Pinegina, 

A. Lebedeva, A. Shpektor, L. Margolis, E. Vasilieva, USA, Russia 1485 

Inflammation 

83 NADPH OXIDASE/ROS-DEPENDENT PYK2 ACTIVATION IS INVOLVED 

IN TNF-A-INDUCED MATRIX METALLOPROTEINASE-9 EXPRESSION IN 

RAT HEART-DERIVED H9C2 CELLS 

Chuen-Mao Yang, Taiwan R.O.C. 119 

84 HIGH-CHOLESTEROL DIET STIMULATES 11Β-HYDROXYSTEROID 

DEHYDROGENASE TYPE 1 IN ATHEROSCLEROTIC LESIONS OF 

APOE-DEFICIENT MICE 

L. Rehakova, P. Ergang, F. Kolar, R. Poledne, Jiri Pacha, Czech Republic 249 

85 FLUVASTATIN SIGNIFICANTLY REDUCES LPS-STIMULATED 

INTERLEUKIN-6, BUT NOT INTERLEUKIN-1, IN THE STANDARD 

VASCULAR SMOOTH MUSCLE - MONOCYTE COCULTURE 

Harald Loppnow, C. Jaschke, H. Fu, K. Schlecht, S. Gielen, U. Müller- 

Werdan, H. Ebelt, M. Buerke, K. Werdan, Germany 298 

86 ULTRASOUND EVIDENCE OF ATHEROGENESIS IN MOUSE LEMUR 

PRIMATES 

Fabien Chauveau, A. Sérusclat, E. Canet-Soulas, M. Wiart, J.-B. Langlois, 

R. Bolbos, F. Aujard, M. Perret, M. Dhenain, N. Nighoghossian, France 369 

87 ACTIVATION OF Α7 NICOTINIC ACETYLCHOLINE RECEPTOR 

SUPPRESSES ATHEROSCLEROSIS 

Toshihiro Ichiki, T. Hashimoto, K. Sunagawa, Japan 474 

88 MAPKAP 2/3: A NOVEL DRUG TARGET FOR CHOLESTEROL INDUCED 

CARDIOVASCULAR DISEASES IN VIVO? 

Naveed Akbar, M. Gaestel, J.J.F. Belch, F. Khan, UK, Germany 500 

89 TRANSCRIPTIONAL LEUKOTRIENE PATHWAY ACTIVATION IN 

APOLIPOPROTEIN-E DEFICIENT MICE EXPOSED TO INTERMITTENT 

HYPOXIA: ROLE IN ATHEROSCLEROSIS PROGRESSION 

E. Gautier 1,2 , M. Bäck, C. Arnaud, M. Petri, P. Levy 1,4,5 , Françoise Stanke- 

Labesque 1,2,5 , France, Sweden 515 

64



90 ROLE OF INTERLEUKIN-6 IN АCUTE CORONARY SYNDROME 

Azizjon Abdumatlubovich Nizomov, Uzbekistan 523 

91 DIETARY NITRATE REDUCES LEUKOCYTE ACTIVATION IN THE 

APOLIPOPROTEIN E KNOCKOUT MOUSE 

Rayomand S. Khambata, S.M. Ghosh, A. Ahluwalia, UK 574 

92 LIPID BIOMARKERS PREDICT MONOCYTE POLARISATION AND 

CYTOKINE RELEASE IN HEALTHY CONTROLS 

John Fletcher, H. Williams, G. Cassorla, C. Wang, K. Hitos, N. Marmash, H. 

Medbury, Australia 684 

93 TGFΒ BUT NOT BMPS ACTIVATES SMAD1/5 PATHWAY IN PRIMARY 

HUMAN MACROPHAGES AND INDUCES EXPRESSION OF 

PROATHEROGENIC GENES 

D. Nurgazieva, W. Ming, I. Ovsyi, A. Popova, N. Wang, Julia 

Kzhyshkowska 3,4 , A. Gratchev 2,4 , Russia, Germany 952 

94 INCREASED INTERLEUKIN 9 IN ATHEROSCLEROTIC DISEASE 

Ida Gregersen, K. Holven 2,3 , M. Skjelland, S. Holm, L. Gullestad 3,5 , K. Krogh- 

Sørensen 3,6 , P. Aukrust 1,3,7 , B. Halvorsen 1,3 , Norway 980 

95 EMPHYSEMA ALONE DOES NOT EXPLAIN THE HIGHER RISK OF 

DEVELOPING ATHEROSCLEROSIS IN COPD PATIENTS: A ROLE FOR 

CHRONIC PULMONARY INFLAMMATION? 

P.P.S.J. Khedoe 1,2 , M.C. Wong 1,2 , I. Meurs, J.J. Plomp, G.T.M. Wagenaar, M. 

van Eck, L.M. Havekes 1,6,7 , P.C.N. Rensen, P.S. Hiemstra, Jimmy Berbée 1,8 , 

The Netherlands, Greece 1040 

96 NLRP1-INFLAMMASOME, A KEY IN THE TURN OFF OF THE 

ENDOTHELIAL CELL TO THE PROINFLAMMATORY STATE OF THE 


Silvia Bleda, J. De Haro, C. Varela, I. Lopez de Maturana, J. Rodriguez, F. 

Acin, Spain 1081 

97 LYSINE RICH CATIONIC PEPTIDES MAY ATTENUATE INFLAMMATION 

AND ATHEROSCLEROSIS 

Sampath Parthasarathy, A.N. Chandrakala, K. Selvarajan, USA 1148 

98 POXYTRINS, A NEW FAMILY OF LIPOXYGENASE PRODUCTS FROM 

POLYUNSATURATED FATTY ACIDS, ARE DOTED OF ANTI- 

ATHEROTHROMBOTIC POTENTIAL 

Miao Liu, P. Chen, E. Véricel, T. Boussetta, F. Driss, M. Lagarde, M. 

Guichardant, France, China 1178 

99 THE ANTIATHEROSCLEROTIC POTENTIAL OF VILDAGLIPTIN: THE 

CONCEPT OF ANTIINFLAMMATORY AND ANTIOXIDANT PROPERTIES 

Najah R. Hadi, S. Majeed, H. Abdelkadhem, A. Al-Jenabi, Iraq 1204 

100 HIGH LEVELS OF COX-2 GENE EXPRESSION IN PERIPHERAL BLOOD 

OF CARDIOEMBOLIC COMPARED TO ATHEROTHROMBOTIC STROKE 

PATIENTS 

S. Ferronato, S. Olivato, C. Patuzzo, A. Scuro, P.F. Pignatti, S. Mazzucco, 

Macarena Gomez Lira, Italy 1322 

65



101 HIGH EXPRESSION OF ARACHIDONATE 15-LIPOXYGENASE AND 

PROINFLAMMATORY MARKERS IN HUMAN ISCHEMIC HEART TISSUE 

L.M. Hultén, Annika Lundqvist, L.U. Magnusson, C. Hermansson, A. 

Jeppsson, Sweden 1354 

102 THEAFLAVINS-RICH FRACTION INHIBITS LIPOPOLYSACCHARIDE- 

STIMULATED NUCLEAR FACTOR- ҠB ACTIVATION IN HUMAN 


Nur Hidayah Mohd Ishak, A. Mohd Ismail, G.R.A. Froemming, T.H. Abdul 

Rahman, H. Mohd Nawawi, Malaysia 1450 

103 PERIVASCULAR INFLAMMATION IN HYPERTENSIVE RATS 

Ryszard Nosalski, T.P. Mikolajczyk, J. Maciag, T.J. Guzik, Poland 1582 

Innate immunity 

104 ASSOCIATION OF TOLL-LIKE RECEPTOR 4 WITH LUMINAL STENOSIS 

IN PATIENTS WITH STABLE ANGINA 

Bahador Bagheri, A. Garjani, B. Sohrabi, S. Mashayekhi, A. Movassaghpur, 

Iran 57 

105 HYDROCORTIOSNE REDUCES MONOCYTE EXPRESSION AND 

RESPONSE OF TOLL-LIKE RECEPTOR 4 IN PATIENTS UNDERGOING 

PERCUTANEOUS CORONARY INTERVENTION 

Bahador Bagheri, A. Garjani, B. Sohrabi, S. Mashayekhi, A. Movassaghpur, 

Iran 127 

106 NOD2 INDUCES COX2-MPGES-1-PGE2 AS PROXIMAL INNATE IMMUNE 

SIGNALING IN ATHEROSCLEROSIS 

H.-Q. Liu 1,2 , Xiao-Ying Zhang 1,3 , K. Edfeldt, M.M.O. Nijhuis, H. Idborg, M. 

Bäck, J. Roy, U. Hedin, P.-J. Jakobsson, J.D. Laman, D.P.V.D. Kleijn, G. 

Pasterkamp, G.K. Hansson, Z.-Q. Yan, Sweden, China, Netherlands Antilles 303 

107 RECOVERY OF NATURAL KILLER CELLS IN PATIENTS WITH 

CORONARY ARTERY DISEASE. A ONE YEAR FOLLOW-UP STUDY 

Karin Backteman, J. Ernerudh, L. Jonasson, Sweden 332 

108 5-LIPOXYGENASE PLAYS A CENTRAL ROLE IN TLR4-MEDIATED 

MONOCYTE ADHESION TO VASCULAR ENDOTHELIAL CELLS 

Chi Dae Kim, S.J. Lee, E.K. Choi, S.Y. Park, Republic of Korea 463 

109 DIFFERENTIAL EXPRESSION OF GM1, A MARKER OF LIPID RAFTS, IN 

HUMAN MONOCYTE SUBPOPULATIONS MAY BE INVOLVED THE 

PATHOGENESIS OF ATHEROSCLEROSIS 

Valentina Shishkina, T. Pavlunina, M. Chelombitko, E. Gracheva, A. 

Kaminnyi, Y. Romanov, N. Samovilova, N. Prokazova, Russia 565 

110 MODIFIED LIPOPROTEINS MODULATE DENDRITIC CELL IMMUNE 

FUNCTION 

Laure Perrin-Cocon 1,2 , O. Diaz 1,2 , P. André 1,2,3 , V. Lotteau 1,2 , France 992 

111 SPLENIC DENERVATION ACCELERATES ATHEROSCLEROSIS IN 

APOE-/- MICE 

Marcus A. Ulleryd, P.A. Micallef, L.J. Yang, S. Hua, M.E. Johansson, 

Sweden 1003 

66



112 MACROPHAGIC VERSATILE OUTCOME IN CRITICAL CAROTID 

STENOSIS AND ACUTE AORTIC DISSECTION 

Livia Ferri, M. Proietta, C. di Gioia, L. Tritapepe, M. Leopizzi, C. Fantozzi, C. 

Chiappetta, I. Nofroni, C. Della Rocca, E. Marinari, A.P. Mitterhofer, A. 

Negro, A. Koverech, M. Taurino, F. Del Porto, Italy 1111 

113 NATURAL KILLER CELL APOPTOSIS IN CORONARY ARTERY 

DISEASE: IS IT REFLECTED BY SOLUBLE APOPTOTIC MARKERS? 

Anna Lundberg, C. Evaldson, W. Li, K. Backteman, J. Ernerudh, L. 

Jonasson 1,2 , Sweden 1139 

114 THE ROLE OF IKKΑ IN ATHEROSCLEROSIS 

Pathricia Tilstam, H. Noels, M. Gijbels, B. Zhou, W. Theelen, M. de Winther, 

C. Weber, Germany, Netherlands Antilles 1159 

115 CHARACTERIZATION OF INVARIANT NATURAL KILLER CELL 

SUBSETS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA 

Sergey Alexandrovich Bondarenko, A. Baragetti 1,2 , F. Pellegatta, A.L. 

Catapano 1,3 , G.D. Norata 1,2 , Italy 1269 

116 TLR4 -2604G>A VARIANT CONFERS DNA BINDING CAPACITY TO 

GATA FAMILY TRANSCRIPTION FACTORS, MODIFYING GENE 

EXPRESSION IN ATHEROSCLEROTIC PATIENTS PERIPHERAL BLOOD 

S. Ferronato, S. Olivato, M. Menegazzi, A. Scuro, M.G. Romanelli, E. Diani, 

S. Mazzucco, Macarena Gomez Lira, Italy 1283 

117 THE NEURON-DERIVED ORPHAN RECEPTOR1 (NOR1) IS INDUCED IN 

HUMAN ALTERNATIVE MACROPHAGES AND CONTROLS THE 

EXPRESSION OF ALTERNATIVE POLARIZATION MARKERS 

Federica De Paoli, C. Copin, J. Vanhoutte, C. Zawadzki, B. Jude, S. Haulon, 

J. Eeckhoute, P. Lefebvre, B. Staels, G. Chinetti-Gbaguidi, Nuclear 

Receptors, Cardiovascular Diseases, Diabet, France 1291 

118 PHENOTYPE CHANGES OF CIRCULATING BLOOD MONOCYTES (MN) 

IN THE HYPERCHOLESTEROLEMIC SWINE MODEL OF CORONARY 

ARTERY DISEASE (CAD) 

S. Sbrana, M.R. Puntoni, F. Viglione, G. Pelosi, Federico Vozzi 3,4 , M.G. 

Trivella, O. Parodi, Italy 1369 

119 DISTRIBUTION OF M1 AND M2 MACROPHAGES SUBPOPULATIONS IN 

DIFFERENT TYPES OF CAROTID ATHEROSCLEROTIC PLAQUES 

Valentina S. Shishkina, M.A. Chelombitko, O.P. Ilyinskaya, E.M. Tararak, 

Russia 1391 

120 INCREASING SURVIVAL OF MACROPHAGES DELAYS PROGRESSION 

OF ESTABLISHED ATHEROSCLEROTIC LESIONS 

Laura Bouchareychas, J. Pirault, F. Saint-Charles, E. Gautier, P. Giral, T. 

Huby, P. Lesnik, France 1402 

67



Adaptive immunity 

121 ACTIVE IMMUNIZATION AGAINST SULFATED 

GLYCOSAMINOGLYCANS AS A NOVEL THERAPEUTIC AVENUE IN 


Katia Mellal, V. Brito, S.G. Portelance, A. Pérez, Y. Soto, D. deBlois, H. 

Ong, A.M. Vázquez, S. Marleau, Canada, Cuba 628 

122 ROLE OF PI3K-C2BETA IN T LYMPHOCYTES DEVELOPMENT AND 


Gianpaolo Tibolla 1,2 , S. Bertoni, F. Sala, G.D. Norata 1,2 , A.L. Catapano 1,3 , 

Italy 695 

123 ATTENUATION OF EARLY ATHEROSCLEROSIC LESIONS IN A MURINE 

MODEL BY IMMUNOTOLERANCE WITH BETA-2-GLYCOPROTEIN AND 

THE IMMUNOMODULATORY EFFECTORS IL-2 AND IL-10 

Joaquín De Haro, L. Esparza, C. Varela, S. Bleda, I. López-Maturana, J. 

Rodríguez, C. González, F. Acin, Spain 722 

124 METHOTREXATE AND ETOPOSIDE, BOTH ASSOCIATED WITH LIPID 

NANOEMULSIONS, INCREASES FOXP3 T LYMPHOCYTES IN THE 

INTIMA OF HYPERCHOLESTEROLEMIC RABBITS 

Antonio Carlos de Arruda Leite Jr 1,2 , A. Bulgarelli, E.R. Tavares, R.C. 

Maranhão 1,2 , Brazil 901 

125 LOSS OF B-CELL FUNCTION IN MRAS- KNOCK-OUT MOUSE AND 

REDUCED INFLAMMATION IN ATHEROSCLEROTIC PLAQUES AT THE 

AORTIC ROOT 

Jennifer Freyer 1,2 , M. Behrensen 1,2 , Z. Aherrahrou 1,2 , J.F.P. Berbée, H. 

Schunkert 4,5 , J. Erdmann 1,2 , Germany, The Netherlands 1133 

126 MCS-18 INHIBITS THE PROGRESSION OF ATHEROSCLEROSIS IN 

APOE-DEFICIENT MICE BY MODULATING THE IMMUNE RESPONSE 

Barbara Dietel, R. Münch, R. Altendorf, I. Cicha, A. Steinkasserer, E. Zinser, 

S. Achenbach, C. Garlichs, F. Kerek, Germany 1157 

127 CD137 SIGNALING IN THE PATHOGENESIS OF ATHEROSCLEROSIS 

I.-H. Jung 1,2 , J. Jin, D.-Y. Kim, Goo Taeg Oh, Republic of Korea 1427 

128 CHARACTERIZATION OF MEMORY T CELL SUBSETS IN PATIENTS 


Federica Sala, F. Pellegatta, A. Baragetti, G.D. Norata 1,2 , A.L. Catapano 1,3 , 

Italy 1462 

68



Hormones and atherosclerosis 

129 MEN WITH POOR CARDIORESPIRATORY FITNESS COMBINED WITH 

LOWER TESTOSTERONE HAVE HIGH OXIDIZED LDL LIPIDS - BEING 

FIT PREVENTS THIS RELATIONSHIP 

Jussi Kosola, M. Ahotupa, H. Kyrolainen, M. Santtila, T. Vasankari, Finland 117 

130 THE THYROID HORMONE RECEPTOR TRΑ PROTECTS AGAINST 

ATHEROSCLEROSIS DEVELOPMENT: AN NEW ROLE FOR TRΑ AS AN 

ANTI-INFLAMMATORY FACTOR 

C. Billon, L. Canaple, J. Samarut, Karine Gauthier, France 224 

131 EFFECT OF ESTRADIOL ON ATHEROSCLEROSIS OF THE COMMON 

CAROTID ARTERY IN WOMEN: A POSTMORTEM ANALYSIS 

Ho-Dirk Kim, Republic of Korea 467 

132 INCREASED NEOINTIMAL FORMATION AFTER VASCULAR INJURY IN 

ANDROGEN RECEPTOR KNOCKOUT MICE 

Anna S. Wilhelmson, J. Bourghardt-Fagman, M.E. Johansson, K. De 

Gendt, G. Verhoeven, P. Fogelstrand, Å. Tivesten, Sweden, USA, Belgium 774 

133 INVOLVEMENT OF P27 IN THE PROGESTERONE-INDUCED MIGRATION 

INHIBITION IN RAT AORTIC SMOOTH MUSCLE CELLS 

Hui-Jane Wang, S.-P. Hsu, S.-F. Chang, C. Hsu, W.-S. Lee, Taiwan R.O.C. 910 

134 THE ROLE OF DISCOIDIN DOMAIN RECEPTOR SIGNALLING AND 

EFFECT OF ALENDRONATE IN CAROTID ARTERY LIGATION-INDUCED 

INTIMAL THICKENING IN MICE 

Buket Reel, S. Ozbal, B.U. Ergur, O. Yilmaz, D. Keles, G. Oktay, G. Sevin, 

Z. Kerry, Turkey 1228 

69

POSTERS TRACK 2 LIPID AND LIPOPROTEIN METABOLISM: FROM ALTERATIONS TO 

TREATMENTS 


apoB-Containing lipoproteins / Modified lipoproteins 

135 PROTEIN DISULFIDE ISOMERASE MODIFICATION BY OXIDIZED LDL 

IMPAIRS ITS FUNCTION AND CONTRIBUTES TO APOPTOSIS. A ROLE 

IN ATHEROSCLEROSIS? 

C. Muller, J. Bandemer, C. Vindis, R. Salvayre, Anne Negre-Salvayre, 

France 1123 

136 ANTAGONISTIC EFFECTS OF IL-10 AND IL-6 ON LDL OXIDATION; 

PROBABLE EVIDENCE FOR A CYTOKINIC MODULATORY MECHANISM 

IN ATHEROGENESIS 

Adel Abedpour Dehkordi 1,2 , G.A. Naderi, H. Nayeri, M. Boshtam, N. Jafari 

Dinanai, Iran 415 

137 MODIFIED ATHEROGENIC LDL INDUCES OVEREXPRESSION OF BOTH 

PRO-INFLAMMATORY CYTOKINE TNFA AND ANTI-INFLAMMATORY 

CHEMOKINE CCL18 

Nikita G. Nikiforov 1,2 , Y.V. Bobryshev 1,3,4 , V. Aladinsky, E.N. Borodachev, O. 

Gorlova, A. Temchenko, N. Pervushina, I.A. Sobenin 1,2,3 , A.N. Orekhov 1,3 , 

Russia, Australia 674 

apoB-Containing lipoproteins / Lp(a) 

138 ELEVATED LIPOPROTEIN(A) IS ASSOCIATED WITH WORSE 

PROGNOSIS IN DIABETIC PATIENTS WITH CORONARY ARTERY 

DISEASE 

Sung Woo Kwon, J.-J. Cha, B.K. Lee, J.-Y. Kim, E.-Y. Choi, P.-K. Min, Y.W. 

Yoon, B.-K. Hong, S.-J. Rim, H.M. Kwon, Republic of Korea 71 

139 EVALUATION OF HOMOCYSTEINE AND LIPOPROTEIN(A) PLASMA 

LEVELS CAN REVEAL ADVANCED SYSTEMIC ATHEROSCLEROTIC 

BURDEN IN ACUTE CORONARY SYNDROME PATIENTS 

Gabriele Cioni, R. Marcucci, A.M. Gori, S. Fedi, A. Galassini, E. Ganugi, A. 

Rogolino, C. Giglioli, S. Valente, G.F. Gensini, R. Abbate, M. Boddi, Italy 1083 

140 LIPOPROTEIN (A) ANALYSES IN A FAMILY WITH PREMATURE 


Reyhana Yahya, R. Vongpromek, L. van der Zee, J. Touw, E. Sijbrands, A. 

Verhoeven, J. Roeters van Lennep, M. Mulder, The Netherlands 1469 

HDL / CETP 

141 HOW ANACETRAPIB INHIBITS THE ACTIVITY OF THE CHOLESTERYL 

ESTER TRANSFER PROTEIN? INSIGHT GAINED THROUGH ATOMISTIC 

SIMULATIONS 

Tarja Äijänen, A. Koivuniemi, T. Rog, I. Vattulainen, Biological Physics and 

Soft Matter Group, Finland 1436 

142 ENDOGENOUS CETP ACTIVITY AS A PREDICTOR OF 

CARDIOVASCULAR RISK 

E.F. Villard, M.-C. Federspiel, V. Fesel-Fouquier, C. Cherfils, E. Bruckert, K. 

Clement, D. Bonnefont-Rousselot, W. Le Goff, R. Bittar, P. Couvert, Maryse 

Guerin, France 1046 

70

POSTERS TRACK 2: LIPID AND LIPOPROTEIN METABOLISM: FROM ALTERATIONS TO 

TREATMENTS (contd.) 


143 PLASMA CHOLESTERYL ESTER TRANSFER PROTEIN: A BIOMARKER 

FOR HEPATIC MACROPHAGES IN MICE AND HUMANS 

Yanan Wang, S.J.L. van der Tuin 1,2 , V. Bieghs, R. Shiri-Sverdlov, H.M.G. 

Princen, J.A. Romijn, M.G.M. Wolfs, S. Rensen, L.M. Havekes 1,4,7 , M.H. 

Hofker, K. Willems van Dijk, P.C.N. Rensen, The Netherlands 847 

144 ELEVATED CETP ACTIVITY IS ASSOCIATED WITH LOW, 

DYSFUNCTIONAL HDL IN SOUTH ASIANS 


145 HIGH CETP ACTIVITY IN MYOCARDIAL INFARCTION PREDICTS 

SHORT-TERM MORTALITY BY INDUCING ENDOTHELIAL 

DYSFUNCTION, POOR CORONARY FLOW AND MICROVASCULAR 

HYPOPERFUSION 

L.S. Carvalho, S. Santos, V.W. Virginio, F. Alexandre, Natalia B. Panzoldo, 

O. Nobrega, E.C. de Faria, J.C.Q. Silva, A.C. Sposito, Brazilian Heart Study, 

Brazil 1421 

HDL / Cholesterol efflux 

146 REGULATION OF ATP-BINDING CASSETTE TRANSPORTER A1 

EXPRESSION IN RAW264.7 MACROPHAGES UNDER HYPERGLYCEMIC 

STRESS 

Anna Chiang, Y.-C. Chang, W.H.-H. Sheu, Y.-S. Chien, P.-C. Tseng, 

Taiwan R.O.C. 122 

147 METABOLIC PHENOTYPING OF AN ENDOTHELIAL SPECIFIC ABCA1 

KNOCKOUT MOUSE MODEL IN A NORMAL CHOW AND A HIGH 

CHOLESTEROL DIET 

Reda Hasballa, L. Rohrer, A. von Eckardstein, Switzerland 385 

148 PI-3 KINASE- BUT NOR ERK1/2-MEDIATED SIGNALING PATHWAY IS 

INVOLVED IN BERBERINE-INDUCED ABCA1 MODULATION 

Francesca Zimetti, M.P. Adorni, S. Costa, N. Ronda, F. Bernini, E. Favari, 

Italy 1007 

149 EFFECT OF ARECOLINE IN ATP-BINDING CASSETTE TRANSPORTER 

A1 EXPRESSION IN RAW 264.7 MACROPHAGE-DERIVED FOAM CELLS 

X.-P. Ouyang, Chao-Ke Tang, China 1328 

150 EFFECT OF MUTANT APOA-I FORMS BOUND TO RECONSTITUTED 

HDL ON ABCG1-DEPENDENT CHOLESTEROL EFFLUX 

Georgios Daniil, V.I. Zannis, A. Chroni, Greece, USA 1366 

151 ATHEROSCLEROTIC CELLS FOR ESTIMATION OF CHOLESTEROL 

EFFLUX 

Alrexander N. Orekhov 1,2 , I.A. Sobenin 1,2,3 , A.A. Melnichenko 1,2 , V.A. 

Orekhova 1,3 , Y.V. Bobryshev 1,2,4 , Russia, Australia 325 

152 A SIMPLE METHOD TO MEASURE THE ABILITY OF PLASMA 

LIPOPROTEINS TO ACCEPT CHOLESTEROL FROM PLASMA 

MEMBRANES 

Antonio Carlos de Arruda Leite Jr 

71 

1,2,3 , D.L. Bispo, T.B. Moreira, J.C. dos 

Santos, R.C. Maranhão 1,3 , Brazil 821




HDL / Function and metabolism 

153 FUNCTIONAL LIPID-PROTEIN CLUSTERS IN HUMAN PLASMA HDL: A 

SYSTEMS BIOLOGY APPROACH 

Ekaterina Chernova 1,2 , M. Lhomme, L. Camont, S. Chantepie, W. Le Goff, 

M.J. Chapman, A. Orekhov, W.S. Davidson, A. Kontush, France, Russia, 

USA 1550 

154 A NOVEL HIGH-DENSITY LIPOPROTEIN ANTIOXIDANT CAPACITY 

ASSAY AND ITS APPLICATION TO HIGH-DENSITY LIPOPROTEIN 

FRACTIONS 

Krisztina Gaál, H. Lőrincz, I. Seres, M. Harangi, A.V. Oláh, G. Paragh, 

Hungary 832 

155 LOW NORMAL FREE T4 CONFERS DECREASED HIGH DENSITY 

LIPOPROTEIN ANTI-OXIDATIVE FUNCTIONALITY IN THE CONTEXT OF 

HYPERGLYCEMIA 

Michela Triolo, J.F. de Boer, W. Annema, A. Kwakernaak, U. Tietge, R. 

Dullaart, The Netherlands 612 

156 THE INVERSE RELATIONSHIP OF HDL ANTI-OXIDATIVE 

FUNCTIONALITY WITH SERUM AMYLOID IS ABSENT IN METABOLIC 

SYNDROME 

Robin P. Dullaart, J.F. de Boer, W. Annema, U.J. Tietge, The Netherlands 96 

157 HDL-BINDING ANTIBODIES SELECTED FROM PHAGE ANTIBODY 

LIBRARY 

Janita Lövgren, N. Elonen, E.-C. Brockmann, T. Huovinen, K. Pettersson, 

M. Jauhiainen, U. Lamminmäki, Finland 1456 

158 HIGH DENSITY LIPOPROTEINS FROM PATIENTS WITH LIPID 

TRANSFER ALTERATIONS AND CORONARY ARTERY DISEASE ARE 

ASSOCIATED WITH INCREASED PLATELET AGGREGATION 

Antonio Carlos de Arruda Leite Jr 1,2,3 , T.B. Moreira 2,3 , D.L. Bispo 2,3 , J.C. 

dos Santos 2,3 , M.C.O. Sprandel, A. Casella-Filho, W. Hueb, R.C. 

Maranhão 1,3,4 , Brazil 820 

159 ENHANCED OXIDATIVE STRESS STATUS IN SUBJECTS WITH LOW 

HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) IS NOT 

ASSOCIATED WITH LECITHIN CHOLESTEROL ACYLTRANSFERASE 

(LCAT) 

Farah Hanis Sakri, N.A. Mohd Mokhsin, T.H. Abdul Rahman, B.P. Hoh, A. 

Mohd Ismail, H. Mohd Nawawi, Malaysia 1448 

160 WEARING THE HAT OF HIGH HDL CHOLESTEROL? 

Shamanna S. Iyengar, S. Chavan, N. Basha, India 190 

161 HIGH PARAOXONASE 1 ACTIVITY STRENGTHENS HDL'S IN VITRO 

ANTI-OXIDANT FUNCTION IN STATIN TREATED DYSLIPIDEMIC 

PATIENTS AND IN HEALTHY SUBJECTS 

Rahul Yadav, Y. Liu, S. Kwok, V. Charlton-Menys, M. France, R. Eatough, 

S. Hama, N. Younis, B. Issa, B.J. Ammori, H. Soran, UK 1141 

72




162 LP A-I, LP A-II AND LP A-I/A-II IN THE PRE-BETA MOBILITY FRACTION, 

ARISING BY THE INTERACTION BETWEEN HDL AND LIPOSOMES 

Anna Wolska, M. Bednarek, K. Domitrz, A. Szutowicz, M. Wróblewska, 

Poland 123 

163 ARE SMALL HDL PARTICLES PROTECTIVE IN CAROTID 

ATHEROSCLEROSIS ? 

D. Diallo, S. Delbosc, G. Lambert, Olivier Meilhac, France 1056 

164 REGRESSION OF LUMINAL STENOSIS AT THE SITE OF SILENT 

PLAQUE DISRUPTION AND HIGH-DENSITY LIPOPROTEIN 

CHOLESTEROL 

Takayoshi Nemoto, K. Matsuo, Y. Ueda, Japan 1564 

HDL / apoA1 functions 

165 BOVINE APOLIPOPROTEIN (APO) A-I DEMONSTRATE ENHANCED 

ANTI-OXIDANT ACTIVITY WITH DIFFERENT STRUCTURE-FUNCTION 

CORRELATIONS RELATIVE TO HUMAN APOA-I 

G.-Y. Park 1,2 , S.-M. Kim 1,2 , Kyung-Hyun Cho 1,2 , Republic of Korea 308 

166 SHORT TERM EFFECTS OF MDCO-216 (APOA-I MILANO WITH POPC) 

ON LIPIDS AND (APO)LIPOPROTEIN LEVELS IN CYNOMOLGUS 

MONKEYS 

Herman Kempen, M. Gomaraschi, L. Calabresi, S.E. Bellibas, P.L. 

Wijngaard, Switzerland, Italy, USA 181 

167 STRUCTURAL PROPERTIES OF FUNCTIONAL HDL AND MILANO 

VARIANT OF APOA-I 

Jitka Petrlova, J. Dalla-Riva, L. Zhu, M. Mörgelin, H. Hebert, C. 

Jegerschöld, J.C. Voss, J.O. Lagerstedt, Sweden, USA 270 

168 A PROTEOLIPOSOME CONTAINING V156K-APOA-I ENHANCES RAPID 

TUMOR REGRESSION ACTIVITY OF ONCOLYTIC ADENOVIRUS IN 

TUMOR-BEARING ZEBRAFISH AND MICE 

J. Kim 1,2 , Kyung-Hyun Cho 1,2 , Republic of Korea 676 

Intracellular metabolism 

169 PHARMACOLOGICAL EVIDENCE FOR THE DOMINANT ROLE OF 

NEUTRAL CE HYDROLASE 1 IN THE HYDROLYSIS OF CE IN MURINE 

MACROPHAGES 

Kent Sakai, S. Nagashima, M. Takahashi, D. Yamamuro, H. Yagyu, J.-I. 

Osuga, S. Ishibashi, Japan 677 

170 FARNESOID X RECEPTOR UP-REGULATES EXPRESSION 

FIBROBLASTGROWTH FACTOR 21 IN HEPG2 AND THE STUDY OF ITS 

MECHANISM* 

Yongchao Wang, H. Liu, J. Peng, Y. Zhang, J. Dong, X. Liu, Y. Jiang**, 

China 1214 

73




171 INTESTINAL RE-EXPRESSION OF APOA5 TROUGH DEMETHYLATION 

WITH 5-AZA-2′-DEOXYCYTIDINE OF ITS PROMOTER AND CPG ISLAND 

Montse Guardiola, A. Guillaumet, I. Oliva, R. Rosales, J.C. Vallvé, F. 

Sabench, D. Del Castillo, M. Esteller, D. Monk, J. Ribalta, Spain 1002 

172 BIS(MONOACYLGLYCERO)PHOSPHATE PROTECTS FROM OXIDIZED 

LDL-INDUCED APOPTOSIS IN MACROPHAGES 

Maud Arnal, C. Costaz, I. Vandenbroucke, France 698 

173 REGULATION OF LIPOGENIC PATHWAY BY LXR AGONISTS IN 

VASCULAR SMOOTH CELLS OF PSAMMOMYS OBESUS 

Nadjiba Hamlat Khennaf, S. Neggazi, S. Aouichat Bouguerra, M. Beylot, 

Algeria, France 1237 

174 LIVER X RECEPTOR ACTIVATION DECREASES CHYLOMICRON 

ASSEMBLY AND IMPROVES POST-PRANDIAL TRIGLYCERIDEMIA VIA 

INTESTINAL SR-BI DOWNREGULATION 

Olivier Briand, S. Colin, V. Touche, A. Tailleux, V. Clavey, B. Staels, S. 

Lestavel, France 191 

175 PREPONDERANT ROLE OF LXRΑ IN CHOLESTEROL EFFLUX FROM 

HUMAN FOAM CELLS THROUGH A SPECIFIC ABCA1-DEPENDENT 

PATHWAY 

Alexandre Superville, E. Frisdal, C.M. Quinn, M.-J. Kim, W. Jessup, M. 

Guerin, W. Le Goff, France, Australia 598 

176 OXYPHYTOSTEROL FORMATION IN HUMANS; IDENTIFICATION OF 

HIGH AND LOW OXIDIZERS 

Sabine Baumgartner, R.P. Mensink, G. den Hartog, A. Bast, O. Bekers, U. 

Diczfalusy, C. Husche, D. Lütjohann, J. Plat, The Netherlands, Sweden, 

Germany 433 

177 NATIVE LDL TRAFFICKING AND EFFECTS ON PRIMARY HUMAN 

MONOCYTE DERIVED MACROPHAGES 

N. Nikiforov, F. Li, N. Wang, M. Moisenovich, A.N. Orekhov 1,4 , Julia 

Kzhyshkowska 2,4 , Russia, Germany 859 

Lipases and lipoprotein metabolism 

178 A NEW ROUTINE ASSAY FOR REPRODUCIBLE LPL ACTIVITY 

MEASUREMENT IN POST HEPARIN PLASMA 

Mathilde Di Filippo 1,2 , C. Marçais 2,3 , M. Broyer, M. Merlin, A. Nollace, M. 

Delay, O. Marmontel, S. Charrière 2,4 , P. Moulin 2,4 , A. Sassolas 1,2 , France 1094 

179 INCREASES OF SERUM MASS OF ENDOTHELIAL LIPASE IMPACT 

PLASMA HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL 

CONCENTRATIONS IN ACUTE MYOCARDIAL INFARCTION 

Kenta Mori, T. Ishida, K. Miyashita, N. Kinoshita, H. Nakajima, T. 

Yasuda, R. Toh, M. Kawata, S. Sakamoto, K. Nakajima, K.-I. Hirata, 

Akashi KOBE study (AKB study) Group, Japan 1276 

74




180 HDL METABOLISM BY HTGL, EL AND LPL 

Katsuyuki Nakajima, K. Miyashita, N. Kinoshita, S. Imamura, T. Ishida, K. 

Hirata, T. Machida, H. Sumino, M. Nara, M. Murakami, Japan 1301 

181 LOCALIZATION AND FUNCTION OF THE LIPOPROTEIN LIPASE 

SYSTEM IN MOUSE KIDNEY 

Rakel Nyrén, E. Vorrsjö, M. Ericsson, S. Nilsson, S. Kersten, G. Olivecrona, 

Sweden, The Netherlands 1466 

182 CONTROL OF POSTPRANDIAL LIPEMIA BY CEREBRAL GLP-1 

Thibault Deblache, C. Cabou, F. Reichardt, A. Colom, F. Tercé, R. Burcelin, 

X. Collet, France 1248 

183 ROLE OF ENDOTHELIAL LIPASE IN HIGH-DENSITY LIPOPROTEIN 

METABOLISM IN HUMANS 

Tatsuro Ishida, K.-I. Hirata, Japan 1523 

Lp-PLA2 

184 A STUDY OF LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 

(LPPLA2) AS AN EMERGING BIOMARKER IN CORONARY ARTERY 

DISEASE 

Saswati Das, S.K. Gupta, G. M.P., P.C. Ray, India 52 

185 TREATMENT WITH BETABLOCKERS IS ASSOCIATED WITH LOWER 

LEVELS OF LP-PLA2 AND SUPAR IN CAROTID PLAQUES 

Giuseppe Asciutto, A. Edsfeldt, N.V. Dias, J. Nilsson, C. Prehn, J. 

Adamski 3,4 , I. Gonçalves 2,5 , Sweden, Germany 359 

186 LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 LEVELS IS 

INFLUENCED BY CARDIAC DISEASE, EXTENSION OF 

ATHEROSCLEROSIS AND TREATMENTS 

Jean-Paul Charniot, R. Bittar, J.-P. Albertini, P. Giral, C. Cherfils, C. 

Cosson, E. Guillerm, P. Leprince, I. Gandjbakhch, D. Bonnefont Rousselot, 

France 416 

187 INTEREST OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN 

THE PREOPERATIVE STATUS PRIOR AORTIC STENOSIS SURGICAL 

VALVE REPLACEMENT 

Jean-Christophe Charniot, R. Bittar, J.-P. Albertini, P. Giral, C. Cherfils, C. 

Cosson, E. Guillerm, P. Leprince, I. Gandjbakhch, D. Bonnefont Rousselot, 

France 420 

188 PROGNOSTIC ROLE OF LIPOPROTEIN-ASSOCIATED 

PHOSPHOLIPASE A2 ASSAYS IN PATIENTS WITH CARDIOGENIC 

SHOCK SYNDROME. A PILOT STUDY 

Jean-Christophe Charniot, R. Bittar, J.-P. Albertini, C. Cherfils, C. Cosson, 

E. Guillerm, D. Bonnefont Rousselot, France 437 

189 COMPARING OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 

SERUM LEVELS IN CORONARY ARTERY DISEASE PATIENTS 

DEPENDING ON DIABETES MELLITUS PRESENCE 

Anna Semenova, D. Nozadze, I. Sergienko, T. Vlasik, I. Rybalkin, Russia 559 

75




190 DECREASED ACTIVITY OF THE ANTI-ATHEROGENIC HDL- 

ASSOCIATED LPPLA2 AND INCREASED PROPORTION OF SMALL 

HDL3 PARTICLES IN SUBJECTS WITH IMPAIRED FASTING GLUCOSE 

T.D. Filippatos, E.C. Rizos, V. Tsimihodimos, A.D. Agouridis, E. Tzavella, Z. 

Mitrogianni, A.D. Tselepis, Moses S. Elisaf, Greece 696 

191 ELEVATED LEVELS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE 

A2 AMONG DIABETIC PATIENTS WITH CORONARY ARTERY DISEASE 

Aymen Bekir, M. Belhabib, M. Caslake, J. Cooney, A. Lewis, D. Bedford, H. 

Chahed, T. Trimech, K. Ben Hamda, F. Maatouk, S. Ferchichi, A. Miled, 

Tunisia, UK 709 

192 PLASMA LP-PLA2 ACTIVITY IS RELATED TO PLAQUE STABILITY AS A 

POTENTIAL BIOMARKER FOR ACUTE CORONARY SYNDROME 

Byoung Kwon Lee, H. Chung, H.M. Kwon, Y. Yoon, E.-Y. Choi, Republic of 

Korea 797 

193 THE USE OF LP-PLA2 MEASUREMENT AS A CARDIOVASCULAR 

„FINETUNER“ 

Ursula Kassner, T. Grenkowitz, E. Steinhagen-Thiessen, Germany 1113 

194 EVEROLIMUS THERAPY IS ASSOCIATED WITH REDUCED 

LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) ACTIVITY 

AND OXIDATIVE STRESS IN HEART TRANSPLANT RECIPIENTS 

Jerzy-Roch Nofer, K. Rosing, M. Fobker, F. Kannenberg, J. Stypmann, 

Germany 1163 

195 CORONARY CALCIUM SCORE IS RELATED TO POLYMORPHISMS OF 

GENES OF PHOSPHOLIPASE A2 AND OF CHROMOSOME 9 

A. Bertolami, C. Gonzaga, M. Sulzbach, D.B. Araujo, H. Zatz, Y. Nakamura, 

L. Wang, P. Lima, M. Hirata, A. Garofaro, A.A. Faludi, Marcelo Chiara 

Bertolami, Brazil 1167 

Biomarkers / Lipid metabolism 

196 MONITORING OF DIET-RELATED CHANGES OF THE PLASMA 

LIPIDOMICS PROFILE IN YOUNG HYPERCHOLESTEROLEMIC 

PATIENTS USING A MALDI-TOF-MS/MS APPROACH 

Gerald Stübiger, L. Hedjazi, M. Wuczkowski, O. Belgacem, K. Widhalm, 

Austria, France, UK 798 

197 PLASMA PCSK9 IS A BIOMARKER OF SEVERITY IN PATIENTS WITH 

SEVERE TRAUMA INJURY 

Bertrand Cariou, M. Le Bras, A. Roquilly, F. Feuillet, V. Deckert, L. Lagrost, 

K. Asehnoune, P. Costet, France 869 

198 CIRCULATING PCSK9 DISTRIBUTION IN RELATION TO AGE AND 

GENDER,AND ITS RELATION TO MARKERS OF CHOLESTEROL 

METABOLISM IN A SWEDISH COHORT 

Moumita Ghosh 1,2 , B. Angelin 1,2 , M. Rudling 1,2 , Sweden 999 

76




199 CHANGES IN THE FATTY ACID PROFILE OF ARTERIAL WALL AND 

BLOOD PLASMA IN PATIENTS WITH ATHEROSCLEROSIS 

Alexander Nikolaevich Osipenko, A.N. Osipenko, N.V. Akulich, Belarus 1389 

Dyslipidaemia: epidemiology, biomarkers / HDL 

200 DEVELOPMENT OF A NOVEL HOMOGENEOUS ASSAY FOR HDL 

SUBCLASSES 

Yasuki Ito, N. Sato, Japan 409 

201 VALIDATION OF "BRINTON´S RATIO" FOR ESTIMATING HDL SIZE 

USING NMR-SPECTROSCOPY DATA FROM THE HIFUN STUDY 

Norman A. Mazer, E. Damonte, S. Rossomanno, M. Abt, R. Benghozi, 

Switzerland 691 

202 HIGH DENSITY LIPOPROTEIN CHOLESTEROL, ANGIOGRAPHIC 

CORONARY ARTERY DISEASE, AND CARDIOVASCULAR MORTALITY 

Günther Silbernagel 1,2 , T.B. Grammer, H. Scharnagl, M.E. Kleber 5,6 , A. 

Ritsch, B.O. Boehm, U. Landmesser, W. März 3,4,10 , Germany, Austria, 


203 RECENT HDL-C LEVEL OF JAPANESE GENERAL POPULATION 

INCREASED BY THE INTENSIVE LIFESTYLE MODULATION 

Koki Takata, Japan 1304 

204 LOW CHOLESTEROL AND PHOSPHATIDYLCHOLINE PLASMA 

CONCENTRATIONS OF HDL SUBCLASSES IN SUBJECTS WITH HIGH 

CORONARY CALCIUM SCORE 

Oscar Pérez-Méndez, C. García-Sánchez, G. Vargas-Alarcón, C. Posadas- 

Romero, Mexico 1418 

205 CALCULATED LDL CHOLESTEROL BY FRIEDEWALD SUBSTANTIALLY 

UNDERESTIMATES LDL-C BELOW 70 MG/DL 

Evan Stein, S.M. Wasserman, I. Bridges, USA, UK 10 

Dyslipidaemia: epidemiology, biomarkers 

206 PREVALENCE OF SEVERE HYPERCHOLESTEROLEMIA IN A 

PREVENTIVE CARDIOLOGY CLINIC 

Jean Ferrières, D. Taraszkiewicz, J. Fourcade, S. Lemozy, D. Allemandou, 

V. Bongard, France 50 

207 LIPID METABOLISM IN PERIMENOPAUSAL WOMEN WITH LOW TO 

MODERATE CARDIOVASCULAR RISK 

Anna Isayeva, M. Vovchenko, V. Volkov, I. Komir, Ukraine 319 

208 RISK OF HYPERCHOLESTEROLEMIA ON CARDIOVASCULAR DISEASE 

AND POPULATION ATTRIBUTABLE FRACTION IN A 24-YEAR COHORT 

STUDY OF JAPANESE GENERAL POPULATION 

Daisuke Sugiyama, T. Okamura, T. Ohkubo, K. Miura, A. Okayama, H. 

Ueshima, NIPPON DATA 80/90 Research Group, Japan 465 

77




209 OXLDL TO OXLDL-AB RATIO - THE NEW BIOMARKER ASSOCIATED 

WITH CAROTID ATHEROSCLEROSIS AND CARDIOVASCULAR 

COMPLICATIONS IN DIALYZED PATIENTS 

Krystyna Pawlak, M. Mysliwiec, D. Pawlak, Poland 477 

210 TRIGLYCERIDE/HDL RATIO, APOLIPOPROTEIN B, NON-HDL 

CHOLESTEROL ARE USEFUL PREDICTORS FOR LDL PARTICLE SIZE 

WITH STATIN TREATMENT IN CORONARY ARTERY DISEASE 

Sang-Hyun Kim, H.-L. Lee, D.-G. Park, K. Hack-Ryoung, J.-B. Seo, W.-Y. 

Chung, J.-H. Zo, M.-A. Kim, Republic of Korea 615 

211 AGE AND SEXUAL ASPECTS OF THE HYPERCHOLESTEROLEMIA 

I.G. Leschenko, V.A. Leschenko, Roman Iosifovich Vorobyev, E.N. 

Vorobyeva, Russia 655 

212 TRIGLYCERIDE IS A PREDICTOR OF HYPERTENSION IN AN 8-YEAR 

COHORT STUDY IN THE JAPANESE WORKERS 

Naomi Miyamatsu, A. Shima 1,2 , Y. Kawatsu, T. Nishikawa, D. Sugiyama, A. 

Kadota, A. Morimoto, Y. Tatsumi 1,6 , N. Sonoda, A. Morino, T. Okamura, 

Japan 705 

213 A NON-RADIOMETRIC METHOD FOR ESTIMATION OF CHOLESTERYL 

ESTERS 

Hardik Gandhi, P. Pal, R. Giridhar, M.R. Yadav, India 1636 

214 APOLIPOPROTEIN B:A1 RATIO IS INDEPENDENTLY ASSOCIATED 

WITH SUB-CLINICAL AND INCIDENT CORONARY HEART DISEASE IN 

BRITISH SOUTH ASIAN AND EUROPEAN MEN 

Therese Tillin, J. Heasman, A. Wright, P. McKeigue, A.D. Hughes, N. 

Chaturvedi, UK 739 

215 IMPACT OF SEASONALITY ON THE PREVALENCE OF DYSLIPIDEMIA: 

A LARGE POPULATION STUDY 

E.S. Parra, A.C. Sposito, F. Moura, M.S. Dutra-Rodrigues, A. Cassol, 

V.H.D.S. Zago, F. Alexandre, I.V. Calanca, F. Vendrame, V.W. Virginio, F.K. 

Saraiva, O.R. Coelho, E. Naknadakare, E.C.R. Quintao, Eliana C. de Faria, 

Brazil 816 

216 PREVALENCE OF DYSLIPIDEMIA IN OUTPATIENT CLINIC OF SAMARA 

CITY 

Mikhail A. Kachkovskii, V.V. Simerzin, I.M. Nazarkina, L.S. Fedoseeva, I.H. 

Sytdykov, E.R. Bulatova, O.A. Rubanenko, Russia 829 

217 SMALL DENSE LDL AND OXIDIZED LDL ARE DIFFERENTLY 

ASSOCIATED WITH PROGRESSING ATHEROSCLEROSIS 

M. Budkhashvili, A. Sapegin, A. Titkov, S. Urazgildeeva, L. Vasina, Victor 

Gurevich, Russia 830 

218 NOT ALL QUIET ON THE EASTERN FRONT. FAVORABLE CHANGES IN 

THE LIPID LEVELS OF PATIENTS WITH HIGH RISK IN HUNGARY 

Istvan Reiber, I. Mező, L. Márk, G. Paragh, G. Pados, I. Karádi, Z. Kiss, 

Hungary 863 

78




219 PROGNOSTIC VALUE OF APOLIPOPROTEIN B LEVEL IN PATIENTS 

WITH HEART FAILURE WHO SUFFERED ACUTE CORONARY 

SYNDROME 

Natalya Koziolova, E. Polyanskaya, Russia 935 

220 LOW DENSITY LIPOPROTEIN SUBFRACTIONS IN PATIENTS WITH 

DIFFERENT GRADE OF CORONARY ATHEROSCLEROSIS 

Victoria A. Metelskaya, I.N. Ozerova, N.V. Perova, N.E. Gavrilova, O.I. 

Chernushevich, Russia 966 

221 MARKERS OF SUBCLINICAL ATHEROSCLEROSIS - OXIDIZED LOW 

DENSITY LIPOPROTEINS 

Loreta Bagdonaite, Z.A. Kucinskiene, Lithuania 1006 

222 ATHEROGENIC LIPID DISORDERS IN SIBERIAN ADOLESCENT 

POPULATION: PREVALENCE, TRENDS AND ASSOCIATIONS 

Diana Denisova, L. Zavyalova, Russia 1217 

223 DEVELOPEMENT OF A REFERENCE METHOD FOR LDL-P AND 

PRODUCTION OF NEW REFERENCE STANDARDS IN LIPID TESTING: 

THE BIO-SITRACE PROJECT 

Vincent Delatour, M. Heuillet, B. Lalere, S. Vaslin-Reimann, H. Parkes, 

France, UK 1362 

224 ESTIMATION OF SMALL DENSE LDL LEVEL USING THE SIMPLE 

PRECIPITATION METHOD IN TUNISIAN PATIENTS WITH CORONARY 

ARTERY DISEASE 

H. Aoua, A. Ben Khalfallah, Y. Nekaies, K. Charradi, M. Sakly, Nebil Attia, 

Tunisia 1376 

225 DIFFERENT LIPOPROTEIN PROFILES IN EXAMINED INDIVIDUALS 

WITH DYSLIPOPROTEINEMIA IDENTIFIED BY LIPOPRINT SYSTEM 

Stanislav Oravec, J. Bulas, Ľ. Gašpar, A. Dukát, I. Vacula, Slovak Republic1499 

226 HIGH SERUM REMNANT-LIKE LIPOPROTEIN PARTICLE 

CHOLESTEROL LEVELS ARE INDEPENDENTLY ASSOCIATED WITH 

INCREASED NECROTIC COMPONENTS IN CORONARY PLAQUES IN 

STATIN-TREATED PATIENTS 

Tetsuro Matsuoka, T. Matsuoka, A. Kato, Y. Makino, S. Kihara, Japan 1508 

227 EXTENDED CHARACTERIZATION OF LIPIDIC PROFILE: EVALUATION 

OF LIPOPROTEIN SUBFRACTIONS 

F. Leitão, S. Berguete, S. Tania, G. Alexandra, Bourbon Mafalda 1,2 , 

Portugal 1568 

Familial hypercholesterolaemia 

229 ATYPIC ISOLATED GIANT XANTHOMAS ASSOCIATED WITH SEVERE 

MIXED DYSLIPIDEMIA WITHOUT FAMILIAL 


Jean-Christophe Charniot, R. Bittar, A. Carrié, P. Couvert, R. Kidouche, O. 

Verola, E. Brucker, D. Bonnefont Rousselot, France 423 

79




230 PREVALENCE AND CHARACTERISTICS OF AUTOSOMAL DOMINANT 

HYPERCHOLESTEROLEMIA IN PERSONS SCHEDULED FOR 

CORONARY ANGIOGRAPHY. LUDWIGSHAFEN RISK AND 

CARDIOVASCULAR HEALTH STUDY (LURIC) 

Hubert Scharnagl, T.B. Grammer, M.E. Kleber, T. Stojakovic, U. Kassner, 

E. Steinhagen-Thiessen, W. März 1,2,4 , Austria, Germany 431 

231 SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLEMIA ARE 

CHARACTERIZED BY A PRO-INFLAMMATORY PHENOTYPE DESPITE 

LONG-TERM INTENSIVE CHOLESTEROL-LOWERING TREATMENT 

Ingunn Narverud, P. Aukrust, H.W. Lindvig, B. Halvorsen, G. Langslet, L. 

Ose, K. Retterstøl, K.B. Holven, Norway 449 

232 GENETIC DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA (FH) 

BY DIFFERENT NEXT GENERATION SEQUENCING PLATFORMS 

Marianne Stef, D. Arteta, E. Olano-Martin, N. Aizpuru, L. Grandoso, L. 

Alonso, J. Nieves, B. Sanz, X. Ugarte-Pedrero, X. Cantero, P. Galán-Garcia, 

I. Santos, L. Osaba, D. Tejedor, L. Palacios, Spain 576 

233 PCSK9 GENETIC HETEROGENEITY IN FAMILIAL 

HYPERCHOLESTEROLEMIA (FH) PATIENTS 

L. Palacios, L. Grandoso, D. Arteta, A. Etxebarria 2,3 , C. Martin 2,3 , N. Aizpuru, 

L. Alonso, L. Osaba, D. Tejedor, Marianne Stef, Spain 586 

234 DEFINING PATIENTS AT EXTREMELY HIGH RISK FOR CORONARY 

ARTERY DISEASEIN HETEROZYGOUS FAMILIAL 


Mariko Harada-Shiba, H. Makino, T. Okamura, I. Kishimoto, Y. Miyamoto, 

H. Tomoike, S. Yokoyama, Japan 643 

235 BENEFICIAL EFFECT OF LDL-APHERESIS AND PLASMAPHERESIS ON 

PARAOXONASE CONCENTRATION AND LDL SUBCLASSES IN A 

PATIENT WITH SEVERE TYPE III HYPERLIPIDEMIA 

Mariann Harangi, I. Seres, M. Katkó, J. Padra, H. Lőrincz, G. Paragh, 

Hungary 667 

236 NOVEL PCSK9 GENE VARIANT IN A FAMILIAL 

HYPERCHOLESTEROLAEMIA FAMILY FROM POLAND 

Malgorzata Walus-Miarka, M. Futema, B. Idzior-Waluś, M. Sanak, R.A. 

Whittall, K.W. Li, S.E. Humphries, Poland, UK 1500 

237 COMMON PCSK9 VARIANT AS GENETIC BACKGROUND OF FAMILIAL 

COMBINED HYPERLIPIDEMIA IN JAPAN 

Atsushi Nohara, T. Noguchi, M.-A. Kawashiri, T. Inoue, S. Katsuda, M. Mori, 

C. Nakanishi, K. Yagi, A. Inazu, M. Yamagishi, H. Mabuchi, Japan 880 

238 WOLMAN DISEASE: THE IMPORTANCE OF EARLY DIAGNOSIS. A 

REVIEW OF 6 CASES WITH COMPLETE LYSOSOMAL ACID LIPASE 

DEFICIENCY 

Pascale Benlian, A. Pagnier, K. Mention, F. Feillet, T. Levade, D. Plantaz, 

P. De Lonlay, V. Valayannopoulos, France 905 

80




239 AMINOTRANSFERASE ELEVATIONS OBSERVED IN A PHASE 3 STUDY 

OF PATIENTS WITH HOMOZYGOUS FAMILIAL 

HYPERCHOLESTEROLEMIA TREATED WITH LOMITAPIDE WERE 

CLINICALLY MANAGEABLE 

Marina Cuchel, E.A. Meagher, D.J. Blom, H.D.T. Theron, A.D. Marais, R.A. 

Hegele, M.R. Averna, C.R. Sirtori, P.K. Shah, D. Gaudet, C. Stefanutti, G.B. 

Vigna, A.M. Du Plessis, L.T. Bloedon, D.J. Rader, USA, South Africa, 

Canada, Italy 915 

240 CLINICAL VERSUS MOLECULAR DIAGNOSIS OF FAMILIAL 


Mahtab Sharifi, A. Nair, D. Harvey, S.E. Humphries, D. Nair, UK 1150 

241 A LARGE PROPORTION OF PATIENTS WITH FAMILIAL 

HYPERCHOLESTEROLEMIA ARE UNDER-TREATED: RESULTS OF A 

CROSS SECTIONAL STUDY IN 1757 FRENCH PATIENTS 

Sophie Béliard, V. Carreau, A. Carrié, P. Giral, E. Duchêne, M. Farnier, J. 

Ferrières, A. Fredenrich, M. Krempf, G. Luc, P. Moulin, E. Bruckert, France 1211 

242 PREGNANCY IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA 

- WHEN THE THINGS ARE GOING WELL 

M. Blaha, M. Lanska, Vladimir Blaha, L. Boudys, I. Zimmerova, Czech 

Republic 1387 

243 SECRETORY PHOSPHOLIPASE A2 ACTIVITY IN CHILDREN WITH 

HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND TWO- 

YEAR EFFICACY OF PRAVASTATIN 

Marjet Braamskamp, S. Tsimikas, A. Wiegman, J. Kastelein, B. Hutten, The 

Netherlands, USA 1538 

244 PATHOGENICITY ASSESSMENT OF LDLR VARIANTS IN PATIENTS 


Ana Margarida Medeiros 1,2 , A.C. Alves 1,2 , A. Extebarria, C. Martin, Portugal, 

Spain 1541 

245 APOB: OLD GENE, NEW PERSPECTIVE FOR FAMILIAL 

HYPERCHOLESTEROLAEMIA 

Ana Catarina Alves 1,2 , A. Extebarria, C. Martin, M. Bourbon 1,2 , Portugal, 

Spain 1542 

246 P450 OXIDOREDUCTASE (POR) *28 ALLELE IS ASSOCIATED WITH 

LIPID LOWERING RESPONSE TO ATORVASTATIN IN CHILDREN AND 

ADOLESCENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA 

G. Ragia, E. Drogari, V. Kolovou, L. Elens, V. Mollaki, A. Tavridou 1,5 , R. van 

Schaik, G. Kolovou, Vangelis George Manolopoulos 1,5 , Greece, The 


Primary dyslipidaemia 

247 FAMILIAL COMBINED HYPERLIPIDEMIA: SHOULD WE CONSIDER IT IN 

PEDIATRICS? 

Francesca Abello, P. Cagliero, O. Guardamagna, Italy 1026 

81




248 OCCURRENCE OF TYPE V HYPERCHYLOMICRONEMIA IN 

DYSBETALIPOPROTEINEMIC PATIENTS: A CASE CONTROL STUDY 

Audrey Garon, C. Marcais, M. Di-Filippo, S. Charriere, A. Sassolas, P. 

Moulin, France 1087 

249 TREATMENT OF EXTREME HYPERTRIGLYCERIDEMIA IN ZIEVE´S 

SYNDROME. A CASE REPORT 

Ioannis Terzis, T. Bitsis, I. Mallias, E. Papastefanou, T. Milidis, Greece 1234 

250 LIPOPEROXIDATION IN CHRONIC PANCREATITIS - PRELIMINARY 

DATA 

Marek Vecka 1,2 , A. Žák 1,2 , L. Vávrová 1,2 , J. Kodydková 1,2 , J. Macášek, M. 

Urbánek, T. Krechler, B. Staňková 1,2 , Czech Republic 1577 

251 MTTP MUTATIONS Y528H, R540C AND N649S ARE ASSOCIATED WITH 

ABETALIPOPROTEINEMIA AND REDUCE IN VITRO MICROSOMAL 

TRIGLYCERIDE TRANSFER PROTEIN ACTIVITY 

S.A. Miller, J.R. Burnett 1,2 , F.M. van Bockxmeer 1,2 , Amanda J. Hooper 1,2 , 

Australia 402 

252 A NEW CASE OF FAMILIAL COMBINED HYPOLIPIDEMIA (FHBL2) WITH 

NEW HOMOZYGOUS ANGPTL3 MUTATION AND ABNORMAL ORAL 

FAT LOAD 

Mathilde Di Filippo 1,2 , O. Marmontel 1,2 , P. Moulin 2,3 , S. Charrière 2,3 , A. 

Sérusclat, L. Perrot, S. Nony, S. Dumont, D. Bozon, A. Sassolas 1,2 , France 1089 

253 A CASE OF TANGIER DISEASE RESTRICTED TO VERY LOW HDL-C 

AND CHD 

Diana Muačević-Katanec, A. Merkler, A. Carrié, M. Barešić, M. Vučić, Ž. 

Reiner, P. Couvert, Croatia, France 1638 

254 CLINICAL AND BIOCHEMICAL ASPECTS OF 

PSEUDOHYPERTRIGLYCERIDEMIA RESULTING FROM 

HYPERGLYCEROLEMIA 

P. Giral 1,2 , Randa Khani Bittar 2,3 , V.F. Fouquier, D. Rosenbaum, C. Vatier, 

B. Hansel, D.B. Rousselot 3,5 , France 1059 

Secondary dyslipidaemia 

256 OXIDIZED LOW DENSITY LIPOPROTEIN CONCENTRATION IS 

ASSOCIATED WITH THYROTROPIN LEVELS IN EUTHYROID 

NORMOCHOLESTEROLEMIC SUBJECTS 

Gustavo Giunta, G. Duaip, D. Rojo, G. Yannarelli 1,2 , N. Pacienza 1,2 , L. 

Maggi, L. Cuniberti 1,2 , Argentina 772 

257 SUBCLINICAL THYROID DYSFUNCTION AS A PROGNOSTIC FACTOR 

FOR FIRST-EVER ISCHEMIC STROKE 

Christina Voulgari, L. Moulopoulos, A. Kanellou, V. Giannopoulou, A. 

Anagnostopoulos, S. Pagoni, Greece 1317 

258 EARLY MARKERS OF ATHEROSCLEROSIS IN HYPOTHYROID WOMEN 

WITH ARTERIAL HYPERTENSION 

O. Mitchenko, Maksym Gvozdyk, V. Romanov, Ukraine 1145 

82




259 STIMULATION OF HUMAN CHOLESTEROL AND LIPOPROTEIN 

METABOLISM IN HYPERTHYROIDISM: IMPORTANCE OF LIVER- 

SPECIFIC HORMONE ACTIONS 

Ylva Bonde 1,2 , O. Breuer, D. Lütjohann, S. Sjöberg, B. Angelin 1,2 , M. 

Rudling 1,2 , Sweden, Germany 396 

260 HIV PROTEASE INHIBITORS INDUCE PREMATURE SENESCENCE AND 

CALCIFICATION OF VASCULAR SMOOTH MUSCLE CELLS IN VITRO 

Pauline Afonso, M. Auclair, C. Vigouroux, M. Caron-Debarle, France 1545 

261 LIPID PROFILE AND ACHIEVEMENT OF LIPIDS GOALS AMONG HIV- 

INFECTED PATIENTS COMPARED TO HIV-UNINFECTED PATIENTS 

AFTER ACUTE CORONARY SYNDROME 

Franck Boccara 1,2 , J. Miantezila Basilua, M. Mary-Krause, S. Lang, D. 

Costagliola, M. Guiguet, A. Cohen, France 1240 

262 PSORIASIS ALTERS HDL COMPOSITION AND FUNCTION 

Gunther Marsche, P. Wolf, M. Holzer, Austria 1279 

Genetics / HDL metabolism 

263 ABCA1 GENE POLYMORPHISMS IN CORONARY ARTERY DISEASE 

Arzu Ergen, S. Isbir, H. Karagedik, T. Isbir, Turkey 131 

264 ASSOCIATION OF THE G30S MUTATION OF LECITHIN: CHOLESTEROL 

ACYLTRANSFERASE (LCAT) WITH AN INCREASE OF CORONARY 

STENOSIS IN A TUNISIAN POPULATION 

J. Rejeb, Asma Omezzine, I. Boumaiza, L. Rebhi, A. Moussa, S. Kacem, N. 

Ben Rejeb, A. Ben Abdelaziz, E. Boughzala, A. Bouslama, Tunisia 490 

265 ASSOCIATIONS OF ABCA1, CETP, APOAI, SCARB1, PON1, PON2 AND 

LCAT POLYMORPHISMS WITH CORONARY STENOSIS IN A TUNISIAN 

POPULATION 

J. Rejeb, Asma Omezzine, I. Boumaiza, L. Rebhi, A. Moussa, N. Ben Rejeb, 

A. Ben Abdelaziz, E. Boughzala, A. Bouslama, Tunisia 496 

266 INFLUENCES OF ABCG1, ABCG5 AND ABCG8 SINGLE NUCLEOTIDE- 

POLYMORPHYSMS ON PLASMA LIPIDS AND LIPOPROTEINS OF A 

REPRESENTATIVE BRAZILIAN POPULATION 

Vanessa Helena De Souza Zago, E.S. Parra, N.B. Panzoldo, D.Z. Scherrer, 

J.H.G. Colletes, E.I.L. Gomes, V.S. Nunes, E. Nakandakare, E.C.R. Quintao, 

E.C. de Faria, Brazil 826 

Genetics / Lipid metabolism 

267 SMOKING, APOLIPOPROTEIN E GENOTYPES AND MORTALITY (THE 

LUDWIGSHAFEN RISK AND CARDIOVASCULAR HEALTH STUDY) 

Tanja Grammer, M.M. Hoffmann, H. Scharnagl, M.E. Kleber, G. Silbernagel, 

S. Pilz, A. Tomaschitz, E. Lerchbaum, R. Siekmeier, W. März 1,3,8 , Germany, 

Austria 234 

83




268 THE INFLUENCE OF CETP, LPL AND APO CIII POLYMORPHISMS ON 

POSTPRANDIAL LIPEMIA 

Katherine Anagnostopoulou, C. Mihas, V. Kolovou, D. Manolopoulou, K. 

Sorontila, S. Lekka, P. Kostakou, D. Damaskos, D.V. Cokkinos, G. Kolovou, 

Greece 451 

269 APOLIPOPROTEIN E GENOTYPE AND PROTEIN LEVEL, DEMENTIA 

AND CEREBROVASCULAR DISEASE - A STUDY OF 76,000 

INDIVIDUALS FROM THE GENERAL POPULATION 

Katrine L. Rasmussen, A. Tybjærg-Hansen, B.G. Nordestgaard, R. Frikke- 

Schmidt, Denmark 564 

270 THE RELATIONSHIP BETWEEN THE LEVELS OF SPLA2-IIA, 

VARIATION IN THE SPLA2-IIA GENE AND THE SEVERITY OF 

CORONARY ATHEROSCLEROSIS 

Tatyana Olegovna Pavlunina, Y.A. Shuvalova, Z. Khasanova, E.V. 

Samoylova, A.A. Korotaeva, V.V. Kukharchuk, A.I. Kaminnyi, Russia 567 

271 ASSOCIATION OF PCSK9 GENE POLYMORPHISMS WITH THE RISK OF 

CORONARY ARTERY DISEASE IN THAI 

Parnsak Pitivej Thurakit, C. Settasatian, N. Settasatian, N. Komanasin, P. 

Intharapetch, U. Kukongwiriyapan, K. Tantipanichteerakul, V. Senthong, 

Cardiovascular Research Group, Khon Kaen University, Thailand 831 

272 ASSOCIATION OF GENETIC VARIABILITY AT LDLR PROMOTER AND 

PRIMARY HYPERCHOLESTEROLEMIA 

Isabel De Castro-Orós 1,2 , J. Pérez-López, R. Mateo-Gallego 2,4 , M. 

Ledesma 5,6,7 , M. León 6,7 , M. Cofán, J.A. Casasnovas 6,7 , E. Ros, J.C. 

Rodríguez-Rey, F. Civeira, M. Pocoví 1,7 , Spain 986 

273 THE PNPLA3 I148M VARIANT IS ASSOCIATED WITH HIGHER 

PREVALENCE OF TYPE 2 DIABETES IN SUBJECTS WITH METABOLIC 

SYNDROME 

Laura D'Erasmo, L. Polimeni, F. Baratta, A. Di Costanzo, N. Virga, M. 

Maranghi, M. Del Ben, F. Angelico, M. Arca, Italy 994 

274 THE POLYMORPHISM OF APOLIPOPROTEIN CIII GENE AND LIPID 

PROFILE IN CAUCASIAN POPULATION OF WEST SIBER 

E. Shakhtshneider, I. Kulikov, V. Maksimov, Y. Nikitin, S. Malyutina, Mikhail 

Voevoda, Russia 1110 

275 THE POLYMORPHISM OF APOLIPOPROTEIN E GENE AND LIPID 

PROFILE IN CAUCASIAN POPULATION OF WEST SIBERIA 

Mikhail Voevoda, E. Shakhtshneider, I. Kulikov, V. Maksimov, M. Ivanova, 

Y. Nikitin, S. Malyutina, Russia 1114 

276 HPA1 GENE POLYMORPHISM IN APOLIPOPROTEIN C1 GENE IS 

ASSOCIATED WITH TYPE II DIABETES IN CAD PATIENTS 

Yann Pucheu, X. Pillois, A. Horovitz, A. Reynaud, J. Bonnet, France 1121 

84




277 GENOTYPIC INTERACTIONS OF GENES IMPLICATED IN LIPOPROTEIN 

METABOLISM WITH TYPE 2 DIABETES IN TUNISIAN POPULATION 

Raja Chaaba, S. Mehri, N. Attia, S. Hammami, M. Smaoui, K. Ben Hamda, 

A. Nakbi, N. Koubaa, M. Hammami, Tunisia 1185 

278 ASSOCIATION OF HEPATIC LIPASE -514T ALLELE WITH CAD AND 

ANKLE-BRACHIAL INDEX, DEPENDENCE ON THE LIPOPROTEIN 

PHENOTYPE: THE GENES STUDY 

Céline Verdier, J.-B. Ruidavets, V. Bongard, D. Taraszkiewicz, L. Martinez, 

M. Elbaz 1,3 , J. Ferrières 2,3 , B. Perret, France 1231 

279 LDL RECEPTOR EXPRESSION AND FUNCTIONAL POLYMORPHISMS 

OF MMP 1 GENE IN CORONARY ARTERY DISEASE 

Kodapalli Mrudula Spurthi, G. Rajesh Kumar, G. Kishor Kumar, K. Sanjib 

Sahu, N. Prathiba, H. Surekha Rani, India 1626 

280 ASSOCIATION OF HAPLOTYPES IN THE 3'UTR OF THE LDLR GENE 

WITH LOW-DENSITY LIPOPROTEIN LEVELS IN A BLACK SOUTH 

AFRICAN POPULATION 

Tertia Van Zyl, G.W. Towers, K.R. Conradie, J.C. Jerling, South Africa 1644 

Lipid-lowering therapy / Ezetimibe 

283 EFFECTS OF EZETIMIBE (EZE), SIMVASTATIN (SIMVA) AND 

EZETIMIBE/SIMVASTATIN (EZE/SIMVA) ON APOB, LDL-C AND NON- 

HDL-C TARGETS IN PATIENTS WITH PRIMARY 


Michel Farnier, J.R. Guyton, E. Jensen, A.B. Polis, A.O. Johnson-Levonas, 

P. Brudi, France, USA 120 

284 EFFECTS OF EZETIMIBE, EZETIMIBE COADMINISTERED WITH 

STATINS AND STATIN THERAPIES ON FASTING GLUCOSE CHANGES 

IN PATIENTS WITH HYPERCHOLESTEROLEMIA 

P.P. Toth, A. Catapano, M. Farnier, J. Foody, Joanne E. Tomassini, E. 

Jensen, A.B. Polis, T. Musliner, A.M. Tershakovec, USA, Italy, France 196 

285 VARIABILITY OF THE LDL-C LOWERING RESPONSE TO STATINS AND 

EZETIMIBE + STATIN THERAPY IN HYPERCHOLESTEROLEMIC 

PATIENTS 

O Descamps, J. Lin, J.E. Tomassini, A.B. Polis, A. Shah, P. Brudi, A.M. 

Tershakovec, Belgium, USA 201 

286 EZETIMIBE IMPAIRS ENDOTHELIAL TURNOVER IN STABLE PATIENTS 

AT HIGH CARDIOVASCULAR RISK WITH ELEVATED C-REACTIVE 

PROTEIN 

L.C. Lins, C.N. França, F.A. Fonseca, S.P. Barbosa, A.C. Aguirre, H.T. 

Bianco, J.B. Amaral, L.N. Matos, Maria Cristina de Oliveira Izar, Brazil 357 

287 LOW DOSE SIMVASTATIN PLUS EZETIMIBE TREATMENT REDUCE 

INFLAMMATORY CYTOKINES WITHOUT MODIFICATION OF HSPCR 

LEVELS IN HYPERCHOLESTEROLEMIC PATIENTS 

A. Cerda, C.M. Fajardo, E.S. Guimaraes, E.L. Dorea, M.C. Gosukuma, G.A. 

Pinto, Mario Hiroyuki Hirata, R.D.C. Hirata, Brazil 921 

85




288 COMPARISON OF LIPID LOWERING EFFECTS BETWEEN EZETIMIBE 

AND PRAVASTATIN: RESULTS FROM A PILOT CROSSOVER STUDY 

Noriaki Kume 1,2 , Japan 1311 

289 DO SERUM LIPID CHANGES WITH STATIN/EZETIMIBE DIFFER 

SUBSTANTIVELY BY BMI CATEGORY? AN ACT II STUDY ANALYSIS 

Dominik Lautsch 1,2 , H. Toplak, C. Saely 1,4 , M. Pichler, P. Brudi, 

Liechtenstein, Austria, USA 1639 

290 EZETIMIBE AND ATORVASTATIN COADMINISTRATION VERSUS 

ATORVASTATIN UP-TITRATION OR SWITCHING TO ROSUVASTATIN IN 

PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND HIGH 

CARDIOVASCULAR RISK 

Michel Farnier, M. Averna, C. Majul, D. Muller-Wieland, A. De Pellegrin, H. 

Giezek, R. Lee, R.S. Lowe, P. Brudi, J. Triscari, H.E. Bays, France, Italy, 

Argentina, Germany, Belgium, USA 1640 

Lipid-lowering therapy / Miscellaneous 

291 DIFFERENCES IN THE ATHEROGENIC RISK OF PATIENTS TREATED 

BY LIPOPROTEIN APHERESIS ACCORDING TO THEIR LDL 

CHOLESTEROL AND LIPOPROTEIN(A) LEVELS 

Ulrich Julius, M. von Dryander, S. Fischer, G. Müller, Germany 107 

292 BEZAFIBRATE IMPROVES POSTPRANDIAL LIPEMIA AND 

POSTPRANDIAL ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH 

METABOLIC SYNDROME 

Toru Miyoshi, H. Oe, Y. Ohno, K. Nakamura, H. Morita, K. Kusano, H. Ito, 

Japan 337 

293 COLESEVELAM WITH LOW-DOSE STATIN IS ASSOCIATED WITH A 

FAVORABLE EFFECT ON MARKERS OF INSULIN RESISTANCE 

COMPARED WITH A HIGHER-DOSE STATIN 

M. Florentin, Evangelos N. Liberopoulos, A.A. Kei, C.V. Rizos, M.S. Elisaf, 

Greece 361 

294 LIPOPROTEIN APHERESIS DURING THE FIRST-YEAR AFTER CABG IN 

PATIENTS WITH HYPERLIPIDEMIA 

Marat Ezhov, L. Il`ina, R. Adzhiev, O. Afanasieva, M. Safarova, E. Vlasova, 

I. Adamova, G. Konovalov, S. Pokrovsky, Russia 991 

295 THE PPAR AGONIST TETRADECYLTHIOACETIC ACID REDUCES 

ATHEROSCLEROSIS PROGRESSION IN APOE -/- MICE BEYOND 

PLASMA LIPID LOWERING 

Rita Vik, M. Busnelli, C. Prolini, B. Bjørndal, S. Holm, T. Brattelid, S. 

Manzini, G. Banzetti, P. Aukrust, G. Chiesa, R.K. Berge, Norway, Italy 1038 

296 UNITED STATES TRENDS IN THE USE AND COST OF LIPID LOWERING 

MEDICATIONS FROM 2004 THROUGH 2012 

L. Goldman Rosas, M. Shahbaz, S. Thiyagarajan, Randall Stafford, USA 1273 

86




Lipid-lowering therapy / Nicotinic acid 

297 PHENOTYPIC DETERMINANTS OF LIPID RESPONSES TO TREATMENT 

WITH NICOTINIC ACID AND LAROPIPRANT IN HONG KONG CHINESE 

PATIENTS WITH DYSLIPIDAEMIAV 

Y.L. Yang, Miao Hu, B. Tomlinson, Hong Kong S.A.R. 738 

298 EFFECT OF EXTENDED-RELEASE NIACIN/ LAROPIPRANT 

COMBINATION ON FASTING LIPIDS, GLUCOSE, INSULIN AND 

ADIPONECTIN LEVELS IN CHINESE PATIENTS WITH DYSLIPIDAEMIA 

Y.L. Yang, M. Hu, S. Yamashita, D. Masuda, Brian Tomlinson, Hong Kong 

S.A.R., Japan 746 

299 NIACIN EFFICACY AND SAFETY IN APPARENTLY HEALTHY MEN WITH 

LIPOPROTEIN(A) EXCESS 

Nadezhda Artemeva, M. Safarova, M. Ezhov, O. Afanasieva, O. Dmitrieva, 

S. Pokrovsky, Russia 818 

Lipid-lowering therapy / PCSK9 

300 AFFITOPE ®- BASED ANTI-PCSK9 VACCINES - AN INNOVATIVE 

APPROACH FOR LONG TERM CHOLESTEROL MANAGEMENT 

Gergana Galabova, C. Juno, W. Kirchstetter, E. Bilcikova, M. Edjlalipour, G. 

Winsauer, S. Brunner, F. Mattner, W. Schmidt, A. von Bonin, G. Staffler, 

Austria 371 

301 DYNAMICS BETWEEN THE MONOCLONAL ANTIBODY 

SAR236553/REGN727, PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 

TYPE 9 (PCSK9) AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL 

(LDL-C) LEVELS (FUNDING: REGENERON/SANOFI) 

James M. McKenney, G.D. Swergold, T. DiCioccio, P. Belomestnov, C. 

Hanotin, A. Brunet, W.J. Sasiela, E.A. Stein, USA, France 485 

302 THE EFFECTS OF SINGLE DOSE ADMINISTRATION OF RN316 (PF- 

04950615), A HUMANIZED MONOCLONAL ANTIBODY BINDING PCSK9, 

IN HYPERCHOLESTEROLEMIC SUBJECTS 

B. Gumbiner, C. Udata, T. Joh, H. Liang, H. Wan, D. Shelton, P. Forgues, S. 

Billotte, J. Pons, C. Baum, Pamela D Garzone, USA 1268 

303 THE EFFECTS OF MULTIPLE DOSE ADMINISTRATION OF RN316 (PF- 

04950615), A HUMANIZED MONOCLONAL ANTIBODY BINDING PCSK9, 

IN HYPERCHOLESTEROLEMIC SUBJECTS 

B. Gumbiner, C. Udata, T. Joh, H. Liang, H. Wan, D. Shelton, P. Forgues, S. 

Billotte, J. Pons, C. Baum, Pamela D Garzone, USA 1270 

Lipid-lowering therapy / Statins 

305 ROSUVASTATIN EVALUATION PROGRAM FOR ESTABLISHING 

EFFICACY AND SAFETY IN INDIAN HYPERLIPIDEMIA PATIENTS 

ROSUVEES 

Navneet Wadhwa, B. Kotak, C. Shah, ROSUVEES Study Group, India 1016 

87




306 PREOPERATIVE STATIN TREATMENT IN CARDIAC SURGERY IS MORE 

EFFECTIVE IN PATIENTS WITH PREVIOUS ACTIVATION OF THE 

INFLAMMATORY SYSTEM 

Jose Rubio Alvarez, J.M. Martinez Comendador, J. Sierra Quiroga, E. 

Teijeira Fernandez, B. Adrio Nazar, Spain 21 

307 EFFECT OF SIMVASTATIN/EZETIMIBE 10/10 MG VERSUS 

SIMVASTATIN 40 MG ON SERUM VITAMIN D LEVELS 

S.E. Makariou 1,2 , E.N. Liberopoulos, E. Moutzouri, M. Kostapanos, I. 

Panagopoulou, A. Challa, Moses Elisaf, Greece 26 

308 ROSUVASTATIN SIGNIFICANTLY IMPROVES ARTERIAL STIFFNESS 

PARAMETERS BY PULSE-WAVE ANALYSIS IN HIGH RISK PATIENTS 

WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA 

Olga N. Korneeva, O.M. Drapkina, L. Palatkina, E. Zyatenkova, N. 

Balachonova, V. Ivashkin, Russia 118 

309 ROSUVASTATIN INFLUENCE ON CAROTID ATHEROSCLEROSIS. 

DADA 

Nataliya Gamletovna Dadamyants, F. Djalalov, Uzbekistan 237 

310 EFFECTS OF ROSUVASTATIN VERSUS PROBUCOL ON LIPID 

ABNORMALITIES IN PATIENTS WITH CHRONIC KIDNEY DISEASE 

STAGE 3 AND ABOVE 

Gen Yasuda, K. Yatsu, S. Saka, N. Hirawa, Japan 244 

311 NO PHARMACOGENETIC PRAVASTATIN EFFECT ON 

CARDIOVASCULAR EVENTS IN THE PROSPER/PHASE STUDY. IS 

PERSONALIZED MEDICINE WITH REGARD TO STATINS STILL 

REALISTIC? 

Iris Postmus 1,2 , S. Trompet 1,2,3 , A.J.M. de Craen 1,2 , D. Shiffman, J.J. Devlin, 

I. Ford, P.E. Slagboom 2,6 , R.G.J. Westendorp 1,2 , J.W. Jukema 3,7,8 , The 

Netherlands, USA, UK 283 

312 LONG-TERM EFFECT OF STATIN ON FASTING BLOOD GLUCOSE 

LEVELS IN ASIAN HYPERCHOLESTEROLEMIC PATIENTS 

Chee Jeong Kim, M.-A. Kim, Republic of Korea 333 

88




313 STATIN USE IS ASSOCIATED WITH DEPRESSION IN MINORITY ETHNIC 

GROUPS IN UK 

Emily D. Williams, R. Stewart, T. Tillin, N. Chaturvedi, A.D. Hughes, UK 554 

314 ROSUVASTATIN CAN REDUCE AORTIC STIFFNESS IN 

HYPERCHOLESTEROLEMIC PATIENTS BY FAVORABLE 

HEMODYNAMIC CHANGES, INDEPENDENT OF LIPID LOWERING AND 

ANTI-INFLAMMATORY EFFECTS 

P.C. Oh, Seung Hwan Han, J. Seo, K.K. Koh, T.H. Ahn, E.K. Shin, Republic 

of Korea 644 

315 EFFECTS OF TWO DIFFERENT STATINS ON VASCULAR 

INFLAMMATION MARKERS IN ACUTE CORONARY SYNDROMES 

DURING IN-HOSPITAL FOLLOW-UP 

Ali Çoner, A. Aydınalp, V. Çamkıran, K. Okyay, U.A. Bal, A. Yıldırır, H. 

Müderrisoğlu, Turkey 708 

316 PRAVASTATIN COMBINED WITH VALSARTAN SHOWS ADDITIVE 

BENEFICIAL VASCULAR EFFECTS IN PATIENTS WITH 


Kwang Koh, M. Quon, Republic of Korea, USA 727 

317 COMBINATION THERAPY WITH PRAVASTATIN AND VALSARTAN HAS 

ADDITIVE EFFECTS TO IMPROVE METABOLIC PHENOTYPES OVER 

MONOTHERAPY IN HYPERCHOLESTEROLEMIC PATIENTS 

Kwang Koh, M. Quon, Republic of Korea, USA 728 

318 EFFECT OF ROSUVASTATIN ON ATHEROSCLEROSIS OF CAROTID 

ARTERIES 

M. Kenjaev, Azizjon Nizomov, M.B. Urinov, Uzbekistan 873 

319 EFFICACY OF ROSUVASTATIN ON INFLAMMATORY MARKERS IN 

PATIENTS WITH ACUTE CORONARY SYNDROME 

Azizjon Abdumatlubovich Nizomov, Uzbekistan 893 

320 ATORVASTATIN INDUCES ENDOGLIN AND ENOS EXPRESSION IN 


Lenka Zemankova, M. Varejckova, Z. Strasky, P. Nachtigal, Czech Republic1011 

321 EFFECT OF PRAVASTATIN ON ATHEROSCLEROSIS IN 

BRAHIOCEPHALIC ARTERY IN APOE/LDL R -/- MICE FED LOW 

CARBOHYDRATE HIGH PROTEIN DIET 

Magdalena Anna Franczyk-Zarow, E. Maslak, I. Czyzynska, A. Drahun, A. 

Jasztal, L. Mateuszuk, S. Chlopicki, R.B. Kostogrys, Poland 1050 

89




322 PROTECTION BY L-CARNITINE OF STATIN INDUCED MUSCLE 

MITOCHONDRIAL DYSFUNCTION 

P.G. La Guardia, L.C. Alberici, F.G. Ravagnani, R.R. Catharino, Anibal E. 

Vercesi, Brazil 1063 

323 EFFECT OF ROSUVASTATIN ON MICRORNAS EXPRESSION IN HUMAN 

ATHEROSCLEROTIC PLAQUES: RESULTS FROM QUASAR STUDY 

Pamela Marcantonio, D. Santovito, D. Mastroiacovo, C. Mandolini, V. De 

Nardis, G. De Blasis, A. Mezzetti, G. Desideri, F. Cipollone, Italy 1064 

324 STATIN IS ASSOCIATED WITH LOWER DEEP VEIN THROMBOSIS 

INCIDENCE CONFIRMED BY CT ANGIOGRAPHY IN PATIENTS 

UNDERGOING TOTAL KNEE REPLACEMENT ARTHROPLASTY 

Sang-Ho Jo, H.-S. Kim, Republic of Korea 1253 

325 CUMULATIVE MORTALITY DUE TO HIGH DOSES OF ATORVASTATIN 

GIVEN TO HYPERCHOLESTEROLEMIC MICE 

Juan C. Diaz-Zagoya, I.E. Juárez-Rojop, A.E. Castell-Rodríguez, J.L. Blé- 

Castillo, R. Miranda-Zamora, Mexico 1302 

326 EFFECTS OF PITAVASTATIN ON HIGH DENSITY LIPOPROTEIN 

CHOLESTEROL IN ELDERLY PATIENTS WITH DIABETES 

Hyang-Lim Lee, S.-H. Kim, D.-G. Park, Republic of Korea 1494 

327 ATORVASTATIN AND THE RISK TO DEVELOP DIABETES MELLITUS 

Renato Alves, G. Paranhos, N. Scalissi, J. Salles, Brazil 1589 

328 PITAVASTATIN HAS NEUTRAL EFFECTS ON GLYCAEMIC 

PARAMETERS IN METABOLIC SYNDROME: THE CAPITAIN AND 

PREVAIL US TRIALS 

N. Hounslow, P. Giral, C.A. Sponseller, P. Robillard, A. Orsoni, M John 

Chapman, UK, France, USA 1615 

329 NEUTRAL EFFECT OF PITAVASTATIN ON GLYCAEMIC PARAMETERS 

IN METABOLIC SYNDROME : THE CAPITAIN TRIAL 

M John Chapman, N. Hounslow, A. Orsoni, M. Suzuki, P. Robillard, P. Giral, 

France, UK 1616 

330 NEW INSIGHTS INTO STATIN ACTION ON THE DYSLIPIDEMIA OF 

METABOLIC SYNDROME: NORMALISATION OF BIOACTIVE 

PLASMALOGENS AND SPHINGOLIPIDS IN HDL 

Peter J. Meikle, G. Wong, A.R. Tan, B.A. Kingwell, A.K. Orsoni, N. 

Hounslow, P. Giral, M.J. Chapman, France, UK 1643 

90

POSTERS TRACK 3: RISK FACTORS, EPIDEMIOLOGY, PREVENTION, AND TREATMENT 

OF CARDIOVASCULAR DISEASES 


Cardiovascular epidemiology 

331 DYNAMICS OF ATHEROSCLEROTIC LOADING OF CAROTID ARTERIES 

IN MOSCOW POPULATION UNDER TWO-YEAR OBSERVATION 

Olga Pogorelova, M. Tripoten, A. Rogoza, V. Kukharchuk, Y. Karpov, S. 

Boytsov, T. Balakhonova, Russia 1128 

332 ESTIMATION OF CORONARY ARTERY DISEASE ACCORDING TO 

CARDIAC RISK FACTORS IN IRANIAN URBAN POPULATION 

Sepideh Sokhanvar, S.A.N. Kazemi, S.N. Mousavinasab, Iran 1358 

333 LONG TERM MORTALITY FOLLOWING CAROTID ENDARTERECTOMY 

IS GOOD 

Gareth Harrison, G. Lawrence, A. Stead, C. Chan, UK 1606 

334 PREVALENCE OF HEART DISEASE RISK FACTORS IN THE AZORES 

Rita Ferin, E. Schaefer, K. Horvath, J. Baptista, M.L. Pavão, Portugal, USA 139 

335 MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULT 

CONGENITAL HEART DISEASE: AN ASIA POPULATION-BASED LONG- 

TERM STUDY 

Pao-Hsien Chu, Y.-S. Lin, C.-J. Chang, Taiwan R.O.C. 458 

336 CAROTID ATHEROSCLEROSIS AMONG GENERAL JAPANESE WITH 

ESTIMATED 10-YEAR ABSOLUTE RISK OF CAD DEATH ACCORDING 

TO THE JAPAN ATHEROSCLEROSIS SOCIETY GUIDELINE2012 

Aya Kadota, K. Miura, T. Okamura, A. Fujiyoshi, T. Ohkubo, T. Kadowaki, N. 

Takashima, T. Hisamatsu, Y. Nakamura, F. Kasagi, H. Maegawa, A. 

Kashiwagi, H. Ueshima, the SESSA Research Group and the NIPPON 

DATA80/90 Research Group, Japan 469 

337 ASSOCIATION OF ELECTROPHYSIOLOGICAL MARKERS OF SUDDEN 

CARDIAC DEATH INCREASED RISK WITH LIPID METABOLISM AND 

INFLAMMATION BIOMARKERS IN CORONARY ATHEROSCLEROSIS 

Sergei Ponkin, A. Kuznetsov, Y. Ragino, A. Chernyavskiy, M. Voevoda, 

Russia 470 

338 RISK FACTORS FOR HEART DISEASE IN MIDDLE-AGED WOMEN 

DRIVING CAR 

A.V. Petrischeva, Natalya Koryagina, Russia 563 

339 THE ESTIMATED RISK OF FATAL CARDIOVASCULAR DISEASE IN 

ASYMPTOMATIC ROMANIAN AERONAUTICAL PERSONNEL 

ACCORDING TO ESC CRITERIA 

Mirela Anghel, Romania 614 

340 ENDOTHELIUM FUNCTION MARKERS AT CARDIOVASCULAR 

DISEASES 

Roman Iosifovich Vorobyev, E.N. Vorobyeva, Russia 654 

91


OF CARDIOVASCULAR DISEASES (contd.) 


341 CONTROL OF CORONARY RISK WITH USE OF THE COMPUTER 

PROGRAMS 

Roman Iosifovich Vorobyev, E.N. Vorobyeva, Russia 656 

342 ESTIMATION OF THE GLOBAL CARDIOVASCULAR RISK IN THE HSHS 

“HAMMAM-SOUSSE SAHLOUL HEART STUDY” AND COMPARISON OF 

4 FORMULAS 

A. Moussa, K. Rouis, Asma Omezzine, I. Boumaiza, J. Rejeb, L. Rebhi, L. 

Bouacida, S. Neffati, N. Ben Rejeb, A. Ben Abdelaziz, A. Bouslama, Tunisia 666 

343 LIPID, HEMOSTASIS AND HEMODYNAMIC ASPECTS OF PREDICTING 

THE RISK OF CARDIOVASCULAR DEATH IN PATIENTS OF HIGH AND 

VERY HIGH RISK 

Mikhail A. Kachkovskii, V.V. Simerzin, O.A. Rubanenko, N. Kirichenko, 

Russia 669 

344 CARDIOVASCULAR RISK FACTORS FOR MULTIVESSEL DISEASE 

Marina Fernandes, V.H. Pereira, J. Português, J. Guardado, F. Canário- 

Almeida, F. Ferreira, I. Quelhas, A. Pereira, A. Lourenço, Portugal 802 

345 CORONARY HEART DISEASE RISK FACTOR CONTROL AND 

TREATMENT IN REPUBLIC OF SRPSKA PATIENTS WITH KNOWN 

CORONARY HEART DISEASE( ROSCOPS) 

Dusko Vulic, D. Djekic, M. Krneta, A. Lazarevic, L. Sormaz, R. Skrbic, 

Bosnia-Herzegovina 822 

346 RISK FACTORS FOR MULTIVESSELS CORONARY HEART DISEASES 

IN BOSNIAN POPULATION 

Belma Pojskic, A. Macic Dzankovic, A. Rosic, D. Mehinagic, M. Pojskic, 

Bosnia-Herzegovina 835 

347 COMBINATION OF HEARTSCORE- AND SHAPE (SOCIETY FOR HEART 

ATTACK PREVENTION AND ERADICATION)-BASED ALGORITHMS IN 

CARDIOVASCULAR RISK ASSESSMENT 

Frederic Kontny, B. Selseth, T. Fjornes, U. Gisletun, A. Paus, M. Fortun, M. 

Hamre, G. Kjoelsnes, P. Tillander, Norway 965 

348 THE CORRELATION IN PATIENTS WITH ACUTE CORONARY 

SYNDROMES BETWEEN HYPERTENSION, OXIDATIVE STRESS, 

PLATELETS HYPERACTIVITY, ENDOTHELIAL DYSFUNCTION AND 

PROGNOSIS 

Elena Bobescu 1,2 , A. Covaciu, D. Dobreanu, N. Aldulea, Romania 1147 

349 INFLUENCE OF VASCULAR RISK FACTORS IN THE MEDIUM-TERM 

EVOLUTION OF PERCUTANEOUS REVASCULARIZATION OF 


Luisa Cabeza Letrán, R. Toro, M. Sobrino, M.C. Durán, I. Tinoco, C. 

Rodríguez, D. Corrales, J.M. Ibañez, A. Mangas, Spain 1306 

92




350 COMBINED EFFECTS OF BLOOD PRESSURE AND SERUM 

CHOLESTEROL LEVEL IN CARDIOVASCULAR DISEASE: AN ELDERLY 

TAIWANESE COHORT STUDY 

Kuo-Yang Wang, W.-W. Lin, W.-H. Yin, Taiwan R.O.C. 1308 

351 HIGHER CARDIOVASCULAR RISK PROFILE IN PATIENTS WITH 

DEGENERATIVE AORTIC VALVE STENOSIS AND ASSOCIATED 

CORONARY ARTERY DISEASE 

D. Gilmanov, A. Vianello, A. Miceli, G. Bianchi, S. Bevilacqua, S. Berti, M. 

Glauber, Annamaria Mazzone, Italy 1598 

Woman and cardiovascular risk 

352 MINIMUM VALUE OF THYROID FAILURE TO STRUCTURE AND 

FUNCTION HEART WOMAN OF REPRODUCTIVE AGE 

Natalya Koryagina, A. Petrischeva, Russia 549 

353 CV RISK SELF-ASSESSMENT FOR PERIMENOPAUSAL WOMEN 

Ljiljana Trtica Majnaric, A. Vcev, M. Zulj, Croatia 603 

354 EFFECT OF DIFFERENTS COMBINED ORAL CONTRACEPTIVES IN THE 

VASCULAR ENDOTHELIUM 

Bianca Stocco, H.F. Fumagalli, F.J. Bianchini, S.A. Franceschini, C.M. 

Marzocchi-Machado, M.R. Torqueti, Brazil 866 

355 NEGATIVELY AFFECTED ARTERY WALL LAYER DIMENSIONS IN 

WOMEN WITH PREVIOUS PREECLAMPSIA - AN INVESTIGATION BY 

NON-INVASIVE HIGH-FREQUENCY ULTRASOUND 

Tansim Akhter, M. Larsson, A.-K. Wikström, T. Naessen, Sweden 887 

356 ISCHEMIA MODIFIED ALBUMIN IN POSTMENOPAUSAL WOMEN WITH 

CORONARY DISEASE IN RELATION TO NT-PROBNP AND HSCRP: A 

BIOMARKER OF ATHEROSCLEROSIS BURDEN? 

K. Kazanis, M. Dalamaga, E. Kassi, I. Vagionas, G. Jullien, Amalia 

Dionyssiou-Asteriou, Greece 1393 

Biomarkers 

357 A NOVEL ANTI-INFLAMMATORY ADIPOKINE, SECRETED FRIZZLED- 

RELATED PROTEIN 5, IS ASSOCIATED WITH CORONARY ARTERY 

DISEASE IN NON-ELDERLY POPULATION 

Masayuki Doi, T. Miyoshi, M. Iwamoto, M. Kajiya, K. Nosaka, K. Ohkawa, R. 

Nakayama, W. Takagi, K. Takeda, S. Hirohata, S. Kusachi, H. Ito, Japan 378 

358 DEVELOPMENT OF A FULLY AUTOMATED LATEX ENHANCED TIA 

FOR ADIPONECTIN 

Yosuke Meguro, Y. Ito, Y. Minakawa, H. Mizue, Japan 408 

93




359 INCREMENTAL VALUE OF CIRCULATING ADIPONECTIN LEVELS IN 

PREDICTING THE EXTENT OF CORONARY ATHEROSCLEROSIS 

ASSESSED BY COMPUTED TOMOGRAPHY ANGIOGRAPHY 

Morihiro Matsuda, R. Tamura, O. Nishimoto, K. Kanno, T. Segawa, K. 

Nakamoto, H. Nishiyama, T. Kawamoto, Japan 899 

360 A PRELIMINARY STUDY ABOUT NT-PROBNP AS A SCREENING TEST 

FOR HEART FAILURE IN A HEALTH CHECK 

Jiro Suwa, Japan 128 

361 PROGNOSTIC SIGNIFICANCE OF LONG PENTRAXIN-3 LEVEL IN 

PATIENT WITH ACUTE CORONARY SYNDROME 

S. Altay, Huseyin Altug Cakmak, T. Kemaloglu, A. Turer, B. Erer, G. Can, I. 

Keles, M. Eren, Turkey 436 

1 

362 H-NMR SPECTROMETRIC IDENTIFICATION OF BIOMARKERS OF 

ATHEROSCLEROSIS IN THE APOLIPOPROTEIN-E KNOCKOUT MOUSE 

Peshang Abdulhannan 1,2 , S. Saha, N. Yuldasheva, S. Wheatcroft, D. 

Russell 1,3 , S. Homer-Vanniasinkam 1,3 , J. Fisher, UK 592 

363 CIRCULATING ANTI-BETA2-GLYCOPROTEIN-I ANTIBODIES OF 

PERIPHERAL ARTERIAL DISEASE PATIENTS TRIGGERS A GENOMIC 

OVER-EXPRESSION OF TOLL-LIKE RECEPTOR 4 IN ENDOTHELIAL 

CELLS 

Cesar Varela, J. De Haro, S. Bleda, L. Esparza, A. Ferruelo, F. Acin, Spain 681 

364 THE MONITORING OF EFFECTS OF LIPOIC ACID FOCUSING ON CELL 

PROLIFERATION AND THE DETERMINATION OF ITS CONCENTRATION 

IN PLASMA 

Soňa Bencová, P. Žáková, K. Královec, L. Geryk, Czech Republic 735 

365 THE RELATIONSHIP BETWEEN PLASMA LONG PENTRAXIN-3 LEVEL 

AND RENAL FUNCTIONS IN ACUTE CORONARY SYNDROME 

Ibrahim Keles, S. Altay, H.A. Cakmak, T. Kemaloglu, A. Turer, F.O. 

Karadeniz, G. Can, B. Erer, M. Eren, Turkey 783 

366 TOTAL BILIRUBIN IN YOUNG MEN AND WOMEN : ASSOCIATION WITH 

RISK MARKERS FOR CARDIOVASCULAR DISEASES 

Marina Stojanov, A. Stefanovic, G. Dzingalasevic, J. Ivanisevic, M. 

Miljkovic, S. Mandic-Radic, M. Prostran, Serbia 1190 

367 SERUM CALPROTECTIN LEVELS IN APPARENTLY HEALTHY 

JAPANESE SUBJECTS 

Yukio Ikeda, Y. Kumon, T. Ohguro, N. Hisakawa, J. Nishiuchi, S. 

Yamanaka, T. Sugiura, Japan 1232 

368 FIBRONECTIN EXTRA DOMAIN-A AND CARDIOVASCULAR DISEASE: 

EVIDENCES FROM ANIMAL MODELS 

Vivek Krishna Pulakazhi Venu, R. Baetta, P. Uboldi, N. Ferri, A. Muro, A. 

Corsini, G.D. Norata 1,3 , A.L. Catapano 1,4 , Italy 1254 

94




369 TMAO: A NEW MARKER OF ATHEROSCLEROSIS? 

Samira De Oliveira 1,2 , V. Ferchaud-Rouchet, K. Bach, Y. Goueffic, K. 

Ougerram 1,2 , M. Krempf 1,2 , France 1265 

370 HAIR SELENIUM CONCENTRATION OF HYPERLIPIDEMIC PATIENTS 

WITH VARIOUS RISK FACTORS OF ATHEROSCLEROSIS 

Péter Fülöp, I. Seres, I. Juhász, Z. Jenei, G. Paragh, Hungary 1267 

Functional assessment of arterial wall 

371 ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH IN- 

HOSPITAL EARLY CLINICAL OUTCOME AFTER ISCHEMIC STROKE 

Christina Voulgari, E. Jude, S. Avgeri, S. Paximadas, S. Pagoni, Greece, 

UK 311 

372 EVALUATION OF ULTRASOUND ASSESSED FLOW-MEDIATED 

VASODILATION IN THE GÖTTINGEN MINIPIG 

Trine Pagh Ludvigsen, N. Wiinberg, B.Ø. Christoffersen, S.G. Moesgaard, 

H.D. Pedersen, L.H. Olsen, Denmark 400 

373 COLOR DOPPLER ULTRASOUND (CDUS) ANALYSIS OF TURBULENT 

FLOW IN THREE DIFFERENT ANIMAL MODELS 

J.J. Elias, K. Mata, C.R. Fernandes, Simone Gusmão Ramos, Brazil 511 

374 NON-INVASIVE DETECTION OF CORONARY ARTERY DISEASE USING 

COMPUTERIZED ANALYSIS OF DIASTOLIC HEART SOUNDS 

Samuel Emil Schmidt, S. Winther, N.R. Holm, E. Toft, J.J. Struijk, M. 

Bøttcher, Denmark 547 

375 ASSOCIATION BETWEEN PULSE WAVE VELOCITY AND CORONARY 

ARTERY CALCIFICATION IN A GENERAL JAPANESE MALE 

POPULATION: SESSA 

Sayuki Torii, T. Ohkubo, A. Fujiyoshi, A. Kadota, N. Takashima, S. 

Kadowaki, T. Hisamatsu, Y. Saitoh, N. Miyagawa, M. Zaid, Y. Murakami, K. 

Miura, H. Ueshima, Shiga Epidemiological Study of Subclinical 

Atherosclerosis (SESSA) Research Group, Japan 551 

376 SOUTH ASIANS HAVE REDUCED LEFT VENTRICULAR SYSTOLIC 

LONGITUDINAL FUNCTION THAT IS NOT EXPLAINED BY THEIR 

EXCESS CARDIOVASCULAR DISEASE RISK 

Chloe May Park, K. March, T. Tillin, N. Chaturvedi, A.D. Hughes, UK 566 

377 ABNORMAL METABOLIC PARAMETERS ARE INDEPENDENT 

FACTORS FOR INCREASED AORTIC STIFFNESS IN HEALTHY, NO 

DRUG TREATMENTS SUBJECTS 

Seung Hwan Han, H.S. Hwang, J. Moon, S.Y. Suh, K.H. Lee, K.K. Koh, T.H. 

Ahn, I.S. Choi, E.K. Shin, Republic of Korea 646 

378 EVALUATION OF INTIMA MEDIA THICKNESS AND VASCULAR 

COMPLIANCE AT COMMON CAROTID AND FEMORAL ARTERIES IN 

ATHLETES AND YOUNG CONTROLS 

Gabriele Cioni, R. Marcucci, A.M. Gori, A. Rogolino, G.F. Gensini, R. 

Abbate, M. Boddi, Italy 1085 

95




379 ATTENUATED VASCULAR ENDOTHELIAL FUNCTION ASSESSED BY 

PERIPHERAL ARTERIAL TONOMETRY IS ASSOCIATED WITH 

CARDIOVASCULAR RISK FACTORS IN MIDDLE-AGED FEMALE 

WORKERS 

Jussi Konttinen, H. Lindholm, J. Sinisalo, J. Uitti, Finland 1152 

380 THE CLINICAL SIGNIFICANCE OF CONDITIONS PRESENTED BY ECG 

CHANGES MIMICKING ACUTE MYOCARDIAL INFARCTION 

Malka Yahalom, N. Roguin, Y. Turgeman 1,2 , Israel 1294 

381 DIFFERENCES IN ARTERIAL STIFFNESS BETWEEN ISCHEMIC 

STROKE SUBTYPES 

Peter Wohlfahrt, A. Krajcoviechova, O. Mayer, J. Vanek, J. Filipovsky, R. 

Cifkova, Czech Republic 1335 

382 ADDITIVE VALUE OF LOWER EXTREMITY ARTERIAL STIFFNESS TO 

AORTIC STIFFNESS FOR PREDICTING TARGET ORGAN DAMAGE 

Peter Wohlfahrt 1,2 , A. Krajcoviechova, J. Seidlerova, O. Mayer, J. Filipovsky, 

S. Laurent, R. Cifkova, Czech Republic, France 1339 

383 REACTIVE HYPEREMIC INDEX MEASURED BY PERIPHERAL ARTERY 

TONOMETRY ASSOCIATES WITH RADIAL ARTERY INTIMA-MEDIA- 

THICKNESS, PATIENTS WITH SUSPECTED CORONARY ARTERY 

DISEASE 

Charlotte Eklund, L.-M. Gan 1,2 , Sweden 1371 

Imaging / IMTc 

384 PREVALENCE AND CARDIAC RISK FACTORS PREDICTORS OF 

SUBCLINICAL ATHEROSCLEROSIS, INCREASED CAROTID INTIMA- 

MEDIA THICKENING AND CARDIOVASCULAR DISEASE IN MORBID 

OBESITY 

Julio Oscar Bono, R. Chiosso, R. Del Valle, J.M. Foscarini, C. Esquivel, L. 

Ahuad, E. Moreyra, A. Surur, Argentina 864 

385 CAROTID INTIMA MEDIA THICKNESS AS A RISK FACTOR FOR 

INCREASED CORONARY CALCIUM SCORE 

A. Bertolami, C. Gonzaga, M. Sulzbach, D.B. Araujo, H. Zatz, R. Gonçalves, 

A.A. Faludi, Marcelo Chiara Bertolami, Brazil 1164 

386 IMAGING METHODS OF CAROTID ARTERIES STENOSIS 

Nataliya Dadamyants, Uzbekistan 1266 

387 CA-IMT AND QT PARAMETERS IN DYSLIPIDEMIC PATIENTS IN 

PRIMARY PREVENTION AT DIFFERENT ESC/EAS CARDIOVASCULAR 

RISK LEVELS 

G. Mombelli, Barbara Terraneo, F. Pazzucconi, C. Pavanello, R. Bosisio, M. 

Triolo, V. Barbieri, P. Magni, S. Castelnuovo, C.R. Sirtori 1,2 , Italy 1340 

96




Imaging / Calcifications assessment 

388 PATHOGENESIS OF CALCIFIED AORTIC VALVE STENOSIS: A 

SPECTROSCOPIC STUDY 

Ioannis E. Mmamarelis, K. Pissaridi, E. Koutoulakis, V. Dritsa, C. Kotoulas, 

V. Mamareli, J. Anastassopoulou, Greece 61 

389 THE STATE OF CALCIUM METABOLISM AND LIPID PROFILE FOR 

PATIENTS WITH CORONARY ARTERY DISEASE DEPENDING ON THE 

SMOKING STATUS 

Irina Grebenshchikova, S. Levashov, E. Volkova, Russia 384 

390 MARKER OF CALCIFIED ATHEROSCLEROSIS AT CARDIOVASCULAR 

DISEASES 

I.G. Leschenko, V.A. Leschenko, Roman Iosifovich Vorobyev, E.N. 

Vorobyeva, Russia 649 

391 CORONARY CALCIFICATION IS SUPERIOR TO EXERCISE TOLERANCE 

TESTING IN PREDICTING SIGNIFICANT CORONARY ARTERY 

STENOSIS IN SYMPTOMATIC PATIENTS 

Tarek Bengrid, R. Nicoll, A. Schmermund, M. Henein, Sweden, Germany 762 

392 CORONARY CALCIFICATION CORRELATES WITH THE PRESENCE 

AND SEVERITY OF VALVE CALCIFICATION IN ANGINA PATIENTS 

WITH NO AORTIC STENOSIS 

George Koulaouzidis, R. Nicoll, P. Jenkins, M. Henein, Sweden, UK 765 

393 SCREENING OF ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES 

AND HIGH CVD-RISKS FOR SILENT CHD: BENEFIT OF CORONARY 

ARTERY CALCIUM SCORING 

Maria Karlinskaya, Y. Poteshkin, I. Glinkina, A. Zilov, S. Ternovoy, G. 

Melnichenko, Russia 850 

394 ATHEROSCLEROTIC EVALUATION WITH WHOLE-BODY CTA (WB-CTA) 

IN PATIENTS WITH CV RISK FACTORS: ARE CORONARY ARTERIES 

AND EXTRA-CORONARY VESSELS EQUALLY INVOLVED? 

Fulvio Zaccagna, A. Napoli, G. Cartocci, V. Noce, F. Boni, C. Catalano, Italy877 

395 IN VIVO QUANTIFICATION OF ATHEROSCLEROTIC BURDEN: CTA´S 

PROGNOSTIC ACCURACY IN RELATION TO TRADITIONAL 

CARDIOVASCULAR RISK INDEX AND 5-YEAR FOLLOW-UP 

Fulvio Zaccagna, A. Napoli, G. Cartocci, V. Noce, F. Boni, C. Catalano, Italy878 

396 EVALUATION OF PATIENTS PRIOR TO NON CORONARY CARDIAC 

SURGERY BY CARDIAC CT 

Sara Casquero Dominguez, N. Romero Rodriguez, M. Romero 

Vazquianez, M. Villa Gil-Ortega, M. Fernandez Quero, A. Guisado Rasco, A. 

Martinez Martinez, Spain 1566 

97




Imaging / Miscellaneous 

397 THE ROLE OF QUANTITATIVE CORONARY ARTERIOGRAPHY IN 

ANALYSIS IN PROGRESSION OF CORONARY STENOSIS TO A TOTAL 

OCCLUSION, NEW WAY 

Jovica Saponjski, B. Beleslin, V. Vukcevic, Serbia 169 

398 MYOCARDIAL PERFUSION IMAGING USING 99M TC-SESTAMIBI SPECT: 

A CARDIAC PHANTOM STUDY 

Mansour Almoudi, Z. Sun, Australia 206 

399 QUANTIFICATION OF CORONARY VESSEL WALL ENHANCEMENT: 

REPRODUCIBILITY OF METHODS AND FEASIBILITY OF 

QUANTIFICATION IN HEALTH AND DISEASE 

Niharika Varma, R. Botnar, D. D'Cruz, A. Indermuehle, S. Peel, G. Greil, T. 

Hussain, E. Nagel, V. Puntmann, UK 890 

400 ASSESSMENT OF INTEGRATED MULTIMODAL BASED NANO-IMAGING 

FOR EARLY DIAGNOSIS OF CAROTID ATHEROSCLEROSIS 

ASSOCIATED WITH NEUROLOGICAL DISORDERS 

Lina H. Machtoub, Austria 947 

401 GEOMETRIC APPROACH IN EVALUATING ATHEROSCLEROSIS IN 

LEFT CORONARY ARTERY 

Young Ho Choi, S.-H. Suh, H.-H. Kim, Republic of Korea 1474 

402 NON-INVASIVE ASSESSMENT OF BYPASS GRAFTS AND NATIVE 

CORONARY VERSUS INVASIVE CORONARY ANGIOGRAPHY BY 

CADIAC CT 

Sara Casquero Dominguez, N. Romero Rodriguez, M. Romero 

Vazquianez, M. Fernandez Quero, A. Guisado Rasco, M. Villa Gil-Ortega, A. 

Martinez Martinez, Spain 1575 

Imaging / Vulnerability 

403 CORONARY CT ANGIOGRAPHY OF CORONARY PLAQUES: AN 

INVESTIGATION OF INTRALUMINAL APPEARANCES AND 

CORRELATION OF LEFT BIFURCATION ANGULATION WITH PLAQUE 

FORMATION 

Zhonghua Sun, M. Almoudi, Australia 207 

404 IMAGING VULNERABLE ATHEROSCLEROTIC PLAQUES BY 

TARGETING CO-STIMULATORY MOLECULES 

Adrienne Müller, L. Mu, K. Beck, R. Meletta, Z. Rancic, K. Drandarov, P.A. 

Kaufmann, R. Schibli 1,2 , S.M. Ametamey, S.D. Krämer, Switzerland 548 

405 MORPHOLOGICAL PLAQUE FEATURES SUGGEST CONTRALATERAL 

CAROTID VULNERABILITY IN SYMPTOMATIC BUT NOT 

ASYMPTOMATIC PATIENTS 

Fisnik Jashari, P. Ibrahimi, E. Johansson, C. Gronlund, G. Bajraktari, P. 

Wester, M. Henein, Sweden 605 

98

POSTERS TRACK 3: RISK FACTORS, EPIDEMIOLOGY, PREVENTION, AND 

TREATMENT OF CARDIOVASCULAR DISEASES (contd.) 


406 SYMPTOMATIC PATIENTS WITH CAROTID DISEASE HAVE MORE 

VULNERABLE CONTRALATERAL PLAQUES THAN ASYMPTOMATIC 

Pranvera Ibrahimi, F. Jashari, E. Johansson, C. Gronlund, G. Bajraktari, P. 

Wester, M. Henein, Sweden 611 

407 RISK ASSESSMENT OF ATHEROSCLEROTIC PLAQUES BASED ON 

GLOBAL BIOMECHANICS 

Simone Melchionna, H.-E. Lee, G. Amati, M. Bernaschi, M. Bisson, S. 

Succi, Italy, Republic of Korea 769 

408 EVALUATION OF [18F]-FLUORODEOXYGLUCOSE UPTAKE IN THE 

AORTIC ARCH OF APOLIPOPROTEIN E-DEFICIENT MICE 

Jakub Toczek, A. Broisat, P. Perret, D. Fagret, L.M. Riou, C. Ghezzi, France1331 

Genetics 

409 ASSOCIATION STUDY OF 10 GENE VARIANTS WITH ANGIOGRAPHIC 

SEVERITY OF CORONARY ARTERY DISEASE 

Martin Javorsky 1,2 , V. Vitanov, L. Klimcakova, V. Habalova, J. Zidzik, E. 

Babjakova 1,2 , J. Salagovic, B. Stancak, I. Tkac 1,2 , Slovak Republic 291 

410 POSSIBLE GENE-GNDER INTERACTION BETWEEN THE SLCO1B1 

POLYMORPHISM AND STATIN TREATMENT EFFICACY 

Jaroslav Hubacek, D. Dlouha, V. Adamkova, V. Lanska, R. Ceska, M. 

Vrablik, Czech Republic 345 

411 LACK OF AN ASSOCIATION BETWEEN THE MRAS POLYMORPHISM 

AND ACS RISK IN CZECH POPULATION 

Jaroslav A. Hubacek, V. Adamkova, V. Lanska, R. Ceska, M. Vrablik, R. 

Poledne, M. Gebauerova, V. Stanek, J. Pitha, Czech Republic 349 

412 MCP1 POLYMORPHISMS ARE ASSOCIATED WITH SEVERAL 

CARDIOMETABOLIC PARAMETERS BUT NOT WITH PREMATURE 

CORONARY ARTERY DISEASE IN THE MEXICAN POPULATION 

Gilberto Vargas-Alarcón, T. Villarreal-Molina, R. Posadas-Sánchez, E. 

Alvarez-León, S. Canizales-Quinteros, E. Kimura-Hayama, S. Romero- 

Hidalgo, J.G. Juárez-Rojas, E. Larrieta-Carrasco, V. Acuña-Alonzo, E. Jorge- 

Galarza, C. Posadas-Romero, Mexico 525 

413 ASSOCIATION BETWEEN THE A603G TISSUE FACTOR GEN 

POLYMORPHISM, MARKERS OF ENDOTHELIAL DYSFUNCTION AND 

INCIDENCE OF MYOCARDIAL INFARCTION IN RUSSIA 

Elena Gennadyevna Sergeeva 1,2 , M.A. Karpenko, Z.I. Ionova, G.V. 

Alekseeva, S. Saha, D. Saha, Russia 670 

414 POLYMORPHISMS OF METHYLENETETRAHYDROFOLATE 

REDUCTASE GENE (MTHFR), HOMOCYSTEINE LEVEL, AND RISK 

FACTORS FOR CAD IN THAI 

Ingkarat Sarutipaiboon, N. Settasatian, C. Settasatian, N. Komanasin, U. 

Kukongwiriyapan, P. Intharapetch, K. Tantipanichteerakul, V. Senthong, 


99




415 PROBABLE IMPACT OF POLYMORPHIC VARIANTS SOME 

HAEMOSTATIC AND FOLATE SYSTEM GENES IN THE RISK OF 

RESTENOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION 

Galina Chumakova 1,2 , A. Dashkova 1,2 , A. Momot, N. Veselovskaya 2,4 , 

Russia 759 

416 THE LEVEL OF HETEROPLASMY OF MITOCHONDRIAL GENOME IS AN 

EXPLANATORY BIOMARKER FOR BOTH SUBCLINICAL AND 

MANIFESTED ATHEROSCLEROSIS 

Igor A. Sobenin 1,2 , M.A. Sazonova 1,2 , M.M. Chicheva-Ivanova, K.Y. 

Mitrofanov, A.V. Zhelankin, Y.V. Bobryshev 2,3 , A.N. Orekhov 2,3 , Russia 861 

417 GENETIC APPROACH TO CARDIOVASCULAR DISEASE PREVENTION: 

POLYMORPHISMS IN CANDIDATE GENES INVOLVED IN RISK 

FACTORS FOR CARDIOVASCULAR DISEASE 

Chatri Settasatian, N. Settasatian, P. Intharapetch, P. Yongsakulchai, I. 

Sarutipaiboon, P. Pitivej Thurakit, K. Tantipanichteerakul, V. Senthong, 


418 GENETIC VARIATIONS IN PEROXISOME PROLIFERATOR-ACTIVATED 

RECEPTORS (PPARS) AND THEIR RELATED GENES INFLUENCE 

CARDIOVASCULAR DISEASE RISK IN THAI 

Pratthana Yongsakulchai, C. Settasatian, N. Settasatian, N. Komanasin, U. 

Kukongwiriyapan, P. Intharapetch, K. Tantipanichteerakul, V. Senthong, 


419 THE ROLE OF +405G/C AND -2578C/A POLYMORPHISMS OF VEGF IN 


Ignacio López de Maturana Carrasco, S. Bleda Moreno, J. de Haro 

Miralles, L. Esparza Gómez, C. Varela Casariego, J. Rodriguez Padilla, F. 

Acín García, Spain 1129 

420 PPARΓ MUTATIONS RESPONSIBLE FOR LIPODYSTROPHY WITH 

SEVERE HYPERTENSION ACTIVATE THE CELLULAR RENIN- 

ANGIOTENSIN SYSTEM 

Franck Boccara 1,2 , M. Auclair, C. Vigouroux, E. Capel, C. Vigeral, B. Guerci, 

O. Lascols, J. Capeau, M. Caron-Debarle, France 1249 

421 ASSOCIATION OF ADIPOQ GENE VARIANTS AND HEART FAILURE IN 

AN ITALIAN POPULATION 

Silvana Pileggi, S. Barlera, C. Casola, L. Crociati, S. Pietri, C. Specchia 1,2 , 

M.G. Franzosi, Italy 1260 

422 TERC RS12696304C ALLELE AND TRF1 RS2975843C ALLELE 

SIGNIFICANTLY INCREASE THE RISK OF EARLY-ONSET ISCHEMIC 

STROKE 

Fang-I Hsieh, W.-Y. Lin, H.-J. Lin, L.-M. Lien 3,4 , C.-C. Yu, Y.-R. Chen, H.-Y. 

Chiou, Taiwan R.O.C. 1443 

100




423 OPERATIONAL REDEFINITION OF THE TISSUE ANGIOTENSIN SYSTEM 

FROM GENE CO-EXPRESSION IN ATHEROGENESIS 

Catherine Cerutti, S. Barrot, M.-P. Gustin, H. Ayari, C. Paultre, P. Feugier, 

L. Legedz, G. Bricca, France 1465 

424 INTERACTION BETWEEN I148M IN THE ADIPONUTRIN GENE (PNPLA3) 

AND DIETARY INTAKES OF CARBOHYDRATES AND N-6/N-3- 

POLYUNSATURATED FATS ON FASTING TRIGLYCERIDE LEVELS 

I.A. Stojkovic, U. Ericson, G. Rukh, Marju Orho-Melander, Sweden 1548 

425 GENOME-WIDE ASSOCIATION STUDY IDENTIFIES THREE GENOMIC 

LOCI SIGNIFICANTLY ASSOCIATED WITH SERUM LEVELS OF 

HOMOARGININE - THE ATHEROREMO CONSORTIUM 

Marcus Edi Kleber 1,2 , I. Seppälä, S. Pilz 4,5 , M.M. Hoffmann, A. Tomaschitz, 

N. Oksala 3,8 , E. Raitoharju, L.-P. Lyytikäinen, K.-M. Mäkelä, R. Laaksonen, 

M. Kähönen, O.T. Raitakari 10,11 , J. Huang, C. Drechsler, V. Krane, C. 

Wanner, B.O. Böhm, W. König, T. Lehtimäki, W. März 1,15,16 , A. Meinitzer, 

Germany, Finland, The Netherlands, Austria 1561 

426 THE AGT M235T POLYMORPHISM ASSOCIATES WITH AMI RISK AND 

INFLUENCES CAD SEVERITY 

Sounira Mehri, R. Chaaba, M. Hammami, Tunisia 1602 

Obesity and fat distribution 

427 EFFECT OF VARIOUS BARIATRIC SURGICAL PROCEDURES ON 

PLASMA APO-CIII LEVELS 

N. Padilla, M. Maraninchi, B. Berthet, A. Bégu-Le Corroller, N. Dubois, R. 

Grangeot, C. Mattei, B. Vialettes, René Valéro, France 970 

428 OBESITY MODULATES THE IMMUNE RESPONSE TO OXIDIZED LDL 

AND INFLAMMATORY MILIEU IN HYPERTENSIVE PATIENTS 

H.A. Fonseca 1,2 , F.A. Fonseca, A.M. Monterio, H.T. Bianco, S.A. Brandão, M. 

Gidlund, Maria Cristina Izar, Brazil 240 

429 WEIGHT LOSS INDUCED IMPROVEMENTS IN LIPIDS IN 

OVERWEIGHT/OBESE SUBJECTS TREATED WITH 

PHENTERMINE/TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER) 

Hermann Toplak, S. Klein, W.W. Day, Austria, USA 391 

430 BMI OR WAIST CIRCUMFERENCE - WHICH IS THE MORE RELIABLE 

MARKER FOR PREDICTING CARDIOVASCULAR DISEASE? 

Helen Marcoyannopoulou Fojas, E. Barrios, Philippines 480 

431 REDUCTION OF P WAVE DISPERSION AFTER THERAPEUTIC WEIGHT 

LOSS IN OVERWEIGHT AND OBESE PATIENTS 

Anna Giulia Falchi, C. Muggia, C. Tinelli, Italy 522 

432 CALORIC RESTRICTION INDUCES OBESITY AND DIABETES AND 

AGGRAVATES SPONTANEOUS ATHEROSCLEROSIS DEVELOPMENT 

IN HYPERCHOLESTEROLEMIC MICE 

G.G. Dorighello, J.C. Rovani, C.J.F. Luhman, B.A. Paim, A.E. Vercesi, 

Helena C F Oliveira, Brazil 620 

101




433 LONG TERM STATUS OF METABOLIC PARAMETERS ARE RISK 

FACTORS FOR ABNORMAL CORONARY ENDOTHELIAL FUNCTION IN 

PATIENTS WITHOUT SIGNIFICANT CAD 

Seung Hwan Han, J. Seo, P.C. Oh, W.J. Chung, K. Lee, S.Y. Suh, W.C. 

Kang, K.K. Koh, T.H. Ahn, E.K. Shin, Republic of Korea 641 

434 EPICARDIAL ADIPOSITY AS A MARKER OF SUBCLINICAL CORONARY 


N. Veselovskaya 1,2 , Galina Chumakova 1,3 , A. Ott, Russia 734 

435 RISK OF ATHEROSCLEROSIS AND WAIST CIRCUMFERENCE CUT-OFF 

POINTS IN SIBERIAN POPULATION 45-69 YEARS OLD 

(EPIDEMIOLOGICAL STUDY) 

Galina Simonova, S. Mustafina, Russia 1001 

436 BENEFICIAL EFFECTS OF PPARG ACTIVATION ON LIPID 

METABOLISM IN LIPODYSTROPHIC BSCL2 -/- MICE 

X. Prieur, L. Dollet, M. Takhashi, J. Capeau, B. Feve, C. Le May, P. Costet, 

J. Magrè, Bertrand Cariou, France 1009 

437 MYELOPEROXIDASE, MATRIX METALLOPROTEASE-9 AND 

PARAOXONASE-1 ACTIVITY IN OVERWEIGHT HYPERLIPIDEMIC 

PATIENTS WITH AND WITHOUT VASCULAR COMPLICATIONS 

Peter Koncsos, N. Zsíros, M. Harangi, H. Lőrincz, I. Seres, G. Paragh, 

Hungary 1018 

438 CORRELATION OF TRIGLYCERIDES AND TYPE OF FAT 

ACCUMULATION INVESTIGATED BY COMPUTED TOMOGRAPHY IN 

OBESE PATIENTS 

Gabor Simonyi, M. Medvegy, R.J. Bedros, Hungary 1028 

439 MORBID OBESITY IS A INDEPENDENT RISK FACTOR FOR 

DEVELOPING SUBCLINICAL ATHEROSCLEROSIS? 

Julio Oscar Bono, R. Del Valle, R. Chiosso, J.M. Foscarini, C. Esquivel, L. 

Ahuad, E. Moreyra, Argentina 1160 

440 HYPOXIA INDUCES A HIF-1ALPHA DEPENDENT SIGNALLING 

CASCADE TO MAKE A COMPLEX METABOLIC SWITCH IN SGBS- 

ADIPOCYTES 

Andreas Leiherer 1,2 , K. Geiger, S. Geller-Rhomberg, A. Mündlein 1,2 , H. 

Drexel 1,2,3 , Austria, Liechtenstein 1176 

441 METABOLICALLY HEALTHY OBESE INDIVIDUALS HAVE AVERAGE 

SUBCLINICAL ATHEROSCLEROSIS PARAMETERS COMPARED WITH 

METABOLICALLY UNHEALTHY INDIVIDUALS 

Jordi Merino, R. Ferré, D. Pedrico, M. Llort, J.P. Lonzi, N. Plana, D. 

Ibarretxe, L. Masana, Spain 1319 

442 ASSOCIATION BETWEEN OBESITY INDICES AND SERUM LIPIDS IN 

OBESE NON-DIABETIC PATIENTS 

A. Stępień, M. Stępień, R.N. Wlazeł, M. Paradowski, Maciej Banach, J. 

Rysz, Poland 1324 

102




443 SERUM PHOSPHOLIPIDS AS A MARKER OF ABDOMINAL OBESITY IN 

POSTMENOPAUSAL OBESE WOMEN 

K. Charradi 1,2 , A. Trimeche, F. Ben Hassine, E. Aouani 1,2 , M. Sakly 2,5 , Nebil 

Attia 2,5 , Tunisia 1458 

444 RELATIONSHIP BETWEEN INTRAABDOMINAL FAT DISTRIBUTION, 

PLASMA BIOMARKER LEVELS AND ENDOTHELIAL FUNCTION IN 

HYPERCHOLESTEROLEMIC SUBJECTS 

Peteris Tretjakovs, G. Krievina, I. Skuja, A. Jurka, I. Stukena, G. Bahs, 

Latvia 1529 

445 PLASMA APOLIPOPROTEIN B-48 TRANSPORT IN OBESE MEN: AN IN 

VIVO STABLE-ISOTOPE STUDY IN POSTPRANDIAL STATE 

Dick C. Chan, A.T.Y. Wong, J. Pang, G.F. Watts, P.H.R. Barrett, Australia 1633 

Metabolic syndrome 

446 ADIPONECTIN INHIBITS ANGIOTENSIN II-MEDIATED VASCULAR 

INFLAMMATION AND ACCELERATED ATHEROSCLEROSIS 

C.V. Stijn, J. Kim, D. Bacerra, U.J. Tietge, Rajendra K. Tangirala, USA, 

Netherlands Antilles 1280 

447 RESISTIN, AN ADIPOCYTOKINE, PROMOTES ANGIOGENESIS AND 

VASCULAR PERMEABILITY 

Hyun-Joung Lim, H. Kim, H.-Y. Park, M.-C. Cho, Republic of Korea 1426 

448 TRIGLYCERIDE IS A PREDICTOR OF DIABETES MELLITUS 

IRRESPECTIVE OF BMI IN AN 8-YEAR COHORT STUDY IN THE 

JAPANESE WORKERS 

Tomofumi Nishikawa, T. Okamura, A. Shima 3,4 , Y. Kawatsu, D. Sugiyama, 

A. Kadota, A. Morimoto, Y. Tatsumi 4,6 , A. Morino, N. Sonoda, N. Miyamatsu, 

Japan 743 

449 ATHEROGENIC DYSLIPIDEMIA IN METABOLIC SYNDROME AS A 

PREDICTOR OF COMPLICATIONS AFTER CORONARY ARTERY 

BYPASS GRAFTING 

Olesya Gritsenko 1,2 , G. Chumakova 1,2 , N. Veselovskaya 2,3 , E. 

Vahromeeva 1,3 , Russia 748 

450 ANTIOXIDATIVE FUNCTION OF HDL IN METABOLIC SYNDROME: 

IMPACT OF A LIFESTYLE PROGRAM 

Boris Hansel, A. Orsoni, S. Chantepie, R. Bittar, D. Bonnefont-Rousselot, P. 

Giral, E. Bruckert, M.J. Chapman, A. Kontush, France 1407 

451 ASSOCIATION OF LIPOPROTEIN SUBCLASS DISTRIBUTION WITH 

METABOLIC RISK FACTORS IN JAPANESE MEN 

Ryotaro Takahashi, K. Okumura, N. Taguchi, M. Suzuki, N. Ikeda, T. 

Murohara, Japan 1604 

452 EFFECTCS OF DERANGED GLUCOSE HOMEOSTASIS ON ARTERIAL 

STIFFNESS IN PATIENTS WITH PRE-DIABETES MELLITUS 

Chang-Hua Chou, J.-Y. Chen 2,3 , M.-C. Wang, C.-S. Ho, W.-C. Tsai, Taiwan 

R.O.C. 13 

103




453 THE EFFECT OF 25(OH)VITD ADMINISTRATION ON URINE 8- 

ISOPROSTANE LEVELS IN PATIENTS WITH METABOLIC SYNDROME 

S.E. Makariou 1,2 , E.N. Liberopoulos, A. Challa, K. Tellis, A. Tselepis, Moses 

Elisaf, Greece 25 

454 THE EFFECT OF MOLYBDENO-ENZYMES ON ATHEROSCLEROTIC 

HYPERURICAEMIC PATIENTS 

Ioannis E. Mamarelis, K. Pissaridi, E. Koutoulakis, V. Dritsa, C. Kotoulas, V. 

Mamareli, J. Anastassopoulou, Greece 62 

455 RELATIONSHIP ENDOTHELIAL DYSFUNCTION-CHRONOBIOLOGY TO 

OVERWEIGHT AND OBESE PATIENTS 

Teodora Gabriela Alexescu, A.V. Sitar-Taut, A. Cozma, O. Mislea, V. 

Negrean, M. Motocu, Romania 163 

456 IMBALANCE BETWEEN ENDOTHELIAL DAMAGE AND REPAIR IN 

CHILDHOOD OBESITY: USE OF NOVEL BIOMARKERS 

Luc Bruyndonckx 1,2,3 , H. Franckx, E. Basslé, S. van Ierssel 1,2 , A. Van 

Craenenbroeck 1,2 , E. Van Craenenbroeck 1,2,5 , V. Hoymans 1,2 , C. Vrints 1,2,5 , D. 

Vissers, J. Ramet, V. Conraads 1,2,5 , Belgium 184 

457 METABOLIC SYNDROME AND SEVERITY OF CORONARY ARTERY 

DISEASE IN WEST OF IRAN 

Shila Berenjy, Iran 278 

458 DECREASED HIGH DENSITY LIPOPROTEIN-INDUCED NO SYNTHESIS 

IN TYPE 2 DIABETES, TYPE 1 DIABETES AND OBESITY 

Laurence Duvillard 1,2 , S. Monier, L. Perségol, I. Robin, M.-C. Brindisi 2,3 , J.- 

M. Petit 2,3 , B. Vergès 2,3 , France 346 

459 THE IMPAIRED GLUCOSE REGULATION IN NON-DIABETIC SUBJECTS 

IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENT 

Fouzia Kessal, R. Guermaz, A. Mammeri, A. Hatri, S. Taharboucht, S. Zekri, 

M. Brouri, Algeria 376 

460 ASSOCIATION BETWEEN PLASMA LEPTIN CONCENTRATIONS AND 

DYSLIPIDEMIA IN OBESITY WITH AND WITHOUT METABOLIC 

SYNDROME IN A TUNISIAN POPULATION 

Fadoua Gannar, F. Marzougui, L. Khanfir, M. Sakly, N. Attia, Tunisia 424 

461 PREVALENCE OF METABOLIC SYNDROME IN HAMMAM-SOUSSE 

SAHLOUL HEART STUDY ACCORDING THREE DEFINITIONS 

I. Boumaiza, Asma Omezzine, M. Romdhane, J. Rejeb, L. Rebhi, L. 

Bouacida, S. Neffati, N. Ben Rejeb, A. Ben Abdelaziz, A. Bouslama, Tunisia 495 

462 THE CHANGES IN VARIOUS HYDROXYPROLINE FRACTIONS IN 

AORTIC TISSUE OF RABBITS ARE CLOSELY RELATED TO THE 

PROGRESSION OF ATHEROSCLEROSIS 

Mohamed Anwar K. Abdelhalim, M.M. Ghannam, Saudi Arabia 742 

104




463 CARBOHYDRATE AND METABOLIC ABNORMALITIES IN ADULT 

SURVIVORS OF YOUTH BRAIN TUMORS 

Tatyana Y. Tselovalnikova, E.E. Gybernatorova, M.G. Pavlova, A.V. Zilov, 

N.A. Mazerkina, A.V. Moshkin, Russia 862 

464 INFLUENCE OF METABOLIC SYNDROME IN CRITICAL PATIENT 

MORBIDITY 

Jerusalen Villegas del Ojo, Spain 1193 

465 IMPACT OF OCCUPATIONAL FACTORS ON METABOLIC SYNDROME. 

A PREVENTIVE STRATEGY FOR PRACTITIONERS? 

Yolande Esquirol, V. Bongard, J.B. Ruidavets, J. Ferrieres, France 1285 

466 THE RENAL RISK IN NON-DIABETIC SUBJECTS WITH METABOLIC 

SYNDROM 

Fouzia Kessal, R. Guermaz, S. Taharboucht, A. Hatri, F. Hamrour, N. 

Teffahi, S. Zekri, M. Brouri, Algeria 1406 

467 THE ACCUMULATION OF RISK FACTORS OF METABOLIC SYNDROME 

IS ASSOCIATED WITH THE INCREASE IN ARTERIAL STIFFNESS 

AMONG MIDDLE-AGED FINNISH MALES 

Janne Halonen, H. Lindholm, H. Sistonen, H. Gylling, Finland 1498 

NASH and related disorders 

468 CORRELATION OF HEPATIC ELASTICITY AND ARTERIAL STIFNESS IN 

SUBJECTS WITH NORMAL BODY WEIGHT, OBESITY OR TYPE 2 

DIABETES 

Marinos Fysekidis, E. Cosson, Y. Jaber, E. Ngallhy, K. Ben Belkacem, D. 

Roulot, C. Pillegand, S. Chiheb, I. Banu, P. Valensi, France 1149 

469 HIGHER LEVELS OF WITHIN-NORMAL-LIMITS LIVER ENZYMES AND 

THE PREVALENCE OF THE METABOLIC SYNDROME 

Itzhak Shapira, A. Steinvil, O. Kliuk Ben-Bassat, M. Cohen, S. Berliner, O. 

Rogowski, Israel 77 

470 CONTROL OF HEPATIC GLUCONEOGENESIS THROUGH THE TUMOR 

SUPPRESSOR P16 INK4A 

Sarah Hannou 1,2,3 , K. Bantubungi-Blum 1,2,3 , S. Caron-Houde 1,2,3 , E. 

Vallez 1,2,3 , A. Lucas 1,2,3 , K. Wouters 1,2,3 , B. Staels 1,2,3 , A. Tailleux 1,2,3 , R. 

Paumelle 1,2,3 , Diabetes, France 192 

471 OBESE HUMAN SERUM STIMULATES APOLIPOPROTEIN B 

OVERPRODUCTION BY HUMAN HEPATOCYTES 


472 EFFECTS OF TUMOR-BEARING ON SERUM AND LIVER LIPID LEVELS 

IN SATO LUNG CARCINOMA (SLC)-IMPLANTED RATS 

Masashi Kawasaki, Japan 212 

105




473 REDUCED EXPRESSION OF INTRACELLULAR LIPID TRANSPORTERS 

ASSOCIATES WITH DYSLIPIDAEMIA AND STEATOSIS IN A RODENT 

MODEL OF GENETIC OBESITY 

Ugo Soffientini, S. Dolan, A. Graham, UK 430 

474 ASSOCIATION OF NEUROMEDIN U WITH LIPID METABOLISM 

Mika Hori, T. Mizuno, M. Harada-Shiba, Japan 540 

475 SIGNIFICANT WEIGHT GAIN IN MICE EXPOSED TO THE POLLUTANT 

BENZO[A]PYRENE IS ASSOCIATED WITH CHANGES IN HEPATIC 

LIPOPROTEIN METABOLISM 

Hamed Layeghkhavidaki 1,2 , M.-C. Lanhers, S. Akbar, N. Grova, B. 

Appenzeller, C. Feidt, C. Corbier, F.T. Yen, France, Luxembourg 635 

476 NICOTINIC ACID AMELIORATES DYSLIPIDEMIA AND PREVENTS 

STEATOHEPATITIS IN MONOSODIUM GLUTAMATE-TREATED OBESE 

MICE 

Masumi Hara, M. Kurano, K. Tsuneyama, K. Kikuchi, A. Takai, T. 

Matsushima, N. Ishizaka, K. Tsukamoto, Japan 680 

477 ENDOTHELIAL DYSFUNCTION, INSULIN RESISTANCE AND OBESITY 

IN MICE MODELS OF NAFLD 

Edyta Maślak, A. Jasztal, B. Sitek, B. Proniewski, M. Sternak, A. 

Fedorowicz, T. Skórka, K. Jasiński, S. Chłopicki 1,3 , Poland 1071 

478 LIVER MARKERS AND METABOLIC SYNDROME-RELATED FACTORS 

OVER 5 YEARS IN THE STANISLAS STUDY 

Ndeye Coumba Ndiaye, B. Herbeth, G. Siest, S. Visvikis-Siest, France 1321 

479 IS HOMOCYSTEINE ( HCY) A NEW MARKER OF THE 

CARDIOVASCULAR RISK OF NON-ALCOHOLIC 

STEATOHEPATITIS(NASH)? 

Nicoleta Valentina Leach, M. Dronca, R. Tarau, R. Rusu, T. Alexescu, 

Romania 1592 

480 CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH 

ASYMPTOMATIC NAFL 

Ilze Skuja, I. Stukena, G. Krievina, A. Lejnieks, Latvia 1597 

Sub inflammatory states 

481 SUBCLINICAL HEART INVOLVEMENT IN PATIENTS WITH SYSTEMIC 

SCLEROSIS 

Charalampos Papagoras, K. Achenbach, N. Tsifetaki, S. Tsiouris, A. 

Fotopoulos, A.A. Drosos, Greece 218 

482 PROGRESSION OF SUBCLINICAL ATHEROSCLEROSIS OVER FIVE 

YEARS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS 

Anna Södergren, K. Karp, E. Lundström, T. Smedby, B. Möller, S. 

Rantapää-Dahlqvist, S. Wållberg-Jonsson, Sweden 232 

106




483 VASCULAR INFLAMMATION MARKERS IN MEDIUM AND HIGH RISK 

ACUTE CORONARY SYNDROMES 

Ali Çoner, A. Aydınalp, K. Okyay, E. Özçalık, U.A. Bal, A. Yıldırır, H. 

Müderrisoğlu, Turkey 347 

484 POSSIBILITIES OF ENDOTELIAL DYSFUNCTION ASSESSMENT AT 

WOMEN WITH RHEUMATOID ARTHRITIS BY DOPPLER LASER 

FLUOMETRIA 

Dmitrij Bublikov, E. Vorobjova, A. Andrienko, V. Lychov, O. Lapshataeva, 

Russia 389 

485 WHETHER WE CAN USE SCALE SCORE IN POPULATION OF 

PATIENTS WITH RHEUMATOID ARTHRITIS 

Dmitrij Bublikov, E. Vorobjova, A. Andrienko, V. Lychov, R. Vorobjov, 

Russia 390 

486 ORANGE JUICE AND HESPERIDIN CONSUMPTION ALTER 

LEUKOCYTE GENE EXPRESSION TO AN ANTI-INFLAMMATORY AND 

ANTI-ATHEROGENIC PROFILE IN HEALTHY VOLUNTEERS 

Dragan Milenkovic, C. Dubray, A. Mazur, C. Morand, France 440 

487 LIPID PROFILE AND INFLAMMATORY RESPONSE IN PATIENTS WITH 

UNSTABLE ANGINA AFTER CORONARY STENTING: A PROSPECTIVE 

STUDY 

Natalia Musikhina, T. Petelina, L. Gapon, N. Dementjeva, V. Kuznetsov, A. 

Takkand, Russia 539 

488 CHRONIC INFLAMMATORY RHEUMATIC DISEASE INCREASES THE 

RISK OF ARTERIOSCLEROSIS: CLINICAL-ULTRASOUND STUDY 

Olga Malysheva, H. Barghan, K. Mühlberg, C. Klein, C. Baerwald, Germany675 

489 HIGH SENSITIVITY C-REACTIVE PROTEIN LEVELS ARE ASSOCIATED 

WITH TOTAL CORONARY ARTERY OCCLUSIONS 

Gustavs Latkovskis 1,2,3 , M. Zabunova 1,2 , M. Berzina, D. Juhnevica, I. 

Urtane, L. Zarakauska, A. Erglis 1,2,3 , Latvia 750 

490 THE CORRELATION BETWEEN INFLAMMATORY SYNDROME AND 

PRECLINICAL ATHEROSCLEROSIS IN OBESE PATIENTS 

Vasile Negrean, I. Cheta, O. Mislea, T. Alexescu, Romania 855 

491 IDENTIFICATION OF ESSENTIAL SIGNALING PATHWAYS IN SAA- 

INDUCED MCP-1 PRODUCTION IN VASCULAR SMOOTH MUSCLE 

CELLS 

Nicole Prüfer, M. Schuchardt, T. Huang, J. Prüfer, M. Tölle, W. Zidek, M. 

van der Giet, Germany 1044 

492 TEMPORAL EVOLUTION OF INFLAMMATORY MARKERS AFTER BARE 

METAL STENT OR DRUG-ELUTING STENT IMPLANTATION 

A. Imaeva, S. Minelli, N. Cosentino, E. Falcioni, R. Antonazzo Panico, D. 

Schiavino, G. Niccoli, F. Crea, Giorgia Copponi, Russia, Italy 1182 

107




493 DIFFERENT PATTERN OF ACUTE SYSTEMIC INFLAMMATORY 

RESPONSE IN YOUNG AND ELDERLY STEMI PATIENTS UNDERGOING 

PRIMARY PCI 

Annamaria Mazzone, N. Botto, U. Paradossi, E. Galli, A.R. De Caterina, C. 

Palmieri, A. Clerico, S. Berti, A. Taddei, Italy 1245 

494 INFLAMMATORY BIOMARKERS IN PATIENTS WITH TIA: CLINICAL 

FEATURES AND STROKE RISK FOR PATIENTS WITH DIFFERENT TIA 

SUBTYPES 

Olena Y. Fartushna 1,2 , Ukraine, UK 1496 

Diabetes macroangiopathy / Dyslipidaemia 

495 LIPID PROFILE, GLUCOSE LEVEL AND WHITE BLOOD CELL 

SUBTYPES IN TYPE 2 DIABETES MELLITUS PATIENTS 

Nongnuch Settasatian, P. Singparu, C. Sumrit, C. Settasatian, Y. 

Teerajetgul, P. Sanyanusin, Cardiovascular Research Group, Khon Kaen 

University, Thailand 729 

496 DIFFERENT PATTERN OF ATHEROGENIC DYSLIPIDAEMIA AMONG 

NEWLY DIAGNOSED, UNTREATED PATIENTS WITH TYPE 2 DIABETES 

MELLITUS 

Andrej Dukat, P. Sabaka, L. Fabryova, J. Gajdosik, M. Zelina, S. Oravec, 

Slovak Republic 846 

497 POTENTIAL ROLE OF MITOCHONDRIAL DYSFUNCTION IN DIABETIC 

HYPERTRIGLYCERIDEMIA 

Sampath Parthasarathy, P. Mordhwaj, D. Litvinov, USA 1144 

498 THE HYPOLIPIDEMIC EFFICACIES OF AN ESSENTIAL PHOSPHOLIPIDS 

WITH METHIONINE AND ATORVASTATIN IN HYPERLIPIDEMIC 

PATIENTS WITH TYPE 2 DIABETES MELLITUS 

Marina Gennadievna Bubnova, D.M. Aronov, Russia 1367 

499 DEFECTIVE HDL PARTICLES IN TYPE 2 DIABETES EXHIBIT AN 

ALTERED LIPIDOME 

L. Gomez Rosso 1,2 , M. Lhomme, T. Meroño, L. Camont, A. Dellepiane, P. 

Robillard, S. Chantepie, A. Zerrad, F. Brites, J.M. Chapman, Anatol 

Kontush, France, Argentina 1492 

Diabetes macroangiopathy / Treatment 

500 DECREASED CRP LEVELS IN RESPONSE TO A SIX-WEEK, ONCE- 

DAILY ORAL INSULIN REGIMEN 

R. Eldor, Miriam Kidron, Y. Miteva, E. Arbit, Israel, Switzerland 47 

501 EFFECT OF DIPEPTIDLY PEPTIDASE-4 INHIBITOR TREATMENT ON 

LEFT VENTRICULAR STIFFNESS BY TISSUE DOPPLER IMAGING IN 

PATIENTS WITH TYPE 2 DIABETES 

Hideto Sako, S. Miura, S. Furuyama, A. Matsunaga, K. Saku, Japan 178 

108




502 EFFECT OF SITAGLIPTIN ON ENDOTHELIAL CELL FUNCTION IN 

ISCHEMIC HEART DISEASE PATIENTS WITH DIABETES MELLITUS 

Hitoshi Adachi, H. Takamatsu, J. Tomono, S. Oshima, Japan 401 

503 INSULIN-SENSITIZING EFFECTS OF EMBELIA RIBES EXTRACT IN 

HIGH FAT DIET- AND LOW DOSE STREPTOZOTOCIN-INDUCED TYPE 2 

DIABETES IN WISTAR RATS 

Uma Bhandari, H.S. Chaudhari, India 476 

504 TREATMENT OF LINAGLIPTIN CAN ATTENUATE POSTPRANDIAL 

HYPERLIPIDEMIA 

Daisaku Masuda, T. Kobayashi, T. Okada, H. Nakaoka, R. Kawase, K. 

Nakatani, T. Ohama 1,2 , M. Nishida 1,2 , A. Matsuyama, I. Komuro, S. 

Yamashita, Japan 752 

505 LAPAROSCOPIC SLEEVE GASTRECTOMY AND ROUX-EN-Y GASTRIC 

BYPASS ARE EQUALLY EFFECTIVE IN CORRECTING INSULIN 

RESISTANCE AND DIABETES 

D. Benaiges, J.A. Flores Le-Roux, J.J. Chillarón, M. Renard, A. Parri, J.M. 

Ramón, M. Pera, Juan Pedro-Botet, Spain 840 

506 FROM THE GUIDES TO CLINICAL PRACTICE: PERCUTANEOUS 

REVASCULARIZATION IN THE DIABETIC POPULATION WITH 


Rocío Toro, M. Sobrino, L. Cabeza Letrán, C. Rodriguez, M.C. Durán, N. 

Caro, I. Tinoco, E. Segura, A. Mangas, Spain 1307 

507 ALOGLIPTIN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL 

IN PATIENTS TAKING STATINS 

Takayoshi Nemoto, K. Kashiwase, Y. Ueda, Japan 1420 

Diabetes macroangiopathy / Miscellaneous 

508 USE OF ALPHALIPOIC ACID IN PREVENTION OF CONTRAST INDUCED 

NEPHROPATHY IN DIABETIC PATIENTS 

M. Cicek, A. Yildirir, Kaan Okyay, A.C. Yazici, A. Aydinalp, S. Kanyilmaz, H. 

Muderrisoglu, Turkey 1552 

509 CARDIO-ANKLE VASCULAR INDEX MIGHT REFLECT ENDOTHELIAL 

FUNCTION IN TYPE 2 DIABETES 

Kei Endo, A. Saiki, T. Yamaguchi, N. Kon, H. Imamura, H. Kawana, N. Ban, 

A. Nagumo, D. Nagayama, M. Ohira, K. Shirai, I. Tatsuno, Japan 243 

510 IMPAIRED ANTIOXIDANT ACTION OF HIGH DENSITY LIPOPROTEIN 

FROM TYPE 1 DIABETIC PATIENTS WITH NORMOALBUMINURIA AND 

MICROALBUMINURIA 

E. Sampaio, D.S. Barbosa, T.L. Mazzuco, V.S. Nunes, M. Passarelli, E. 

Nakandakare, Alexandre Carrilho, Brazil 317 

109




511 NO IMPAIRED ENDOTHELIAL FUNCTION IN PATIENTS WITH DIABETES 

MELLITUS ACCORDING TO A POPULATION-BASED PROPENSITY 

SCORE MATCHING ANALYSIS 

K. Empen, Roberto Lorbeer, H. Völzke, T. Reffelmann, S. Schipf, M. Nauck, 

W. Kerner, H. Wallaschofski, S.B. Felix, M. Dörr, Germany 348 

512 IS DIABETIC RETINOPATHY AN INDICATOR FOR PROGRESSIVE 

ATHEROSCLEROSIS: INSIGHTS FROM A 5-YEAR OBSERVATIONAL 

STUDY 

Ayman El-Menyar, H. Al-Thani, A. Hussein, A. Sadek, A. Sharaf, V. Koshy, 

Qatar 732 

513 ICAM AND SELECTIN RECEPTOR EXPRESSION ON MONOCYTES IN 

PATIENTS WITH CARDIOVASCULAR DISEASE AND DIABETIC 

NEPHROPATHY 

Ivan Topchii, P. Semenovykh, V. Galchinskaya, N. Yefimova, Ukraine 744 

514 EARLY DIAGNOSIS OF COMPLICATED ATHEROSCLEROTIC PLAQUES 

IN TYPE 2 DIABETES MELLITUS-BIOMARKERS AND IMAGING 

Oana Vittos, B. Toana, F. Halici, D. Marta, A. Vittos, E. Moldoveanu, 

Romania 753 

515 SYNERGIC EFFECTS OF DIABETES AND HYPERTENSION IN THE 

INCREASE OF PULSE WAVE VELOCITY OVER POSTER BOARD NO. 

Paolo Meani, F. Cesana, C. Colombo, A. Fallanca, M. Stucchi, M. Baroni, F. 

Soriano, C. Giannattasio, Italy 768 

516 ATHEROSCLEROTIC PLAQUES IN SUBJECTS WITH DIABETES 

BECOME SYMPTOMATIC AT A LOWER LEVEL OF INFLAMMATION 

Andreas Edsfeldt, I. Goncalves 1,2 , H. Grufman 1,2 , M. Nitulescu, A. 

Persson 1,2 , M. Nilsson 1,2 , C. Prehn, J. Adamski 3,4,5 , J. Nilsson, Sweden, 

Germany 824 

517 ROLE OF A1C IN THE POSTPARTUM SCREENING OF WOMEN WITH 

GESTATIONAL DIABETES 

D. Benaiges, J.J. Chillarón, J.A. Flores Le-Roux, A. Mas, J. Puig de Dou, E. 

Segarra, M.J. Carrera, A. Goday, Juan Pedro-Botet, Spain 834 

518 BIOCHEMICAL MARKERS OF INFLAMMATION AND 

ATHEROSCLEROSIS IN PATIENTS WITH STABLE ANGINA AND 

DIABETES MELLITUS OF TYPE 2 

Tatiana Petelina, N. Musikhina, L. Gapon, N. Dementjeva, V. Kuznetsov, N. 

Galeeva, N. Lystsova, T. Petrashevskaya, Russia 931 

519 EFFECTS OF BODY WEIGHT REDUCTION ON BODY FAT AND PLASMA 

LEPTIN IN OBESE PATIENTS WITH TYPE 1 DIABETES MELLITUS 

Frantisek Musil, V. Blaha, A. Ticha, R. Hyspler, M. Haluzik, J. Lesna, A. 

Smahelova, L. Sobotka, Czech Republic 971 

520 ACUTE HEMODYNAMIC MODIFICATIONS AFTER A COLD PRESSURE 

TEST IN HEALTHY SUBJECTS AND IN TYPE 2 DIABETIC PATIENTS 

Marinos Fysekidis, K. Takbou, Y. Jaber, M.T. Nguyen, E. Cosson, P. 

Valensi, France 

110 

1246




521 CLINICAL IMPACT OF FOLLOW-UP GLYCOSYLATED HEMOGLOBIN 

ON CARDIOVASCULAR OUTCOMES IN DIABETIC PATIENTS WITH ST- 

SEGMENT ELEVATION MYOCARDIAL INFARCTION AFTER 

SUCCESSFUL REVASCULARIZATION 

J. Ahn, Taek Jong Hong, H.W. Lee, J.-H. Oh, J.H. Choi, H.C. Lee, K.S. Cha, 

the Korea Working Group on Myocardial Infarction Investigators, Republic of 

Korea 1320 

522 PREDICTIVE VALUE OF GLYCOSYLATED HEMOGLOBIN ON 

CARDIOVASCULAR OUTCOMES IN PREDIABETIC PATIENTS WITH ST- 

SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING 

PERCUTANEOUS CORONARY INTERVENTION 

J. Ahn, Taek Jong Hong, H.W. Lee, J.-H. Oh, J.H. Choi, H.C. Lee, K.S. Cha, 

the Korea Working Group on Myocardial Infarction Investigators, Republic of 

Korea 1346 

523 EXERCISE CAPACITY & HEART RATE VARIABILITY IN HEART 

FAILURE WITH DIABETES MELLITUS 

Teresita Corvera-Tindel 1,2 , L.V. Doering, F. Mody, USA 1429 

Nephropathy 

524 PROBUCOL SUPPRESSES INITIATION OF CHRONIC HEMODIALYSIS 

THERAPY AND RENAL DYSFUNCTION-RELATED DEATH IN DIABETIC 

NEPHROPATHY PATIENTS: SAKURA STUDY 

Kei Endo, A. Saiki, T. Yamaguchi, K. Sakuma, H. Sasaki, H. Imamura, Y. 

Sato, D. Nagayama, N. Ban, H. Kawana, A. Nagumo, M. Ohira, T. Murano, 

S. Yamamura, K. Shirai, I. Tatsuno, Japan 239 

525 HYPERHOMOCYSTEINEMIA AND THE PRESENCE OF CVD ARE 

ASSOCIATED WITH KYNURENIC ACID LEVELS AND CAROTID 

ATHEROSCLEROSIS IN PATIENTS UNDERGOING PERITONEAL 

DIALYSIS 

Dariusz Pawlak, M. Mysliwiec, K. Pawlak, Poland 479 

526 A HIGHER SERUM ARSENIC LEVEL IS ASSOCIATED WITH A HIGHER 

RISK FOR INCIDENT MYOCARDIAL INFARCTION IN HEMODIALYSIS 

PATIENTS 

Masaki Ohsawa, K. Tanno, K. Kato, Y. Fujishima, K. Itai, A. Okayama, T. 

Onoda, K. Sakata, T. Fujioka, The KAREN Study, Japan 534 

527 BIOCHEMICAL DISORDERS IN MILD CHRONIC RENAL IMPAIRMENT A 

MODEL BUILDING APPROACH 

Ljiljana Majnaric, A. Vcev, Croatia 624 

528 CARDIOVASCULAR DISEASE RISK AND EVENTS IN HYPERTENSIVE 

PATIENTS WITH CKD IN A RETROSPECTIVE COHORT IN A PRIMARY 

CARE SETTING 

Yook Chin Chia 1,2 , S.M. Ching, Malaysia, Australia 944 

111




529 CONTROL OF CARDIOVASCULAR DISEASE RISK FACTORS AMONG 

HYPERTENSIVE PATIENTS WITH OR WITHOUT CHRONIC KIDNEY 

DISEASE IN PRIMARY CARE SETTING 

SiewMooi Ching, Y.C. Chia 2,3 , Malaysia, Australia 1034 

530 THE ENDOTHELIAL PROTECTIVE EFFECTS OF HIGH DENSITY 

LIPOPROTEIN IS DIMINISHED USING HDL FROM PATIENTS WITH 

CHRONIC RENAL FAILURE 

Mirjam Schuchardt, N. Prüfer, S. Chebli, S. Schmid, L. Klöckl, M. Tölle, W. 

Zidek, M. van der Giet, Germany 1045 

531 THE 9P21 ALLELE AND CHRONIC ALLOGRAFT NEPHROPATHY 

Jan Kvasnicka, J. Hajkova, Z. Krska, O. Viklicky, T. Kvasnicka, P. 

Bobcikova, Czech Republic 1166 

532 THE CLOPIDOGREL HYPO-RESPONSIVENESS RATE IN CHRONIC 

KIDNEY DISEASE SUBJECTS 

Ping-Yen Liu, L.-J. Hsu, Taiwan R.O.C. 1198 

533 URINE ALBUMIN CREATININE RATIO COULD PREDICT CORONARY 

HEART DISEASE RISK IN REAL WORLD KOREAN POPULATIONS 

Seung Pyo Hong, Y.W. Park, S.W. Jeon, K.R. Bae, Y.S. Lee, J.B. Lee, J.K. 

Ryu, J.Y. Choi, K.S. Kim, S.G. Chang, Republic of Korea 1222 

534 LOW HDL CHOLESTEROL IS AN INDEPENDENT PREDICTOR OF 

CHRONIC KIDNEY DISEASE PROGRESSION 

Andrea Baragetti 1,2 , G.D. Norata 1,2 , C. Sarcina, F. Rastelli, L. Grigore, F. 

Pellegatta, K. Garlaschelli, P. Uboldi, I. Baragetti, C. Pozzi, A.L. Catapano 1,4 , 

Italy 1434 

535 ANDROID/GYNOID RATIO IS A MARKER OF VISCERAL ADIPOSITY IN 

CHRONIC KIDNEY DISEASE 

Andrea Baragetti 1,2 , K. Garlaschelli, C. Sarcina, L. Grigore, F. Pellegatta, C. 

Tidone, G.D. Norata 1,2 , I. Baragetti, C. Pozzi, A.L. Catapano 1,4 , Italy 1437 

536 PROGRESS OF STENOSIS IN ARTERIOVENOUS GRAFT FOR 

HEMODIALYSIS 

Young Ho Choi, H.-H. Kim, S.-H. Suh, Republic of Korea 1478 

Thrombosis 

537 ARTEFACTUAL ELEVATION OF PLASMA SOLUBLE CD40 LIGAND BY 

RESIDUAL PLATELETS IN CARDIOVASCULAR DISEASE 

Regent Lee, A.S. Antonopoulos, Z. Alexopoulou, M. Margaritis, R.K. 

Kharbanda, R.P. Choudhury, C. Antoniades, K.M. Channon, UK 133 

538 MEAN PLATELET VOLUME DECREASES AFTER EXTRACORPOREAL 

LDL-CHOLESTEROL ELIMINATION 

M. Blaha, M. Kostal, Vladimir Blaha, M. Lanska, S. Filip, P. Zak, Czech 

Republic 88 

112




539 VARYING EFFECTS OF DIFFERENT TYPES OF HEMODYNAMIC 

FORCES ON TISSUE FACTOR (TF) EXPRESSION IN ENDOTHELIAL 

CELLS (EC) 

Bauer Sumpio, USA 226 

540 PARTICIPATION OF THROMBOXANE A2 IN SEROTONIN AND 

BRADYKININ EFFECTS ON RAT COMMON CAROTID AND FEMORAL 

ARTERY 

Marko Stojanović, M. Radenković, N. Skorupan, M. Prostran, Serbia 387 

541 MACROPHAGES AND PLATELETS ARE THE MAJOR SOURCE OF THE 

FACTOR SEVEN ACTIVATING PROTEASE IN HUMAN 

ATHEROSCLEROTIC PLAQUES: IMPLICATIONS FOR 

ATHEROTHROMBOSIS 

Michael Worsch, M. Grebe, S. Kanse, B. Parviz, H. Tillmanns, H. 

Hoelschermann, M. Parahuleva, Germany 568 

542 IMAGING MURINE ATHEROTHROMBOSIS: VALIDATION OF SCANNING 

ELECTRONY MICROSCOPY (SEM) FOR ASSESSING PLAQUE 

RUPTURE IN MICE 

A.-L. Charles, P. Tilly, S. Ludwig, A. Sayeh, P. Choquet, Jean-Etienne 

Fabre, France 685 

543 PREVALENCE OF DRUG-DRUG INTERACTION IN THE PRIMARY 

HEALTH CARE DURING CLOPIDOGREL THERAPY 

Inga Urtane, K. Pukite, A. Aitullina, A.S. Stokmane, Latvia 852 

544 THE HOMEOSTATIC CHEMOKINE CCL21 PREDICTS MORTALITY IN 

AORTIC STENOSIS PATIENTS AND IS NECESSARY FOR 

DEVELOPMENT OF COMPENSATORY CONCENTRIC HYPERTROPHY 

Trine Ranheim, A.V. Finsen 1,2 , T. Ueland, I. Sjåstad 2,3 , E.T. Askevold 1,2 , M. 

Lipp, L. Gullestad 1,2 , G. Christensen 2,3 , P. Aukrust 1,2 , A. Yndestad 1,2 , Norway, 

Germany 1189 

545 A DOUBLE-BLIND RANDOMIZED PLACEBO PILOT STUDY 

COMPARING AGGRENOX VERSUS PLACEBO IN HEART FAILURE 

PATIENTS (ASAP-HF TRIAL) 

Ping-Yen Liu, L.-M. Tsai, C.-H. Lee, J.K. Liao, J.-H. Chen, Taiwan R.O.C., 

USA 1199 

546 DIFFERENTIAL RELATIONSHIPS BETWEEN CYSTEIN AND 

HOMOCYSTEIN WITH HEMOSTASIS FACTORS IN DYSLIPIDEMIC 

PATIENTS 

Philippe Giral, D. Rosenbaum, N. Jacob, A. Carrié, X. Girerd, A. Ankri, 

France 1298 

547 INTERRELATIONSHIPS BETWEEN CARDIAC DYSFUNCTION, 

ACTIVATED COAGULATION SYSTEM, PLATELET HYPERACTIVITY 

AND ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH STABLE 

CORONARY ARTERY DISEASE 

Severina V. Golovach, I.V. Golovach, Belarus 1314 

113




548 INTRINSIC PLATELET REACTIVITY AND THROMBUS BURDEN IN 

PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION 

Ioanna Xanthopoulou, G. Tsigkas, A. Damelou, K.C. Theodoropoulos, G. 

Makris, V. Gizas, G. Kassimis, P. Davlouros, G. Hahalis, D. Alexopoulos, 

Greece 1439 

549 TICAGRELOR VS PRASUGREL ON THE CORONARY BLOOD FLOW 

VELOCITY IN PATIENTS WITH ACUTE CORONARY SYNDROME 

UNDERGOING PCI 

Ioanna Xanthopoulou, N. Koutsogiannis, A. Moulias, A. Kakkavas, E. 

Mavronasiou, P. Davlouros, G. Hahalis, D. Alexopoulos, Greece 1441 

550 ΕFFECTS OF TICAGRELOR ON PLATELET-MEDIATED THROMBOSIS 

AND INFLAMMATORY RESPONSE IN PATIENTS WITH ACUTE 

CORONARY SYNDROMES 

Maria Tsoumani, P. Tatsidou, I. Ntalas, K. Kalantzi, I. Goudevenos, A. 

Tselepis, Greece 1445 

551 CIRCULATING MICRORNAS AS NOVEL BIOMARKERS FOR PLATELET 

ACTIVATION 

Anna Zampetaki, P. Willeit, K. Dudek, D. Kaudewitz, A. King, N.S. Kirkby, 

H.S. Markus, T.D. Warner, S. Kiechl, M. Mayr, UK, Austria 1588 

Aneurysms 

552 INTRACELLULAR CYCLOPHILIN A IN HUMAN ABDOMINAL AORTIC 

ANEURYSM IS INFLUENCED BY SIMVASTATIN 

A. Piechota-Polanczyk, S. Denyanets, M. Mittlboeck, C. Domenig, C. 

Neumayer, J. Wojta, J. Nanobachvili, M. Klinger, O. Nykonenko, Ihor Huk, 

Austria, Ukraine 236 

553 ABDOMINAL AORTIC ANEURYSMS AND CORONARY ARTERY 

DISEASE: A RETROSPECTIVE POPULATION-BASED STUDY 

Hassan Al-Thani, A. El-Menyar, A. Tabib, M. AlSulaiti, A. Almalki, Qatar 736 

554 ANGIOGENESIS IN HUMAN THORACIC AORTIC ANEURYSMS 

Ketty Kessler, R. Vranckx, J.-B. Michel, France 1084 

Arteriopathy 

555 EFFECTS OF PERIPHERAL ARTERY COMPLIANCE ON EXERCISE 

CAPACITY IN ELDERLY MALES 

Wei-Chuan Tsai, C.-H. Chou, J.-Y. Chen, M.-C. Wang, C.-S. Ho, P.-Y. Liu, 

L.-M. Tsai, C.-H. Wu, Taiwan R.O.C. 81 

556 A CASE OF PSEUDO-XANTHOMA ELASTICUM PRESENTING WITH 

ISCHAEMIC CLAUDICATION 

Christopher Lamb, R. Johns, P. Gallagher, A. Odurny, C. Shearman, UK 804 

557 THE COST OF TREATING END STAGE ATHEROSCLEROTIC LOWER 

LIMB DISEASE IN THE NORTH WEST OF ENGLAND 

Colin Chan, G. Harrison, G. Lawrence, UK 889 

114




558 PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY (PTA) IN 

PERIPHERAL ARTERY DISEASE: RESULTS OF A 5 YEARS FOLLOW 

UP STUDY 

Alessandro Cavarape, A. Da Porto, M.L. Casagrande, D. Gasparini, L.A. 

Sechi, Italy 1355 

559 PERIPHERAL ARTERIAL DISEASE RISK FACTORS IN RELATIONS TO 

NEW BIOMARKERS OF INFLAMMATION AND ANGIOGENESIS 

Sonja Perkov, M.M. Kardum Paro, V. Vidjak, Z. Flegar-Meštrić, Croatia 1447 

560 FLOATING THROMBUS IN THE DESCENDING THORACIC AORTA A 

RARE CAUSE OF SYSTEMIC THROMBOEMBOLIZATION 

Hassan Al-Thani, A. El-Menyar, Qatar 1601 

561 ATHEROSCLEROSIS IN TAKAYASU'S ARTERITIS 

Ahmed Hatri, F. Kessal, S. Taharboucht, A. Mameri, F. Hamrour, R. 

Guermaz, S. Zekri, M. Brouri, Algeria 157 

Lifestyle and CV risk / Exercise 

562 SHORT-TERM EXERCISE TRAINING CHANGES TRIGLYCERIDES 

MOLECULAR CONTENT OF THE LDL AND HDL PARTICLES 

AFFECTING THEIR FUNCTIONAL CHARACTERISTICS IN METABOLIC 

SYNDROME 

A. Casella-Filho, I.C. Trombetta, P.M. Dourado, Antonio Carlos de Leite Jr, 

M.C. Sprandel, A. Segre, R.D. Santos, C.E. Negrao, R.C. Maranhao, A.C.P. 

Chagas, Brazil 34 

563 RELATIONSHIPS BETWEEN HDL FUNCTIONAL CHARACTERISTICS 

AND ENDOTHELIAL VASCULAR FUNCTION AFTER SHORT-TERM 

EXERCISE TRAINING IN PATIENTS WITH THE METABOLIC SYNDROME 

A. Casella-Filho, I. Trombeta, P.M. Dourado, Antonio Carlos de Leite Jr, V. 

Jonke, A. Segre, R.D. Santos, C.E. Negrao, R.C. Maranhao, A.C.P. Chagas, 

Brazil 35 

564 OVARIECTOMY IN RATS IS ASSOCIATED WITH A REDUCTION OF 

HEPATIC LDLR, LRP1 AND PCSK9 GENE EXPRESSION; IMPACT OF 

EXERCISE TRAINING 

Emilienne Tudor Ngo Sock, J.-M. Lavoie, Canada 452 

565 THE EXERCISE HAS DIFFERENT EFFECTS ON COLLAGEN AND 

ELASTIC FIBERS OF THE AORTA IN NORMAL AND LDL KNOCKOUT 

MENOPAUSED ANIMALS 

C. Marchon, Ledimar Brianezi 1,2 , L. Maifrino 3,4 , R. Souza, Brazil 711 

566 EFFECTS OF EXERCISES ON THE RIGHT VENTRICLE OF FEMALE 

MICE SUBMITTED TO OVARIAN HORMONE DEPRIVATION 

Ledimar Brianezi 1,2 , K. Ressureição 2,3 , L. Maifrino 2,4 , Brazil 713 

567 INFLUENCE OF SHORT-TERM EXERCISE ON THE SIZE OF 

LIPOPROTEIN PARTICLES AMONG YOUNG HEALTHY SEDENTARY 

MALES 

Peter Sabaka, S. Oravec, J. Gajdosik, M. Zelina, A. Dukat, Slovak Republic 757 

115




568 COMPARED OUTCOME IN PATIENTS POST ACUTE CORONARY 

SYNDROME WITH VERSUS WITHOUT CARDIAC REHABILITATION 

FOLLOWING THE EVENT 

Eliezer Klainman, D. Mossinson, R. Cohen, L. Valinsky, A. Yarmolovsky, G. 

Fink, Israel 781 

569 EFFECTS OF CARDIAC REHABILITATION ON ENDOTHELIAL 

FUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE 

Marta Nogueira, T. Silva, A. Abreu, N. Santos, P. Rio, C. Fundinho, S. Silva, 

R. Ferreira, Portugal 791 

570 DO LEISURE POSTER BOARD NO. PHYSICAL ACTIVITY AND 

SEDENTARY BEHAVIOR AFFECT CARDIOVASCULAR RISK FACTORS 

ONLY WEAKLY? 

Gerda-Maria Haas, T. Bertsch, E. Liepold, P. Schwandt, Germany 811 

571 DAILY PHYSICAL ACTIVITY RELATED TO COMPOSITE RISK FACTOR 

SCORE FOR CVD IN CHILDREN 

Magnus Dencker, T. Tahna, O. Thorsson, M.K. Karlsson, P. Wollmer, L.B. 

Andersen, Sweden, Denmark 194 

572 VISCERAL OBESITY, LIFESTYLE AND PHYSICAL ACTIVITY LEVELS OF 

BRAZILIANS: TRYING TO CHANGE THE TENDENCY 

Marcia Braz Rossetti, A.M. Girodo, C.C. Jardim, G.M. Diniz, Brazil 849 

573 THE EFFECT OF CHRONIC SUPERVISED PHYSICAL TRAINING ON 

INFLAMMATORY PARAMETERS IN PERIPHERAL BLOOD IN 

PREHYPERTENSIVE SUBJECTS 

Magdalena Filip, J. Głodzik, T. Mikołajczyk, A. Sałakowski, K. Rewiuk, T. 

Grodzicki, T. Guzik, Poland 876 

574 EXERCISE MEDIATES SELECTED MICRORNA EXPRESSION AND 

PROMOTES PLAQUE REGRESSION 

Mahdi Garelnabi, J. Jin, H. Mahini, F. Chai, USA 913 

575 THE INFLUENCE OF GLYCEMIC CONTROL AND INSULIN RESISTANCE 

ON EXERCISE CAPACITY IN PATIENTS WITH CORONARY ARTERY 

DISEASE AND TYPE 2-DIABETES 

Rune Byrkjeland 1,2 , E. Edvardsen 3,4 , I. Unhammer Njerve 1,2 , M. Aulie, L.A. 

Toftegaard, H. Arnesen 1,2 , I. Seljeflot 1,2 , S. Solheim 1,2 , Norway 1065 

576 THE ROLE OF TRANSPORTATION ACTIVITY IN IMPROVEMENT OF 

HEALTHY LIFESTYLE IN THE POPULATION OF MEDICINE STUDENTS 

Dariusz Kalka 1,2 , Z.A. Domagala, L. Rusiecki, M. Syrycki, P. Koleda, T. 

Sebzda, L. Kipinski, A. Bielolus - Wilk, T. Szawrowicz-Pelka, W. Pilecki, 

Poland 1565 

577 INFLUENCE OF LEISURE POSTER BOARD NO. PHYSICAL ACTIVITY 

ON FITNESS OF ELDERY PATIENS 

Dariusz Kalka 1,2 , Z.A. Domagala, L. Rusiecki, A. Rakowska, J. 

Wojcieszczyk, W. Marciniak, A. Skalska, K. Womperski, W. Pilecki, Poland 1578 

116




Lifestyle and CV risk / Miscellaneous 

578 ACUTE CORONARY SYNDROME IN COCAINE USERS. ALWAYS 

VASOSPASM? THE IMPORTANCE OF CARDIOVASCULAR RISK 

FACTORS 

María Thiscal López Lluva, E. Marchan Carranza, M.D. Mañas García, M. 

Marina Breysse, C. Llanos Guerrero, N. Pinilla Echeverri, J. Piqueras Flores, 

M.C. Espinosa González, J.M. Arizón Muñoz, L. Ruiz-Valdepeñas Herrero, 

Spain 637 

579 SLEEP DISTURBANCES AND 16 YEARS RISK OF STROKE AND 

BEHAVIORAL HABITS IN FEMALE POPULATION AGED 25-64 YEARS IN 

RUSSIA 

Valery Gafarov 1,2 , D. Panov 1,2 , E. Gromova 1,2 , I. Gagulin 1,2 , A. Gafarova 1,2 , 

Russia 720 

580 "EATING HABITS AND LIFE STYLE OF THE UNIVERSITARY STUDENTS 

OF THE SCHOOL OF NURSING" 

Hazel Ester Anderson Vasquez, C. Wanden-Berghe, E.C. Garrido 

Zambrano, I.C. Pernalete Bustos, E. Rivera Bernardoni, Venezuela, Spain 794 

Lifestyle and CV risk / Tobacco 

581 LIPOPROTEINS FROM YOUNG SMOKERS WITH MODERATE EXTENT 

CAUSED MORE CELLULAR SENESCENCE AND EXHIBITED MORE 

ATHEROGENIC PROPERTIES 

Ki-Hoon Park 1,2 , D.-G. Shin 2,3 , J.-R. Kim, K.-H. Cho 1,2 , Republic of Korea 242 

582 FUNCTIONAL IN VITRO CHARACTERIZATION OF SASH1 GENE 

LINKING SMOKING TO ATHEROSCLEROSIS 

Henri Weidmann, C. Proust, R. Verdugo, D. Stengel, T. Zeller, S. 

Blankenberg, L. Tiret, F. Cambien, E. Ninio, France, Germany 383 

583 COMPARISON OF THE RESULTS OF EXERCISE TESTING IN SMOKERS 

AND NON-SMOKERS PATIENTS 

Haydeh Hashemizadeh, Iran 545 

584 ESTIMATION OF SMOKING CESSATION BENEFITS ON 

CARDIOVASCULAR RISK VIA LIPIDOMICS AND TRANSCRIPTOMICS 

ANALYSIS OF APOE -/- MICE LIVER 

Stephanie Boue, H. de Leon, S. Lebrun, M.C. Peitsch, J. Hoeng, 


Lifestyle and CV risk / Therapeutic education 

585 THE IMPORTANCE OF THERAPEUTIC EDUCATION IN PRIMARY 

PREVENTION FOR REDUCING SOME RISK FACTORS OF 


Marc Baudet, C. Daugareil, S. Caspar Bauguil, France 683 

117




586 PATIENT COMPLIANCE IMPROVES LDL-CHOLESTEROL GOAL 

ATTAINMENT IN THE HUNGARIAN MULTI GAP 2012 STUDY 

Laszlo Mark, I. Reiber, G. Paragh, I. Karadi, G. Pados, I. Mező, Z. Kiss, 

Hungary 874 

587 IMPROVING DRUG ADHERENCE IS CORRELATED WITH BETTER LIPID 

LOWERING EFFICACY IN HUNGARIAN MULTI GAP 2010-2012 STUDIES 

Zoltán Kiss, I. Reiber, I. Mező, I. Karadi, G. Paragh, G. Pados, L. Mark, 

Hungary 954 

588 EFFECTS OF GROUP EDUCATION FOR SECONDARY PREVENTION TO 

PATIENTS WITH ACUTE MYOCARDIAL INFARCTION BY MEDICAL 

TEAM IN CARDIAC REHABILITATION 

Chiharu Noda, T. Masuda, M. Kawano, Y. Ebina, A. Igarashi, K. Kamiya, N. 

Hamazaki, N. Aoyama, S. Niwano, Japan 1233 

Lifestyle and CV risk / Psychosocial factors 

589 ANXIETY IN PATIENTS WITH METABOLIC SYNDROME BEFORE AND 

AFTER CORONARY ARTERY BYPASS SURGERY 

Galina Chumakova 1,2 , Y. Chugunova, N. Veselovskaya 2,3 , Russia 809 

590 EFFECTS OF EMOTIONAL AND PHYSIOLOGICAL STRESS ON PLAQUE 

INSTABILITY IN APOLIPOPROTEIN E KNOCKOUT MICE 

Tao Zhang, H.B. Liu, Y.Z. Zhai, China 963 

591 IMPACT OF ANXIETY AND DEPRESSION ON BIOCHEMICAL BLOOD 

PARAMETERS IN GENERAL LITHUANIAN POPULATION 

Dovilė Karčiauskaitė, A. Mažeikienė, N. Burokienė, Z.A. Kučinskienė, 

Lithuania 1137 

Nutrition and CV risk / Alcohol 

592 VINEATROL AND CARDIOVASCULAR DISEASE: BENEFICIAL EFFECTS 

OF A VINE-SHOOT PHENOLIC EXTRACT IN A HAMSTER 

ATHEROSCLEROSIS MODEL 

Cindy Romain, S. Gaillet, J. Vidé, J. Carillon, J. Ramos, J.-C. Izard, J.-P. 

Cristol, J.-M. Rouanet, France 260 

593 RED WINE EXTRACT OF ONION ON THE PREVENTION AND 

IMPROVEMENT OF CARDIOVASCULAR DISEASES-A HUMAN 

CLINICAL TRIAL 

Chin-Kun Wang, Taiwan R.O.C. 1425 

Nutrition and CV risk / Antioxidants 

594 NUTRIGENOMICS REVEALS A COMMON MECHANISM OF ACTION OF 

DIETARY POLYPHENOLS UNDERLYING THEIR ANTI-ATHEROGENIC 

PROPERTIES 

C. Morand, A. Mazur, Dragan Milenkovic, France 441 

595 EFFECTS OF ONE-YEAR CONSUMPTION OF LUTEIN-ENRICHED EGG 

YOLKS ON SERUM LIPID AND LIPOPROTEIN CONCENTRATIONS 

Sanne M. van der Made, T.T.J.M. Berendschot, J. Plat, The Netherlands 556 

118




596 PREVENTIVE EFFECTS OF LYCOPENE AGAINST CARDIOVASCULAR 

DISEASES IN HIGH DOSE METHIONINE FEED RATS 

Aicha Yefsah 1,2 , K. Othmani, R. Taghlit, N. Hamdis, Y. Benazzoug, Algeria 1394 

597 RESVERATROL WINE POLYPHENOL RELAXES RAT RENAL ARTERY 

IN DIABETIC RAT: THE ROLE OF SMOOTH MUSCLE VOLTAGE- 

SENSITIVE POTASSIUM CHANNELS 

L. Gojkovic-Bukarica, J. Markovic-Lipkovski, S. Cirovic, R. Novakovic, H. 

Heinle, Vladmiri Kanjuh, Serbia, Germany 1620 

Nutrition and CV risk / Carbohydrates/fibres 

598 HIGH-DENSITY LIPOPROTEINS MODIFIED BY ARTIFICIAL 

SWEETENER, ASPARTAME AND SACCHARIN EXHIBIT LOSS OF ANTI- 

ATHEROSCLEROTIC ACTIVITY WITH EMBRYONIC TOXICITY 

J.-M. Baek 1,2 , J.-Y. Kim 1,2 , Kyung-Hyun Cho 1,2 , Republic of Korea 294 

599 IMPAIRED METABOLISM AND WORSENING OF ATHEROSCLEROTIC 

LESIONS OBSERVED AFTER COLA BEVERAGES´ DRINKING IN APO-E 

(-/-) MICE 

M. Otero-Losada, S. Mc Loughlin, G. Rodríguez-Granillo, A. Muller, G. 

Ottaviano, Juan C. Cutrin 1,2 , J. Milei, Argentina, Italy 1132 

600 EFFECT OF CHIOS MASTIC GUM ADMINISTRATION ON LIPID AND 

GLUCOSE METABOLISM IN STREPTOZOTOCIN-INDUCED DIABETIC 

MICE 

I. Georgiadis, T. Karatzas, G. Agrogiannis, Laskarina-Maria Korou, I.S. 

Vlachos, I. Tzanetakou, I. Doulamis, A. Pantopoulou, N.L. Katsilambros 1,3 , 

D.N. Perrea, Greece 1555 

Nutrition and CV risk / Fatty acids 

601 CIRCULATING BIOMARKERS AND LIPID CLASSES INDICATIVE OF 

CARDIOVASCULAR RISK: EFFECTS OF DAIRY FOOD CONSUMPTION 

Paul Nestel, K. Croft, P. Meikle, T. Mori, Cardiovascular Nutrition, Australia 258 

602 EFFECTS OF OLIVE OIL AND CANOLA OIL ON THE LIPID PROFILE IN 

POSTMENOPAUSAL WOMEN 

Hazel Ester Anderson Vasquez, P. Perez Martinez, J. Changarotti, I. 

Fernandez, Y. Hernandez, Venezuela, Spain 771 

603 SESAME OIL AND ITS ROLE IN OXIDATION OF ISOLATED LOW- 

DENSITY LIPOPROTEINS AND OF TOTAL SERUM LIPOPROTEINS IN 

VITRO 

K. Makedou, S. Iliadis, M. Gogou, E. Kara, Areti Makedou, G. 

Papageorgiou, Greece 803 

604 TOTAL SERUM AND HDL-PHOSPHOLIPIDS ARE ASSOCIATED TO 

DIETARY MONOUNSATURATED FATTY ACIDS IN CAD PATIENTS 

FROM BIZERTA AREA, TUNISIA 

Y. Nekaies, A. Ben Khalfallah, H. Aoua, K. Charradi, M. Sakly, Nebil Attia, 

Tunisia 1103 

119




605 IMPACT OF SERUM TRANS FATTY ACID LEVEL IN RISKS OF 

CORONARY ARTERY DISEASE IN JAPAN 

Kenta Mori, T. Ishida, N. Tanaka, T. Mori, T. Monguchi, M. Sasaki, K. 

Kondo, M. Hasokawa, H. Nakajima, Y. Haraguchi, L. Sun, T. Yasuda, M. 

Shinohara, R. Toh, K.-I. Hirata, Japan 1138 

Nutrition and CV risk / Miscellaneous 

606 A DIET-INDUCED ATHEROSCLEROSIS IN RABBIT MODEL PROVIDES 

AN INSIGHT INTO ESSENTIAL ELEMENTS CONCENTRATIONS IN 


Adeniran Sanmi Adekunle, T. Adelusi, J.O. Fatoki, B. Oyedokun, Nigeria 64 

607 EFFECTS OF HYPERCHOLESTEROLEMIA ON TRACE ELEMENTS 

LEVELS IN RABBIT TISSUES USING ATOMIC ABSORPTION 

SPECTROSCOPY 

Magdy Mohammed Ghannam, M.A.K. Abdelhalim, Medical Biophysics, 

Saudi Arabia 703 

608 INCREASED COFFEE CONSUMPTION IS ASSOCIATED WITH HIGHER 

LIKELIHOOD OF ACUTE CORONARY SYNDROME AND ISCHEMIC 

STROKE NON-FATAL EVENTS: A CASE/CASE-CONTROL STUDY 

Christina-Maria Kastorini, H.J. Milionis, D. Kantas, V. Euthimiou, E. Trichia, 

A. Litsardopoulou, V. Nikolaou, K.N. Vemmos, J.A. Goudevenos, D.B. 

Panagiotakos, Greece 745 

609 SPIRULINA PLATENSIS AND PHYCOCYANOBILIN MODULATE THE 

ATHEROPROTECTIVE ENZYME HEME OXYGENASE (HMOX1) 

Zbynek Strasky, L. Zemankova, I. Nemeckova, J. Pfeiferova, L. Muchova, I. 

Subhanova, J. Vanikova, L. Vitek 2,3 , P. Nachtigal, Czech Republic 785 

610 THE POTENTIAL OF LUPIN PROTEIN TO EXERT 

ANTIATHEROSCLEROTIC EFFECTS 

Melanie Bähr, A. Fechner, G. Jahreis, Germany 990 

611 BIFIDOBACTERIUM SUPPLEMENTATION: EFFECTS ON PLASMA LIPID 

PROFILE IN DYSLIPIDEMIC CHILDREN 

Francesca Abello, P. Cagliero, O. Guardamagna, Italy 1030 

612 EFFECT OF GRAPE SEED AND SKIN EXTRACT ON HIGH-FAT DIET- 

INDUCED RENAL LIPOTOXICITY IN RAT 

K. Charradi, Nebil Attia 2,3 , F. Limam, E. Aouani 1,3 , Tunisia 1452 

613 WATER INTAKE AND LDL CHOLESTEROL 

Ronan Roussel 1,2 , O. Lantieri, B. Balkau, M. Marre, The D.E.S.I.R. Study 

Group, France 1479 

614 EFFECTS OF FENUGREEK AND SAPONINS ON THE BIOMARKERS OF 

INFLAMMATION AND ENDOTHELIAL ACTIVATION IN STIMULATED 

HUMAN CORONARY ARTERY ENDOTHELIAL CELLS 

Radzi Ahmad 1,2 , T. Rahman, G.R.A. Froemming, H. Nawawi, Malaysia 1530 

120




615 GRAPE SEED AND SKIN EXTRACT MODULATES LIPASE ACTIVITY IN 

WISTAR RATS FED A HIGH-FAT DIET 

K. Charradi 1,2 , Nebil Attia 2,3 , F. Limam, E. Aouani 2,5 , Tunisia 1547 

616 CHARACTERISATION OF ATHEROSCLEROSIS LESIONS IN 

APOE/LDLR -/- MICE FED LOW CARBOHYDRATE, HIGH PROTEIN DIET 

(LCHP) 

R.B. Kostogrys, Magdalena Franczyk-Zarow, E. Maslak, I. Czyzynska, A. 

Drahun, A. Jasztal, B. Sitek, L. Mateuszuk, M. Gajda, S. Chlopicki, Poland 1153 

617 CHARACTERIZATION OF PROTEIN PROFILES RELATED TO DIET AND 

EXERCISE AS MOLECULAR SIGNATURES OF VASCULAR WELLNESS 

M.C. Duran, R. Toro, J. Alonso, Carmen Rodriguez Leal, I. Tinoco, M.L. 

Cabeza-Letran, D. Corrales, N. Caro, E. Segura, A. Mangas, Spain 1303 

618 CASE CONTROL STUDY OF THE EFFECT OF A NUTRITIONAL 

STRATEGY «GOURMET NUTRITION» ON THE COMPLIANCE TO 

CARDIOVASCULAR LIFESTYLES RECOMMENDATIONS 

Francois Allaert, F. Paillard, T. Coutureau, France 285 

619 EVOLUTION OF CARDIOVASCULAR LIFESTYLE BEHAVIOURS AND 

LIPID PARAMETERS OCCURRING IN HYPERCHOLESTEROLEMIC 

PATIENTS CONCOMITANTLY TO THE INTAKE OF PHYTOSTEROL- 

SUPPLEMENTED YOGHURT 

E. Bruckert, L. Massama, O. Descamps, E. Bosi, Francois Allaert, M.J. 

Chapman, France, Spain, Belgium, Italy 937 

Omega-3 fatty acids 

620 CALORIC RESTRICTION AND POSTPRANDIAL STRESS MARKERS IN 

HEALTHY AND OBESE PERSONS UNDER SUPPLEMENTATION WITH 

N-3 POLYUNSATURATED FATTY ACIDS (PUFA) 

Malgorzata Malczewska Malec, D. Siedlecka, J.S. Mozwillo, B.K. Wilk, M. 

Malecki, A.D. Kiec, Poland 108 

621 BENEFICIAL CARDIOVASCULAR EFFECTS OF FLAXSEED 

SUPPLEMENTATION IN STZ- DIABETIC RATS 

Nilay Tarhan, Y. Fidan, C. Tufan, B. Konuklugil, N. Arı, G. Ozansoy, Turkey 380 

622 ASSOCIATION OF SERUM OMEGA-3 TO OMEGA-6 

POLYUNSATURATED FATTY ACID RATIO WITH MICROALBUMINURIA 

IN A POPULATION OF COMMUNITY-DWELLING JAPANESE 

A. Fukami, Hisashi Adachi, Y. Hirai, M. Enomoto, A. Obuchi, A. Yoshimura, 

T. Imaizumi, Japan 406 

623 ASSOCIATION BETWEEN SERUM N-3/N-6 POLYUNSATURATED FATTY 

ACID RATIO AND CORONARY AND AORTIC PLAQUE INSTABILITY 

Yukihiko Momiyama, R. Ohmori, R. Kato, H. Taniguchi, F. Ohsuzu, Japan 497 

121




624 OMEGA 3 FATTY ACIDS REDUCE CARDIOVASCULAR RISK BY 

IMPROVING THE METABOLISMS OF SPHINGOLIPIDS AND 

TRIGLYCERIDES IN VLDL 

Veronique Ferchaud Roucher, C. Nael, A. Aguesse, M. Krempf, K. 

Ouguerram, France 601 

625 OMEGA-3 FATTY ACID DECREASES BOTH SYSTEMIC INFLAMMATION 

OF RETICULO-ENDOTHELIAL SYSTEM AND INFLAMMATION AT 

VASCULAR PLAQUE 

Sungeun Kim, H.S. Seo, E.J. Kim, J.H. Na, J.H. Park, C.-G. Park, C.U. 

Choi, H.E. Lim, J.W. Kim, S.-W. Rha, D.J. Oh, Republic of Korea 690 

626 THE PARADOX OF OMEGA 3 PUFAS: ATHEROPROTECTIVE 

ALTHOUGH HIGHLY SUSCEPTIBLE TO PEROXIDATION 

Cecile Gladine, M. Zmojdzian, J. Newman, T. Durand, L. Joumard- 

Cubizolles, M.-A. Verny, J.-M. Galano, C. Demougeot, O. Berdeaux, E. 

Pujos-Guillot, A. Mazur, B. Comte, France, USA 1438 

627 MARINE OIL EXTRACTED FROM THE COPEPODE CALANUS 

FINMARCHICUS REDUCES AORTA ATHEROSCLEROSIS IN FEMALE 

APOLIPOPROTEIN E-DEFICIENT MICE 

Karl-Erik Eilertsen, H.K. Mæhre, I.-J. Jensen, H. Devold, E.O. Elvevoll, B. 

Østerud, Norway 1446 

628 DOCOSAHEXAENOIC ACID SUPPLEMENTATION IN APOLIPOPROTEIN- 

E DEFICIENT MICE EXPOSED TO INTERMITTENT HYPOXIA: EFFECT 

ON ATHEROGENESIS PREVENTION 

Laetitia Van Noolen 1,2,3 , M. Bäck, C. Arnaud, A. Rey, M.H. Petrii, P. Levy 1,3 , 

P. Faure 1,2,3 , F. Stanke-Labesque 1,2,3 , France, Sweden 1457 

629 DIETARY ENRICHMENT WITH MARINE OIL AND TAURINE REDUCE 

HEPATIC EXPRESSION OF PROINFLAMMATORY GENES WITHOUT 

AFFECTING ATHEROSCLEROSIS IN APOLIPOPROTEIN E-DEFICIENT 

MICE 

Ida Johanne Jensen, H. Mæhre, H. Devold, E. Elvevoll, B. Østerud, K.-E. 

Eilertsen, Norway 1490 

630 INCREASE IN THE SERUM LEVEL OF EICOSAPENTAENOIC ACID IS 

ASSOCIATED WITH THE STABILIZATION OF CORONARY 

VULNERABLE PLAQUE 

Takayoshi Nemoto, A. Hirata, Y. Ueda, Japan 1560 

631 YOUNGER PATIENTS WITH STABLE CORONARY ARTERY DISEASE 

HAVE LOWER RATIO OF SERUM EICOSAPENTAENOIC ACID TO 

ARACHIDONIC ACID 

Takayoshi Nemoto, M. Nishio, Y. Ueda, Japan 1563 

122




Phytosterols 

632 CARDIOVASCULAR PROFILE OF CONSUMERS OF A PHYTOSTEROL- 

ENRICHED YOGURT IN A REAL-LIFE SETTING: A FRENCH 

OBSERVATIONAL TRANSVERSAL STUDY 

J. Dallongeville, F. Paillard, Eric Bruckert, G. Naelten, P. Picard, E. Van 

Ganse, France 604 

634 GENETIC BASIS FOR HETEROGENEITY OF RESPONSE OF LDL 

CHOLESTEROL TO PLANT STEROLS 

Dylan Stapenhorst MacKay, D. Baer, P. Eck, P.J. Jones 1,3 , Canada, USA 1645 

Treatment / Miscellaneous 

635 RESVERATROL PROMOTES EXPRESSIONS OF SIRT1 AND LPL TO 

INHIBIT TG ACCUMULATION IN DIFFERENTIATED 3T3-L1 

PREADIPOCYTES 

Haruki Imamura, T. Yamaguchi, Y. Sato, N. Ban, H. Kawana, D. Nagayama, 

A. Nagumo, M. Ohira, K. Endo, A. Saiki, N. Ishihara, F. Watanabe, K. Shirai, 

I. Tatsuno, Japan 653 

636 IN VIVO PHARMACOLOGICAL ACTIVITY OF NOVEL 5-FLUORO-N-(9,10- 

DIHYDRO-9,10-DIOXOANTHRACEN-8-YL)-1H-INDOLE-2-CARBOXAMIDE 

DERIVATIVES ON PLASMA LIPID PROFILE OF TRITON-WR-1339- 

INDUCED WISTAR RATS 

Ghassan Shattat, T. Al-Qirim, G. Abu Sheikha, Y. Alhiari, K. Sweidan, R. 

Alqirim, Jordan 86 

637 ATHEROPROTECTION OF ANTI-LDL(-) SCFV CONJUGATED TO 

NANOPARTICLES IN EXPERIMENTAL ATHEROSCLEROSIS 

Marcela Frota Cavalcante, S.M. Kazuma, A.R. Pohlmann, S.S. Guterres, 

E.A. Bender, M.D. Adorne, D.S.P. Abdalla, Brazil 150 

638 PROBUCOL AND CILOSTAZOL EXERT A SYNERGISTIC ANTI- 

ATHEROGENIC EFFECT IN CHOLESTEROL-FED RABBITS 

Enqi Liu, Y. Chen, S. Zhao, J. Fan, China, Japan 171 

639 CSL112, A NOVEL FORMULATION OF HUMAN APOLIPOPROTEIN A-I, 

IN HEALTHY SUBJECTS ENHANCES CHOLESTEROL EFFLUX 

CAPACITY AND MOBILIZES CHOLESTEROL FROM TISSUES 

Andreas Gille, R. Easton, S.D. Wright, C.L. Shear, Australia, USA 330 

640 EFFECT OF MYRICETIN TREATMENT ON LIPOPROTEIN METABOLISM 

IN 13-HODE EXPOSED HEPG2 CELLS 

Mahdi Garelnabi, H. Mahini, USA 535 

641 ADD-ON EFFECT OF PROBUCOL IN ATHEROSCLEROTIC, 

CHOLESTEROL-FED RABBITS TREATED WITH ATORVASTATIN 

Y. Keyamura 1,2 , C. Nagano, M. Kohashi, M. Niimi, M. Nozako, T. Koyama, R. 

Okutsu, A. Fukuda, K. Mitani, H. Itabe, Tomohiro Yoshikawa, Japan 536 

123




642 THE BOTANICAL PRODUCT XUEZHIKANG (XZK): ITS EFFICACY AND 

SAFETY FOR LIPID-LOWERING THERAPY WHEN COMPARED TO 

PLACEBO 

Patrick M. Moriarty, Z. Duan, S. Guo, P. Liu, Y. Zhang, S. Li, WPU-201 

Study Group, USA, China 630 

643 EDARAVONE ATTENUATES ANGIOTENSIN II-INDUCED 

ATHEROSCLEROSIS AND ABDOMINAL AORTIC ANEURYSMS IN 

APOLIPOPROTEIN E DEFICIENT MICE 

Haruhito Adam Uchida, H. Uchida, R. Umebayasi, K. Shikata, H. Makino, 

Japan 1290 

644 THE IMPACT OF STRATEGIC UK NATIONAL HEALTH SERVICE (NHS) 

FUNDING ON THE PATIENT RECRUITMENT 

TO“ATHEROTHROMBOSIS” RESEARCH STUDIES 

Alistair S. Hall, D.E. Newby, C.P. Gale, R.G. Gillott, S. Scarlett, S.M. Wood, 

J.D. Gower, B. Williams, M.J. Caulfield, UK NHS Atherothrombosis Research 

Network, UK 1338 

645 THE IMPACT OF COORDINATED NATIONAL SYSTEMS TO AID 

PATIENT RECRUITMENT AND FOLLOW-UP IN “ATHEROTHROMBOSIS” 

RESEARCH: THE EMMACE-3 STUDY 

Christopher P. Gale, R.G. Gillott, R. Khatib, J.H. Barth, C. Forrest, R.E. 

Maindonald, K.L. Willan, P.D. Batin, S. Scarlett, S.J. Howell, D. Lawson, J.D. 

Gower, D.E. Newby, B. Williams, M.J. Caulfield, A.S. Hall, the UK NHS 

Atherothrombosis Research Network, UK 1349 

646 AMP-ACTIVATED PROTEIN KINASE ACTIVATION BY XANTHOHUMOL 

AMELIORATES ATHEROSCLEROTIC PLAQUE FORMATION, 

HYPERCHOLESTEROLEMIA AND HEPATIC STEATOSIS IN APOE- 

DEFICIENT MICE 

Branislav Radovic, P. Doddapattar, J.V. Patankar, S. Obrowsky, K. Jandl, 

C. Nusshold, D. Kolb, N. Vujic, M. Goeritzer, H. Ahammer, G. Hoefler, W. 

Sattler, D. Kratky, Austria 1463 

647 ANTIBODIES AGAINST OXIDIZED BUT NOT NATIVE CARDIOLIPIN AND 

PHOSPHATIDYLSERINE AS NOVEL PROTECTION MARKERS IN 

ATHEROSCLEROSIS DEVELOPMENT 

A. Frostegård, U. de Faire, Johan Frostegård, Sweden 1599 

Treatment / Blood pressure treatment 

648 HIGH-DOSE ARB VERSUS ARB PLUS CCB COMBINATION THERAPY 

FOR SUPPRESSING CAROTID ATHEROSCLEROSIS IN HYPERTENSIVE 

PATIENTS WITH HYPERCHOLESTEROLEMIA 

Yasunori Sawayama, Japan 49 

649 COMPARISON OF THE EFFECT OF M - AND N-CHOLINOBLOCKERS 

AND VAGOTOMY ON PHYSICOCHEMICAL PROPERTIES OF 

LIPOPROTEINS IN RAT BLOOD PLASMA 

Nina Solomonovna Parfenova, A.S. Kuznetsov, Russia 87 

124




650 EFFECTS OF ALISKIREN ON BLOOD PRESSURE, RENAL AND 

CARDIAC FUNCTION, BAPWV AND CAROTID ARTERIAL ELASTIC 

MODULUS IN HYPERTENSIVE PATIENTS 

Toshio Yamagishi, K. Omata, H. Hasegawa, H. Kanai, Japan 299 

651 EXTENDED RELEASE NIACIN LOWERS IN VITRO HDL OXIDIZABILITY 

AND MEDIATORS OF VASCULAR INFLAMMATION IN STATIN TREATED 

DYSLIPIDEMIC PATIENTS 

R. Yadav, Y. Liu, S. Kwok, V. Charlton-Menys, M. France, R. Eatough, S. 

Hama, N. Younis, B.J. Ammori, B. Issa, Handrean Soran, UK 1098 

652 EFFECT OF ALISKIREN ON (PRO)RENIN RECEPTOR EXPRESSION 

AND ACTIVITY IN CULTURED SMOOTH MUSCLE CELLS 

Nicola Ferri, F. Panariti, G. Maiocchi, A. Corsini, Italy 1255 

653 LONG TERM EFFECT OF SPECIFIC TREATMENT OF PRIMARY 

ALDOSTERONISM ON CAROTID INTIMA MEDIA THICKNESS 

Robert Holaj, J. Rosa, T. Zelinka, B. Strauch, O. Petrak, D. Michalsky, K. 

Novak, J. Widimsky, Czech Republic 1596 

Intravascular procedures 

654 SUSTAINED PHARMACOLOGIC PRECONDITIONING OF THE CONDUIT 

ARTERY WITH SILDENAFIL: A HUMAN IN VIVO STUDY 

K. McLaughlin, A. Liuni, John David Parker, Canada 906 

655 LOW LEVEL LASER THERAPY PROTECT INFLAMMATION-INDUCED 

ENDOTHELIALDYSFUNCTION 

Yu-Jung Cheng, Taiwan R.O.C. 570 

656 PREDICTORS OF THE ADVERSE OUTCOMES AFTER CORONARY 

STENTING 

Galina Chumakova 1,2 , N. Veselovskaya 2,3 , V. Elikomov 1,3 , O. Gritsenko 1,2 , 

Russia 741 

657 THE FEASIBILITY OF ENDOVASCULAR AORTIC BIOPSY DURING 

ENDOVASCULAR INTERVENTIONS 

Michał Stanisić, W. Majewski, J. Kulesza, P. Majewski, A. Marszałek, A. 

Zarzecka, G. Oszkinis, Poland 766 

658 PSEUDOANEURYSM OF THE ASCENDING AORTA FOLLOWING RIGHT 

CORONARY STENTING 

Jose Rubio Alvarez, J. Sierra Quiroga, B. Adrio Nazar, J. Garcia Carro, L. 

Reija Lopez, A. Gandara, C. Rubio Taboada, Spain 22 

659 NONINVASIVE IDENTIFICATION OF LEFT MAIN CORONARY 

RESTENOSIS 

Milana Zabunova, I. Mintale, I. Narbute, S. Jegere, I. Zakke, A. Erglis, Latvia 32 

660 NON-INVASIVE FOLLOW-UP - A KEY POINT FOR PATIENTS AFTER 

LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION 

I. Mintale, Milana Zabunova, I. Narbute, S. Jegere, I. Zakke, A. Erglis, Latvia 33 

125




Miscellaneous 

665 APOA-I DEPLETION AND ATHEROSCLEROSIS IN APOE-KO MICE: THE 

RIGHT WAY TOWARDS A MURINE MODEL OF OCCLUSIVE CORONARY 

ARTERY DISEASE? 

G. Ganzetti, Marco Busnelli, C. Parolini, S. Manzini, F. Dellera, C.R. Sirtori, 

G. Chiesa, Italy 1507 

666 CURCUMIN MODULATION OF ATHEROSCLEROSIS AND 

HEPATOSTEATOSIS IN LDLR-/- MICE 

Mohsen Meydani, S.T. Hasan, J.-M. Zingg, P. Kwan, D. Smith, USA 916 

667 ASPIRIN RESISTANCE OCCURS ALSO IN YOUNG HEALTHY MEN AND 

IS ASSOCIATED WITH PREACTIVATION OF PLATELETS 

Agnieszka Janus 1,2 , P. Ilnicka 1,2 , M. Jakubowski, E. Szahidewicz-Krupska 1,2 , 

A. Szuba 1,2 , A. Doroszko 1,2 , Poland 188 

668 ENDOTHELIAL DYSFUNCTION IN YOUNG HEALTHY MEN IS 

ASSOCIATED WITH ASPIRIN RESISTANCE 

Adrian Doroszko 1,2 , M. Jakubowski, A. Janus 1,2 , P. Ilnicka 1,2 , E. 

Szahidewicz-Krupska 1,2 , A. Szuba 1,2 , Poland 1156 

669 ENDOTHELIAL DYSFUNCTION AND ASPIRIN RESISTANCE IN YOUNG 

HEALTHY MEN IS RELATED TO INCREASED ACTIVITY OF THE 

RENNIN-ANGIOTENSIN-ALDOSTERONE SYSTEM 

A. Doroszko 1,2 , P. Ilnicka 1,2 , A. Janus 1,2 , Maciej Jakubowski, E. 

Szahidewicz-Krupska 1,2 , A. Szuba 1,2 , Poland 187 

670 DO LOW HDL CHOLESTEROL LEVELS PREDICT DIABETES MELLITUS 

ONSET? 

Alp Burak Catakoglu, V. Aytekin, E. Usta, M.G. Ercan, H. Kurtoglu, M. 

Sener, H. Celebi, S. Aytekin, Turkey 707 

671 CARDIOVASCULAR RISK PROFILE OF PATIENTS WITH 

SPONDYLOARTHRITIS 

Charalampos Papagoras, T.E. Markatseli, P. Margariti, A.K. Zikou, Y. 

Alamanos, A.A. Drosos, Greece 217 

672 RELATIONSHIP BETWEEN CETP AND CHOLESTEROL EFFLUX 

Raja Chaaba, S. Mehri, N. Attia, S. Hammami, M. Smaoui, K. Ben Hamda, 

A. Nakbi, N. Koubaa, M. Hammami, Tunisia 1173 

673 CAROTID ATHEROSCLEROSIS IN ASYMPTOMATIC NEWLY 

DIAGNOSED TYPE 2 DIABETIC SUBJECTS 

Marta Catalan, Z. Herreras, M. Pinyol, A. Sala, R. Gilabert, E. Ortega, Spain998 

674 PANORAMIC RADIOGRAPHY AND COLOR DOPPLER IN THE 

DIAGNOSIS OF CALCIFIED CAROTID ATHEROMATOUS PLAQUES 

T.Q. Abreu, Sebastião Barreto De Brito Filho, K.P.F.d. Sales, E.B. 

Ferreira, A.E.F.D. Oliveira, Brazil 113 

126




674 PANORAMIC RADIOGRAPHY AND COLOR DOPPLER IN THE 

DIAGNOSIS OF CALCIFIED CAROTID ATHEROMATOUS PLAQUES 

T.Q. Abreu, Sebastião Barreto De Brito Filho, K.P.F.d. Sales, E.B. 

Ferreira, A.E.F.D. Oliveira, Brazil 113 

675 FETUIN-A AND CARDIOVASCULAR MORBIDITY AND MORTALITY IN 

PATIENTS WITH PERIPHERAL VASCULAR DISEASE IN NON-DIALYSED 

PATIENTS 

Zoltan Szeberin, M. Fehérvári, M. Krepuska, A. Apor, H. Sarkadi, L. Entz, B. 

Merkely, Hungary 82 

676 MULTIPLE RISK FACTORS AND CAROTID ATHEROSCLEROSIS IN 

JAPANESE IN THE PRIME OF LIFE 

Wakoh Takahashi, T. Uesugi, T. Ohnuki, S. Takizawa, Japan 334 

677 BIOMARKERS OF ATHEROSCLEROTIC PLAQUES INSTABILITY AND 

THEIR RELATION WITH LONG-TERM RESULTS OF SURGICAL 

MYOCARDIAL REVASCULARIZATION 

Yulia Ragino, A. Chernyavskiy, S. Tcimbal, L. Scherbakova, Y. Polonskaya, 

M. Voevoda, Russia 468 

678 INTRA-FAMILIAL ASSOCIATIONS OF CARDIOVASCULAR RISK 

FACTORS IN 515 HEALTHY FAMILIES - THE PEP FAMILY HEART 

STUDY 2007 

Peter Schwandt, T. Bertsch, E. Liepold, G.-M. Haas, Germany 806 

679 "LIFESTYLE AND HABITS FOOD OF STUDENTS NEW INCOME THE 

SCHOOL OF NUTRITION AND DIETETICS" 

Hazel Ester Anderson Vasquez, C. Wanden-Berghe, D.C. Araujo Castillo, 

E.R. Labrador Aldana, K.D. Rodríguez Ortega, Venezuela, Spain 799 

680 THE ROLE OF DRUGS WITH REDUCING EFFECTS ON OXIDATIVE 

STRESS, PLATELETS HYPERACTIVITY AND ENDOTHELIAL 

DYSFUNCTION IN CORONARY ARTERY DISEASE 

Alexandru Covaciu, E. Bobescu 1,2 , N. Aldulea, Romania 1158 

682 DEVELOPMENT OF NEW RAC1 INHIBITORS AS POTENTIAL 

PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF 


Sergio Kevin Bernini, A. Contini, A. Corsini, N. Ferri, Italy 1256 

683 APO C-III CORRELATES WITH ARTERIAL STIFFNESS IN PATIENTS 

WITH CLINICAL DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA 

(FH) 

Małgorzata Waluś-Miarka, B. Idzior-Waluś, D. Czarnecka, M. Sanak, P. 

Miarka, W. Wojciechowska, M. Kloch-Badełek, M.T. Małecki, E. 

Woźniakiewicz, J. Starzyk, Poland 724 

127




684 LECITHIN CHOLESTEROL ACYLTRANSFERASE RS 5922 AND RS5923 

SINGLE-NUCLEOTIDE POLYMORPHISMS AND INSULIN RESISTANCE: 

A BRAZILIAN POPULATION STUDY 

Eliane Soler Parra, N.B. Panzoldo, V.S. Nunes, J. Metso, M. Jauhiainen, 

V.H.S. Zago, D.Z. Scherrer, F. Alexandre, E.R. Nakandakare, E.C.R. 

Quintão, E.C. de Faria, Brazil, Finland 1649 

685 PATIENT DETERMINANTS OF HYPERCHOLESTEROLEMIA 

UNDERTREATMENT IN CENTRALIZED PAN-RUSSIAN SURVEY ON THE 

UNDERTREATMENT OF HYPERCHOLESTEROLEMIA (CEPHEUS) 

Yunona Khomitskaya. Eliane Soler Parra, Sergey Boytsov, Moscow, 

Russia 838 

686 INFLAMMATORY RESPONSE MODIFICATION AFTER CARDIAC 

RESYNCHRONIZATION IN HEART FAILURE PATIENTS-PRELIMINARY 

RESULTS 

Ana Abreu, M. Mota Carmo, T. Pinheiro, H. Santa Clara, M. Selas, P. 

Cunha, M. Oliveira, M. Nogueira Siva, R. Ferreira, Lisbon, Portugal 1382 

687 MARKEDLY INCREASED FREQUENCY OF UNDETECTED PERIPHERAL 

ARTERIAL DISEASE IN THE ELDERLY WITH DEMENTIA 

Ilker Tasci, U. Safer, I., Naharci, E. Bozoglu, M. Gezer, O. Demir, H. Doruk, 

Ankara, Turkey 823 

128

INDEX

L 

Arteriosclerosis, Thrombosis, 

and Vascular Biology 

The forum for publication of basic, translational, clinical, and population research in the 

area of arteriosclerosis, thrombosis, and vascular biology 

Submit Your Manuscript 

http://atvb-submit.aha-journals.org 

6.368 

Download the iPad 

app for a print-like, 

full-text experience 

Read and search 

with ease on your Internetenabled 

smartphone 

With an Impact Factor of 6.368, ATVB ranks 3rd 

among 68 journals in Peripheral Vascular Disease 

and 7th among 68 journals in Hematology subject 

categories. It is the #1 journal dedicated to the 

study of atherosclerosis and thrombosis in relation 

to vascular biology. 

2011 Journal Citation Reports® (Thomson Reuters, 2012) 

atvb.ahajournals.org 

A subscription includes access to ATVB online and on your iPad ® . 

Rapid Online publicatiOn Within 5 tO 10 daYS Of acceptance 

Join the aha * 

Call: 1-800-787-8984 (United States) 

+1-301-223-2307 (Rest of World) 

Visit my.americanheart.org/membership 

Subscribe † 

editOR-in-chief 

Alan Daugherty, PhD, DSc, FAHA 

Call: 1-800-638-3030 (United States) 

+44 (0) 20 7981 0525 (Europe) 

+1-301-223-2300 (Rest of World) 

Visit http://lww.com/atvb 

* Premium Professional Plus Members receive full access to all 11 AHA journals online and for their iPad as a benefit of membership. Premium Professional, Early Career, and Student/Trainee Members have 

limited access to journals and features as indicated by their selected level. Full-access options are available for each level of membership when you join. To have access to the iPad edition, Members with 

online journal benefits must indicate ATVB as one of their online selections. 

† Non-member individual and resident subscriptions are ordered via LWW. Institutional print subscriptions are ordered via LWW, and institutional online access is available via Ovid. Visit www.ovid.com or 

contact your Ovid Sales Representative directly. 

Apple and iPad are trademarks of Apple Inc., registered in the U. S. and other countries. App Store is a service mark of Apple Inc.

A 

Aalkjær, C. ............................................ 8 

Abbate, R. ..................................... 70, 95 

Abdalla, D.S.P. ................................. 123 

Abdelhalim, M.A.K. .................. 104, 120 

Abdeli, L. ............................................. 11 

Abdelkadhem, H. ............................... 65 

Abdollahi, M. ........................... 45, 49, 50 

Abdul, Rahman, T.H. ............. 58, 66, 72 

Abdulhannan, P. ................................ 94 

Abedpour, Dehkordi, A. ..................... 70 

Abello, F. ..................................... 81, 120 

Abifadel, M. ................................... 26, 50 

Abot, A. .......................................... 29, 37 

Abreu, A. ..................................... 53, 116 

Abreu, T.Q. ............................... 126, 127 

Abt, M. ................................................. 77 

Abu, Sheikha, G. .............................. 123 

Achenbach, K. .................................. 106 

Achenbach, S. .................................... 68 

Acin, F. .................................... 65, 68, 94 

Acín, García, F. ................................ 100 

Ackermans, M. ................................... 36 

Acosta, E. ............................................ 38 

Acuña-Alonzo, V. ............................... 99 

Adachi, H. ........................... 35, 109, 121 

Adamkova, V. ..................................... 99 

Adamova, I. ......................................... 86 

Adamski, J. ................................. 75, 110 

Adekunle, A.S. .................................. 120 

Adelusi, T. ......................................... 120 

Adlanmerini, M. .................................. 37 

Adorne, M.D. .................................... 123 

Adorni, M.P. ........................................ 71 

Adrio, Nazar, B. .......................... 88, 125 

Adzhiev, R. ......................................... 86 

Aerts, H. .............................................. 55 

Afanasieva, O. .............................. 86, 87 

Afonso, M. ........................................... 30 

Afonso, P. ........................................... 83 

Agakov, F. ........................................... 36 

Aggeli, C. ............................................. 38 

129 

Agianniotis, A. .................................... 60 

Agouridis, A.D. ................................... 76 

Agrawal, D.K. .......................... 43, 51, 60 

Agrogiannis, G. ................................ 119 

Aguesse, A. ...................................... 122 

Aguirre, A.C. ....................................... 85 

Ahammer, H. .................................... 124 

Aherrahrou, Z. .................................... 68 

Ahimastos, A.A. ................................. 44 

Ahluwalia, A. ...................................... 65 

Ahmad, R.......................................... 120 

Ahn, J. ............................................... 111 

Ahn, T.H. ............................... 89, 95, 102 

Ahnmark, A. ....................................... 35 

Ahotupa, M. ........................................ 69 

Ahuad, L. .................................... 96, 102 

Äijänen, T. .......................................... 70 

Aittokallio, T. ....................................... 22 

Aitullina, A. ....................................... 113 

Aizpuru, N. .......................................... 80 

Akao, H. .............................................. 45 

Akbar, N. ............................................. 64 

Akbar, S. ........................................... 106 

Akhter, T. ............................................ 93 

Akimoto, K. ......................................... 58 

Akulich, N.V. ....................................... 77 

Aladinsky, V. ...................................... 70 

Alamanos, Y. .................................... 126 

Alavi, A. ............................................... 45 

Albayrak, G. ....................................... 60 

Alberici, L.C. ....................................... 90 

Albertini, J.-P. ..................................... 75 

Albizem, M.......................................... 44 

Aldulea, N. .................................. 92, 127 

Alekseeva, G.V. ................................. 99 

Alexandra, G. ..................................... 79 

Alexandre, F. ......................... 71, 78, 128 

Alexescu, T. ............................. 106, 107 

Alexescu, T.G. ................................. 104 

Alexopoulos, D................................. 114 

Alexopoulou, Z. ................................ 112 

Alfakry, H. ........................................... 61 

Alhiari, Y. .......................................... 123 

Ali, H. ................................................... 11

Al-Jenabi, A. ....................................... 65 

Alla, F. ................................................. 32 

Allaert, F. ........................................... 121 

Allemand, H. ....................................... 32 

Allemandou, D. ................................... 77 

Almalki, A. ......................................... 114 

Almoudi, M. ......................................... 98 

Alonso, J. .................................... 57, 121 

Alonso, L. ............................................ 80 

Alqirim, R. ......................................... 123 

Al-Qirim, T. ........................................ 123 

Alsac, J.-M. ......................................... 38 

AlSulaiti, M. ....................................... 114 

Altay, S. ............................................... 94 

Altendorf, R. ........................................ 68 

Al-Thani, H. ....................... 110, 114, 115 

Altwegg, L.A. ...................................... 47 

Alvarez, E. ........................................... 57 

Alvarez, I. ............................................ 38 

Alvarez-León, E.................................. 99 

Alves, A.C. .......................................... 81 

Alves, R. .............................................. 90 

Alves, T. .............................................. 53 

Amadio, P. .......................................... 34 

Amar, M. .............................................. 22 

Amaral, J.B. ........................................ 85 

Amarenco, P. .......................... 34, 56, 57 

Amati, G. ............................................. 99 

Ametamey, S.M.................................. 98 

Amigó, N. ............................................ 36 

Aminpour, S. ....................................... 39 

Ammori, B.J. ............................... 72, 125 

Amouyel, P. ........................................ 54 

Amstutz, C. ......................................... 17 

Anagnostopoulos, A. ......................... 82 

Anagnostopoulou, K. ......................... 84 

Anastassopoulou, J. .................. 97, 104 

Andersen, L.B. .................................. 116 

Andersen, M.R. .................................... 8 

Anderson, L. ....................................... 56 

Anderson, Vasquez, H.E. 117, 119, 127 

Andia, M.E. ......................................... 58 

André, P. ............................................. 66 

Andréasson, A.-C. ............................. 35 

Andres-Lacueva, C. ........................... 33 

130 

Andrienko, A. ................................... 107 

Angelico, F. ........................................ 84 

Angelin, B. ............................... 39, 76, 83 

Anghel, M. .......................................... 91 

Ankri, A. ............................................ 113 

Annema, W. ................................. 49, 72 

Anniballi, G. ........................................ 43 

Annuzzi, G. ......................................... 43 

Antlanger, M. ...................................... 49 

Antonazzo, Panico, R. .................... 107 

Antoniades, C. ................................. 112 

Antoniadis, A.P. ........................... 29, 55 

Antonopoulos, A.S. ......................... 112 

Antunes, R.......................................... 11 

Aoua, H. ...................................... 79, 119 

Aouani, E. .......................... 103, 120, 121 

Aouichat, Bouguerra, S. ................... 74 

Aoyama, N.................................. 56, 118 

Apor, A. ............................................. 127 

Appenzeller, B. ................................ 106 

Arai, T. ................................................ 62 

Araujo, Castillo, D.C........................ 127 

Araujo, D.B. .................................. 76, 96 

Araújo, H.A. ........................................ 62 

Arbit, E. ............................................. 108 

Arca, M. ............................. 10, 15, 31, 84 

Arca, Marcello ...................................... 6 

Arciello, M. .......................................... 16 

Arefieva, T. ......................................... 47 

Arens, R. ....................................... 41, 47 

Arfian, N. ............................................. 11 

Arı, N. ................................................ 121 

Arizón, Muñoz, J.M. ........................ 117 

Arnaboldi, L. ................................. 33, 62 

Arnal, J.-F. ............................... 29, 37, 49 

Arnal, M. ............................................. 74 

Arnaud, C. .................................. 64, 122 

Arnesen, H. ................................ 55, 116 

Aronov, D.M. .................................... 108 

Arós, F. ............................................... 35 

Arregui, M. .......................................... 32 

Artemeva, N. ...................................... 87 

Arteta, D. ............................................ 80 

Arun, M. .............................................. 60 

Arun, M.Z. ........................................... 59

Asciutto, G. ......................................... 75 

Asehnoune, K. .................................... 76 

Ashikhmin, Y....................................... 39 

Askevold, E.T. .................................. 113 

Astola, N. ............................................. 63 

Asztalos, B. ......................................... 22 

Attia, N. ..79, 85, 103, 104, 119, 120, 121, 

126 

Aubert, J.-F. ........................................ 17 

Auclair, M. ................................... 83, 100 

Audigier, Y. ......................................... 59 

Auerbach, B. ....................................... 22 

Aujard, F. ............................................. 64 

Aukrust, P. ...................... 65, 80, 86, 113 

Aulie, M. ............................................ 116 

Auriac, A. ............................................. 52 

Averna, M. ............................... 23, 51, 86 

Averna, M.R. ....................................... 81 

Averna, Maurizio ................................ 16 

Avgeri, S. ............................................. 95 

Ayabe, M. ............................................ 54 

Ayari, H........................................ 63, 101 

Aydinalp, A. ....................................... 109 

Aydınalp, A. ................................ 89, 107 

Aytekin, S. ......................................... 126 

Aytekin, V. ......................................... 126 

Ayyobi, A. ............................................ 40 

Azahri, N.S. ................................... 37, 38 

B 

Babjakova, E. ..................................... 99 

Bacerra, D. ........................................ 103 

Bach, K. ............................................... 95 

Bäck, M. ................................ 64, 66, 122 

Bäcklund, A......................................... 63 

Backteman, K. .............................. 66, 67 

Badimon, L. ........................................... 6 

Bae, J. ........................................... 38, 59 

Bae, J.U. ............................................. 59 

Bae, K.R. ........................................... 112 

Baek, J.-M. ........................................ 119 

Baer, D. ............................................. 123 

Baertschi, A.J. .................................... 59 

Baerwald, C. ..................................... 107 

131 

Baetta, R. ............................................ 94 

Bagdonaite, L. .................................... 79 

Bagheri, B. .......................................... 66 

Bähr, M. ............................................ 120 

Bahs, G. ............................................ 103 

Bajraktari, G. ................................ 98, 99 

Bakker, S.J.L. ..................................... 49 

Bakker-Arkema, R. ............................ 22 

Bal, U.A. ...................................... 89, 107 

Balachonova, N. ................................ 88 

Balakhonova, T. ................................. 91 

Baldi, S. ........................................ 20, 35 

Baleanu-Curaj, A. .............................. 45 

Balkau, B. ......................................... 120 

Balla, G. .............................................. 29 

Balla, J. ............................................... 29 

Ballantyne, C.M. ............................ 9, 44 

Ballantyne, Christie ............................. 9 

Balsano, C. ......................................... 16 

Ban, N. ......................... 31, 109, 111, 123 

Banach, M. ...................... 45, 49, 50, 102 

Bandemer, J. ...................................... 70 

Bantubungi, K. ................................... 28 

Bantubungi-Blum, K. ....................... 105 

Banu, I............................................... 105 

Banzetti, G.......................................... 86 

Baptista, J. .......................................... 91 

Baragetti, A. .......................... 67, 68, 112 

Baragetti, I. ....................................... 112 

Baratta, F. ........................................... 84 

Barbieri, S.S. ...................................... 34 

Barbieri, V. .......................................... 96 

Barbosa, D.S. ................................... 109 

Barbosa, S.A. ..................................... 43 

Barbosa, S.P. ..................................... 85 

Barešić, M. ......................................... 82 

Bargalló, N.......................................... 26 

Barghan, H. ...................................... 107 

Barlera, S.......................................... 100 

Barlow, C.K. ....................................... 30 

Baroni, M. ......................................... 110 

Barrett, P.H.R. ........................... 22, 103 

Barrett-Connor, E. ............................... 7 

Barrios, E. ......................................... 101 

Barrot, S. .................................... 63, 101

Barter, P. ......................................... 4, 13 

Barter, P.J. .......................................... 27 

Barth, J.H. ......................................... 124 

Bartrés-Faz, D. ................................... 26 

Basha, N. ............................................ 72 

Baskar, K. ........................................... 60 

Basslé, E. .......................................... 104 

Bast, A. ................................................ 74 

Basta, G. ............................................. 59 

Batin, P.D. ......................................... 124 

Baud, S................................................ 61 

Baudet, M. ......................................... 117 

Baum, C. ....................................... 44, 87 

Baumgartner, S. ................................. 74 

Bays, H. ............................................... 44 

Bays, H.E. ........................................... 86 

Beck, K. ............................................... 98 

Beck-Nielsen, H. ................................ 50 

Becquer, M.A. ..................................... 38 

Bedford, D. .................................... 31, 76 

Bednarek, M. ...................................... 73 

Bedros, R.J. ...................................... 102 

Beghin, L. .............................................. 7 

Bégu-Le, Corroller, A....................... 101 

Behrendt, M. ....................................... 10 

Behrensen, M. .................................... 68 

Bekers, O. ........................................... 74 

Bekir, A. ......................................... 31, 76 

Belch, J.J.F. ........................................ 64 

Beleslin, B. .......................................... 98 

Belgacem, O. ...................................... 76 

Belhabib, M. .................................. 31, 76 

Béliard, S. ........................................... 81 

Bellibas, S.E. ...................................... 73 

Belloc, I................................................ 28 

Belomestnov, P. ................................. 87 

Bełtowski, J. ........................................ 41 

Ben, Abdelaziz, A. ............... 83, 92, 104 

Ben, Belkacem, K. ........................... 105 

Ben, Hamda, K. .................... 76, 85, 126 

Ben, Hassine, F................................ 103 

Ben, Khalfallah, A. ..................... 79, 119 

Ben, Rejeb, N. ...................... 83, 92, 104 

Benaiges, D. ............................. 109, 110 

Benazzoug, Y. .................................. 119 

132 

Bencová, S. ........................................ 94 

Bender, E.A. ..................................... 123 

Benetos, G. ........................................ 38 

Benghozi, R. ....................................... 77 

Bengrid, T. .......................................... 97 

Benlian, P. .......................................... 80 

Benn, M. .............................. 7, 32, 40, 54 

Bennia, S. ........................................... 60 

Bensadoun, A. ................................... 10 

Beraia, E. ............................................ 56 

Beraia, M. ........................................... 56 

Berbée, J. ........................................... 65 

Berbée, J.F.P. .................................... 68 

Berdeaux, O. .................................... 122 

Berendschot, T.T.J.M. .................... 118 

Berenjy, S. ........................................ 104 

Berenson, G.S. .............................. 7, 32 

Berezin, A.E. ...................................... 56 

Berge, E. ............................................. 52 

Berge, K.E. ......................................... 50 

Berge, R.K. ......................................... 86 

Berger, J.M. .......................................... 6 

Bergström, G. ..................................... 53 

Berguete, S. ....................................... 79 

Berliner, S. ........................................ 105 

Bermudez, G. ..................................... 40 

Bernardi, F.......................................... 60 

Bernaschi, M. ..................................... 99 

Bernini, F. ........................................... 71 

Bernini, S.K. ..................................... 127 

Berrougui, H. ...................................... 42 

Berthet, B.......................................... 101 

Berti, S. .................................. 61, 93, 108 

Bertolami, A. ................................. 76, 96 

Bertolami, M.C. ............................ 76, 96 

Bertolotto, M. ...................................... 47 

Bertoncelli, A. ..................................... 64 

Bertoni, S. ........................................... 68 

Bertsch, T. ......................... 116, 127, 128 

Berzina, M. ....................................... 107 

Besseling, J. ................................. 26, 51 

Betriu, À. ............................................. 54 

Bevilacqua, S. .................................... 93 

Beygui, F. ............................................. 8 

Beylot, M. ............................................ 74

Bhandari, U. ...................................... 109 

Bianchi, G. .......................................... 93 

Bianchini, F.J. ..................................... 93 

Bianco, H.T. ................................ 85, 101 

Bieghs, V. ................................ 16, 22, 71 

Bielolus, -, Wilk, A. ........................... 116 

Bilcikova, E. ........................................ 87 

Billon, C. .............................................. 69 

Billon-Gales, A. .................................. 29 

Billotte, S. ............................................ 87 

Binder, C. ............................................ 21 

Binder, C.J. ......................................... 41 

Binder, Christoph ............................... 21 

Bisoendial, R.J. .................................. 27 

Bispo, D.L. .................................... 71, 72 

Bisserier, M. ........................................ 37 

Bisson, M. ........................................... 99 

Bitsis, T................................................ 82 

Bittar, R. .................... 30, 70, 75, 79, 103 

Bittar, R.K. ........................................... 82 

Björkbacka, H. .................................... 18 

Bjørndal, B. ......................................... 86 

Blaak, E. .............................................. 36 

Blache, D. ........................................... 27 

Blaha, M. ..................................... 81, 112 

Blaha, V. .............................. 81, 110, 112 

Blaise, S. ....................................... 52, 61 

Blanco, G. ........................................... 58 

Blanco-Colio, L.M. ............................. 41 

Blanco-Vaca, F. ............................ 10, 33 

Blankenberg, S. ............................ 8, 117 

Blé-Castillo, J.L. ................................. 90 

Bleda, Moreno, S. ............................ 100 

Bleda, S. .................................. 65, 68, 94 

Blirando, K. ......................................... 60 

Bloedon, L.T. ...................................... 81 

Blom, D.......................................... 23, 44 

Blom, D.J. ........................................... 81 

Blomberg, B.A. ................................... 45 

Bobcikova, P..................................... 112 

Bobescu, E. ................................ 92, 127 

Bobik, A. .............................................. 18 

Bobryshev, Y.V. ................... 70, 71, 100 

Boby, C................................................ 43 

Boccara, F............................. 52, 83, 100 

133 

Bochaton-Piallat, M.-L. ............... 59, 60 

Bochem, A. ......................................... 42 

Boddi, M. ...................................... 70, 95 

Boehm, B.O. ....................................... 77 

Boeing, H. ........................................... 32 

Bogachev, O. ..................................... 30 

Böhm, B.O. ....................................... 101 

Boileau, C. .................................... 26, 50 

Bolbos, R. ........................................... 64 

Boldrini, B. .......................................... 20 

Bombo, R............................................ 30 

Bonacina, F. ................................. 33, 34 

Bond, M. ............................................. 59 

Bondarenko, S.A. .............................. 67 

Bonde, Y. ............................................ 83 

Bongard, V. ........................... 77, 85, 105 

Boni, F. ................................................ 97 

Bonnefont, Rousselot, D. ........... 75, 79 

Bonnefont-Rousselot, D.30, 50, 70, 103 

Bonnet, F. ........................................... 35 

Bonnet, J. ........................................... 84 

Bonnet, Jacques ................................ 25 

Bono, J.O.................................... 96, 102 

Boren, J. ............................................. 16 

Borén, J. ............................................. 53 

Boren, Jan .......................................... 28 

Borodachev, E.N. .............................. 70 

Borràs, M. ........................................... 54 

Borucka, J. ......................................... 62 

Boshtam, M. ....................................... 70 

Bosi, E. .............................................. 121 

Bosisio, R. .......................................... 96 

Bot, I. ................................................... 41 

Botnar, R. ........................................... 98 

Botnar, R.M. ....................................... 58 

Bottazzi, B. ......................................... 34 

Bøttcher, M. ........................................ 95 

Botto, N. ............................................ 108 

Bouacida, L. ............................... 92, 104 

Bouchaert, E. ..................................... 28 

Bouchard, P. ...................................... 64 

Bouchareychas, L. ............................ 67 

Boudys, L............................................ 81 

Boue, S. ............................................ 117 

Boughzala, E. ..................................... 83

Bouillet, B. ........................................... 27 

Bouloumié, A. ..................................... 49 

Boumaiza, I. .......................... 83, 92, 104 

Bourbon, M. ........................................ 81 

Bourghardt-Fagman, J. ..................... 69 

Bouslama, A. ........................ 83, 92, 104 

Boussel, L. .......................................... 46 

Boussetta, T. ...................................... 65 

Bouzourene, K. .................................. 17 

Boytsov, S. .......................................... 91 

Bozon, D. ............................................ 82 

Bozzetto, L. ......................................... 43 

Braamskamp, M. ................................ 81 

Bracho, M. ........................................... 40 

Brady, A.J. .......................................... 17 

Brady, Adrian JB ................................ 17 

Brady, I. ............................................... 36 

Brandão, S.A. ................................... 101 

Brattelid, T........................................... 86 

Braunersreuther, V. ........................... 48 

Breuer, O. ........................................... 83 

Briand, O. ............................................ 74 

Brianezi, L. ........................................ 115 

Bricca, G. .............................. 60, 63, 101 

Bridges, I. ............................................ 77 

Brindisi, M.-C. ................................... 104 

Brinton, E.A......................................... 33 

Brites, F. ............................................ 108 

Brito, Filho, S.B.D. ................... 126, 127 

Brito, V. .......................................... 38, 68 

Brockmann, E.-C................................ 72 

Broisat, A. ........................................... 99 

Brokopp, C. ......................................... 47 

Brøndum-Jacobsen, P. ............... 40, 54 

Broniec, A. .......................................... 57 

Brouri, M. ........................... 104, 105, 115 

Brouwers, M. ...................................... 50 

Broyer, M. ........................................... 74 

Brucker, E. .......................................... 79 

Bruckert, E. .....3, 15, 30, 50, 70, 81, 103, 

121, 123 

Bruckert, Eric ...................................... 20 

Brudi, P.......................................... 85, 86 

Brufau, G. ............................................ 30 

Brun, C. ............................................... 59 

134 

Brunet, A. ............................................ 87 

Brunner, S. ......................................... 87 

Brusberg, M. ....................................... 35 

Bruyndonckx, L. ............................... 104 

Bublikov, D. ...................................... 107 

Bubnova, M.G. ................................. 108 

Budkhashvili, M. ................................ 78 

Buerke, M. .......................................... 64 

Buijsse, B............................................ 32 

Bulas, J. .............................................. 79 

Bulatova, E.R. .................................... 78 

Bulgarelli, A. ....................................... 68 

Burcelin, R. ................................... 49, 75 

Burnett, J.R. ....................................... 82 

Burns, T.L. ............................................ 7 

Burokienė, N. ................................... 118 

Bursill, C. ............................................ 42 

Buscato, M. ........................................ 37 

Busch, M. ............................................ 47 

Busnelli, M. .... 33, 35, 58, 62, 63, 86, 126 

Butoi, E. .............................................. 41 

Byrkjeland, R. ................................... 116 

C 

Cabeza, Letrán, L. ..................... 92, 109 

Cabeza-Letran, M.L. ....................... 121 

Cabou, C. ........................................... 75 

Cabré, A. ............................................ 36 

Cagliero, P.................................. 81, 120 

Cain, V.A. ........................................... 44 

Cakmak, H.A. ............................... 59, 94 

Cakmak, S. ......................................... 46 

Cal, R. ................................................... 6 

Calabresi, L. ................................. 58, 73 

Calanca, I.V. ....................................... 78 

Calandra, S. ....................................... 26 

Calandra, Sebastiano ......................... 5 

Caligiuri, G.................................... 21, 38 

Calin, M. .............................................. 41 

Calzada, C.......................................... 34 

Camaré, C. ......................................... 38 

Cambien, F. ............................. 8, 15, 117 

Çamkıran, V. ...................................... 89 

Camont, L. ............................. 42, 72, 108

Camponova, P. .................................. 42 

Can, G. ................................................ 94 

Canaple, L. ......................................... 69 

Canário-Almeida, F. ........................... 92 

Canet-Soulas, E. ................................ 64 

Canizales-Quinteros, S. .................... 99 

Canonne-Hergaux, F. ........................ 52 

Cantero, X. .......................................... 80 

Cantor, H. ............................................ 38 

Cao, A.................................................. 18 

Cao, G. .................................................. 6 

Capeau, J. ................................. 100, 102 

Capel, E. ........................................... 100 

Cappelli, S. ......................................... 61 

Caraballo, R. ....................................... 10 

Carillon, J. ......................................... 118 

Cariou, B. .......................... 6, 44, 76, 102 

Carlsson, M......................................... 53 

Carlzon, D. ............................................ 7 

Caro, N. ..................................... 109, 121 

Caron-Debarle, M. ..................... 83, 100 

Caron-Houde, S. .............................. 105 

Carreau, V. ................................... 50, 81 

Carrera, M.J. ..................................... 110 

Carretta, R. ......................................... 35 

Carrié, A. ................... 50, 79, 81, 82, 113 

Carrilho, A. ........................................ 109 

Cartland, S. ......................................... 11 

Cartland, S.P. ..................................... 42 

Cartocci, G. ......................................... 97 

Carvalho, L.S. ..................................... 71 

Casagrande, M.L. ............................ 115 

Casasnovas, J.A. ............................... 84 

Casella-Filho, A. ......................... 72, 115 

Caslake, M. ................................... 31, 76 

Casola, C. ......................................... 100 

Caspar, Bauguil, S. .......................... 117 

Casquero, Dominguez, S. .......... 97, 98 

Cassol, A. ............................................ 78 

Cassorla, G. ........................................ 65 

Castagné, R. ......................................... 8 

Castaing-Berthou, A. ......................... 52 

Castellano, J. ........................................ 6 

Castell-Rodríguez, A.E. .................... 90 

Castelnuovo, S. .................................. 96 

135 

Castiñeiras-Landeira, M.I. ................ 57 

Catakoglu, A.B. ................................ 126 

Catalan, M. ....................................... 126 

Catalano, C. ....................................... 97 

Catalano, G. ....................................... 63 

Cataneo, L. ......................................... 40 

Catapano, A. ...................................... 85 

Catapano, A.L.2, 3, 4, 13, 33, 34, 37, 52, 

62, 67, 68, 94, 112 

Catapano, Alberico L. ........ 2, 3, 4, 5, 13 

Catharino, R.R. .................................. 90 

Caulfield, M.J. .................................. 124 

Caussy, C. .......................................... 31 

Cavalcante, M.F. ............................. 123 

Cavarape, A. .................................... 115 

Cecchettini, A. .................................... 62 

Cefalù, A.B. ........................................ 51 

Celebi, H. .......................................... 126 

Cerda, A. ............................................ 85 

Cerillo, A. ............................................ 61 

Cerutti, C. ................................... 63, 101 

Cesana, F. ........................................ 110 

Ceska, R. ............................................ 99 

Cha, J.-J. ............................................ 70 

Cha, K.S. .......................................... 111 

Chaaba, R. .......................... 85, 101, 126 

Chaabane, C. ..................................... 59 

Chacin, L. ........................................... 40 

Chagas, A.C.P. ................................ 115 

Chahed, H. ................................... 31, 76 

Chahine, M.N. .................................... 60 

Chai, F. ............................................. 116 

Chaichana, T. ..................................... 60 

Chaignot, C. ....................................... 32 

Chakraborty, M. ................................... 6 

Challa, A. .................................... 88, 104 

Chalmers, N. ...................................... 18 

Chan, C. ...................................... 91, 114 

Chan, D.C. .................................. 22, 103 

Chan, T. .............................................. 46 

Chandrakala, A.N. ............................. 65 

Chang, C.-J. ....................................... 91 

Chang, S.-F. ....................................... 69 

Chang, S.G. ..................................... 112 

Chang, Y.-C. ...................................... 71

Changarotti, J. .................................. 119 

Channon, K.M. ................................. 112 

Chantepie, S. ...................... 72, 103, 108 

Chantzichristos, V. ............................. 57 

Chao, T.-H. ......................................... 29 

Chapman, J.M. ................................. 108 

Chapman, M John ......................... 2, 25 

Chapman, M.J. ...... 2, 13, 22, 42, 72, 90, 

103, 121 

Chapouly, C. ....................................... 28 

Charles, A.-L............................... 34, 113 

Charlton-Menys, V. .................... 72, 125 

Charnaux, N. ...................................... 57 

Charniot, J.-C. .............................. 75, 79 

Charniot, J.-P. .................................... 75 

Charradi, K. ......... 79, 103, 119, 120, 121 

Charriere, S. ....................................... 82 

Charrière, S. ........................... 31, 74, 82 

Chatelais, M. ....................................... 51 

Chaturvedi, N. .................. 49, 78, 89, 95 

Chatzizisis, Y. ....................................... 5 

Chaudhari, H.S. ................................ 109 

Chaudhari, S.M. ................................. 47 

Chauveau, F. ...................................... 64 

Chavan, S. .......................................... 72 

Chebli, S. ........................................... 112 

Chelombitko, M. ................................. 66 

Chelombitko, M.A. ............................. 67 

Chen, C.-C. ......................................... 46 

Chen, H. .............................................. 52 

Chen, I.-C. ........................................... 29 

Chen, J.-H. .................................. 29, 113 

Chen, J.-Y. ................................ 103, 114 

Chen, P. .............................................. 65 

Chen, S. .............................................. 56 

Chen, Y. ................................ 29, 40, 123 

Chen, Y.-R. ....................................... 100 

Cheng, Y.-J. ...................................... 125 

Cherfils, C. .................................... 70, 75 

Chernova, E. ....................................... 72 

Chernushevich, O.I. ........................... 79 

Chernyavskiy, A. ........................ 91, 127 

Cheta, I. ............................................. 107 

Chi, Y. .................................................. 33 

Chia, Y.C. .................................. 111, 112 

136 

Chiang, A. ........................................... 71 

Chiappetta, C. .............................. 28, 67 

Chiappino, D. ..................................... 61 

Chiara, M. ..................................... 62, 63 

Chicheva-Ivanova, M.M. ................. 100 

Chien, M. ............................................ 18 

Chien, Y.-S. ........................................ 71 

Chiesa, G....... 33, 35, 58, 62, 63, 86, 126 

Chiharu, N. ......................................... 56 

Chiheb, S. ......................................... 105 

Chillarón, J.J. ........................... 109, 110 

Chin-Dusting, J. ................................. 27 

Chinetti-Gbaguidi, G. ........................ 67 

Ching, S. ........................................... 112 

Ching, S.M........................................ 111 

Chiosso, R. ................................. 96, 102 

Chiou, H.-Y. ...................................... 100 

Chlopicki, S. ............................... 89, 121 

Chłopicki, S. ............................... 57, 106 

Chmielewska, M. ............................... 38 

Chmilewsky, F. .................................. 57 

Cho, K.-H. ............................ 73, 117, 119 

Cho, M.-C. .................................. 32, 103 

Cho, T.-H. ........................................... 46 

Choi, B. ............................................... 36 

Choi, C. ............................................... 36 

Choi, C.U. ........................ 36, 53, 63, 122 

Choi, D.-J...................................... 32, 43 

Choi, E.K. ........................................... 66 

Choi, E.-Y. .................................... 70, 76 

Choi, I.S. ............................................. 95 

Choi, J.H. .......................................... 111 

Choi, J.Y. .......................................... 112 

Choi, S.H. ........................................... 49 

Choi, Y.H. ................................... 98, 112 

Choquet, P. ...................................... 113 

Choqueux, C. ..................................... 62 

Chou, C.-H. .............................. 103, 114 

Choudhury, R.P. .............................. 112 

Christensen, G. ................................ 113 

Christoffersen, B.Ø. .......................... 95 

Chroni, A. ............................................ 71 

Chu, P.-H. ..................................... 29, 91 

Chugunova, Y. ................................. 118 

Chukkapalli, S. ................................... 63

Chumakova, G. 100, 102, 103, 118, 125 

Chung, H. ............................................ 76 

Chung, I.-M. ........................................ 43 

Chung, W.J. ...................................... 102 

Chung, W.-Y. ...................................... 78 

Cicek, M. ........................................... 109 

Cicha, I. ............................................... 68 

Cifkova, R. .................................... 40, 96 

Cinquanta, P. ...................................... 58 

Ciociola, E. .......................................... 31 

Cioni, G. ........................................ 70, 95 

Cipollone, F......................................... 90 

Cipriano, P. ......................................... 43 

Cirovic, S. .......................................... 119 

Citti, L. ................................................. 62 

Civeira, F. ............................................ 84 

Clara, F................................................ 58 

Claude, S. ........................................... 43 

Clavey, V. ............................................ 74 

Clement, K. ................................... 30, 70 

Clement, M. ........................................ 38 

Clément, N. ......................................... 60 

Clerico, A. ......................................... 108 

Cochran, B.J. ...................................... 27 

Cocozza, S. ........................................ 43 

Coelho, O.R. ....................................... 78 

Coen, M. .............................................. 60 

Cofán, M. ............................................. 84 

Cohen, A. ...................................... 52, 83 

Cohen, M. ......................................... 105 

Cohen, R. .......................................... 116 

Cokkinos, D.V. .................................... 84 

Coletta, P. ........................................... 31 

Colhoun, H. ......................................... 36 

Colin, S. ............................................... 74 

Collet, X. .............................................. 75 

Collet, Xavier ...................................... 27 

Colletes, J.H.G. .................................. 83 

Colom, A. ............................................ 75 

Colombo, C. ...................................... 110 

Combescure, C. ................................. 47 

Comte, B. .......................................... 122 

Condorelli, G....................................... 37 

Çoner, A. ..................................... 89, 107 

Conraads, V. ..................................... 104 

137 

Conradie, K.R. ................................... 85 

Conte, F. ............................................. 43 

Conti, B. .............................................. 16 

Contini, A. ......................................... 127 

Contreras-Duarte, S. ......................... 34 

Cooney, J. .................................... 31, 76 

Cooper, S. .......................................... 56 

Copin, C. ............................................. 67 

Copponi, G. ................................ 40, 107 

Corbier, C. ........................................ 106 

Corral, P. ............................................ 58 

Corrales, D. ................................ 92, 121 

Correa, M............................................ 60 

Correig, X. .......................................... 36 

Corsini, A. ................ 37, 62, 94, 125, 127 

Corti, R. ............................................... 47 

Corvera-Tindel, T. ........................... 111 

Cosentino, N. ............................. 40, 107 

Coskun, A.U. ................................ 29, 55 

Cosson, C. .......................................... 75 

Cosson, E. ................................ 105, 110 

Costa, L. ............................................. 52 

Costa, S. ............................................. 71 

Costabile, G. ...................................... 43 

Costagliola, D. ............................. 52, 83 

Costaz, C. ........................................... 74 

Costet, P. ........................... 6, 37, 76, 102 

Cotoi, O. .............................................. 18 

Cottin, Y. ....................................... 53, 58 

Couraud, P.O. .................................... 34 

Courtier, A. ......................................... 47 

Coutureau, T. ................................... 121 

Couvert, P. .............................. 70, 79, 82 

Covaciu, A. ................................. 92, 127 

Covas, M.I. ......................................... 35 

Cozma, A. ......................................... 104 

Crea, F. .................................... 5, 40, 107 

Crisci, I. ............................................... 51 

Cristol, J.-P. ...................................... 118 

Crociati, L. ........................................ 100 

Croft, K. ............................................. 119 

Cruz, Ferreira, R. ............................... 53 

Cuchel, M. ...................................... 3, 81 

Cudejko, C.......................................... 28 

Cuesta, Torres, L.F. .......................... 27

Cuniberti, L. ........................................ 82 

Cutrin, J.C. ........................................ 119 

Cutuli, L. ........................................ 33, 34 

Czarnecka, D. ................................... 127 

Czyzynska, I. .............................. 89, 121 

D 

Da, Porto, A. ..................................... 115 

Dadamyants, N. ................................. 96 

Dadamyants, N.G. ............................. 88 

D'Agostino, M.N. ................................ 51 

Dahlbom, I. ......................................... 18 

Dalamaga, M. ..................................... 93 

Dalla-Riva, J. ...................................... 73 

Dallegri, F. ........................................... 47 

Dallinga-Thie, G. .......................... 10, 36 

Dallinga-Thie, G.M. ...................... 51, 55 

Dallinga-Thie, Geesje ........................ 22 

Dallongeville, J. ................................ 123 

Damaskos, D. ..................................... 84 

Damelou, A. ...................................... 114 

Damonte, E. ........................................ 77 

Dang, B.Q. .................................... 34, 56 

D'Angelo, A. ........................................ 51 

Daniels, S.R. ......................................... 7 

Daniil, G. ............................................. 71 

Dart, A.M. ............................................ 27 

Das, S. ................................................. 75 

Dashkova, A. .................................... 100 

Daugareil, C. ..................................... 117 

Davey-Smith, G. ................................... 7 

Davids, J. ............................................ 52 

Davidson, W.S. .................................. 72 

Davies, A.H. ........................................ 63 

Davlouros, P. .................................... 114 

Day, W.W. ......................................... 101 

D'Cruz, D. ............................................ 98 

De, Blasis, G. ...................................... 90 

de, Boer, J.F. ................................ 49, 72 

de, Bruin, R.G. ...................................... 8 

De, Castro-Orós, I. ............................. 84 

De, Caterina, A.R. ............................ 108 

de, Craen, A.J.M. ............................... 88 

de, Faire, U. ...................................... 124 

138 

de, Faria, E.C. ................. 71, 78, 83, 128 

De, Gendt, K. ..................................... 69 

De, Haro, J. ............................. 65, 68, 94 

de, Haro, Miralles, J. ....................... 100 

De, Henauw, S..................................... 7 

de, Jager, S.C.A. ......................... 41, 61 

de, Jong, R.C.M........................... 18, 47 

de, Leite, Jr, A.C. ............................. 115 

de, Leon, H. ...................................... 117 

De, Lonlay, P. .................................... 80 

De, Nardis, V. ..................................... 90 

de, Oliveira, Izar, M.C. ...................... 85 

De, Oliveira, S. ................................... 95 

De, Paoli, F. ....................................... 67 

De, Pellegrin, A. ................................. 86 

De, Smet, E. ....................................... 30 

de, Smet, E.D. ................................... 22 

De, Vos, W. ........................................ 36 

De, Vries, M.R. ................. 18, 41, 47, 61 

de, Winther, M. .................................. 67 

De, Winther, M. .................................. 18 

Deanfield, J.E. ................................... 13 

Debelle, L. .......................................... 61 

Deblache, T. ....................................... 75 

deBlois, D. .......................................... 68 

Deckert, V. .......................................... 76 

deFaire, U. .......................................... 36 

Defesche, J. ....................................... 51 

Defesche, J.C. ............................. 26, 51 

Dejouvencel, T. .................................. 48 

Del, Ben, M. ....................................... 84 

Del, Castillo, D. .................................. 74 

Del, Porto, F. ........................... 28, 62, 67 

Del, Turco, S. ..................................... 59 

Del, Valle, R. .............................. 96, 102 

Delatour, V. ........................................ 79 

Delay, M. ............................................ 74 

Delbosc, S. ............ 34, 38, 48, 57, 64, 73 

Delcore, M.G. ..................................... 43 

Delgado, L. ......................................... 38 

Della, Corte, G. .................................. 43 

della, Latta, D. .................................... 61 

Della, Pepa, G. .................................. 43 

Della, Rocca, C. ........................... 28, 67 

Dellepiane, A. ................................... 108

Dellera, F. ......................................... 126 

Dementjeva, N. ........................ 107, 110 

Demougeot, C. ................................. 122 

den, Hartog, G. ................................... 74 

Dencker, M. ...................................... 116 

Deniset, J.F......................................... 60 

Denisova, D. ....................................... 79 

Dent, R. ............................................... 44 

Denyanets, S. ................................... 114 

D'Erasmo, L. ....................................... 84 

Derex, L. .............................................. 46 

Descamps, O. ............................. 85, 121 

Desgranges, C. .................................. 28 

Desideri, G. ......................................... 90 

Desilles, J.P. ....................................... 34 

Devillers, M. .................................. 26, 50 

Devlin, J.J. .......................................... 88 

Devold, H. ......................................... 122 

Dhaouadi, N. ....................................... 63 

Dhar, K. ............................................... 51 

Dhenain, M. ........................................ 64 

Di, Bartolo, B. ......................... 11, 37, 42 

Di, Bartolo, B.A. .................................. 38 

Di, Costanzo, A. ................................. 84 

Di, Filippo, M. .......................... 31, 74, 82 

di, Gioia, C. ................................... 28, 67 

di, Giuseppe, R. ................................. 32 

Di, Leo, E. ........................................... 51 

Di, Marino, L. ...................................... 43 

Di, Taranto, M.D. ................................ 51 

Diallo, D. ............................ 48, 56, 57, 73 

Diani, E. ............................................... 67 

Dias, N.V. ............................................ 75 

Diaz, O. ............................................... 66 

Diaz-Zagoya, J.C. .............................. 90 

Dibrov, E. ............................................ 60 

DiCioccio, T. ....................................... 87 

Diczfalusy, U. ...................................... 74 

Diederichsen, A.C.P. ......................... 45 

Dierke, J. ............................................. 32 

Dietel, B. .............................................. 68 

Di-Filippo, M. ...................................... 82 

Dijkstra, M. .......................................... 31 

Dikkers, A. ........................................... 49 

Dikur, O. .............................................. 39 

139 

Diniz, G.M. ........................................ 116 

Dionyssiou-Asteriou, A. .................... 93 

Djalalov, F. ......................................... 88 

Djekic, D. ............................................ 92 

Dlouha, D............................................ 99 

Dmitrieva, O. ...................................... 87 

Dobordzhginidze, L. .......................... 40 

Dobrcucki, L.W. ................................. 57 

Dobreanu, D. ...................................... 92 

Dobrucki, I.T. ...................................... 57 

Doddapattar, P................................. 124 

Doering, L.V. .................................... 111 

Doi, M. ................................................. 93 

Dolan, S. ........................................... 106 

Dollet, L. ............................................ 102 

Domagala, Z.A. ................................ 116 

Domei, T. ............................................ 29 

Domeij, H. ........................................... 63 

Domenig, C. ..................................... 114 

Domitrz, K. .......................................... 73 

Dong, J. .............................................. 73 

Dorea, E.L. ......................................... 85 

Dorighello, G.G. ............................... 101 

Doroszko, A. ..................................... 126 

Dörr, M. ............................................. 110 

dos, Santos, J.C. ......................... 71, 72 

Douek, P.-C. ....................................... 46 

Doulamis, I. ...................................... 119 

Dourado, P.M. .................................. 115 

Drahun, A. .................................. 89, 121 

Drake, I. .............................................. 17 

Drakopoulou, M. .......................... 38, 45 

Drandarov, K. ..................................... 98 

Drapkina, O.M. ................................... 88 

Drechsler, C. .................................... 101 

Drexel, H. .......................................... 102 

Driss, F. .............................................. 65 

Dritsa, V. ..................................... 97, 104 

Drogari, E. .......................................... 81 

Dronca, M. ........................................ 106 

Drosos, A.A. ............................. 106, 126 

Drożdż, K.M. ...................................... 38 

Du, Plessis, A.M. ............................... 81 

Duaip, G. ............................................ 82 

Duan, Z. ............................................ 124

Dubois, N. ......................................... 101 

Dubray, C. ......................................... 107 

Duca, L. ......................................... 52, 61 

Duchateau, G.S.M.J.E. ..................... 43 

Duchêne, E. ........................................ 81 

Ducimetiere, P. ................................... 54 

Dudek, K. .......................................... 114 

Dukat, A. ................................... 108, 115 

Dukát, A. ............................................. 79 

Dulak, M.G. ......................................... 60 

Dullaart, R. .......................................... 72 

Dullaart, R.P. ...................................... 72 

Dullaart, R.P.F. ................................... 49 

Dumitriu, I.E. ....................................... 11 

Dumont, S. .......................................... 82 

Dunér, P. ............................................. 18 

Dunn, L. ............................................... 42 

Duran, M.C. ...................................... 121 

Durán, M.C. ................................ 92, 109 

Durand, T. ......................................... 122 

Durante, C. ......................................... 31 

Durlach, V. .......................................... 61 

Durlach, Vincent ................................. 26 

Dutra-Rodrigues, M.S. ...................... 78 

Duvillard, L. ................................. 27, 104 

Dwyer, T. ......................................... 7, 32 

Dzięgiel, P. .......................................... 38 

Dzingalasevic, G. ............................... 94 

E 

Easton, R. ......................................... 123 

Eastwood, S. ...................................... 49 

Eatough, R. ................................. 72, 125 

Ebelt, H................................................ 64 

Ebina, Y. ............................................ 118 

Eck, P. ............................................... 123 

Edfeldt, K. ........................................... 66 

Edjlalipour, M. ..................................... 87 

Edsfeldt, A. ................................. 75, 110 

Edvardsen, E. ................................... 116 

Eeckhoute, J. ...................................... 67 

Egido, J. .............................................. 41 

Ehnholm, C. ............................ 10, 33, 48 

Eilertsen, K.-E. ................................. 122 

140 

Eisenhofer, G. .................................... 40 

Eklund, C. ........................................... 96 

Ekmekci, H. ........................................ 59 

Ekmekci, O.B. .................................... 59 

Ekroos, K. ........................................... 35 

El, Khoury, P. ............................... 30, 63 

Elbaz, M. ............................................. 85 

Eldor, R. ............................................ 108 

Elens, L. .............................................. 81 

Elia, L. ................................................. 37 

Elias, J.J. ............................................ 95 

Elikomov, V. ..................................... 125 

Elisaf, M. ..................................... 88, 104 

Elisaf, M.S. ................................... 76, 86 

El-Menyar, A. .................... 110, 114, 115 

Elofsson, M. ....................................... 10 

Elonen, N. ........................................... 72 

Elvevoll, E. ........................................ 122 

Elvevoll, E.O. ................................... 122 

Emoto, N. ............................................ 11 

Empana, J.-P. .................................... 54 

Empen, K. ......................................... 110 

Endo, K. ....................... 31, 109, 111, 123 

Endo, T. .............................................. 62 

Endoh, H. ............................................ 32 

Enomoto, M. ..................................... 121 

Enquist, P.-A. ..................................... 10 

Entz, L. .............................................. 127 

Ercan, M.G. ...................................... 126 

Erdmann, J. ........................................ 68 

Eren, M. .............................................. 94 

Erer, B. ................................................ 94 

Ergang, P............................................ 64 

Ergen, A. ............................................. 83 

Erglis, A. ................................... 107, 125 

Ergur, B.U. .......................................... 69 

Ericson, U. ............................. 17, 39, 101 

Ericsson, M. ....................................... 75 

Eriksson, J. ......................................... 33 

Eriksson, M. ............................ 10, 31, 44 

Eriksson, U. ........................................ 31 

Erlinge, D. ........................................... 22 

Ernerudh, J. .................................. 66, 67 

Escolà-Gil, J.C. .................................. 33 

Esparza, Gómez, L. ........................ 100

Esparza, L. .................................... 68, 94 

Espinosa, González, M.C. .............. 117 

Esquirol, Y. ....................................... 105 

Esquivel, C. ................................. 96, 102 

Esteller, M. .......................................... 74 

Estruch, R. .......................................... 35 

Etxebarria, A. ...................................... 80 

Euthimiou, V. .................................... 120 

Evaldson, C. ....................................... 67 

Evans, I. .............................................. 59 

Ewing, M.M. ...................... 18, 41, 47, 61 

Extebarria, A. ...................................... 81 

Ezhov, M. ...................................... 86, 87 

F 

Fabre, A. ............................................. 49 

Fabre, J.-E. ................................. 34, 113 

Fabris, B. ............................................. 35 

Fabryova, L. ...................................... 108 

Fagret, D. ............................................ 99 

Fajardo, C.M. ...................................... 85 

Falchi, A.G. ....................................... 101 

Falcioni, E. ........................................ 107 

Falcón, V. ............................................ 38 

Fallanca, A. ....................................... 110 

Faludi, A.A. ................................... 76, 96 

Fan, J. .......................................... 29, 123 

Fang, L. ............................................... 27 

Fantozzi, C. ............................. 28, 62, 67 

Farnier, M. ..................... 9, 13, 81, 85, 86 

Farnier, Michel ...................................... 9 

Fartushna, O.Y. ................................ 108 

Fatoki, J.O......................................... 120 

Faure, P. ........................................... 122 

Favari, E. ............................................. 71 

Fechner, A. ....................................... 120 

Federspiel, M.-C. ............................... 70 

Fedi, S. ................................................ 70 

Fedorowicz, A. ............................ 57, 106 

Fedoseeva, L.S. ................................. 78 

Fehérvári, M. .................................... 127 

Feidt, C. ............................................. 106 

Feig, J.E. ............................................. 37 

Feillet, F. ............................................. 80 

141 

Feinstein, S.B. ................................... 28 

Feinstein, Steven B. .......................... 28 

Feldman, C.L. .............................. 29, 55 

Felekos, I. ........................................... 38 

Felix, S.B. ......................................... 110 

Ferchaud, Roucher, V. ................... 122 

Ferchaud-Rouchet, V........................ 95 

Ferchichi, S. ................................. 31, 76 

Ferin, R. .............................................. 91 

Fernandes, C.R. ................................ 95 

Fernandes, M. .................................... 92 

Fernández, E. .............................. 38, 54 

Fernandez, I. .................................... 119 

Fernandez, Quero, M.................. 97, 98 

Fernández-Laso, V. .......................... 41 

Fernández-Marrero, Y. ..................... 38 

Ferrannini, E. ............................... 20, 35 

Ferré, R. ...................................... 17, 102 

Ferreira, E.B. ............................ 126, 127 

Ferreira, F. .......................................... 92 

Ferreira, R. ....................................... 116 

Ferri, L. ..................................... 28, 62, 67 

Ferri, N. .......................... 37, 94, 125, 127 

Ferrieres, J. ................................ 54, 105 

Ferrières, J. ............................. 77, 81, 85 

Ferronato, S. ........................... 64, 65, 67 

Ferruelo, A.......................................... 94 

Fesel-Fouquier, V. ............................. 70 

Feugier, P. .................................. 63, 101 

Feuillet, F. ........................................... 76 

Feve, B. ............................................ 102 

Fidan, Y. ........................................... 121 

Filip, G. ................................................ 61 

Filip, M. ............................................. 116 

Filip, S. .............................................. 112 

Filipovsky, J. ................................. 40, 96 

Filippatos, T.D. ................................... 76 

Fink, G. ............................................. 116 

Finsen, A.V. ...................................... 113 

Fiol, M. ................................................ 35 

Fiorelli, S. ............................................ 33 

Fischer, S. .......................................... 86 

Fisher, E.A.................................... 11, 37 

Fisher, J. ............................................. 94 

Fiskesund, R. ..................................... 47

Fjornes, T. ........................................... 92 

Flegar-Meštrić, Z. ............................. 115 

Fletcher, J. .......................................... 65 

Florentin, M. ........................................ 86 

Flores, Le-Roux, J.A. ............... 109, 110 

Flouriot, G. .................................... 29, 37 

Fobker, M. ........................................... 76 

Fogelstrand, L. ................................... 41 

Fogelstrand, P. ................................... 69 

Fonseca, F.A. ....................... 43, 85, 101 

Fonseca, H.A. ................................... 101 

Fontaine, C. .................................. 29, 37 

Foody, J. ............................................. 85 

Ford, I. ................................................. 88 

Forgues, P. ................................... 44, 87 

Forrest, C. ......................................... 124 

Fortun, M. ............................................ 92 

Fortunato, G. ...................................... 51 

Foscarini, J.M. ............................ 96, 102 

Fotopoulos, A. .................................. 106 

Fouchier, S.W. .............................. 26, 51 

Fouquier, V.F. ..................................... 82 

Fourcade, J. ........................................ 77 

Fournier, N. ......................................... 30 

Fracassi, F. ......................................... 40 

Fraga, A. ............................................. 38 

França, C.N. ....................................... 85 

France, M. ................................... 72, 125 

Franceschini, G. ................................. 58 

Franceschini, S.A. .............................. 93 

Franckx, H......................................... 104 

Franco, S. ........................................... 60 

Franczyk-Zarow, M. ......................... 121 

Franczyk-Zarow, M.A. ....................... 89 

Franzosi, M.G. .................................. 100 

Fredenrich, A. ..................................... 81 

Freeman, L. ........................................ 22 

Freyer, J. ............................................. 68 

Friand, V. ............................................. 57 

Frias, M. .............................................. 48 

Friberg, P. ........................................... 40 

Frikke-Schmidt, R. ............................. 84 

Frisdal, E. ...................................... 30, 74 

Froemming, G.R.A. .................... 66, 120 

Frostegård, A. ....................... 47, 63, 124 

142 

Frostegård, J. ........................ 47, 63, 124 

Fu, H. .................................................. 64 

Fu, Y. ................................................... 27 

Fuenffinger, N. ................................... 32 

Fuentes, S. ......................................... 36 

Fuentes-Prior, P. ............................... 10 

Fuertes, N. .......................................... 44 

Fujioka, N. .......................................... 45 

Fujioka, T. ......................................... 111 

Fujishima, Y. .................................... 111 

Fujita, Y. ................................................ 6 

Fujiyoshi, A. .................................. 91, 95 

Fukami, A. ........................................ 121 

Fukuda, A. ........................................ 123 

Fukunaga, H. ..................................... 58 

Fülöp, P. ............................................. 95 

Fumagalli, H.F. .................................. 93 

Funck-Brentano, C. ........................... 52 

Fundinho, C. ..................................... 116 

Furukawa, T. ...................................... 58 

Furuyama, S. ................................... 108 

Futema, M. ......................................... 80 

Fysekidis, M. ............................ 105, 110 

G 

Gaál, K. ............................................... 72 

Gabriel, S............................................ 50 

Gadeau, A.P. ..................................... 52 

Gadeau, A.-P. .................................... 28 

Gaestel, M. ......................................... 64 

Gafarov, V. ....................................... 117 

Gafarova, A. ..................................... 117 

Gagliano, T. ........................................ 60 

Gagulin, I. ......................................... 117 

Gaillet, S. .......................................... 118 

Gajda, M. .......................................... 121 

Gajdosik, J................................ 108, 115 

Gajos, G. ............................................ 39 

Galabova, G. ...................................... 87 

Galán-Garcia, P. ................................ 80 

Galano, J.-M. ................................... 122 

Galassini, A. ....................................... 70 

Galchinskaya, V............................... 110 

Gale, C.P. ......................................... 124

Galeeva, N. ....................................... 110 

Gallagher, P. ..................................... 114 

Galli, E. .............................................. 108 

Gambert, P. ........................................ 58 

Gämperli, O. ....................................... 47 

Gan, A.M. ............................................ 41 

Gan, L.-M. ........................................... 96 

Gandara, A. ...................................... 125 

Gandhi, H. ........................................... 78 

Gandjbakhch, I. .................................. 75 

Gannar, F. ......................................... 104 

Ganugi, E. ........................................... 70 

Ganzetti, G. ..................... 35, 62, 63, 126 

Gapon, L. .................................. 107, 110 

Garcia, Carro, J. ............................... 125 

Garcia-Arguinzonis, M......................... 6 

García-Sánchez, C. ........................... 77 

Garelnabi, M. ............................ 116, 123 

Garjani, A. ........................................... 66 

Garlanda, C. ....................................... 34 

Garlaschelli, K. ........................... 33, 112 

Garlichs, C. ......................................... 68 

Garmy-Susini, B. ................................ 38 

Garnotel, R. ........................................ 52 

Garofaro, A. ........................................ 76 

Garon, A. ............................................. 82 

Garrido, Zambrano, E.C. ................ 117 

Garzone, P.D. ............................... 44, 87 

Gasevic, D. ......................................... 40 

Gašpar, &. ........................................... 79 

Gasparini, D. ..................................... 115 

Gaston, A.-T. ...................................... 38 

Gaudet, D. ........................................... 81 

Gauthier, K. ......................................... 69 

Gautier, E. ..................................... 64, 67 

Gautier, T. ..................................... 10, 27 

Gavrilova, N.E. ................................... 79 

Gayral, S. ............................................ 52 

Gebauerova, M. ................................. 99 

Geerling, J.J. ...................................... 16 

Geiger, K. .......................................... 102 

Geller-Rhomberg, S. ....................... 102 

Gensini, G.F. ................................ 70, 95 

Gentile, M. ........................................... 51 

Geny, B. .............................................. 34 

143 

Georgiadis, I. .................................... 119 

Germain, M. ......................................... 8 

Gerszten, R. ....................................... 25 

Geryk, L. ............................................. 94 

Ghaleb, Y............................................ 50 

Ghannam, M.M. ....................... 104, 120 

Ghezzi, C. ........................................... 99 

Ghosh, M. ........................................... 76 

Ghosh, S.M. ....................................... 65 

Giacco, A. ........................................... 43 

Giacco, R. ........................................... 43 

Giacobbe, C. ...................................... 51 

Giannattasio, C. ............................... 110 

Giannopoulou, V. ............................... 82 

Gidlund, M. ....................................... 101 

Gielen, S. ............................................ 64 

Giezek, H. ........................................... 86 

Giglioli, C. ........................................... 70 

Gijbels, M............................................ 67 

Gilabert, R. ................................. 35, 126 

Gilibert, S. ........................................... 57 

Gille, A. ............................................. 123 

Gillott, R.G. ....................................... 124 

Gilly, F.N. .............................................. 4 

Gilmanov, D. ...................................... 93 

Ginsberg, H. ................................... 2, 14 

Giral, P. ... 22, 32, 67, 75, 81, 82, 90, 103, 

113 

Girard, E. ...................................... 26, 30 

Girerd, X. .......................................... 113 

Giridhar, R. ......................................... 78 

Girish, M.P.......................................... 75 

Girodo, A.M. ..................................... 116 

Girona, J. ............................................ 17 

Gisletun, U.......................................... 92 

Giugliano, R.P. ................................... 44 

Giunta, G. ........................................... 82 

Gizas, V. ........................................... 114 

Gkrozou, F.......................................... 57 

Gladine, C. ....................................... 122 

Glauber, M.................................... 61, 93 

Glinkina, I............................................ 97 

Głodzik, J. ......................................... 116 

Goday, A. .......................................... 110 

Goeritzer, M. .................................... 124

Gogou, M. ......................................... 119 

Gohara, S. ........................................... 55 

Gojkovic-Bukarica, L. ...................... 119 

Goldman, Rosas, L. ........................... 86 

Golledge, J. ......................................... 44 

Golovach, I.V. ................................... 113 

Golovach, S.V. ................................. 113 

Gomaraschi, M. .................................. 73 

Gomes, E.I.L....................................... 83 

Gomez, Lira, M. ...................... 64, 65, 67 

Gomez, Rosso, L. ............................ 108 

Gomez-Guerrero, C. .......................... 41 

Gomita, K. ........................................... 47 

Gomułkiewicz, A. ............................... 38 

Goncalves, I. ..................................... 110 

Gonçalves, I. ....................................... 75 

Gonçalves, R. ..................................... 96 

Gonzaga, C................................... 76, 96 

Gonzalez, A. ....................................... 40 

González, C. ................................. 34, 68 

González-Juanatey, J.R. .................. 57 

González-Peteiro, M. ......................... 57 

Gori, A.M. ...................................... 70, 95 

Gori, T.................................................. 53 

Gorlova, O........................................... 70 

Gosukuma, M.C. ................................ 85 

Götberg, M. ......................................... 22 

Gottrand, F. ........................................... 7 

Goudev, A. .......................................... 58 

Goudevenos, I. ................................. 114 

Goudevenos, J.A. ............................ 120 

Goueffic, Y. ......................................... 95 

Goujard, C. ......................................... 63 

Gourdy, P. ............................... 29, 37, 49 

Gower, J.D. ....................................... 124 

Gracheva, E. ....................................... 66 

Graham, A......................................... 106 

Grammer, T. ....................................... 83 

Grammer, T.B. .............................. 77, 80 

Grandoso, L. ....................................... 80 

Grangeot, R. ..................................... 101 

Grass, D.S. ......................................... 10 

Grassos, H. ......................................... 38 

Gratchev, A. ........................................ 65 

Gratsiansky, N. ................................... 40 

144 

Grebe, M. .......................................... 113 

Grebenshchikova, I. .......................... 97 

Gregersen, I. ...................................... 65 

Greil, G. .............................................. 98 

Grenkowitz, T. .................................... 76 

Griffo, E. .............................................. 43 

Grigore, L.................................... 33, 112 

Grillo, A. .............................................. 35 

Griñán, T. ............................................ 38 

Gritsenko, O. ............................ 103, 125 

Grivel, J.-C. ............................. 51, 61, 64 

Grives, A. ............................................ 47 

Grodzicki, T. ..................................... 116 

Groen, B. ...................................... 30, 36 

Gromova, E. ..................................... 117 

Gronlund, C. ................................. 98, 99 

Grova, N. .......................................... 106 

Gruetter, R.......................................... 17 

Grufman, H. ...................................... 110 

Grundtman, C. ................................... 53 

Grunenwald, E. .................................. 29 

Grzegorek, I. ...................................... 38 

Guaita, S. ............................................ 36 

Guardado, J. ...................................... 92 

Guardamagna, O. ...................... 81, 120 

Guardiola, M. ..................................... 74 

Guastella, G. ...................................... 60 

Guedj, K. ....................................... 38, 61 

Guerci, B. .......................................... 100 

Guerin, M. .................... 26, 30, 63, 70, 74 

Guermaz, R. ...................... 104, 105, 115 

Gui, Q.-J. ............................................ 51 

Guichardant, M. ................................. 65 

Guichot, Y.D. ...................................... 22 

Guiguet, M. ......................................... 83 

Guilland, J.-C. .................................... 58 

Guillaume, M. ..................................... 49 

Guillaumet, A. .................................... 74 

Guillerm, E.......................................... 75 

Guimaraes, E.S. ................................ 85 

Guisado, Rasco, A. ..................... 97, 98 

Gullberg, B. ........................................ 39 

Gullestad, L. ............................... 65, 113 

Gumbiner, B. ................................ 44, 87 

Guo, S. .............................................. 124

Gupta, G.K. ......................................... 43 

Gupta, N. ............................................. 50 

Gupta, S.K. ......................................... 75 

Gurevich, V. ........................................ 78 

Gurzeler, E. ......................................... 31 

Gustin, M.-P. ............................... 63, 101 

Guterres, S.S. ................................... 123 

Guyton, J.R. ........................................ 85 

Guzeloglu, M. ..................................... 60 

Guzik, T. ...................................... 61, 116 

Guzik, T.J. ..................................... 60, 66 

Gvozdyk, M. ........................................ 82 

Gybernatorova, E.E. ........................ 105 

Gylling, H. ......................................... 105 

H 

Haas, B................................................ 54 

Haas, G.-M. ...................... 116, 127, 128 

Habalova, V. ....................................... 99 

Habenicht, A. ...................................... 21 

Habibinejad, H. ................................... 63 

Hack-Ryoung, K. ................................ 78 

Haddad, O. ......................................... 57 

Hadi, N.R. ........................................... 65 

Haeggström, J. ................................... 63 

Hägerstrand, L. .................................. 35 

Haghjooy, Javanmard, S. ................. 56 

Hagiwara, N. ....................................... 47 

Hahalis, G. ........................................ 114 

Haidinger, M. ...................................... 49 

Hajkova, J. ........................................ 112 

Hakki, Kazazi, E. ................................ 46 

Halici, F. ............................................ 110 

Hall, A.S. ........................................... 124 

Hällgren, P. ......................................... 61 

Halonen, J. ........................................ 105 

Haluzik, M. ........................................ 110 

Halvorsen, B. ................................ 65, 80 

Hama, S. ..................................... 72, 125 

Hamamatsu, A. .................................. 62 

Hamazaki, N. .................................... 118 

Hamdis, N. ........................................ 119 

Hamlat, Khennaf, N. .......................... 74 

Hammami, M. ..................... 85, 101, 126 

145 

Hammami, S. ............................. 85, 126 

Hamre, M. ........................................... 92 

Hamrefors, V. ..................................... 17 

Hamrour, F. .............................. 105, 115 

Hamsten, A. ....................................... 36 

Han, S.H. ......................... 48, 89, 95, 102 

Han, X. .......................................... 33, 56 

Handberg, A. ...................................... 50 

Handgraaf, S. ..................................... 49 

Hannou, S. ....................................... 105 

Hannou, S.A. ...................................... 28 

Hanotin, C. ......................................... 87 

Hansel, B. .............................. 32, 82, 103 

Hansson, G.K. ............................. 41, 66 

Hara, M. ............................................ 106 

Harada-Shiba, M. ................. 44, 80, 106 

Haraguchi, H. ..................................... 39 

Haraguchi, Y. ................................... 120 

Harangi, M. ............................ 72, 80, 102 

Harith, H. ............................................ 11 

Harnek, J. ........................................... 22 

Harrison, G. ................................ 91, 114 

Harrison, M.J. ..................................... 34 

Harvey, D............................................ 81 

Hasan, S.T. ...................................... 126 

Hasballa, R. ........................................ 71 

Hasegawa, H. .................................. 125 

Hashemizadeh, H. ........................... 117 

Hashimoto, T. ..................................... 64 

Hasokawa, M. ............................ 39, 120 

Hassim, N.F. ...................................... 58 

Hatri, A. .............................. 104, 105, 115 

Haulon, S. ........................................... 67 

Havekes, L.M. ................... 16, 49, 65, 71 

Havinga, R.......................................... 30 

Hayashi, H. ......................................... 42 

Hazan, E. ............................................ 60 

He, Y. .................................................. 47 

Heasman, J. ................................. 49, 78 

Hebert, H. ........................................... 73 

Hecking, M. ........................................ 49 

Hedegaard, M. ..................................... 8 

Hedin, U. ............................................. 66 

Hedjazi, L............................................ 76 

Hedley, T.E. ....................................... 60

Heeren, J. ........................................... 31 

Hegele, R.A. ....................................... 81 

Heinle, H. .......................................... 119 

Heinonen, S. ....................................... 31 

Heinonen, S.E. ................................... 35 

Heizmann, C.W. ................................. 59 

Hellberg, S. ......................................... 46 

Hellstrand, S. ...................................... 39 

Hendrikx, T. ........................................ 22 

Henein, M. ......................... 61, 97, 98, 99 

Hense, H.W. ....................................... 32 

Heras, M. ....................................... 17, 36 

Herbeth, B. ........................................ 106 

Hermanns, H.M. ................................. 47 

Hermansson, C. ................................. 66 

Hernandez, Y. .................................. 119 

Herová, M. .......................................... 41 

Herrera, A.M. ...................................... 60 

Herreras, Z. ....................................... 126 

Hersberger, M. ................................... 41 

Heuillet, M. .......................................... 79 

Heusch, G. .......................................... 37 

Hewing, B. ........................................... 37 

Heyden, M. ......................................... 53 

Hidalgo, P. .......................................... 34 

Hiemstra, H. ........................................ 43 

Hiemstra, P.S. .................................... 65 

Higaki, Y. ............................................. 54 

Hildebrandt, M. ................................... 45 

Hindmarch, C. .................................... 59 

Hindy, G. ............................................. 17 

Hirai, Y. .............................................. 121 

Hirata, A. ........................................... 122 

Hirata, K. ....................................... 39, 75 

Hirata, K.-I. ...................... 11, 74, 75, 120 

Hirata, M. ....................................... 56, 76 

Hirata, M.H. ......................................... 85 

Hirata, R.D.C. ..................................... 85 

Hirawa, N. ........................................... 88 

Hirche, F. ............................................. 32 

Hirohata, S. ......................................... 93 

Hirsch, E. ............................................. 52 

Hisakawa, N. ...................................... 94 

Hisamatsu, T. ............................... 91, 95 

Hitos, K. ............................................... 65 

146 

Hjuler, Nielsen, M. ............................. 50 

Hlaváčková, M. .................................. 60 

Hlawaty, H. ......................................... 57 

Ho, C.-S. ................................... 103, 114 

Hoefler, G. ........................................ 124 

Hoekstra, J. ........................................ 36 

Hoekstra, M. ....................................... 42 

Hoelschermann, H. ......................... 113 

Hoeng, J. .......................................... 117 

Hoerstrup, S. ...................................... 47 

Hoffmann, M.M. ......................... 83, 101 

Hofker, M. ........................................... 16 

Hofker, M.H. ....................................... 71 

Hofker, Marten ................................... 16 

Hoh, B.P. ............................................ 72 

Høilund-Carlsen, P.F. ....................... 45 

Holaj, R. ............................................ 125 

Holleboom, A. .................................... 42 

Holleboom, A.G. ................................ 55 

Holleman, F. ....................................... 36 

Holm, N.R. .......................................... 95 

Holm, S. ........................................ 65, 86 

Holmgren, A. ...................................... 61 

Holst, J. ............................................... 36 

Holven, K. ........................................... 65 

Holven, K.B. ....................................... 80 

Holzer, M. ..................................... 49, 83 

Homan, R. .......................................... 22 

Homer-Vanniasinkam, S. ................. 94 

Honarpour, N. .................................... 22 

Hong, B.-K. ......................................... 70 

Hong, K.W. ......................................... 38 

Hong, S.P. ........................................ 112 

Hong, T.J. ......................................... 111 

Honye, J. ............................................ 29 

Hoogeveen, R. ................................... 44 

Hooper, A.J. ....................................... 82 

Hori, M. ............................................. 106 

Horner, D.S. ................................. 62, 63 

Horovitz, A. ......................................... 84 

Horvath, K. ......................................... 91 

Hosseini, H. ........................................ 18 

Hoteit, C. ............................................. 48 

Ho-Tin-Noé, B. ............................. 30, 48 

Hounslow, N. ................................ 22, 90

Hovingh, G.K. ..................... 2, 42, 51, 55 

Hovingh, K. ......................................... 26 

Howell, S.J. ....................................... 124 

Hoymans, V. ..................................... 104 

Hsieh, F.-I. ........................................ 100 

Hsieh, I.-C. .......................................... 46 

Hsu, C.................................................. 69 

Hsu, L.-J. ........................................... 112 

Hsu, S.-P. ............................................ 69 

Hu, F. ..................................................... 9 

Hu, Frank .............................................. 9 

Hu, M. .................................................. 87 

Hua, S.................................................. 66 

Hua, X.................................................. 63 

Huang, F. ............................................ 44 

Huang, J. ........................................... 101 

Huang, P.-H. ........................... 20, 29, 61 

Huang, T. .......................................... 107 

Huang, Y.-Y. ....................................... 29 

Hubacek, J. ......................................... 99 

Hubacek, J.A. ..................................... 99 

Huby, T. ......................................... 57, 67 

Hueb, W. ............................................. 72 

Hughes, A. .......................................... 49 

Hughes, A.D. .......................... 78, 89, 95 

Huizinga, E.G. .................................... 61 

Huk, I. ................................................ 114 

Hultén, L.M. ........................................ 66 

Humphries, S.E. ........................... 80, 81 

Hunter, W.J. ........................................ 43 

Huovinen, T. ....................................... 72 

Hurme, R. ............................................ 35 

Hurt-Camejo, E. ................................. 10 

Husche, C. .......................................... 74 

Hussain, T. .......................................... 98 

Hussein, A. ....................................... 110 

Hutten, B. ...................................... 26, 81 

Huttl, M. ............................................... 54 

Huusko, J. ........................................... 31 

Huynh, K. ............................................ 30 

Hwang, H.S......................................... 95 

Hyötyläinen, T. ................................... 33 

Hyspler, R. ........................................ 110 

Hϋbner, K. ........................................... 33 

147 

I 

Ibañez, J.M. ........................................ 92 

Ibarretxe, D. .......................... 17, 36, 102 

Ibrahimi, P. ................................... 98, 99 

Ichiki, T. .............................................. 64 

Idborg, H. ............................................ 66 

Idzior-Waluś, B. ......................... 80, 127 

Igarashi, A. ....................................... 118 

Ikeda, N. ..................................... 58, 103 

Ikeda, Y. .............................................. 94 

Ikemoto, T. ......................................... 29 

Ikewaki, K. .......................................... 40 

Ikhlef, S. .............................................. 42 

Ikitimur, B............................................ 59 

Il`ina, L. ............................................... 86 

Ilerigelen, B. ....................................... 59 

Iliadis, S. ........................................... 119 

Iliescu, C. .............................................. 7 

Ilnicka, P. .......................................... 126 

Ilyinskaya, O.P. .................................. 67 

Imaeva, A. .................................. 40, 107 

Imaizumi, T. ...................................... 121 

Imamura, H. ................ 31, 109, 111, 123 

Imamura, S. ........................................ 75 

Inazu, A. ........................................ 50, 80 

Indermuehle, A. ................................. 98 

Inoue, T. ........................................ 50, 80 

Intharapetch, P. .................... 84, 99, 100 

Ionova, Z.I. ......................................... 99 

Iozzo, P. .............................................. 28 

Iozzo, Patricia .................................... 28 

Irvine, H. ............................................. 50 

Isayeva, A. .......................................... 77 

Isbir, S. ................................................ 83 

Isbir, T. ................................................ 83 

Ishibashi, S. ........................................ 73 

Ishida, T. .......................... 39, 74, 75, 120 

Ishihara, N. ....................................... 123 

Ishizaka, N........................................ 106 

Iso, H. .................................................. 48 

Issa, B. ........................................ 72, 125 

Itabe, H. ............................................ 123 

Itai, K. ................................................ 111 

Ito, H. ............................................. 86, 93

Ito, Y. ............................................. 77, 93 

Ivanisevic, J. ....................................... 94 

Ivanova, M. ......................................... 84 

Ivanova, O. ............................. 51, 61, 64 

Ivashkin, V. ......................................... 88 

Iwamoto, M. .................................. 62, 93 

Iyengar, S.S. ....................................... 72 

Izar, M.C. ..................................... 43, 101 

Izard, J.-C. ........................................ 118 

Izumi, T................................................ 56 

J 

Jaber, Y. .................................... 105, 110 

Jabłońska, K. ...................................... 38 

Jacob, M.-P......................................... 62 

Jacob, N. ........................................... 113 

Jafari, Dinanai, N. .............................. 70 

Jahreis, G. ......................................... 120 

Jakic, B. ............................................... 53 

Jakobsson, P.-J.................................. 66 

Jakubowski, M. ................................. 126 

Jalali, A. ............................................... 46 

James, R.W. ....................................... 48 

Jamnitski, A. ....................................... 20 

Jamroz-Wiśniewska, A. ..................... 41 

Janczak, D. ......................................... 38 

Jandl, K. ............................................ 124 

Jang, H.C. ........................................... 49 

Jänis, M. .............................................. 35 

Janus, A. ........................................... 126 

Jaramillo, J.S. ..................................... 60 

Jardim, C.C. ...................................... 116 

Järvelin, M.-R. .................................... 33 

Jaschke, C. ......................................... 64 

Jashari, F. ..................................... 98, 99 

Jasiński, K. ........................................ 106 

Jaspard-Vinassa, B. .......................... 28 

Jasztal, A. ........................... 89, 106, 121 

Jauhiainen, M. ..... 10, 22, 31, 33, 48, 72, 

128 

Jauhiainen, Matti ................................ 10 

Javorsky, M......................................... 99 

Jawad, A.H.M. .................................... 16 

Jegere, S. .......................................... 125 

148 

Jegerschöld, C. .................................. 73 

Jenei, Z. .............................................. 95 

Jeney, V. ............................................. 29 

Jenkins, P. .......................................... 97 

Jennbacken, K. .................................. 35 

Jensen, E............................................ 85 

Jensen, G.B. ...................................... 32 

Jensen, I.J. ....................................... 122 

Jensen, I.-J. ...................................... 122 

Jeon, S.W. ........................................ 112 

Jeppsson, A. ...................................... 66 

Jerling, J.C. ........................................ 85 

Jessup, W. .......................................... 74 

Jeurissen, M. ...................................... 22 

Jevnikar, M. ........................................ 35 

Jezkova, K. ......................................... 57 

Jiang**, Y. ........................................... 73 

Jiang, X.-C............................................ 6 

Jiang, Z.S. .......................................... 29 

Jiang, Z.-S. ......................................... 51 

Jin, J. ........................................... 68, 116 

Jo, S.-H. .............................................. 90 

Joh, T. ........................................... 44, 87 

Johansson, E. .............................. 98, 99 

Johansson, M.E. ..................... 41, 66, 69 

Johns, R. .......................................... 114 

Johnson-Levonas, A.O. .................... 85 

Jonak, P. ............................................. 56 

Jonasson, L. ................................. 66, 67 

Jondeau, G. ........................................ 61 

Jones, P.J. ........................................ 123 

Jonke, V. ........................................... 115 

Jonker, L. ............................................ 36 

Jönsson-Rylander, A.-C. .................. 35 

Jorge-Galarza, E. .............................. 99 

Joumard-Cubizolles, L. ................... 122 

Jozkowicz, A. ..................................... 60 

Juárez-Rojas, J.G. ............................ 99 

Juárez-Rojop, I.E. .............................. 90 

Jude, B. ............................................... 67 

Jude, E. ............................................... 95 

Juhász, I. ............................................ 95 

Juhnevica, D. ................................... 107 

Juhola, J. .............................................. 7 

Jukema, J.W. ........ 18, 41, 47, 49, 61, 88

Jula, A.................................................. 33 

Julius, U. ............................................. 86 

Jullien, G. ............................................ 93 

Julve, J. ......................................... 10, 33 

Jung, I.-H. ........................................... 68 

Juno, C. ............................................... 87 

Juonala, M. ............................... 7, 32, 36 

Jurka, A. ............................................ 103 

K 

Kacem, K. ........................................... 63 

Kacem, S. ........................................... 83 

Kachkovskii, M.A.......................... 78, 92 

Kadota, A. ....................... 78, 91, 95, 103 

Kadowaki, S. ....................................... 95 

Kadowaki, T. ....................................... 91 

Kahli, A. ............................................... 53 

Kähönen, M. ........................... 7, 36, 101 

Kajinami, K. ......................................... 45 

Kajiya, M. ............................................ 93 

Kakino, A. .............................................. 6 

Kakkavas, A. ..................................... 114 

Kalachikov, S. ..................................... 18 

Kalantzi, K. ........................................ 114 

Kalinowski, L....................................... 57 

Kalinskaya, A. ..................................... 58 

Kalka, D. ............................................ 116 

Kaltenecker, C. ................................... 49 

Kaminnyi, A......................................... 66 

Kaminnyi, A.I. ..................................... 84 

Kamiya, K. ......................................... 118 

Kamstrup, P.R. ............................. 20, 32 

Kanai, A. .............................................. 56 

Kanai, H. ........................................... 125 

Kanellakis, P. ...................................... 18 

Kanellou, A. ........................................ 82 

Kang, D.O. .......................................... 36 

Kang, S.M. .......................................... 49 

Kang, W.C......................................... 102 

Kanjuh, V. ......................................... 119 

Kannenberg, F. .................................. 76 

Kanno, K. ............................................ 94 

Kanse, S. ........................................... 113 

Kantas, D. ......................................... 120 

149 

Kanyilmaz, S. ................................... 109 

Kapelak, B. ......................................... 61 

Kara, E. ............................................. 119 

Karabina, S. ....................................... 18 

Karabina, S.-A. .................................. 47 

Karadag, B. ........................................ 59 

Karadeniz, F.O................................... 94 

Karadi, I. ........................................... 118 

Karádi, I. ............................................. 78 

Karagedik, H. ..................................... 83 

Karagiannis, C. .................................. 54 

Karanasos, A. .............................. 38, 45 

Karatzas, T. ...................................... 119 

Karčiauskaitė, D. ............................. 118 

Kardassis, D. ........................................ 5 

Kardum, Paro, M.M. ........................ 115 

Karhunen, P.J. ................................... 63 

Karim, S. ............................................. 40 

Karlinskaya, M. .................................. 97 

Karlson, B.W. ..................................... 44 

Karlsson, M.K. ............................. 7, 116 

Karp, K. ............................................. 106 

Karpenko, M.A. .................................. 99 

Karper, J.C. ....................... 18, 41, 47, 61 

Karpov, Y. ........................................... 91 

Kasagi, F. ........................................... 91 

Kasbi, Chadli, F. ................................ 35 

Kashiwagi, A. ..................................... 91 

Kashiwase, K. .................................. 109 

Kaski, J.C. .......................................... 11 

Kasmas, S.H. ..................................... 43 

Kassi, E. .............................................. 93 

Kassimis, G. ..................................... 114 

Kassner, U.................................... 76, 80 

Kastelein, J. .................................. 26, 81 

Kastelein, J.J.P. ................................. 51 

Kastorini, C.-M. ................................ 120 

Katano, H............................................ 61 

Kathiresan, S. .............................. 50, 51 

Katkó, M. ............................................ 80 

Kato, A. ............................................... 79 

Kato, K. ............................................. 111 

Kato, R. ............................................. 121 

Katsilambros, N.L. ........................... 119 

Katsuda, S. ......................................... 80

Kaudewitz, D. ................................... 114 

Kaufmann, P.A. .................................. 98 

Kauhanen, J. ...................................... 39 

Kautznerova, D. ................................. 28 

Kavurma, M. ................................. 11, 37 

Kavurma, M.M. ............................. 38, 42 

Kawai, Y. ............................................. 45 

Kawakami, M. ..................................... 32 

Kawamoto, T. ..................................... 94 

Kawana, H. ................. 31, 109, 111, 123 

Kawano, M. ....................................... 118 

Kawasaki, M. .................................... 105 

Kawase, R. ....................................... 109 

Kawashiri, M.-A. ........................... 50, 80 

Kawata, M. .......................................... 74 

Kawatsu, Y. ................................. 78, 103 

Kawecki, C. ......................................... 61 

Kazanis, K. .......................................... 93 

Kazdova, L. ......................................... 54 

Kazemi, S.A.N. ................................... 91 

Kazuma, S.M. ................................... 123 

Kee, F. ................................................. 54 

Kei, A.A. .............................................. 86 

Keles, D. .............................................. 69 

Keles, I. ............................................... 94 

Kemaloglu, T. ..................................... 94 

Kempen, H. ......................................... 73 

Kenjaev, M. ......................................... 89 

Kerek, F. .............................................. 68 

Kerksiek, A. ......................................... 30 

Kerner, W. ......................................... 110 

Kerry, Z................................................ 69 

Kersten, S. .................................... 10, 75 

Kersten, Sander ................................. 10 

Kesavalu, L. ........................................ 63 

Kessal, F. .......................... 104, 105, 115 

Kessler, K. ......................................... 114 

Kettunen, J. ......................................... 33 

Keul, P. ................................................ 37 

Keyamura, Y. .................................... 123 

Khachigian, L. ..................................... 37 

Khachigian, L.M. ................................ 38 

Khalil, A. .............................................. 42 

Khallou-Laschet, J. ............................ 38 

Khambata, R.S. .................................. 65 

150 

Khan, F. .............................................. 64 

Khan, N. .............................................. 40 

Khanfir, L. ......................................... 104 

Kharbanda, R.K. .............................. 112 

Khasanova, Z. .................................... 84 

Khatib, R. .......................................... 124 

Khedoe, P.P.S.J. ............................... 65 

Kidouche, R. ....................................... 79 

Kidron, M. ......................................... 108 

Kiec, A.D. .......................................... 121 

Kiechl, S. .......................................... 114 

Kihara, S. ............................................ 79 

Kikuchi, K.......................................... 106 

Kim, B.R. ............................................ 43 

Kim, C.D. ................................. 38, 59, 66 

Kim, C.J. ............................................. 88 

Kim, D.-Y. ........................................... 68 

Kim, E.J. .......................... 36, 53, 63, 122 

Kim, H. .............................................. 103 

Kim, H.-D. ........................................... 69 

Kim, H.-H. ................................... 98, 112 

Kim, H.-J. ............................................ 38 

Kim, H.-S. ........................................... 90 

Kim, J. ......................................... 73, 103 

Kim, J.-R. .......................................... 117 

Kim, J.W. ......................... 36, 53, 63, 122 

Kim, J.-Y. .................................... 70, 119 

Kim, K.S. ........................................... 112 

Kim, M.-A. ..................................... 78, 88 

Kim, M.-J. ..................................... 32, 74 

Kim, S. ................................... 53, 63, 122 

Kim, S.-H. ..................................... 78, 90 

Kim, S.-M. ........................................... 73 

Kim, S.W. ............................................ 36 

Kim, Y. ................................................ 48 

Kim, Y.H. ............................................ 59 

Kimura-Hayama, E. ........................... 99 

Kimura-Wozniak, T............................ 59 

Kindt, I. ................................................ 51 

King, A. ............................................. 114 

Kingwell, B.A. .......................... 22, 30, 44 

Kinoshita, N. ................................. 74, 75 

Kinova, E. ........................................... 58 

Kipinski, L. ........................................ 116 

Kirchstetter, W. .................................. 87

Kirichenko, N. ..................................... 92 

Kirkby, N.S. ....................................... 114 

Kishimoto, I. ........................................ 80 

Kishiro, M. ........................................... 58 

Kishor, Kumar, G. .............................. 85 

Kiss, Z.......................................... 78, 118 

Kitamura, K. ........................................ 47 

Kitas, G.D. ........................................... 20 

Kitayama, M. ....................................... 45 

Kivelä, A. ............................................. 31 

Kiyonaga, A. ....................................... 54 

Kjoelsnes, G. ...................................... 92 

Klainman, E. ..................................... 116 

Kleber, M.E. .................... 77, 80, 83, 101 

Kleijn, D.P.V.D. .................................. 66 

Klein, C. ............................................. 107 

Klein, S. ............................................. 101 

Klimcakova, L. .................................... 99 

Klingenberg, R. .................................. 47 

Klinger, M. ......................................... 114 

Kliuk, Ben-Bassat, O. ...................... 105 

Kloch-Badełek, M. ............................ 127 

Klöckl, L. ............................................ 112 

Knop, F. ............................................... 36 

Knuuti, J. ............................................. 46 

Ko, N. ................................................... 18 

Kobayashi, J. ...................................... 50 

Kobayashi, T............................... 40, 109 

Koch, M. .............................................. 47 

Kodydková, J. ..................................... 82 

Koeda, Y. ............................................ 48 

Koenig, W. .......................................... 28 

Koh, K. ................................................. 89 

Koh, K.K. ............................... 89, 95, 102 

Kohashi, M. ....................................... 123 

Koike, M. ............................................. 30 

Koivuniemi, A. .................................... 70 

Kolar, F. ............................................... 64 

Kolb, D. .............................................. 124 

Koleda, P. ......................................... 116 

Kolovou, G. ................................... 81, 84 

Kolovou, V. ................................... 81, 84 

Komanasin, N. ...................... 84, 99, 100 

Komir, I. ............................................... 77 

Komuro, I. ......................................... 109 

151 

Kon, N. .............................................. 109 

Koncsos, P. ...................................... 102 

Kondo, K. .................................... 39, 120 

Kones, R. ............................................ 17 

König, W. .......................................... 101 

Konings, M. .................................. 22, 30 

Konnov, M. ......................................... 40 

Konovalov, G. .................................... 86 

Konrad, R. .......................................... 50 

Kontny, F. ........................................... 92 

Konttinen, J. ....................................... 96 

Kontush, A. .................... 42, 72, 103, 108 

Konuklugil, B. ................................... 121 

Kootte, R. ............................................ 36 

Kopecky, C. ........................................ 49 

Korandji, C.......................................... 58 

Korbut, R. ..................................... 60, 61 

Koren, M.J. ......................................... 44 

Kormi, I. .............................................. 61 

Korneeva, O.N. .................................. 88 

Korotaeva, A.A................................... 84 

Korou, L.-M. ..................................... 119 

Koryagina, N. ............................... 91, 93 

Kosaki, A. ........................................... 59 

Koshy, V. .......................................... 110 

Kosola, J. ............................................ 69 

Kostakou, P. ....................................... 84 

Kostal, M. .......................................... 112 

Kostapanos, M. .................................. 88 

Kostogrys, R.B. .......................... 89, 121 

Kotak, B. ............................................. 87 

Kotoulas, C. ................................ 97, 104 

Koubaa, N. ................................. 85, 126 

Koulaouzidis, G. ................................ 97 

Koutoulakis, E. ........................... 97, 104 

Koutsogiannis, N. ............................ 114 

Kovalcsik, E. ....................................... 11 

Kovanen, P. ........................................ 14 

Kovanen, P.T. .................................... 22 

Kovanen, Petri ............................. 14, 23 

Kovarik, J. ........................................... 49 

Koverech, A. ............................ 28, 62, 67 

Koyama, T. ....................................... 123 

Kozarov, E. ......................................... 18 

Koziolova, N. ...................................... 79

Krajcoviechova, A. ....................... 40, 96 

Královec, K. ........................................ 94 

Krämer, S.D. ....................................... 98 

Krane, V. ........................................... 101 

Kratky, D. .......................................... 124 

Krause, B. ........................................... 22 

Krechler, T. ......................................... 82 

Krempf, M. ....... 4, 26, 35, 44, 81, 95, 122 

Krempf, Michel ..................................... 7 

Kremzer, A.A. ..................................... 56 

Krepuska, M. .................................... 127 

Krievina, G. ............................... 103, 106 

Krneta, M. ........................................... 92 

Krogh-Sørensen, K. ........................... 65 

Krska, Z. ............................................ 112 

Kryvorot, S. ......................................... 56 

Kucinskiene, Z.A. ............................... 79 

Kučinskienė, Z.A. ............................. 118 

Kühnast, S. ......................................... 49 

Kuiper, J. ........................... 18, 41, 47, 61 

Kuivenhoven, J.A. .................. 26, 42, 55 

Kuivenhoven, Jan A. ......................... 26 

Kukharchuk, V. ................................... 91 

Kukharchuk, V.V. ............................... 84 

Kukongwiriyapan, U. ........... 84, 99, 100 

Kulesza, J. ........................................ 125 

Kulikov, I. ............................................. 84 

Kumahara, H. ..................................... 54 

Kume, N. ............................................. 86 

Kumon, Y. ........................................... 94 

Kuo, M.-S. ............................................. 6 

Kurano, M. ........................................ 106 

Kuranova, A. ....................................... 47 

Kurl, S. ................................................. 39 

Kurteva, T. .......................................... 58 

Kurtoglu, H. ....................................... 126 

Kusachi, S. .......................................... 93 

Kusano, K. .......................................... 86 

Kusters, D.M. ...................................... 51 

Kusuhara, H. ....................................... 42 

Kuznetsov, A. ..................................... 91 

Kuznetsov, A.S. ................................ 124 

Kuznetsov, V. ........................... 107, 110 

Kvasnicka, J. .............................. 40, 112 

Kvasnicka, T. .............................. 40, 112 

152 

Kwakernaak, A................................... 72 

Kwan, P. ........................................... 126 

Kwok, S. ...................................... 72, 125 

Kwon, H.M. ................................... 70, 76 

Kwon, S.W.......................................... 70 

Kyaw, T. .............................................. 18 

Kyrolainen, H. .................................... 69 

Kzhyshkowska, J. ........................ 65, 74 

L 

La, Guardia, P.G. .............................. 90 

La, Motta, C. ....................................... 59 

Laaksonen, R. ............................ 35, 101 

Labbadia, G........................................ 31 

L'Abbate, A. ........................................ 20 

Labrador, Aldana, E.R. ................... 127 

Laffargue, M. ................................ 16, 52 

Lagarde, M. .................................. 34, 65 

Lagerstedt, J.O. ................................. 73 

Lagrost, L...................................... 27, 76 

Lahikainen, A. .................................... 10 

Lähteenmäki, H. ................................ 22 

Lalere, B. ............................................ 79 

Laman, J.D. ........................................ 66 

Lamaze, C. ......................................... 26 

Lamb, C. ........................................... 114 

Lambert, G. ....................... 19, 31, 51, 73 

Lamboley, J.-L. .................................. 46 

Lamminmäki, U. ................................. 72 

Lamotte, C. ........................................... 7 

Lamuela-Raventós, R.M. ................. 35 

Landmesser, U. ........................... 47, 77 

Lang, S. ........................................ 52, 83 

Langlois, J.-B. .................................... 64 

Langslet, G. .................................. 44, 80 

Langsted, A. ....................................... 32 

Lanhers, M.-C. ................................. 106 

Lannoy, M. .......................................... 62 

Lanska, M. .................................. 81, 112 

Lanska, V...................................... 28, 99 

Lantelme, P. ....................................... 63 

Lantieri, O. ........................................ 120 

Lapergue, B............................. 34, 56, 57 

Lappalainen, J. .................................. 30

Lapshataeva, O. ............................... 107 

Larrieta-Carrasco, E. ......................... 99 

Larsson, M. ................................... 10, 93 

Lascols, O. ........................................ 100 

Latkovskis, G. ................................... 107 

Latouche, C. ....................................... 44 

Latz, E. ................................................ 18 

Latz, Eicke .......................................... 18 

Laukkanen, J. ..................................... 39 

Laukkanen, J.A. ................................. 39 

Laurent, S. .......................................... 96 

Laurila, P.-P. ....................................... 33 

Lautsch, D. .......................................... 86 

Laville, M. ............................................ 35 

Lavoie, J.-M. ..................................... 115 

Lavrador, M.S. .................................... 30 

Lawrence, G. .............................. 91, 114 

Lawson, D. ........................................ 124 

Layeghkhavidaki, H. ........................ 106 

Lazarevic, A. ....................................... 92 

Lazaro, I. ............................................. 41 

Le, Bras, M. .................................. 44, 76 

Le, Goff, W. ....................... 30, 70, 72, 74 

Le, May, C..................................... 6, 102 

Le, Q.-H. .............................................. 34 

Leach, N.V. ....................................... 106 

Leander, K. ......................................... 36 

Leask, R.L. .......................................... 56 

Lebedeva, A. .......................... 51, 61, 64 

Lebray, P. ............................................ 32 

Lebrun, S. ......................................... 117 

Lecerf, J.-M. ........................................ 50 

Lechuga-Sancho, A.M....................... 10 

Lecour, S. ............................................ 48 

Ledesma, M. ................................. 60, 84 

Lee, B.-H. ............................................ 37 

Lee, B.K. ....................................... 70, 76 

Lee, B.-S. ............................................ 48 

Lee, C.-H. .......................................... 113 

Lee, E.M. ............................................. 36 

Lee, H.C. ........................................... 111 

Lee, H.-E. ............................................ 99 

Lee, H.-L. ...................................... 78, 90 

Lee, H.W. .......................................... 111 

Lee, J.B. ............................................ 112 

153 

Lee, K. ............................................... 102 

Lee, K.H. ............................................. 95 

Lee, M.K. ............................................ 27 

Lee, R. ........................................ 86, 112 

Lee, S.J. ................................... 38, 59, 66 

Lee, W.-S............................................ 69 

Lee, Y.S. ........................................... 112 

Lee-Rueckert, M. ............................... 33 

Lefai, E. ............................................... 31 

Lefeber, D.J. ....................................... 55 

Lefebvre, P. ........................................ 67 

Legeai, C. ........................................... 63 

Legedz, L. ................................... 63, 101 

Lehtimäki, T. .......................... 33, 63, 101 

Leighton, B. ........................................ 35 

Leiherer, A. ....................................... 102 

Leitão, F. ............................................. 79 

Leite, Jr, A.C.d.A. ................... 68, 71, 72 

Lejnieks, A. ....................................... 106 

Lekka, S. ............................................. 84 

Lemozy, S. ......................................... 77 

Lencova, O. ........................................ 57 

Lenfant, F. .......................................... 37 

León, M. .............................................. 84 

Leopizzi, M. .................................. 28, 67 

Leppänen, P. ...................................... 31 

Leprince, P. ........................................ 75 

Lerchbaum, E. ................................... 83 

Leren, T.P. .......................................... 50 

Leschenko, I.G............................. 78, 97 

Leschenko, V.A. .......................... 78, 97 

Leseche, G. ........................................ 48 

Lesna, J. ........................................... 110 

Lesnik, P. ............................................ 67 

Lestavel, S.................................... 26, 74 

Letessier, E. ......................................... 6 

Letourneur, D. .................................... 57 

Levade, T............................................ 80 

Levashov, S. ...................................... 97 

Levels, J. ............................................ 20 

Levin, M. ............................................. 53 

Levkau, B............................................ 37 

Levonen, A.-L. ................................... 30 

Levy, P. ....................................... 64, 122 

Lewis, A. ....................................... 31, 76

Lewis, G. ............................................. 15 

Lezoualc'h, F. ..................................... 37 

Lhomme, M. .......................... 42, 72, 108 

Li, F. ..................................................... 74 

Li, J.-F.................................................. 51 

Li, J.Y. .................................................. 63 

Li, J.-Y. ................................................ 63 

Li, K.W. ................................................ 80 

Li, S. ................................................... 124 

Li, S.-Y. ................................................ 20 

Li, W. .................................................... 67 

Li, X. ..................................................... 52 

Li, Y.-H. ............................................... 29 

Liang, H. .............................................. 87 

Liao, J.K. ........................................... 113 

Libby, P. ...................................... 1, 4, 62 

Liberopoulos, E.N. ............... 86, 88, 104 

Libersa, C. ............................................. 7 

Lichtenstein, L. ................................... 16 

Lien, L.-M. ......................................... 100 

Liepold, E. ......................... 116, 127, 128 

Liljenbäck, H. ...................................... 46 

Lim, H.E. ......................... 36, 53, 63, 122 

Lim, H.-J. ........................................... 103 

Lim, P. ................................................. 52 

Lim, S. ................................................. 49 

Lim, S.I. ............................................... 36 

Lima, P. ............................................... 76 

Limam, F. .................................. 120, 121 

Limon, I................................................ 60 

Lin, C. .................................................. 30 

Lin, H.-J. ............................................ 100 

Lin, J. ................................................... 85 

Lin, S.-J. .................................. 20, 29, 61 

Lin, W.-W. ........................................... 93 

Lin, W.-Y. .......................................... 100 

Lin, Y. .................................................. 43 

Lin, Y.-S. ............................................. 91 

Lindbom, M. ........................................ 53 

Lindholm, H................................. 96, 105 

Lindvig, H.W. ...................................... 80 

Lins, L.C. ............................................. 85 

Lipp, M. .............................................. 113 

Litsardopoulou, A. ............................ 120 

Litvinov, D. ........................................ 108 

154 

Liu, A. .................................................. 47 

Liu, E. .......................................... 29, 123 

Liu, F.T. ............................................... 29 

Liu, H. .................................................. 73 

Liu, H.B. ............................................ 118 

Liu, H.-Q. ............................................ 66 

Liu, L.S. ............................................... 29 

Liu, M. ................................................. 65 

Liu, P. ................................................ 124 

Liu, P.-Y. ...................... 29, 112, 113, 114 

Liu, Q................................................... 33 

Liu, T. .................................................. 44 

Liu, X. .................................................. 73 

Liu, Y. .......................................... 72, 125 

Liu, Y.-C. ............................................. 46 

Liu, Z. .................................................. 33 

Liuni, A. .................................. 52, 53, 125 

Ljunggren, Ö. ....................................... 7 

Llanos, Guerrero, C. ....................... 117 

Llaverias, G. ....................................... 33 

Llorente-Cortes, V. .............................. 6 

Llort, M. ............................................. 102 

Lodder, R. ........................................... 32 

Lohez, O. ...................................... 60, 63 

Longo, A. ............................................ 16 

Lonsky, V. ........................................... 62 

Lonzi, J.P. ......................................... 102 

Lookene, A. ........................................ 10 

Looker, H. ........................................... 36 

López, de, Maturana, Carrasco, I. 100 

Lopez, de, Maturana, I. ..................... 65 

López, Lluva, M.T. ........................... 117 

López-Maturana, I. ............................ 68 

López-Requena, A. ........................... 38 

Loppnow, H. ....................................... 64 

Lorbeer, R. ....................................... 110 

Loretz, C. ............................................ 41 

Lorgis, L. ............................................. 53 

Lorin, J. ......................................... 53, 58 

Lőrincz, H. ............................. 72, 80, 102 

Losurdo, P. ......................................... 35 

Lotteau, V. .......................................... 66 

Lottenberg, A.M. ................................ 30 

Lou, C. .................................................. 6 

Loued, S. ............................................ 42

Louedec, L. ........... 34, 38, 48, 57, 61, 62 

Lounatmaa, K. .................................... 63 

Lourenço, A. ....................................... 92 

Lourenco, L.P. .................................... 38 

Lövgren, J. .......................................... 72 

Lowe, R.S. .......................................... 86 

Loyau, S. ............................................. 34 

Lu, J. .................................................... 33 

Luc, G. ..................................... 50, 54, 81 

Luca, M.C. ..................................... 52, 53 

Lucas, A. ......................... 28, 52, 63, 105 

Ludvigsen, T.P. .................................. 95 

Ludwig, S. ................................... 34, 113 

Luhman, C.J.F. ................................. 101 

Lundberg, A. ....................................... 67 

Lundberg, A.M. ................................... 41 

Lundqvist, A. ................................. 53, 66 

Lundström, E. ................................... 106 

Lüscher, T.F. ...................................... 47 

Lutjohann, D. ...................................... 22 

Lütjohann, D. .......................... 30, 74, 83 

Lychov, V. ......................................... 107 

Lystsova, N. ...................................... 110 

Lyytikäinen, L.-P. ....................... 40, 101 

M 

Ma, X. .................................................. 52 

Maatouk, F. ................................... 31, 76 

Mabuchi, H. ................................... 50, 80 

Macaluso, L. ....................................... 35 

Macášek, J. ......................................... 82 

Mach, F. ........................................ 47, 48 

Machado, R. ....................................... 30 

Machida, T. ......................................... 75 

Machtoub, L.H. ................................... 98 

Maciag, J. ............................................ 66 

Macic, Dzankovic, A. ......................... 92 

MacKay, D.S. .................................... 123 

Mackay, M........................................... 40 

Madden, S. ......................................... 22 

Madder, R.D. ...................................... 22 

Madjid, M. ........................................... 32 

Madrigal-Matute, J. ............................ 41 

Maegawa, H. ...................................... 91 

155 

Mæhre, H.......................................... 122 

Mæhre, H.K. ..................................... 122 

Mafalda, B. ......................................... 79 

Maggi, L. ............................................. 82 

Maggio, R. .......................................... 16 

Maglione, F. ....................................... 37 

Magni, P. ............................................ 96 

Magnussen, C.G. .......................... 7, 32 

Magnusson, L.U. ............................... 66 

Magré, J. ............................................... 6 

Magrè, J. ........................................... 102 

Mahini, H. ................................. 116, 123 

Maier, W. ............................................ 47 

Maifrino, L. ........................................ 115 

Maillard, L. .......................................... 57 

Maindonald, R.E. ............................. 124 

Maiocchi, G. ..................................... 125 

Majdalawieh, A. ................................. 30 

Majeed, S. .......................................... 65 

Majewski, P. ..................................... 125 

Majewski, W. .................................... 125 

Majnaric, L. ....................................... 111 

Majnaric, L.T. ..................................... 93 

Majul, C. .............................................. 86 

Mak, S. ................................................ 53 

Makariou, S.E. ........................... 88, 104 

Makedou, A. ..................................... 119 

Makedou, K. ..................................... 119 

Mäkelä, K.-M. ................................... 101 

Mäkinen, P. ........................................ 31 

Makino, H. .................................. 80, 124 

Makino, Y............................................ 79 

Makita, Y. ...................................... 29, 55 

Makoveichuk, E. ................................ 31 

Makris, G. ......................................... 114 

Maksimov, V. ..................................... 84 

Malec, M.M. ...................................... 121 

Malecki, M. ....................................... 121 

Małecki, M.T. .................................... 127 

Malek, I. .............................................. 28 

Malet, N. ............................................. 52 

Malinska, H. ....................................... 54 

Mallat, Z. ............................................. 41 

Mallavia, B. ......................................... 41 

Mallias, I. ............................................ 82

Mallol, R. ............................................. 36 

Malysheva, O. .................................. 107 

Malyutina, S. ....................................... 84 

Mamareli, V................................. 97, 104 

Mamarelis, I.E. ................................. 104 

Mameri, A. ......................................... 115 

Mammeri, A. ..................................... 104 

Mañas, García, M.D. ....................... 117 

Mandic-Radic, S. ................................ 94 

Mandolini, C. ....................................... 90 

Manduteanu, I. ................................... 41 

Mangas, A. .......................... 92, 109, 121 

Mangione, A. ...................................... 43 

Manolopoulos, V.G. ........................... 81 

Manolopoulou, D. ............................... 84 

Manthey, H.D. .................................... 47 

Mantovani, A....................................... 34 

Manzini, S. ..... 33, 35, 58, 62, 63, 86, 126 

Marais, A.D. ........................................ 81 

Marais, D. ...................................... 31, 51 

Maranghi, M. ........................... 10, 31, 84 

Maranhao, R.C. ................................ 115 

Maranhão, R.C. ...................... 68, 71, 72 

Maraninchi, M. .................................. 101 

Marcais, C. .......................................... 82 

Marçais, C. .................................... 31, 74 

Marcantonio, P. .................................. 90 

March, K. ............................................. 95 

Marchan, Carranza, E. .................... 117 

Marchetti, G. ....................................... 60 

Marchon, C. ...................................... 115 

Marciniak, W. .................................... 116 

Marcoyannopoulou, Fojas, H. ........ 101 

Marcucci, R. .................................. 70, 95 

Marduel, M. ......................................... 50 

Margariti, P. ...................................... 126 

Margaritis, M. .................................... 112 

Margolis, L. ............................. 51, 61, 64 

Marina, Breysse, M. ......................... 117 

Marinari, E..................................... 28, 67 

Mark, L. ............................................. 118 

Márk, L. ............................................... 78 

Markatseli, T.E. ................................ 126 

Markovic-Lipkovski, J. ..................... 119 

Markus, H.S. ..................................... 114 

156 

Marleau, S. ......................................... 68 

Marmash, N. ....................................... 65 

Marmontel, O. .............................. 74, 82 

Marotta, G. ......................................... 51 

Marques, L. ........................................ 52 

Marques-Pinheiro, A. ........................ 26 

Marre, M. .......................................... 120 

Marsche, G. .................................. 49, 83 

Marszałek, A. ................................... 125 

Marta, D. ........................................... 110 

Martin, C. ...................................... 80, 81 

Martin, L. ............................................. 57 

Martín-Campos, J.M. ........................ 10 

Martinez, Comendador, J.M. ........... 88 

Martinez, L.................................... 52, 85 

Martinez, L.O. .................................... 16 

Martinez, M. ....................................... 54 

Martinez, Martinez, A. ................. 97, 98 

Martínez-González, M.Á................... 35 

Martín-Ventura, J.L. .......................... 41 

Martiny, L. ........................................... 52 

Mary-Krause, M. .......................... 52, 83 

März, W. .......................... 77, 80, 83, 101 

Marzocchi-Machado, C.M. ............... 93 

Marzougui, F. ................................... 104 

Mas, A. .............................................. 110 

Masana, L. ............................. 17, 36, 102 

Mascoli, F. .......................................... 60 

Mashayekhi, S. .................................. 66 

Maslak, E. ................................... 89, 121 

Maślak, E. ......................................... 106 

Masoura, C. ........................................ 44 

Massama, L. ..................................... 121 

Mastroiacovo, D................................. 90 

Masuda, D. ................................. 87, 109 

Masuda, T. ....................................... 118 

Mata, K. .............................................. 95 

Mateo-Gallego, R. ............................. 84 

Mateuszuk, L. ............................. 89, 121 

Matos, L.N. ................................... 43, 85 

Matsuda, M. ....................................... 94 

Matsuda, T. ........................................ 54 

Matsumoto, T. .................................... 32 

Matsumura, T. .................................... 55 

Matsunaga, A. .................................. 108

Matsuo, K. ........................................... 73 

Matsuoka, E. ....................................... 59 

Matsuoka, T. ....................................... 79 

Matsushima, T. ................................. 106 

Matsuyama, A. ................................. 109 

Mattei, C. ........................................... 101 

Matter, C.M. ........................................ 47 

Mattner, F. ........................................... 87 

Maurice, P. .................................... 52, 61 

Mavronasiou, E. ............................... 114 

Mayasari, D.S. .................................... 11 

Mayer, O. ...................................... 40, 96 

Mayr, M. ............................................ 114 

Mažeikienė, A. .................................. 118 

Mazer, N.A. ................................... 33, 77 

Mazerkina, N.A. ................................ 105 

Mazighi, M..................................... 34, 56 

Mazur, A. ........................... 107, 118, 122 

Mazzolai, L. ......................................... 17 

Mazzone, A. .......................... 61, 93, 108 

Mazzucco, S. .......................... 64, 65, 67 

Mazzuco, T.L. ................................... 109 

Mc, Loughlin, S. ............................... 119 

McDonald, K. ...................................... 56 

McKeigue, P. .......................... 36, 49, 78 

McKenney, J.M. ................................. 87 

McLaughlin, K. ............................ 52, 125 

McNamara, R. .................................... 22 

Meagher, E.A. .................................... 81 

Meani, P. ........................................... 110 

Mechtouff, L. ....................................... 46 

Medbury, H. ........................................ 65 

Medeiros, A.M. ................................... 81 

Medvedeva, E. ................................... 60 

Medvegy, M. ..................................... 102 

Meguro, Y. .......................................... 93 

Mehinagic, D....................................... 92 

Mehri, S. .............................. 85, 101, 126 

Mehta, V. ............................................. 59 

Meikle, P. .......................................... 119 

Meikle, P.J. ................................... 22, 30 

Meilhac, O. ....... 34, 38, 48, 56, 57, 64, 73 

Meinitzer, A. ...................................... 101 

Melander, O. ....................................... 17 

Melchionna, S. .................................... 99 

157 

Meletta, R. .......................................... 98 

Mellal, K. ............................................. 68 

Mellis, S. ............................................. 26 

Mellström, D. ........................................ 7 

Melnichenko, A.A. ............................. 71 

Melnichenko, G. ................................. 97 

Melone, M. ............................. 48, 71, 105 

Mendoza, J. ........................................ 26 

Mendoza-Barberà, E. ........................ 10 

Menegazzi, M. ................................... 67 

Mensink, R. ........................................ 30 

Mensink, R.P. ............................... 22, 74 

Mention, K. ......................................... 80 

Merino, J. ............................... 17, 36, 102 

Merkely, B. ....................................... 127 

Merkler, A. .......................................... 82 

Merlin, M. ............................................ 74 

Meroño, T. ........................................ 108 

Metaxa, V. .......................................... 44 

Metelskaya, V.A................................. 79 

Metso, J. ........................................... 128 

Meurs, I. .............................................. 65 

Meydani, M. ...................................... 126 

Mező, I. ....................................... 78, 118 

Mezzano, D. ....................................... 34 

Mezzetti, A.......................................... 90 

Miantezila, Basilua, J. ....................... 83 

Miarka, P. ......................................... 127 

Micallef, P.A. ...................................... 66 

Miccoli, R. ........................................... 51 

Miceli, A. ............................................. 93 

Michalsky, D. .................................... 125 

Michel, J.B. .............................. 34, 38, 48 

Michel, J.-B. .............................. 5, 30, 34 

Michel, J.-B. ....................................... 48 

Michel, J.-B. ....................................... 56 

Michel, J.-B. ....................................... 57 

Michel, J.-B. ....................................... 61 

Michel, J.-B. ....................................... 64 

Michel, J.-B. ..................................... 114 

Michishita, R. ..................................... 54 

Mickley, H. .......................................... 45 

Mihas, C. ............................................ 84 

Mikhailidis, D.P. ...................... 45, 49, 50 

Mikolajczyk, T. ............................. 60, 61

Mikołajczyk, T. .................................. 116 

Mikolajczyk, T.P. ................................ 66 

Miled, A. ........................................ 31, 76 

Milei, J. .............................................. 119 

Milenkovic, D. ..................... 43, 107, 118 

Milidis, T. ............................................. 82 

Milionis, H.J. ..................................... 120 

Miliou, A. ............................................. 44 

Miljkovic, M. ........................................ 94 

Millar, J. ................................................. 2 

Miller, K. .............................................. 26 

Miller, S.A. ........................................... 82 

Min, P.-K. ............................................ 70 

Minakawa, Y. ...................................... 93 

Miname, M. ......................................... 42 

Minelli, S. ........................................... 107 

Ming, J. ................................................ 47 

Ming, W. .............................................. 65 

Minicocci, I. ................................... 10, 31 

Mintale, I. ........................................... 125 

Minutolo, A. ......................................... 16 

Miranda-Zamora, R. .......................... 90 

Mirel, D. ............................................... 33 

Mislea, O. .................................. 104, 107 

Mitani, K. ........................................... 123 

Mitchenko, O. ..................................... 82 

Miteva, Y. .......................................... 108 

Mitrofanov, K.Y. ................................ 100 

Mitrogianni, Z. ..................................... 76 

Mitterhofer, A.P. ........................... 28, 67 

Mittlboeck, M. ................................... 114 

Miura, K. ............................ 48, 77, 91, 95 

Miura, S. ............................................ 108 

Miura, Y. .............................................. 62 

Miyagawa, N. ...................................... 95 

Miyamatsu, N. ............................ 78, 103 

Miyamoto, Y. ....................................... 80 

Miyashita, K. ................................. 74, 75 

Miyoshi, T. ..................................... 86, 93 

Mizue, H. ............................................. 93 

Mizuno, S. ..................................... 29, 55 

Mizuno, T. ................................... 42, 106 

Mlynarik, V. ......................................... 17 

Mmamarelis, I.E. ................................ 97 

Modéer, T. ........................................... 63 

158 

Mody, F. ............................................ 111 

Moesgaard, S.G. ............................... 95 

Mohd, Ishak, N.H. .............................. 66 

Mohd, Ismail, A. ...................... 58, 66, 72 

Mohd, Kornain, N.K. .......................... 58 

Mohd, Mokhsin, N.A.......................... 72 

Mohd, Nawawi, H. .................. 58, 66, 72 

Moisenovich, M. ................................. 74 

Moldoveanu, E. ................................ 110 

Mollaki, V. ........................................... 81 

Möller, B. .......................................... 106 

Mombelli, G. ....................................... 96 

Momiyama, Y. .................................. 121 

Momot, A. ......................................... 100 

Monaco, C. ......................................... 63 

Monguchi, T. .............................. 39, 120 

Monier, S. ......................................... 104 

Monk, D. ............................................. 74 

Montalescot, G................................. 5, 8 

Montali, A............................................ 31 

Montecucco, F. ............................ 47, 48 

Monterio, A.M. ................................. 101 

Moon, J. .............................................. 95 

Moon, M.K. ......................................... 49 

Moore, K. ............................................ 15 

Moore, K.J. ......................................... 37 

Moore, X.L. ......................................... 27 

Morand, C. ........................... 43, 107, 118 

Morange, P.-E. ................................... 54 

Mordhwaj, P. .................................... 108 

Moreira, T.B. ................................ 71, 72 

Moreno, J.-A. ..................................... 56 

Moreno, L.A. ......................................... 7 

Moreyra, E. ................................. 96, 102 

Morgantini, C. ..................................... 35 

Mörgelin, M. ....................................... 73 

Mori, K. ................................... 39, 74, 120 

Mori, M. ......................................... 50, 80 

Mori, T. ...................................... 119, 120 

Mori, Y. ................................................ 59 

Moriarty, P.M. ................................... 124 

Morimoto, A. ............................... 78, 103 

Morino, A. ................................... 78, 103 

Morita, H. ............................................ 86 

Morozov, A. ........................................ 18

Morozov, I.A. ...................................... 62 

Morvan, M. .......................................... 38 

Moshkin, A.V. ................................... 105 

Moskaleva, N. ..................................... 56 

Mossinson, D. ................................... 116 

Mostowik, M. ....................................... 39 

Motazacker, M.M. .............................. 55 

Motocu, M. ........................................ 104 

Moulias, A. ........................................ 114 

Moulin, P. ............. 4, 9, 31, 34, 74, 81, 82 

Moulin, Philippe .............................. 4, 15 

Moulopoulos, L. .................................. 82 

Moura, F. ............................................. 78 

Mousavinasab, S.N. .......................... 91 

Moussa, A. .................................... 83, 92 

Moutzouri, E. ...................................... 88 

Movassaghpur, A. .............................. 66 

Mozwillo, J.S. .................................... 121 

Mrowiecki, T. ...................................... 61 

Mrowiecki, W. ..................................... 61 

Mrudula, Spurthi, K. ........................... 85 

Mu, L. ................................................... 98 

Muačević-Katanec, D. ....................... 82 

Muchova, L. ...................................... 120 

Muderrisoglu, H. ............................... 109 

Müderrisoğlu, H. ......................... 89, 107 

Muggia, C. ......................................... 101 

Mühlberg, K. ..................................... 107 

Mulder, M. ........................................... 70 

Muller, A. ........................................... 119 

Müller, A. ............................................. 98 

Muller, C. ....................................... 37, 70 

Müller, G. ............................................. 86 

Muller, J.E. .......................................... 22 

Müller-Werdan, U. .............................. 64 

Muller-Wieland, D. ............................. 86 

Münch, R. ............................................ 68 

Mündlein, A. ...................................... 102 

Münzel, T. ............................................. 8 

Murakami, M. ...................................... 75 

Murakami, Y. ................................ 48, 95 

Murano, T. ................................... 31, 111 

Muro, A. ................................... 52, 62, 94 

Murohara, T. ............................... 58, 103 

Musikhina, N. ............................ 107, 110 

159 

Musil, F. ............................................ 110 

Musliner, T.......................................... 85 

Mustafina, S. .................................... 102 

Mysliwiec, M. .............................. 78, 111 

N 

Na, J.H. .................................. 53, 63, 122 

Na, J.O. ............................................... 36 

Nachtigal, P. .......................... 57, 89, 120 

Naderi, G.A. ....................................... 70 

Nael, C. ............................................. 122 

Naelten, G. ....................................... 123 

Naessen, T. ........................................ 93 

Nagano, C. ....................................... 123 

Nagashima, S. ................................... 73 

Nagayama, D. ............. 31, 109, 111, 123 

Nagel, E. ............................................. 98 

Nagumo, A. ................. 31, 109, 111, 123 

Nair, A. ................................................ 81 

Nair, D. ................................................ 81 

Nakajima, H. .......................... 39, 74, 120 

Nakajima, K. ................................. 74, 75 

Nakamoto, K. ..................................... 94 

Nakamura, K. ..................................... 86 

Nakamura, M. .............................. 32, 48 

Nakamura, S. ............................... 29, 55 

Nakamura, Y. ............................... 76, 91 

Nakandakare, E. ................... 30, 83, 109 

Nakandakare, E.R. .......................... 128 

Nakanishi, C. ................................ 50, 80 

Nakaoka, H. ..................................... 109 

Nakatani, K. ...................................... 109 

Nakayama, K. .................................... 11 

Nakayama, R. .................................... 93 

Nakbi, A. ..................................... 85, 126 

Naknadakare, E. ................................ 78 

Namiki, A. ........................................... 55 

Nanjee, M.N. ...................................... 33 

Nanobachvili, J. ............................... 114 

Naoi, S. ............................................... 42 

Napoli, A. ............................................ 97 

Nara, M. .............................................. 75 

Narbute, I. ......................................... 125 

Narverud, I.......................................... 80

Nash, G. .............................................. 34 

Näslund, U. ......................................... 61 

Natali, A. ........................................ 20, 35 

Natoli, A.K. .......................................... 44 

Nauck, M. .......................................... 110 

Naukkarinen, J. .................................. 33 

Nawawi, H. ........................................ 120 

Nayeri, H. ............................................ 70 

Nazarkina, I.M. ................................... 78 

Nazih, E.-H. ........................................ 35 

Ndiaye, N.C. ..................................... 106 

Neffati, S. .................................... 92, 104 

Neggazi, S. ......................................... 74 

Negrao, C.E. ..................................... 115 

Negrean, V. ............................... 104, 107 

Negre-Salvayre, A. ............................ 70 

Nègre-Salvayre, A. ...................... 37, 38 

Negro, A. ....................................... 28, 67 

Nekaies, Y. ................................. 79, 119 

Nematbakhsh, M. ............................... 56 

Nemeckova, I. ............................ 57, 120 

Nemoto, T. .......................... 73, 109, 122 

Nessler, J. ........................................... 39 

Nestel, P. ........................................... 119 

Neumayer, C. ................................... 114 

Newby, A.C. ........................................ 59 

Newby, D.E. ...................................... 124 

Newman, J. ....................................... 122 

Ng, T.W. .............................................. 30 

Ngallhy, E. ......................................... 105 

Ngo, Sock, E.T. ................................ 115 

Nguyen, M.T. .................................... 110 

Nguyen, P. .......................................... 35 

Niccoli, G. .................................... 40, 107 

Nicholls, S. .......................................... 22 

Nicholls, S.J. ....................................... 45 

Nicoletti, A. .......................................... 38 

Nicoll, R. .............................................. 97 

Nielsen, S.F. ....................................... 40 

Nieuwdorp, M. .................................... 36 

Nieves, J. ............................................ 80 

Nighoghossian, N. ....................... 46, 64 

Niimi, M. ............................................ 123 

Niiyama, M. ......................................... 32 

Nijhuis, M.M.O. ................................... 66 

160 

Nikfar, S. .................................. 45, 49, 50 

Nikiforov, N. ........................................ 74 

Nikiforov, N.G. ................................... 70 

Nikitin, Y. ............................................ 84 

Nikitskaya, E. ............................... 51, 64 

Nikolaou, C. ........................................ 38 

Nikolaou, V. ...................................... 120 

Nikolic, D. ................................ 45, 49, 50 

Nilsson, J. ........................ 18, 21, 75, 110 

Nilsson, Jan ........................................ 21 

Nilsson, M. .................................... 7, 110 

Nilsson, S. .......................................... 75 

Nilsson, S.K. ................................. 10, 31 

Ninio, E. ................................. 18, 47, 117 

Nishida, M. ....................................... 109 

Nishikawa, T. ............................. 78, 103 

Nishimoto, O. ..................................... 94 

Nishinari, M. ....................................... 56 

Nishio, M. .......................................... 122 

Nishiuchi, J. ........................................ 94 

Nishiyama, H. ..................................... 94 

Nissen, S. ........................................... 15 

Nitulescu, M. .................................... 110 

Niwano, S. ........................................ 118 

Nizomov, A. ........................................ 89 

Nizomov, A.A. .............................. 65, 89 

Noa, M. ............................................... 38 

Nobecourt, E. ..................................... 44 

Nobrega, O. ........................................ 71 

Noce, V. .............................................. 97 

Noda, C. ............................................ 118 

Noels, H. ............................................. 67 

Noeva, E. ............................................ 47 

Nofer, J.-R. ......................................... 76 

Nofroni, I. ...................................... 28, 67 

Noguchi, T. ................................... 50, 80 

Nogueira, M. ............................... 53, 116 

Nohara, A. .................................... 50, 80 

Nollace, A. .......................................... 74 

Nony, S. .............................................. 82 

Norata, D. ........................................... 33 

Norata, G.D. ... 33, 34, 37, 52, 62, 67, 68, 

94, 112 

Norata, Giuseppe Danilo .................. 23 

Nordestgaard, B. ............ 1, 3, 28, 36, 55

Nordestgaard, B.G. 7, 20, 32, 40, 54, 84 

Nordestgaard, Børge ........................... 3 

Nosaka, K. .......................................... 93 

Nosalski, R. ................................... 60, 66 

Noto, D. ............................................... 51 

Novak, K. ........................................... 125 

Novakovic, R. ................................... 119 

Nozadze, D. ........................................ 75 

Nozako, M. ........................................ 123 

Ntalas, I. ............................................ 114 

Nunes, V. ............................................ 30 

Nunes, V.S. ......................... 83, 109, 128 

Núñez, I. .............................................. 35 

Nurgazieva, D. .................................... 65 

Nurmohamed, M.T. ............................ 20 

Nusshold, C. ..................................... 124 

Nykonenko, O. .................................. 114 

Nyrén, R. ............................................. 75 

O 

Obika, S. ............................................. 44 

Obrowsky, S. .................................... 124 

Obuchi, A. ......................................... 121 

Oda, H. ................................................ 58 

Odurny, A. ......................................... 114 

Oe, H. .................................................. 86 

Ogawa, M. ........................................... 32 

Oguiza, A. ........................................... 41 

Ogura, M. ............................................ 40 

Oh, D.J. ........................... 36, 53, 63, 122 

Oh, G.T................................................ 68 

Oh, J.-H. ............................................ 111 

Oh, P.C........................................ 89, 102 

Ohama, T. ......................................... 109 

Ohguro, T. ........................................... 94 

Ohira, M. ..................... 31, 109, 111, 123 

Ohkawa, K. ......................................... 93 

Ohkubo, T. .............................. 77, 91, 95 

Ohlsson, C. ........................................... 7 

Ohmori, R. ......................................... 121 

Ohno, Y. .............................................. 86 

Ohnuki, T. ......................................... 127 

Öhrvik, J. ............................................. 36 

Ohsawa, M. ................................. 48, 111 

161 

Ohsuzu, F. ........................................ 121 

Oikonen, M. .................................. 36, 40 

Oikonomou, E. ................................... 44 

Okada, T. .......................................... 109 

Okamura, T. ........ 48, 77, 78, 80, 91, 103 

Okayama, A. .............................. 77, 111 

Oksala, N. ......................................... 101 

Oktay, G. ............................................ 69 

Okumura, K. ............................... 58, 103 

Okutsu, R.......................................... 123 

Okyay, K. ............................. 89, 107, 109 

Oláh, A.V. ........................................... 72 

Olano-Martin, E. ................................ 80 

Oliva, I. ................................................ 74 

Olivato, S. ................................ 64, 65, 67 

Olivecrona, G. ......................... 10, 31, 75 

Olivecrona, T. ..................................... 31 

Oliveira, A.E.F.D. ..................... 126, 127 

Oliveira, H.C.F. ................................ 101 

Olkkonen, V. ....................................... 31 

Olkkonen, V.M. .................................... 6 

Olkkonen, Vesa M ............................... 6 

Ollivier, V. ..................................... 30, 61 

Olsen, L.H. ......................................... 95 

Omata, K. ......................................... 125 

Omezzine, A. ........................ 83, 92, 104 

Ong, H. ................................................ 68 

Onoda, T. .................................... 32, 111 

Onodera, M. ....................................... 32 

Öörni, K. ........................................ 10, 22 

Opstad, T.B. ....................................... 55 

Oravec, S............................. 79, 108, 115 

Orekhov, A. ........................................ 72 

Orekhov, A.N. ........... 62, 70, 71, 74, 100 

Orekhova, V.A. .................................. 71 

Oresic, M. ........................................... 33 

Orho-Melander, M. ............... 17, 39, 101 

Orsoni, A. .................................... 90, 103 

Orsoni, A.K. ........................................ 22 

Ortega, E. ......................................... 126 

Ortiz, G. .............................................. 34 

Osaba, L. ............................................ 80 

Ose, L. ................................................ 80 

Oshima, S. .................................. 35, 109 

Osipenko, A.N. ................................... 77

Østerud, B. ........................................ 122 

Osuga, J.-I. ......................................... 73 

Oszkinis, G. ...................................... 125 

Otero-Losada, M. ............................. 119 

Othmani, K. ....................................... 119 

Ott, A. ................................................ 102 

Ottaviano, G. .................................... 119 

Ou, H.-Y. ............................................. 29 

Oudar, O. ............................................ 57 

Ougerram, K. ...................................... 95 

Ouguerram, K. ................ 26, 35, 50, 122 

Out, C. ................................................. 36 

Ouyang, X.-P. ..................................... 71 

Ovsyi, I. ............................................... 65 

Oyedokun, B. .................................... 120 

Ozansoy, G. ...................................... 121 

Ozbal, S. ............................................. 69 

Özçalık, E. ......................................... 107 

Ozerova, I.N. ...................................... 79 

Ozturk, Z. ............................................ 59 

P 

Pacha, J. ............................................. 64 

Pacienza, N. ....................................... 82 

Packard, C. ................................... 19, 25 

Packard, Chris .................................... 19 

Padilla, N. .......................................... 101 

Pados, G. .................................... 78, 118 

Padra, J. .............................................. 80 

Padro, T. ............................................... 6 

Pagano, S. .......................................... 47 

Pagnier, A. .......................................... 80 

Pagoni, S. ............................... 54, 82, 95 

Paillard, F. ................................. 121, 123 

Paim, B.A. ......................................... 101 

Pais, de, Barros, J.-P. ....................... 27 

Pais, R. ................................................ 32 

Pal, P. .................................................. 78 

Palacios, L. ......................................... 80 

Palagi, P.M. ........................................ 60 

Palatkina, L. ........................................ 88 

Palladini, G. ........................................ 61 

Palmer, M.K. ....................................... 44 

Palmieri, C. ....................................... 108 

162 

Palombo, D. ....................................... 47 

Palotie, A. ........................................... 33 

Pan, X. ................................................ 30 

Panagiotakos, D.B. ......................... 120 

Panagopoulou, I. ............................... 88 

Panariti, F. ........................................ 125 

Pane, B. .............................................. 47 

Panes, O. ............................................ 34 

Pang, J. ............................................. 103 

Panizon, E. ......................................... 35 

Pankajakshan, D. .............................. 51 

Panov, D. .......................................... 117 

Pantopoulou, A. ............................... 119 

Panzoldo, N.B. ...................... 71, 83, 128 

Papadimitriou, L................................. 44 

Papafaklis, M.I. ............................ 29, 55 

Papageorgiou, G. ............................ 119 

Papagoras, C. .......................... 106, 126 

Papanikolaou, A. ............................... 45 

Papastefanou, E. ............................... 82 

Paradela-Dobarro, B. ........................ 57 

Paradossi, U. ................................... 108 

Paradowski, M. ................................ 102 

Paragh, G. ......... 72, 78, 80, 95, 102, 118 

Parahuleva, M. ................................. 113 

Paranhos, G. ...................................... 90 

Parfenov, A. ....................................... 39 

Parfenova, N.S. ............................... 124 

Parhofer, K. .......................................... 5 

Park, C.G. ........................................... 36 

Park, C.-G. ......................................... 53 

Park, C.-G. ......................................... 63 

Park, C.-G. ....................................... 122 

Park, C.M............................................ 95 

Park, D.-G. ................................... 78, 90 

Park, G.-Y. .......................................... 73 

Park, H.-Y. .................................. 32, 103 

Park, J.E. ............................................ 48 

Park, J.H. .................................... 63, 122 

Park, K.-H. ........................................ 117 

Park, S.Y. ................................ 38, 59, 66 

Park, Y.W. ........................................ 112 

Parker, J. ............................................ 53 

Parker, J.D. ................................ 52, 125 

Parkes, H. ........................................... 79

Parlevliet, E.T. .................................... 16 

Parodi, O. ...................................... 62, 67 

Parolini, C. .......... 33, 35, 58, 62, 63, 126 

Parra, E.S. ............................ 78, 83, 128 

Parri, A. ............................................. 109 

Parthasarathy, S. ................. 11, 65, 108 

Parviz, B. ........................................... 113 

Pasanisi, F. ......................................... 43 

Paschopoulos, M. .............................. 57 

Pashang, M......................................... 46 

Pasqual, N. ......................................... 47 

Passarelli, M. .................................... 109 

Passet, M. ........................................... 30 

Pasterkamp, G. .................................. 66 

Patankar, J.V. ................................... 124 

Patti, L. ................................................ 43 

Patuzzo, C. ......................................... 65 

Paul, J.-L. ............................................ 30 

Paula, H. ............................................. 53 

Paultre, C. ................................... 63, 101 

Paumelle, R. ............................... 28, 105 

Paus, A. ............................................... 92 

Pavanello, C. ...................................... 96 

Pavão, M.L. ......................................... 91 

Pavlova, M.G. ................................... 105 

Pavlunina, T. ....................................... 66 

Pavlunina, T.O. .................................. 84 

Pawlak, D. ................................... 78, 111 

Pawlak, K. ................................... 78, 111 

Paximadas, S. .............................. 54, 95 

Pazzucconi, F. .................................... 96 

Pedersen, H.D. ................................... 95 

Pedersen, T. ....................................... 19 

Pedersen, Terje .................................. 19 

Pedrico, D. ........................................ 102 

Pedro-Botet, J. ......................... 109, 110 

Pedros, C. ........................................... 52 

Peel, S. ................................................ 98 

Peitsch, M.C. .................................... 117 

Peitzsch, M. ........................................ 40 

Pellegatta, F. ........................ 67, 68, 112 

Pellegrin, M. ........................................ 17 

Pellet-Many, C. ................................... 59 

Pelosi, G. ....................................... 62, 67 

Peloso, G. ........................................... 50 

163 

Pencina, M.J. ..................................... 45 

Pende, A. ............................................ 47 

Peng, J. ............................................... 73 

Peng, J.-Y. .......................................... 51 

Pera, M. ............................................ 109 

Pereira, A............................................ 92 

Pereira, V.H. ....................................... 92 

Pereira-da-Silva, T. ........................... 53 

Pérez, A. ....................................... 38, 68 

Perez, Martinez, P. .......................... 119 

Pérez-López, J................................... 84 

Pérez-Méndez, O. ............................. 77 

Pergolini, D. ........................................ 31 

Perkov, S. ......................................... 115 

Perlini, S. ............................................ 61 

Pernalete, Bustos, I.C. .................... 117 

Perova, N.V. ....................................... 79 

Perrea, D.N. ..................................... 119 

Perret, B. ...................................... 16, 85 

Perret, M. ............................................ 64 

Perret, P. ............................................ 99 

Perrin-Cocon, L. ................................ 66 

Perrot, L. ............................................. 82 

Perségol, L. ...................................... 104 

Persson, A. ....................................... 110 

Persson, L. ......................................... 39 

Pervushina, N. ................................... 70 

Pessi, T. .............................................. 63 

Petelina, T. ............................... 107, 110 

Petit, J.-M. .................................. 27, 104 

Petrak, O. ......................................... 125 

Petrashevskaya, T. ......................... 110 

Petrek, M. ........................................... 62 

Petri, M. .............................................. 64 

Petrides, F. ......................................... 51 

Petrii, M.H. ........................................ 122 

Petrischeva, A. ................................... 93 

Petrischeva, A.V. ............................... 91 

Petrkova, J. ........................................ 62 

Petrlova, J. ......................................... 73 

Pettersen, A.Å. ................................... 55 

Pettersson, K. .............................. 18, 72 

Pfeiferova, J. .............................. 57, 120 

Philippe, M.......................................... 38 

Phinikaridou, A................................... 58

Picard, P. ........................................... 123 

Pichler, M. ........................................... 86 

Piechota-Polanczyk, A. ................... 114 

Pierce, G.N. ........................................ 60 

Pietri, S. ............................................. 100 

Pigna, G. ............................................. 31 

Pignatti, P.F. ....................................... 65 

Piksasova, O. ..................................... 36 

Pilecki, W. ......................................... 116 

Pileggi, S. .......................................... 100 

Pillegand, C. ..................................... 105 

Pillois, X. ............................................. 84 

Pillot, B. ................................................. 6 

Pilz, S. ......................................... 83, 101 

Pinegina, N. .................................. 51, 64 

Pinilla, Echeverri, N. ........................ 117 

Pinna, C. ............................................. 58 

Pinotti, E. ............................................. 51 

Pinto, G.A. ........................................... 85 

Pintó, X. ............................................... 35 

Pinyol, M. .......................................... 126 

Piotrowska, A. .................................... 38 

Piqueras, Flores, J. .......................... 117 

Pirault, J. ............................................. 67 

Pirk, J. .................................................. 28 

Pirruccello, J.P. .................................. 50 

Pirvulescu, M. ..................................... 41 

Pirvulescu, M.M.................................. 41 

Pissaridi, K. ................................. 97, 104 

Pitha, J. ......................................... 28, 99 

Pitivej, Thurakit, P. ..................... 84, 100 

Pitsavos, C. ......................................... 44 

Plana, N. ............................... 17, 36, 102 

Plantaz, D. .......................................... 80 

Plat, J. ........................ 14, 22, 30, 74, 118 

Plomp, J.J. .......................................... 65 

Pocoví, M. ........................................... 84 

Podhorska-Okołów, M. ...................... 38 

Pogorelova, O. ................................... 91 

Pohlmann, A.R. ................................ 123 

Poitry-Yamate, C................................ 17 

Pojskic, B. ........................................... 92 

Pojskic, M. ........................................... 92 

Pokrovsky, S. ................................ 86, 87 

Poledne, R. ............................. 28, 64, 99 

164 

Polimeni, L.......................................... 84 

Polis, A.B. ........................................... 85 

Polonskaya, Y. ................................. 127 

Polyanskaya, E. ................................. 79 

Ponkin, S. ........................................... 91 

Pons, J. ............................................... 87 

Popova, A. .......................................... 65 

Portelance, S.G. ................................ 68 

Português, J. ...................................... 92 

Posadas-Romero, C. .................. 77, 99 

Posadas-Sánchez, R. ....................... 99 

Postmus, I. ......................................... 88 

Potekhina, A. ...................................... 47 

Poteshkin, Y. ...................................... 97 

Potor, L. .............................................. 29 

Povoa, R.M. ....................................... 43 

Power, P. ............................... 48, 71, 105 

Pozzi, C. ........................................... 112 

Prathiba, N. ........................................ 85 

Prehn, C. .................................... 75, 110 

Prieur, X. ....................................... 6, 102 

Princen, H.M.G. ........................... 49, 71 

Proietta, M. .............................. 28, 62, 67 

Prokazova, N. .................................... 66 

Prolini, C. ............................................ 86 

Proniewski, B. ............................ 57, 106 

Prosser, H. ......................................... 42 

Prostran, M. ................................ 94, 113 

Protti, A. .............................................. 58 

Proust, C. .......................................... 117 

Provatorov, S. .................................... 47 

Prüfer, J. ........................................... 107 

Prüfer, N. .................................. 107, 112 

Prugger, C. ......................................... 54 

Pucheu, Y. .......................................... 84 

Puig, de, Dou, J. .............................. 110 

Pujos-Guillot, E. ............................... 122 

Pukite, K. .......................................... 113 

Pulakazhi, Venu, V.K. ............ 52, 62, 94 

Puntmann, V. ..................................... 98 

Puntoni, M. ......................................... 62 

Puntoni, M.R. ..................................... 67 

Puri, R. ................................................ 22 

Pussinen, P. ....................................... 61 

Pylaeva, E. ......................................... 47

Pyysalo, M. ......................................... 63 

Q 

Qian, H. ............................................... 40 

Qian, S. ............................................... 33 

Quan, H. .............................................. 40 

Quax, P. ........................................ 18, 61 

Quax, P.H.A. ................................. 41, 47 

Quelhas, I. ........................................... 92 

Quillard, T. .......................................... 62 

Quinn, C.M. ......................................... 74 

Quintao, E. .......................................... 30 

Quintao, E.C.R. ............................ 78, 83 

Quintão, E.C.R. ................................ 128 

Quon, M. ............................................. 89 

R 

Raal, F. .......................................... 22, 44 

Raal, F.J. ....................................... 15, 44 

Rabelink, T.J......................................... 8 

Rabès, J.-P. .................................. 26, 50 

Rached, F.H. ...................................... 42 

Radenković, M. ................................ 113 

Rader, D. ............................................. 10 

Rader, D.J. .................................... 10, 81 

Radovic, B. ....................................... 124 

Ragia, G. ............................................. 81 

Ragino, Y. ................................... 91, 127 

Rahimian, R. ....................................... 56 

Rahman, T. ....................................... 120 

Rainger, E. .......................................... 34 

Raitakari, O. ........................................ 33 

Raitakari, O.T. ............ 7, 32, 36, 40, 101 

Raitoharju, E. .................................... 101 

Rajesh, Kumar, G. ............................. 85 

Rakowska, A..................................... 116 

Ramet, J. ........................................... 104 

Ramón, J.M. ..................................... 109 

Ramos, J. .......................................... 118 

Ramos, S.G. ....................................... 95 

Rancic, Z. ............................................ 98 

Rangé, H. ............................................ 64 

Ranheim, T. ...................................... 113 

165 

Rantakömi, S.H. ................................ 39 

Rantapää-Dahlqvist, S. ................... 106 

Raposeiras-Roubín, S. ..................... 57 

Ras, R.T. ............................................ 43 

Rashid, S. .............................. 48, 71, 105 

Raskina, K. ......................................... 47 

Rasmussen, K.L. ............................... 84 

Rastelli, F.......................................... 112 

Ratziu, V. ............................................ 32 

Raungaard, B. .................................... 50 

Rauramaa, R. ..................................... 39 

Ravagnani, F.G. ................................ 90 

Ray, K.K. ............................................ 45 

Ray, P.C. ............................................ 75 

Raymond-Letron, I. ........................... 37 

Rebhi, L. ................................ 83, 92, 104 

Recio, C. ............................................. 41 

Reddy-Luthmoodoo, M. .................... 44 

Redfors, B. ......................................... 53 

Reel, B. .................................... 59, 60, 69 

Reffelmann, T. ................................. 110 

Rehakova, L. ...................................... 64 

Reiber, I. ..................................... 78, 118 

Reichardt, F. ....................................... 75 

Reija, Lopez, L. ................................ 125 

Reijnders, D. ...................................... 36 

Reiner, Ž. ............................................ 82 

Reiner, Zeljko ..................................... 17 

Rejeb, J. ................................. 83, 92, 104 

Remaley, A. ........................................ 22 

Remaley, A.T. .................................... 27 

Ren, Z. ................................................ 29 

Renard, M. ........................................ 109 

Renault, M.-A. .................................... 28 

Rensen, P.C.N. ................. 16, 49, 65, 71 

Rensen, S. .......................................... 71 

Ressureição, K. ............................... 115 

Retterstøl, K. ...................................... 80 

Revuelta-Lopez, E. .............................. 6 

Rewiuk, K. ........................................ 116 

Rey, A. .............................................. 122 

Reynaud, A. ....................................... 84 

Rha, S.-W. ....................... 36, 53, 63, 122 

Riahin, A. ............................................ 63 

Riant, E. .............................................. 49

Ribalta, J. ...................................... 36, 74 

Riccardi, G. ......................................... 43 

Ricordeau, P. ...................................... 32 

Riga, M. ............................................... 45 

Rigotti, A. ............................................. 34 

Riklund, K. ........................................... 61 

Rim, S.-J. ............................................ 70 

Rio, P. .......................................... 53, 116 

Riou, L.M. ............................................ 99 

Ripatti, S. ............................................. 33 

Ritsch, A. ............................................. 77 

Rivellese, A. ........................................ 17 

Rivellese, A.A. .................................... 43 

Rivera, Bernardoni, E. ..................... 117 

Rivera, M. ............................................ 63 

Rivieccio, A. ........................................ 43 

Rizos, C.V. .......................................... 86 

Rizos, E.C. .......................................... 76 

Rizzo, L. .............................................. 62 

Rizzo, M. ................................. 45, 49, 50 

Ro, H.-S. ............................................. 30 

Roatti, A. ............................................. 59 

Robciuc, M. ......................................... 10 

Robert, L. ............................................ 52 

Roberto, M. ......................................... 40 

Robillard, P. ................................ 90, 108 

Robin, I. ............................................. 104 

Rocchiccioli, S. ................................... 62 

Rochette, L. .................................. 53, 58 

Rodiño-Janeiro, B.K. ......................... 57 

Rodriguez, C..................................... 109 

Rodríguez, C. ..................................... 92 

Rodriguez, J. ...................................... 65 

Rodríguez, J. ...................................... 68 

Rodriguez, Leal, C. .......................... 121 

Rodríguez, M.A. ................................. 36 

Rodríguez, Ortega, K.D. ................. 127 

Rodriguez, Padilla, J. ...................... 100 

Rodríguez-Granillo, G. .................... 119 

Rodríguez-Rey, J.C. .......................... 84 

Roeten, M.K. ......................................... 8 

Roeters, van, Lennep, J. ................... 70 

Roeters, van, Lennep, J.E. ............... 51 

Rog, T. ................................................. 70 

Rogolino, A. .................................. 70, 95 

166 

Rogowski, J. ....................................... 57 

Rogowski, O. .................................... 105 

Rogoza, A. .......................................... 91 

Roguin, N............................................ 96 

Rohrer, L. ............................................ 71 

Roig, R. ............................................... 10 

Roivainen, A. ...................................... 46 

Rojo, D. ............................................... 82 

Romain, C. ....................................... 118 

Romanelli, M.G. ................................. 67 

Romanov, V. ...................................... 82 

Romanov, Y. ...................................... 66 

Romdhane, M. ................................. 104 

Rome, S. ............................................. 31 

Romero, Rodriguez, N. ............... 97, 98 

Romero, Vazquianez, M. ............ 97, 98 

Romero-Hidalgo, S. .......................... 99 

Romero-Mamani, E.S. ...................... 35 

Romier-Crouzet, B. ........................... 61 

Romijn, H. ........................................... 36 

Romijn, J.A. .................................. 16, 71 

Ronda, N. ........................................... 71 

Roquilly, A. ......................................... 76 

Ros, E. ............................... 17, 26, 35, 84 

Rosa, J. ............................................. 125 

Rosales, R. ......................................... 74 

Rosenbaum, D. ..................... 32, 82, 113 

Rosengren, B. .................................... 10 

Rosic, A. ............................................. 92 

Rosing, K. ........................................... 76 

Ross, R. ................................................ 9 

Rossetti, M.B. ................................... 116 

Rossi, M. ............................................. 20 

Rossignol, P. ...................................... 48 

Rossomanno, S. ................................ 77 

Rouanet, J.-M. ................................. 118 

Rouer, M. ............................................ 38 

Rouis, K. ............................................. 92 

Roulot, D. .......................................... 105 

Roussel, R. ................................. 32, 120 

Rousselot, D.B. .................................. 82 

Roux-Lombard, P. ............................. 47 

Rovani, J.C. ...................................... 101 

Roy, J. ................................................. 66 

Rubanenko, O.A. ......................... 78, 92

Rubba, P. ............................................ 51 

Rubio, Alvarez, J. ....................... 88, 125 

Rubio, Taboada, C. ......................... 125 

Rubtsov, P.M. ..................................... 62 

Rudel, L. .............................................. 22 

Rudler, M. ........................................... 32 

Rudling, M. .............................. 39, 76, 83 

Ruidavets, J.B. ................................. 105 

Ruidavets, J.-B. .................................. 85 

Ruivo, J. .............................................. 59 

Ruiz-Gutiérrez, V. .............................. 35 

Ruiz-Valdepeñas, Herrero, L. ......... 117 

Rukh, G. ............................................ 101 

Ruokonen, A. ...................................... 33 

Ruotolo, A. .......................................... 51 

Ruotsalainen, A.-K. ............................ 30 

Rusiecki, L. ....................................... 116 

Russell, D. ........................................... 94 

Rusu, R. ............................................ 106 

Ryazankina, N. ................................... 64 

Rybalkin, I. .......................................... 75 

Rye, K.-A. ................................ 27, 31, 42 

Rysz, J. ............................ 45, 49, 50, 102 

Ryu, J.K. ............................................ 112 

S 

Sabaka, P. ................................ 108, 115 

Sabatine, M.S. .................................... 44 

Sabbadini, R. ...................................... 38 

Sabench, F. ........................................ 74 

Sabin, M.A. ........................................... 7 

Sadeghian, H. ..................................... 46 

Sadek, A. ........................................... 110 

Saely, C. .............................................. 86 

Säemann, M.D. .................................. 49 

Safarova, M. ................................. 86, 87 

Sagan, A. ............................................ 61 

Saha, D. .............................................. 99 

Saha, S.......................................... 94, 99 

Sahebjam, M. ..................................... 46 

Sahoudi, A. ......................................... 52 

Saiki, A. ....................... 31, 109, 111, 123 

Saint-Charles, F. ................................ 67 

Saito, N................................................ 57 

167 

Saito, S. ........................................ 29, 55 

Saito, Y. .............................................. 13 

Saito, Yasushi .................................... 13 

Saitoh, Y. ............................................ 95 

Saka, S. .............................................. 88 

Sakai, K. ............................................. 73 

Sakamoto, S. ..................................... 74 

Sakata, K. .............................. 32, 48, 111 

Sakly, M. ...................... 79, 103, 104, 119 

Sako, H. ............................................ 108 

Sakri, F.H............................................ 72 

Saku, K. ............................................ 108 

Sakuma, K. ....................................... 111 

Sala, A. ............................................. 126 

Sala, F. ..................................... 33, 37, 68 

Salagovic, J. ....................................... 99 

Sałakowski, A. ................................. 116 

Sala-Newby, G.B. .............................. 59 

Salari, P. .................................. 45, 49, 50 

Sala-Vila, A. ................................. 17, 35 

Salazar-Pelaez, L.M.......................... 60 

Sales, K.P.F.d. ......................... 126, 127 

Salleron, J. ........................................... 7 

Salles, J. ............................................. 90 

Salomaa, V. ........................................ 33 

Salvayre, R. ............................. 37, 38, 70 

Samarut, J. ......................................... 69 

Samokhodskaya, L.A. ....................... 62 

Samokhodskaya, L.M. ...................... 62 

Samovilova, N. ................................... 66 

Samoylova, E.V. ................................ 84 

Sampaio, E. ...................................... 109 

Sanak, M. ................................... 80, 127 

Sanders, J.-S.F. ................................. 49 

Sanjib, Sahu, K. ................................. 85 

Santos, I. ............................................ 80 

Santos, N. ................................... 53, 116 

Santos, R.D. ............................ 3, 42, 115 

Santos, Raul D................................... 23 

Santos, S. ........................................... 71 

Santovito, D. ....................................... 90 

Santtila, M. ......................................... 69 

Sanyanusin, P. ................................. 108 

Sanz, B. .............................................. 80 

Sapegin, A. ......................................... 78

Saponaro, C. ...................................... 59 

Saponjski, J. ....................................... 98 

Saraiva, F.K. ....................................... 78 

Saraste, A. .......................................... 46 

Sarcina, C. ........................................ 112 

Sarin, A.-P........................................... 33 

Sarkadi, H. ........................................ 127 

Sartini, S. ............................................. 59 

Sarutipaiboon, I. ......................... 99, 100 

Sasaki, H. .......................................... 111 

Sasaki, M. ......................................... 120 

Sasiela, W.J. ....................................... 87 

Sassolas, A. ............................ 31, 74, 82 

Sastre, C. ............................................ 41 

Sato, K. .......................................... 32, 47 

Sato, N. ............................................... 77 

Sato, Y. ................................ 31, 111, 123 

Sattar, N. ......................................... 1, 20 

Sattar, Naveed ................................... 20 

Sattler, W. ......................................... 124 

Saukko, P. ........................................... 46 

Sawabe, M. ......................................... 62 

Sawamura, T. ....................................... 6 

Sawayama, Y. .................................. 124 

Sayeh, A. ........................................... 113 

Sazonova, M.A. ................................ 100 

Sbrana, S. ........................................... 67 

Scalissi, N. .......................................... 90 

Scarlett, S. ........................................ 124 

Scarpellini, E....................................... 16 

Schaefer, E. .................................. 22, 91 

Schaper, N. ......................................... 50 

Scharin, Täng, M................................ 53 

Scharnagl, H. .......................... 77, 80, 83 

Scherbakova, L. ............................... 127 

Scherrer, D.Z. ............................. 83, 128 

Schiavino, D. .............................. 40, 107 

Schibli, R. ............................................ 98 

Schiopu, A. ......................................... 18 

Schipf, S. ........................................... 110 

Schlecht, K. ......................................... 64 

Schlein, C. ........................................... 31 

Schmermund, A. ................................ 97 

Schmid, M. .......................................... 41 

Schmid, S. ......................................... 112 

168 

Schmidt, C. ......................................... 53 

Schmidt, I.............................................. 8 

Schmidt, S.E. ..................................... 95 

Schmidt, W. ........................................ 87 

Schnecke, V. ...................................... 36 

Schneider, Wolfgang......................... 11 

Schonewille, M................................... 30 

Schoppet, M. ...................................... 11 

Schott, A.-M. ...................................... 46 

Schuchardt, M. ......................... 107, 112 

Schunkert, H. ..................................... 68 

Schwandt, P. ..................... 116, 127, 128 

Schwartz, C. ....................................... 22 

Scott, R. ........................................ 22, 44 

Scuro, A. ....................................... 65, 67 

Sebzda, T. ........................................ 116 

Sechi, L.A. ........................................ 115 

Segarra, E. ....................................... 110 

Segawa, T. .............................. 32, 48, 94 

Segre, A. ........................................... 115 

Segura, E.................................. 109, 121 

Seidlerova, J. ..................................... 96 

Seleznev, E. ....................................... 60 

Seljeflot, I. ................................... 55, 116 

Selseth, B. .......................................... 92 

Selvaraj, V. ......................................... 60 

Selvarajan, K. ..................................... 65 

Selvey, S. ........................................... 44 

Semenova, A. .................................... 75 

Semenovykh, P. .............................. 110 

Sener, M. .......................................... 126 

Senthong, V. ......................... 84, 99, 100 

Sentieri, C. .......................................... 59 

Seo, H.S. ............................... 36, 53, 122 

Seo, H.-S. ........................................... 63 

Seo, J. ......................................... 89, 102 

Seo, J.-B. ............................................ 78 

Seo, K.W. ........................................... 59 

Seppälä, I. ........................................ 101 

Seres, I. ........................... 72, 80, 95, 102 

Sergeeva, E.G. .................................. 99 

Sergienko, I. ....................................... 75 

Serhan, N. .......................................... 16 

Serlie, M. ............................................ 36 

Serrano, Jr, C.V. ................................ 42

Serre, V. .............................................. 50 

Sérusclat, A. ................................. 64, 82 

Settasatian, C. .............. 84, 99, 100, 108 

Settasatian, N. .............. 84, 99, 100, 108 

Sevin, G. ............................................. 69 

Seye, C................................................ 33 

Shah, A................................................ 85 

Shah, C. .............................................. 87 

Shah, P.K. ........................................... 81 

Shahamfar, J. ..................................... 39 

Shahamfar, M. .................................... 39 

Shahbaz, M......................................... 86 

Shakhtshneider, E. ............................ 84 

Shamburek, R. ................................... 22 

Shanahan, C.M. ................................. 11 

Shapira, I. .......................................... 105 

Sharaf, A. .......................................... 110 

Sharifi, M. ............................................ 81 

Sharma, P.L. ......................................... 8 

Sharma, S. ............................................ 8 

Shattat, G. ......................................... 123 

Shchelkunova, T.A. ........................... 62 

Shchukin, Y......................................... 60 

Shear, C.L. ........................................ 123 

Shearman, C. ................................... 114 

Shearston, K. ...................................... 31 

Shelton, D. .......................................... 87 

Sheu, W.H.-H. .................................... 71 

Shi, G.-Y. ............................................. 29 

Shibata, M. .......................................... 55 

Shibata, M.-A. ..................................... 44 

Shiffman, D. ........................................ 88 

Shikata, K. ......................................... 124 

Shima, A. ..................................... 78, 103 

Shimizu, T. .......................................... 58 

Shin, D.-G. ........................................ 117 

Shin, E.K. .............................. 89, 95, 102 

Shin, M.-S. .......................................... 43 

Shinichi, O. ......................................... 56 

Shinohara, M. ............................. 39, 120 

Shirai, K. ...................... 31, 109, 111, 123 

Shiri-Sverdlov, R. ................... 16, 22, 71 

Shishkina, V. ....................................... 66 

Shishkina, V.S. ................................... 67 

Shpektor, A. ...................... 51, 58, 61, 64 

169 

Shuvalova, Y.A. ................................. 84 

Siedlecka, D. .................................... 121 

Siedlinski, M. ...................................... 60 

Siekierzycka, A. ................................. 57 

Siekmeier, R. ..................................... 83 

Sierra, Quiroga, J. ..................... 88, 125 

Siest, G. ............................................ 106 

Signoretto, C. ..................................... 64 

Sijbrands, E. ....................................... 70 

Sijbrands, E.J. .................................... 51 

Silbernagel, G. ............................. 77, 83 

Sillesen, H. ......................................... 25 

Silva, E. ............................................... 40 

Silva, J.C.Q. ....................................... 71 

Silva, S. ....................................... 53, 116 

Silva, T. ............................................. 116 

Silvennoinen, R. ................................ 33 

Silvola, J. ............................................ 46 

Simerzin, V.V. .............................. 78, 92 

Simion, V. ........................................... 41 

Simkus, G. .......................................... 40 

Simonova, G. ................................... 102 

Simonsen, J.A. ................................... 45 

Simonsen, U. ....................................... 8 

Simonyi, G. ....................................... 102 

Singla, D. ............................................ 11 

Singparu, P. ..................................... 108 

Sinisalo, J. .................................... 61, 96 

Siores, E. ............................................ 38 

Sironi, M. ............................................ 34 

Sirtori, C.R. ................ 62, 63, 81, 96, 126 

Sistonen, H. ...................................... 105 

Sitar-Taut, A.V. ................................ 104 

Sitek, B. ............................... 57, 106, 121 

Sivenius, J. ......................................... 39 

Sjåstad, I. .......................................... 113 

Sjöberg, S. .......................................... 83 

Sjouke, B. ..................................... 26, 51 

Skålén, K. ........................................... 53 

Skalska, A. ....................................... 116 

Skjelland, M. ....................................... 65 

Skop, V. .............................................. 54 

Skórka, T. ......................................... 106 

Skorupan, N. .................................... 113 

Skoumas, I. ........................................ 44

Skrbic, R. ............................................. 92 

Skuja, I. ..................................... 103, 106 

Slagboom, P.E. .................................. 88 

Slama, M. ............................................ 52 

Sloan, J.J. ........................................... 10 

Sluimer, J.C. ....................................... 47 

Smahelova, A. .................................. 110 

Smaoui, M. .................................. 85, 126 

Smedby, T......................................... 106 

Smirnov, A.N. ..................................... 62 

Smirnova, N. ....................................... 52 

Smith, D. ........................................... 126 

Soares, M. ........................................... 29 

Sobenin, I.A. ................... 62, 70, 71, 100 

Sobotka, L. ........................................ 110 

Sobrino, M. ................................. 92, 109 

Södergren, A. ................................... 106 

Söderlund, S. ................................ 33, 48 

Soeters, M........................................... 36 

Soffientini, U. .................................... 106 

Sohrabi, B. .......................................... 66 

Sokhanvar, S. ..................................... 91 

Solheim, S. ....................................... 116 

Somleva, D. ........................................ 58 

Son, K.-H. ........................................... 32 

Sonestedt, E. ...................................... 39 

Sonmez, H. ......................................... 59 

Sonoda, N. .................................. 78, 103 

Soran, H. ..................................... 72, 125 

Sörensen, K. ....................................... 61 

Soriano, F. ........................................ 110 

Sormaz, L. ........................................... 92 

Soronen, J. ......................................... 33 

Sorontila, K. ........................................ 84 

Sorsa, T. .............................................. 61 

Soto, Y. .......................................... 38, 68 

Souza, R. .......................................... 115 

Spasova, N. ........................................ 58 

Specchia, C. ..................................... 100 

Spina, R. ............................................. 51 

Spinella, G. ......................................... 47 

Sponseller, C.A. ................................. 90 

Sposito, A.C. ................................. 71, 78 

Sprandel, M.C. ................................. 115 

Sprandel, M.C.O. ............................... 72 

170 

Staels, B. ..................... 6, 28, 67, 74, 105 

Staffler, G. .......................................... 87 

Stafford, R. ......................................... 86 

Stalenhoef, A. .................................... 51 

Stalenhoef,, A. ................................... 25 

Stamboul, K. ....................................... 53 

Stan, D. ............................................... 41 

Stancak, B. ......................................... 99 

Stanek, V. ........................................... 99 

Stangl, G.I. ......................................... 32 

Stanisić, M. ....................................... 125 

Stanke-Labesque, F.................. 64, 122 

Staňková, B. ....................................... 82 

Starzyk, J. ......................................... 127 

Stathogiannis, K. ......................... 38, 45 

Stead, A. ............................................. 91 

Stef, M. ................................................ 80 

Stefanadis, C. ......................... 38, 44, 45 

Stefanovic, A. ..................................... 94 

Stefanutti, C. ...................................... 81 

Steg, P.G. ........................................... 52 

Stehouwer, C. .................................... 50 

Stein, E. .............................................. 77 

Stein, E.A........................... 19, 22, 44, 87 

Steinhagen-Thiessen, E. ............ 76, 80 

Steinkasserer, A. ............................... 68 

Steinvil, A.......................................... 105 

Stender, S. ........................................... 8 

Stengel, D. ........................................ 117 

Stępień, A. ........................................ 102 

Stępień, M. ....................................... 102 

Stepnowska, M. ................................. 57 

Sterba, M. ........................................... 57 

Stergiopulos, N. ................................. 60 

Sternak, M. ................................. 57, 106 

Stewart, R. .......................................... 89 

Stijn, C.V. .......................................... 103 

Stitziel, N. ........................................... 50 

Stocco, B. ........................................... 93 

Stojakovic, T. ..................................... 80 

Stojanov, M. ....................................... 94 

Stojanović, M. .................................. 113 

Stojkovic, I.A. ................................... 101 

Stokmane, A.S. ................................ 113 

Stone, P.H. ................................... 29, 55

Straniero, S. ........................................ 39 

Strasky, Z. ............................. 57, 89, 120 

Strauch, B. ........................................ 125 

Stroes, E. .............................. 5, 9, 36, 42 

Stroes, E.S.G. .................................... 55 

Stroes, Erik ........................................... 8 

Struijk, J.J. .......................................... 95 

Stübiger, G. ......................................... 76 

Stucchi, M. ........................................ 110 

Stukena, I. ................................. 103, 106 

Stutler, K. ............................................ 32 

Stypmann, J. ....................................... 76 

Su, J. .................................................... 63 

Subhanova, I. ................................... 120 

Succi, S. .............................................. 99 

Suffee, N. ............................................ 57 

Sugiura, T. .......................................... 94 

Sugiyama, D. ........................ 77, 78, 103 

Sugiyama, Y. ...................................... 42 

Suh, J.-W. ........................................... 49 

Suh, S.-H. ................................... 98, 112 

Suh, S.Y. ..................................... 95, 102 

Sulzbach, M. ................................. 76, 96 

Sumino, H. .......................................... 75 

Sumpio, B. ........................................ 113 

Sumrit, C. .......................................... 108 

Sun, L. ............................................... 120 

Sun, Z. ..................................... 46, 60, 98 

Sunagawa, K. ..................................... 64 

Superville, A. ...................................... 74 

Sur, S. .................................................. 60 

Surakka, I. ........................................... 33 

Surekha, Rani, H................................ 85 

Surur, A. .............................................. 96 

Sutton, A. ............................................ 57 

Suwa, J................................................ 94 

Suzuki, M. ............................. 58, 90, 103 

Sved, I. ................................................ 56 

Sviridov, D........................................... 27 

Sweidan, K. ....................................... 123 

Swergold, G.D. ............................. 26, 87 

Swiader, A. ......................................... 37 

Synetos, A. ................................... 38, 45 

Syrycki, M. ........................................ 116 

Sytdykov, I.H. ..................................... 78 

171 

Szahidewicz-Krupska, E. ............... 126 

Szawrowicz-Pelka, T. ..................... 116 

Szeberin, Z. ...................................... 127 

Szeffler, A. .......................................... 57 

Szuba, A. .................................... 38, 126 

Szutowicz, A. ..................................... 73 

T 

Tabet, F. ............................................. 27 

Tabib, A. ........................................... 114 

Tada, H. .............................................. 50 

Taddei, A. ......................................... 108 

Taghlit, R. ......................................... 119 

Taguchi, N. ................................. 58, 103 

Taharboucht, S. ................ 104, 105, 115 

Tahna, T. .......................................... 116 

Tailleux, A. ............................. 28, 74, 105 

Takagi, W. .......................................... 93 

Takahashi, K. ..................................... 58 

Takahashi, M. .................................... 73 

Takahashi, R. ............................. 58, 103 

Takahashi, S. ............................... 29, 55 

Takahashi, T. ..................................... 32 

Takahashi, W. .................................. 127 

Takai, A. ............................................ 106 

Takamatsu, H. ........................... 35, 109 

Takashima, N. .............................. 91, 95 

Takata, K. ........................................... 77 

Takbou, K. ........................................ 110 

Takeda, K. .......................................... 93 

Takhashi, M. ..................................... 102 

Takizawa, S. ..................................... 127 

Takkand, A. ...................................... 107 

Tamakoshi, A. .................................... 48 

Tamura, R. ......................................... 94 

Tan, A.R. ............................................ 22 

Tan, R. ................................................ 30 

Tanabe, K. .......................................... 45 

Tanaka, F. .................................... 32, 48 

Tanaka, H. .......................................... 54 

Tanaka, N. ........................................ 120 

Tanaka, S. .......................................... 55 

Tang, C.-K. .............................. 42, 51, 71 

Tang, J. ............................................... 33

Tang, Z.H. ........................................... 29 

Tanganelli, P....................................... 61 

Tangirala, R.K. ................................. 103 

Tania, S. .............................................. 79 

Taniguchi, H. .................................... 121 

Tanno, K. ..................................... 48, 111 

Tantipanichteerakul, K. ....... 84, 99, 100 

Tapper, E. ........................................... 30 

Tararak, E.M. ...................................... 67 

Tarasov, K........................................... 35 

Taraszkiewicz, D. ......................... 77, 85 

Tarau, R. ........................................... 106 

Tarhan, N. ......................................... 121 

Tarugi, P. ............................................. 51 

Taskinen, M.-R. .................... 1, 9, 33, 48 

Taskinen, Marja-Riitta ................... 9, 25 

Tatsidou, P. ....................................... 114 

Tatsumi, Y. .................................. 78, 103 

Tatsuno, I. ................... 31, 109, 111, 123 

Taurino, M. .............................. 28, 62, 67 

Tavares, E.R. ...................................... 68 

Tavridou, A. ........................................ 81 

Tay, C. ................................................. 18 

Tcimbal, S. ........................................ 127 

Teerajetgul, Y. .................................. 108 

Teffahi, N. ......................................... 105 

Tegani, D.M. ....................................... 43 

Teiger, E. ............................................. 52 

Teijeira, Fernandez, E. ...................... 88 

Teixeira, D........................................... 49 

Tejedor, D. .......................................... 80 

Tellis, K.............................................. 104 

Temchenko, A. ................................... 70 

Terasaka, N. ....................................... 42 

Tercé, F. .............................................. 75 

Ternovoy, S. ....................................... 97 

Terraneo, B. ........................................ 96 

Tershakovec, A.M. ............................. 85 

Terzis, I................................................ 82 

Tesfaye, S. .......................................... 54 

Tesmenitsky, Y. .................................. 62 

Thabut, D. ........................................... 32 

Theelen, W. ........................................ 67 

Theodoropoulos, K.C. ..................... 114 

Theron, H.D.T. .................................... 81 

172 

Thiyagarajan, S. ................................ 86 

Thomassen, A. ................................... 45 

Thomsen, M. ................................ 36, 55 

Thorsson, O. .................................... 116 

Tibolla, G. ..................................... 37, 68 

Ticha, A. ............................................ 110 

Tidone, C. ......................................... 112 

Tietge, U. ............................................ 72 

Tietge, U.J. ................................. 72, 103 

Tietge, U.J.F. ............................... 10, 49 

Tillander, P. ........................................ 92 

Tillin, T. .............................. 49, 78, 89, 95 

Tillmanns, H. .................................... 113 

Tilly, P. ........................................ 34, 113 

Tilstam, P............................................ 67 

Tinelli, C. ........................................... 101 

Tinoco, I. .............................. 92, 109, 121 

Tipping, P. .......................................... 18 

Tiret, L. .......................................... 8, 117 

Tiseo, G. ............................................. 31 

Titkov, A. ............................................. 78 

Tivesten, Å. .................................... 7, 69 

Tkac, I. ................................................ 99 

Toana, B. .......................................... 110 

Tobayama, H. .................................... 58 

Tobina, T. ........................................... 54 

Toczek, J. ........................................... 99 

Toda, T. .............................................. 62 

Toft, E. ................................................ 95 

Toftegaard, L.A. ............................... 116 

Toh, B.-H. ........................................... 18 

Toh, R. ................................... 39, 74, 120 

Tokgozoglu, L. ............................. 19, 25 

Tokgozoglu, Lale ................................. 5 

Toledo, E. ........................................... 35 

Tölle, M. .................................... 107, 112 

Tomankova, T. ................................... 62 

Tomaschitz, A. ........................... 83, 101 

Tomassini, J.E. .................................. 85 

Tomaszewski, M. ............................... 23 

Tomlinson, B. ..................................... 87 

Tomoike, H. ........................................ 80 

Tomono, J. ................................. 35, 109 

Tonar, Z. ............................................. 28 

Topchii, I. .......................................... 110

Toplak, H. .................................... 86, 101 

Toprak, M.S. ....................................... 59 

Torii, S. ................................................ 95 

Toro, R. ............................... 92, 109, 121 

Torqueti, M.R. ..................................... 93 

Tosolini, L. ........................................... 50 

Toth, P.P. .......................... 45, 49, 50, 85 

Touat, Z. .............................................. 61 

Touche, V. ........................................... 74 

Tousoulis, D. ....................................... 45 

Toutouzas, K. ............................... 38, 45 

Touw, J. ............................................... 70 

Towers, G.W. ...................................... 85 

Tran-Dinh, A. ................................ 56, 57 

Trautwein, E.A. ................................... 43 

Travert, F. ........................................... 32 

Trayssac, M. ....................................... 38 

Trégouët, D.-A. ..................................... 8 

Tremoli, E. ........................................... 34 

Tretjakovs, P. .................................... 103 

Trichia, E. .......................................... 120 

Trimech, T. .................................... 31, 76 

Trimeche, A. ..................................... 103 

Triolo, M. ....................................... 72, 96 

Tripoten, M. ......................................... 91 

Triscari, J. ........................................... 86 

Tritapepe, L................................... 28, 67 

Trivella, M.G. ................................ 62, 67 

Trnovska, J. ........................................ 54 

Trombeta, I. ...................................... 115 

Trombetta, I.C. ................................. 115 

Trompet, S. ......................................... 88 

Troutt, J. .............................................. 50 

Tsai, L.-M. ................................. 113, 114 

Tsai, S.-H. ........................................... 61 

Tsai, W.-C. ................................ 103, 114 

Tsai, Y.-S. ........................................... 29 

Tsay, P.-K. .......................................... 46 

Tselepis, A. ......................... 57, 104, 114 

Tselepis, A.D. ..................................... 76 

Tselovalnikova, T.Y. ........................ 105 

Tseng, P.-C......................................... 71 

Tseng, S.-Y. ........................................ 29 

Tsiamis, E. .................................... 38, 45 

Tsifetaki, N. ....................................... 106 

173 

Tsigkas, G. ....................................... 114 

Tsimihodimos, V. ............................... 76 

Tsimikas, S. ........................................ 81 

Tsiouris, S. ....................................... 106 

Tsoumani, M. ................................... 114 

Tsuchiya, T. ........................................ 45 

Tsuda, M. ...................................... 29, 55 

Tsukamoto, K. .................................. 106 

Tsuneyama, K. ................................. 106 

Tu, Y.-L. .............................................. 51 

Tufan, C. ........................................... 121 

Turer, A. .............................................. 94 

Turgeman, Y. ..................................... 96 

Tybjærg-Hansen, A. ........... 7, 54, 55, 84 

Tybjaerg-Hansen, Anne ..................... 5 

Tzanetakou, I. .................................. 119 

Tzavella, E.......................................... 76 

U 

Uboldi, P. ......................... 52, 62, 94, 112 

Uchida, H. ......................................... 124 

Uchida, H.A. ..................................... 124 

Ucieda-Somoza, R. ........................... 57 

Udata, C. ...................................... 44, 87 

Ueda, Y. ............................... 73, 109, 122 

Ueland, T. ......................................... 113 

Ueno, E. .............................................. 45 

Ueshima, H. ...................... 48, 77, 91, 95 

Uesugi, T. ......................................... 127 

Ugarte-Pedrero, X. ............................ 80 

Uitti, J. ................................................. 96 

Ulleryd, M.A. ................................. 41, 66 

Umebayasi, R. ................................. 124 

Undas, A. ............................................ 39 

Unhammer, Njerve, I. ...................... 116 

Urazgildeeva, S. ................................ 78 

Urazovskaya, I. .................................. 58 

Urbánek, M. ........................................ 82 

Urbanski, K. ........................................ 61 

Urinov, M.B. ....................................... 89 

Urpi-Sarda, M. ................................... 33 

Urtane, I. ................................... 107, 113 

Usta, E. ............................................. 126

V 

Vacula, I. ............................................. 79 

Vagionas, I. ......................................... 93 

Vahromeeva, E. ................................ 103 

Valayannopoulos, V. ......................... 80 

Valdivielso, J.M. ................................. 54 

Valensi, P. ................................. 105, 110 

Valente, S. .......................................... 70 

Valéra, M.-C. ...................................... 29 

Valéro, R. .......................................... 101 

Valinsky, L. ....................................... 116 

Vallez, E. ..................................... 28, 105 

Valls-Pedret, C. .................................. 26 

Vallvé, J.C. .......................................... 74 

van, Bockxmeer, F.M. ....................... 82 

Van, Craenenbroeck, A................... 104 

Van, Craenenbroeck, E................... 104 

van, den, Oever, I. ............................. 20 

van, der, Giet, M. ..................... 107, 112 

Van, der, Hoorn, J.W.A. .................... 49 

van, der, Made, S.M. ....................... 118 

van, der, Tuin, S.J.L. ............. 16, 49, 71 

van, der, Veer, E.P. ............................. 8 

van, der, Vorst, E. .............................. 42 

van, der, Zee, L. ................................. 70 

van, Eck, M. .................................. 42, 65 

Van, Gaal, L. ......................................... 9 

Van, Ganse, E. ................................. 123 

van, Gils, J.M. ....................................... 8 

van, Gorp, P.J. ................................... 22 

van, Greevenbroek, M....................... 50 

van, Ierssel, S. .................................. 104 

Van, Nood, E. ..................................... 36 

Van, Noolen, L. ................................ 122 

van, Schaik, R. ................................... 81 

van, Zonneveld, A.J. ............................ 8 

Van, Zyl, T........................................... 85 

Vanags, L. ........................................... 42 

Vandenbroucke, I. .............................. 74 

Vandenput, L. ....................................... 7 

Vanderdionck, S. ................................ 28 

Vanek, J. ....................................... 40, 96 

Vanhoutte, J. ................................ 28, 67 

Vanikova, J. ...................................... 120 

174 

Vanoosterhout, S. .............................. 22 

Varbo, A. ......................................... 7, 55 

Varejckova, M. ................................... 89 

Varela, C. ................................. 65, 68, 94 

Varela, Casariego, C. ..................... 100 

Varela, Perez, L.M. ........................... 48 

Varela-Perez, L. ................................. 57 

Vargas-Alarcón, G. ...................... 77, 99 

Varma, N. ........................................... 98 

Varret, M. ................................. 26, 50, 64 

Vasankari, T. ...................................... 69 

Vasilieva, E. ...................... 51, 58, 61, 64 

Vasina, L. ............................................ 78 

Vaslin-Reimann, S. ........................... 79 

Vatier, C. ............................................. 82 

Vattulainen, I. ..................................... 70 

Vávrová, L. ......................................... 82 

Vázquez, A.M. ............................. 38, 68 

Vcev, A. ...................................... 93, 111 

Vecka, M. ............................................ 82 

Vedel, S. ............................................. 50 

Vedie, B. ............................................. 30 

Védie, B. ............................................. 26 

Velsko, I. ............................................. 63 

Vemmos, K.N. .................................. 120 

Vendrame, F. ..................................... 78 

Vengrenyuk, Y. .................................. 37 

Venn, A. .......................................... 7, 32 

Vercesi, A.E. .............................. 90, 101 

Verdier, C. .......................................... 85 

Verdugo, R. ...................................... 117 

Vergely, C. .................................... 53, 58 

Verges, B. ........................................... 27 

Vergès, B. ......................................... 104 

Verhoeven, A. .................................... 70 

Verhoeven, G. .................................... 69 

Véricel, E. ..................................... 34, 65 

Vermeer, M. ....................................... 43 

Verny, M.-A. ..................................... 122 

Verola, O. ........................................... 79 

Veselovskaya, N. ..... 100, 102, 103, 118, 

125 

Vetrani, C............................................ 43 

Vialettes, B. ...................................... 101 

Vianello, A. ................................... 61, 93

Vickers, K.C. ....................................... 27 

Vidal-Piñeiro, D. ................................. 26 

Vidé, J................................................ 118 

Vidjak, V. ........................................... 115 

Vigeral, C. ......................................... 100 

Viglione, F. .................................... 62, 67 

Vigna, G.B. ......................................... 81 

Vigouroux, C. .............................. 83, 100 

Viikari, J. .............................................. 36 

Viikari, J.S. ............................................ 7 

Viikari, J.S.A. ...................................... 32 

Viiri, L. .................................................. 63 

Vik, R. .................................................. 86 

Viklicky, O. ........................................ 112 

Villa, Gil-Ortega, M. ..................... 97, 98 

Villard, E.F. ............................. 30, 63, 70 

Villarreal-Molina, T. ............................ 99 

Villasmil, J.J. ....................................... 40 

Villegas, del, Ojo, J. ......................... 105 

Vinaixa, M. .......................................... 36 

Vindis, C. ....................................... 37, 70 

Vinel, A. ............................................... 29 

Virga, N. .............................................. 84 

Virginio, V.W. ................................ 71, 78 

Viscomi, C. .......................................... 16 

Vissers, D. ......................................... 104 

Visvikis-Siest, S................................ 106 

Vitale, M. ............................................. 43 

Vitanov, V. ........................................... 99 

Vitek, L. ............................................. 120 

Vittos, A. ............................................ 110 

Vittos, O. ........................................... 110 

Vivanco, F. .......................................... 61 

Vlachos, I.S....................................... 119 

Vladimirskaya, T. ............................... 56 

Vlasik, T. ............................................. 75 

Vlaskou, E. .......................................... 47 

Vlasova, E. .......................................... 86 

Vo, S. ................................................... 30 

Voevoda, M........................... 84, 91, 127 

Volkov, V. ............................................ 77 

Volkova, E. .......................................... 97 

Völzke, H. .......................................... 110 

von Eckardstein, Arnold .............. 22, 27 

von, Bonin, A. ..................................... 87 

175 

von, Dryander, M. .............................. 86 

von, Eckardstein, A. .................... 27, 71 

Vongpromek, R. ................................. 70 

Vorobjov, R. ..................................... 107 

Vorobjova, E. ................................... 107 

Vorobyev, R.I. ................... 78, 91, 92, 97 

Vorobyeva, E.N. ............... 78, 91, 92, 97 

Vorrsjö, E. ..................................... 31, 75 

Voss, J.C. ........................................... 73 

Voss, S.S. ........................................... 32 

Voulgari, C............................... 54, 82, 95 

Vovchenko, M. ................................... 77 

Vozzi, F. .............................................. 67 

Vrablik, M............................................ 99 

Vrablík, Michal ................................... 18 

Vranckx, R. ....................................... 114 

Vreugdenhil, A.C.E. .......................... 22 

Vrieze, A. ............................................ 36 

Vrints, C. ........................................... 104 

Vromman, A. ...................................... 60 

Vučić, M. ............................................. 82 

Vuilleumier, N. ................................... 47 

Vujic, N. ............................................ 124 

Vukcevic, V. ....................................... 98 

Vulic, D. .............................................. 92 

W 

Wada, F. ............................................. 44 

Wada, S. ............................................. 44 

Wadhwa, N. ........................................ 87 

Wagenaar, G.T.M. ............................. 65 

Wahbi, K. ............................................ 52 

Walenbergh, S. .................................. 22 

Wallaschofski, H. ............................. 110 

Wållberg-Jonsson, S. ...................... 106 

Walus-Miarka, M. .............................. 80 

Waluś-Miarka, M. ............................ 127 

Wan, H. ............................................... 87 

Wan, Y.-L............................................ 46 

Wanden-Berghe, C. ................ 117, 127 

Wang, C. ............................................. 65 

Wang, C.-K. ...................................... 118 

Wang, G. ............................................ 51 

Wang, H.-J. ........................................ 69

Wang, K.-Y. ........................................ 93 

Wang, L. .............................................. 76 

Wang, M.-C............................... 103, 114 

Wang, N. ....................................... 65, 74 

Wang, P. ............................................. 52 

Wang, R. ....................................... 29, 33 

Wang, Y. ................................. 16, 71, 73 

Wang, Z. ........................................ 29, 56 

Wanner, C. ........................................ 101 

Warner, T.D. ..................................... 114 

Wasserman, S.M. .................. 22, 44, 77 

Watanabe, F. .................................... 123 

Watson, S. .......................................... 34 

Watts, G.F. .................................. 22, 103 

Weber, C. ............................................ 67 

Weidmann, H. ................................... 117 

Weikert, C. .......................................... 32 

Weill, A. ............................................... 32 

Weir, J.M. ............................................ 30 

Wen, M.-S. .......................................... 46 

Wendelin-Saarenhovi, M. ................. 40 

Werdan, K. .......................................... 64 

Werzowa, J. ........................................ 49 

Westendorp, R.G.J. ........................... 88 

Wester, P. ..................................... 98, 99 

Wevers, R. .......................................... 55 

Whatling, C. ........................................ 38 

Wheatcroft, S. ..................................... 94 

White, A.J. ........................................... 30 

Whittall, R.A. ....................................... 80 

Wiart, M. .............................................. 64 

Wick, G. ............................................... 53 

Widhalm, K. ........................................ 76 

Widimsky, J....................................... 125 

Wiegman, A. ....................................... 81 

Wiinberg, N. ........................................ 95 

Wijngaard, P.L. ................................... 73 

Wiklund, O. ....................................... 1, 7 

Wiklund, Olov ................................. 1, 15 

Wikström, A.-K. .................................. 93 

Wild, P.S. .............................................. 8 

Wilhelmson, A.S. ................................ 69 

Wilk, B.K. ........................................... 121 

Willan, K.L. ........................................ 124 

Willeit, P. ........................................... 114 

176 

Willems, van, Dijk, K. ............. 16, 49, 71 

Williams, B........................................ 124 

Williams, E.D. ..................................... 89 

Williams, H. ........................................ 65 

Winsauer, G. ...................................... 87 

Winslop, A. ......................................... 18 

Winther, S. .......................................... 95 

Wirfält, E. ...................................... 17, 39 

Wirth, J. ............................................... 32 

Wlazeł, R.N. ..................................... 102 

Wohlfahrt, P. ................................ 40, 96 

Wohns, D. ........................................... 22 

Wojciechowska, W. ......................... 127 

Wojciechowski, J. .............................. 57 

Wojcieszczyk, J. .............................. 116 

Wójcik, T. ............................................ 57 

Wojta, J. ............................................ 114 

Wolf, P. ............................................... 83 

Wolfs, M.G.M. .................................... 71 

Wollmer, P. ....................................... 116 

Wolska, A. .......................................... 73 

Wolski, K. ............................................ 22 

Womperski, K. ................................. 116 

Wong, A.T.Y. .............................. 22, 103 

Wong, G. ...................................... 22, 30 

Wong, J.Y. .......................................... 27 

Wong, M.C. ........................................ 65 

Wood, S.M........................................ 124 

Worsch, M. ....................................... 113 

Wouters, K.................................. 28, 105 

Wozniak, M. ....................................... 57 

Woźniakiewicz, E. ........................... 127 

Wright, A. ...................................... 49, 78 

Wright, S.D. ...................................... 123 

Wróblewska, M. ................................. 73 

Wu, C.-H. .......................................... 114 

Wu, H.-L. ............................................ 29 

Wu, Y. ................................................. 52 

Wuczkowski, M. ................................. 76 

Wymann, M. ....................................... 52 

Wyss, C.A. .......................................... 47 

X 

Xanthopoulou, I. .............................. 114

Xie, D. .................................................. 51 

Xu, F. ................................................... 22 

Xu, Q. .................................................... 8 

Xu, Qingbo ............................................ 8 

Y 

Yadav, M.R. ........................................ 78 

Yadav, R. .................................... 72, 125 

Yagi, K. .......................................... 11, 80 

Yagyu, H. ............................................ 73 

Yahalom, M......................................... 96 

Yahya, R. ............................................ 70 

Yamada, K. ......................................... 61 

Yamada, M. ........................................ 48 

Yamagishi, M. ............................... 50, 80 

Yamagishi, T..................................... 125 

Yamaguchi, T. ............ 31, 109, 111, 123 

Yamamoto, J. ..................................... 39 

Yamamoto, T. ..................................... 44 

Yamamura, S. ............................ 31, 111 

Yamamuro, D. .................................... 73 

Yamanaka, S. ..................................... 94 

Yamashita, S. ............................. 87, 109 

Yan, B. ................................................. 11 

Yan, Z. ................................................. 63 

Yan, Z.-Q. ..................................... 41, 66 

Yang, C.-M. ......................................... 64 

Yang, L.J. ............................................ 66 

Yang, Y.L. ........................................... 87 

Yannarelli, G. ...................................... 82 

Yao, Q. ................................................ 28 

Yarmolovsky, A. ............................... 116 

Yassin-Norena, L.M. .......................... 60 

Yasuda, G. .......................................... 88 

Yasuda, T. ............................. 39, 74, 120 

Yasuhara, H. ....................................... 44 

Yatsu, K. .............................................. 88 

Yazici, A.C. ....................................... 109 

Yefimova, N. ..................................... 110 

Yefsah, A. ......................................... 119 

Yen, F.T. ........................................... 106 

Yeni, P. ................................................ 63 

Yildirir, A. ........................................... 109 

Yıldırır, A. .................................... 89, 107 

177 

Yilmaz, O. ........................................... 69 

Yin, K............................................. 42, 51 

Yin, W.-H. ........................................... 93 

Ylä-Herttuala, S. .......................... 30, 31 

Yndestad, A. ..................................... 113 

Yokoyama, S. ..................................... 80 

Yongsakulchai, P. ............................ 100 

Yoon, Y. .............................................. 76 

Yoon, Y.W. ......................................... 70 

Yoshida, S. ......................................... 62 

Yoshikawa, T. .................................. 123 

Yoshimura, A. .................................. 121 

Yoshimura, E. .................................... 54 

Younis, N. ................................... 72, 125 

Yu, C.-C. ........................................... 100 

Yu, J. ................................................... 48 

Yu, Z.Y. ............................................... 29 

Yuldasheva, N. .................................. 94 

Yvan-Charvet, L................................. 23 

Z 

Zabunova, M. ........................... 107, 125 

Zaccagna, F. ...................................... 97 

Zachary, I............................................ 59 

Zago, V.H.D.S. ............................. 78, 83 

Zago, V.H.S. ..................................... 128 

Zaid, M. ............................................... 95 

Zair, Y. ................................................ 26 

Žák, A. ................................................. 82 

Zak, P. ............................................... 112 

Zakaroff, A. ......................................... 49 

Zakke, I. ............................................ 125 

Žáková, P. .......................................... 94 

Zalba, G. ............................................. 41 

Zalewski, J.......................................... 39 

Zampetaki, A. ................................... 114 

Zanetti, M............................................ 35 

Zannis, V.I. ......................................... 71 

Zarakauska, L. ................................. 107 

Zarzecka, A. ..................................... 125 

Zatz, H. ......................................... 76, 96 

Zavyalova, L. ...................................... 79 

Zawadzki, C. ...................................... 67 

Zechner, R.......................................... 25

Zeiher, A. ............................................... 8 

Zekri, S. ............................. 104, 105, 115 

Zelina, M. .................................. 108, 115 

Zelinka, T. ......................................... 125 

Zeller, M. ....................................... 53, 58 

Zeller, T. ........................................ 8, 117 

Zemankova, L. ............................ 89, 120 

Zerbinati, C. ........................................ 60 

Zernecke, A. ....................................... 47 

Zerrad, A. .......................................... 108 

Zhai, Y.Z. ........................................... 118 

Zhang, F. ............................................. 33 

Zhang, H. ............................................ 16 

Zhang, J. ............................................. 56 

Zhang, J.-J. ......................................... 51 

Zhang, L. ............................................. 30 

Zhang, R. ............................................ 56 

Zhang, T. ........................................... 118 

Zhang, X.-Y......................................... 66 

Zhang, Y. ..................................... 73, 124 

Zhao, S. ............................................. 123 

Zhelankin, A.V. ................................. 100 

178 

Zheng, D. ............................................ 52 

Zhong, L. ............................................ 52 

Zhou, B. ........................................ 29, 67 

Zhu, L. ................................................. 73 

Zidek, W. .................................. 107, 112 

Zidzik, J. .............................................. 99 

Zikou, A.K. ........................................ 126 

Zilov, A. ............................................... 97 

Zilov, A.V. ......................................... 105 

Zimetti, F. ............................................ 71 

Zimmerova, I. ..................................... 81 

Zingg, J.-M. ...................................... 126 

Zinser, E. ............................................ 68 

Zmojdzian, M. .................................. 122 

Zo, J.-H. .............................................. 78 

Zoetendal, E. ...................................... 36 

Zoroufian, A. ....................................... 46 

Zsíros, N. .......................................... 102 

Zulj, M. ................................................ 93 

Zulkafli, N............................................ 58 

Zyatenkova, E. ................................... 88

FINAL PROGRAMME

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?